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ABSTRACT 
Prostate cancer (PCa) is the most common, non-cutaneous malignancy in men in the developed 
world. It is highly heritable, with twin studies suggesting that as much as 58% of disease risk 
can be explained by genetics. While more than 170 common genetic risk variants have been 
identified, these variants still only explain a minor portion of heritability, are largely of low to 
moderate effect size, and for many their function remains unclear. There has recently been 
significant success in the discovery of rare genetic variants contributing to complex disease 
through next-generation sequencing studies of large families. Mancuso and colleagues (2016) 
have estimated that as much as 42% of PCa risk is due to rare variants, but to date only 6% of 
this risk has been elucidated. With two-thirds of PCa heritability still unexplained, including 
the contribution of rare variants, we hypothesise that the utilisation of PCa families will aid in 
the identification of these rare variants.  
Germline risk variants and somatic tumour alterations have traditionally been regarded as 
unrelated events in cancer. However, there is now increasing evidence to suggest that specific 
germline variants may predispose some somatic tumour events, including copy number 
changes and gene fusions. Of particular interest in PCa, is the fact that germline variants have 
been reported to be significantly associated with the TMPRSS2:ERG fusion. Given the high 
frequency of these fusion events and accumulating evidence from previous studies, we also 
hypothesise that there are inherited determinants of somatic tumour variation, and this will be 
the second focus of this thesis.  
Family studies are proving highly valuable in the study of complex disease and here I will 
explore these hypotheses using the Tasmanian Familial Prostate Cancer Study cohorts, 
comprising genetic material from large families with multiple PCa cases and their relatives 
(Tasmanian Familial Prostate Cancer Cohort), as well as the Tasmanian Prostate Cancer 
Case-Control Study.  
To address the first hypothesis, whole-genome sequencing (WGS) was undertaken in five large 
Tasmanian PCa pedigrees to identify rare genetic variants contributing to disease risk. Variants 
were prioritised on a per-family basis by minor allele frequency, segregation with disease, 
mutation type and predicted functional consequence. Of the 20 prioritised rare variants, four 
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were determined to be significantly associated with PCa risk in the Tasmanian population. This 
included rare variants in the genes RND1, WNT1, EZH2 and the known G84E HOXB13 variant. 
Both RND1 and WNT1 have been found to promote the growth and migration of cancer cells 
and, notably, in our study the variants appeared to be co-inherited.  
The EZH2 variant is a rare, intronic variant (rs78589034) present within a 3’ splice consensus 
sequence. EZH2 encodes the histone methyltransferase enzyme and is constitutively 
overexpressed in a range of cancers, including PCa. EZH2 is a highly variable gene and 
multiple transcripts have been identified. In fact, Chen et al (2017) observed that alternative 
splicing involving the inclusion of exon 14 plays a major role in the tumourigenesis of renal 
cancer. While this variant was significantly associated with PCa risk in the Tasmanian 
population (OR=3.27, p=0.001), functional assays were unable to determine the potential 
impact of this variant on the splicing mechanisms of EZH2.  
The G84E HOXB13 variant (rs138213197) was initially observed in the WGS data and follow-
up genotyping found a significant association with PCa risk in the larger Tasmanian Familial 
Prostate Cancer Study cohorts (OR=6.59, p=4.22x10-5). Although multiple studies have 
demonstrated an association of the G84E variant with PCa risk, no study has assessed the 
functional impact of the variant on HOXB13 gene and protein expression. Here, no difference 
in HOXB13 gene or protein expression was observed between prostate tumours from G84E 
carriers and non-carriers, but interestingly, the variant allele was rarely transcribed in carriers. 
The unbalanced allele transcription did not appear to be caused by methylation differences and, 
thus, other mechanisms, such as DNA copy number variation at the HOXB13 site or rapid 
targeted degradation of the variant mRNA transcript, may underpin the observed allelic 
imbalance. Hence, questions remain regarding how this variant influences tumour 
development. Given the rarity of the G84E variant, achieving a sufficient sample size for 
analyses is challenging, therefore, through collaboration with members of the Prostate Cancer 
Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium, we aim to further explore the function of this variant.  
To address the second hypothesis, germline and tumour samples from PCa cases were utilised 
to explore inherited determinants of somatic tumour variation. Tumours from 14 PcTas9 cases 
were analysed using the TruSight RNA Fusion Panel (Illumina), identifying seven tumours as 
TMPRSS2:ERG fusion positive. Subsequently, analysis of the entire Tasmanian Prostate 
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Tissue Pathology Resource showed that 31.5% of tumours were fusion positive. This event 
was more frequent in tumours from two families, PcTas2 and PcTas9 and, interestingly, was 
not identified in any of the eight sporadic tumours examined. These results suggest that there 
may be an underlying inherited genetic variant(s) predisposing to this fusion event. Subsequent 
work is focusing on screening for germline risk variants previously found to be associated with 
fusion positive tumours, including rare variants in POLI and ESCO1. 
Somatic copy number changes, including amplifications and deletions, are also common events 
in tumours, leading to the suggestion that they may also arise due to germline genetic variation. 
To explore this hypothesis, array comparative genomic hybridisation was applied to 12 PcTas9 
prostate tumours to determine shared altered chromosomal regions. The most consistent 
alteration involved amplification of the EEF2 gene, which is a novel finding. EEF2 is highly 
expressed in human carcinoma tissue and has been suggested as a potential PCa biomarker. 
Immunohistochemistry of the Tasmanian Prostate Tissue Pathology Resource found that the 
EEF2 protein was overexpressed in 49% of malignant compared to matched benign tissue, but 
no difference was observed between tumours from PcTas9 cases and non-PcTas9 cases. 
However, gene expression assays found malignant cells from PcTas9 tumours had significantly 
higher EEF2 5’UTR/exon 2 expression compared to malignant cells isolated from non-PcTas9 
tumours. Thus, these results suggest that the EEF2 amplification may be specific to PcTas9 
and due to an inherited predisposition variant(s). To test this hypothesis, recent WGS data 
generated for this family will be utilised in linkage analysis based on EEF2 amplification 
status.  
Establishing rare variants as disease-causing requires analysis of large cohorts and secondly, 
comprehensive functional analyses. This study has identified four rare germline variants 
significantly associated with PCa risk in the Tasmanian population. Variant screening in larger 
cohorts of PCa cases and controls is required to determine their contribution to other 
populations. Moreover, the functional impact of the EZH2 and HOXB13 variants on gene and 
protein expression remains unclear and requires more comprehensive functional analyses. This 
study also identified recurrent somatic variations in the tumour genomes of Tasmanian PCa 
cases. The TMPRSS2:ERG fusion and amplification of the EEF2 gene is more apparent in 
tumours from the PcTas9 family, suggesting that these somatic tumour events could be 
underpinned by inherited predisposition. 
ix 
There is currently a strong push to implement polygenic risk scores based on common variants 
in the clinical setting, yet with only one-third of genetic predisposition explained, clinical 
implementation may be premature. Studies such as the one described here, aim to directly 
explore genetic contribution to PCa. Rare germline variants and somatic tumour variation are 
of great interest as potential screening biomarkers and therapeutic targets, and if we are to 
understand the genetic determinants of PCa development, a strong focus on fully characterising 
these factors is essential. 
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CHAPTER 1 :  INTRODUCTION 
 
1.1 AN INTRODUCTION TO PROSTATE CANCER 
Prostate cancer (PCa) is the most common, non-cutaneous malignancy in men in the developed 
world, with approximately 1.3 million men diagnosed in 2018, worldwide 5. In Australia it is 
also the most common cancer in men, with 19,508 new cases expected to be diagnosed this 
year, and it is the second leading cause of male cancer-related deaths 6. In Tasmania, an island 
state of Australia, PCa was the most commonly diagnosed cancer in males in 2016, however it 
was the third most common cause of male cancer-related deaths 7, suggesting a large proportion 
of men are diagnosed with indolent disease. Current diagnostic techniques, including the 
prostate-specific antigen (PSA) test cannot distinguish indolent versus aggressive PCa. Lack 
in specificity led to the over-diagnosis and treatment of indolent PCa in the early 1990’s, which 
was associated with a spike in serious complications as a result of over-treatment. It is now 
known that PCa has a strong genetic component (58%) and over 170 common variants have 
been identified that explain approximately one third of this known genetic risk 8. However, the 
underlying mechanism by which these common variants confer risk remains unclear 9. 
Numerous genome-wide association studies (GWAS), comprising tens of thousands of 
individuals, have likely identified the majority of common risk variants. Therefore, it has been 
hypothesised that some of the ‘missing’ heritability is likely due to rare genetic variants 10. The 
recent interest in rare genetic variants has led to a renewed focus on using family pedigrees for 
gene discovery. This is because reduced genetic complexity means rare variants are enriched 
in these families, which reduces the challenges normally associated with the search for disease-
causing rare variants. The decrease in cost of next-generation sequencing (NGS) in recent years 
has also permitted whole-genome sequencing (WGS) to emerge as a useful tool in the 
identification of such rare variants 11-14.  
 
Incidence rates of PCa vary greatly between populations worldwide. For example, Australia 
and New Zealand’s age-standardised incidence rate (ASR) in 2018 was 85.6 per 100,000, 
compared to South-Central Asia with only approximately 5.0 PCa cases per 100,000 men 5. 
These two regions represent the world’s highest and lowest PCa incidence rates, respectively. 
More than 70% of cases recorded in 2018 (893,274) were in more developed regions of the 
world (extracted from GLOBOCAN 2018; the most recent comprehensive worldwide study of 
cancer in the adult population (Figure 1.1; 5). The rates of PCa are highest in more developed 
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countries, such as Australia, New Zealand, Northern and Western Europe and North America 
5,15, and these high incidence rates are likely due to readily available healthcare which drives 
the rate of diagnosis. This includes the practice of PSA testing and subsequent biopsy, which 
has resulted in the detection of clinically insignificant (indolent) disease 16. Mortality rates are 
however reversed, with the number of estimated deaths from PCa in 2018 being greater in less 
developed regions (27.9 ASR per 100,00; South Africa) compared to more developed countries 
(10.0 ASR per 100,000; Australia) 5. This is likely due to a lack of available health care; 
including screening and prevention strategies, as well as access to treatment 17. In terms of 
survival rates, in developed countries these have increased in patients with localised PCa. For 
example, in Australia a 5-year relative-survival rate (RSR) of 59.2% was recorded between 
1986-1990, compared to 95.2% between 2011-2015, according to the Australian Institute of 
Health and Welfare data 6. Although, this is dramatically reduced in men with advanced 
metastatic PCa, with a 5-year RSR of only 29% 18. Overall, there is great disparity in incidence, 
mortality and survival rates worldwide, due to access to healthcare, however within populations 







Presented here is the age-standardised incidence rate per 100,000 men in each country. Higher incidence rates are more prominent in developed countries of the world,  
such as Australia, Northern and Western Europe and North America, where readily available healthcare drives the rate of diagnosis 5,19. 
 
 
Figure 1.1 Prostate cancer incidence rates worldwide in 2018 (age-standardised incidence rate per 100,000 men).  
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1.2 AN INTRODUCTION TO THE PROSTATE 
The prostate, the largest male accessory gland, is located in front of the rectum, below the 
bladder, surrounding the urethra 20 (Figure 1.2). The prostate plays an important role in male 
reproduction; it is a small exocrine gland that produces a fluid containing enzymes, lipids, 
amines and metal ions that comprise part of the semen. This fluid is essential for the normal 
function of spermatozoa and is stored with the sperm in the seminal vesicles until ejaculation. 
As well as its role in the male reproductive system, the prostate participates in the control of 















The prostate is located below the bladder and encompasses the urethra. It is composed of 
four zones, the peripheral (green), anterior (cream), central (pink) and transitional (yellow). 
Approximately 60-70% of all prostate cancer tumours arise in the peripheral zone and about 
10-20% in the transitional zone 21. 
 
 
1.2.1 The development of the normal prostate  
The development of the male reproductive tract, including the prostate is dependent upon 
mesenchymal-epithelial interactions and fetal androgens 22. Androgens, such as testosterone, 
dihydrotestosterone and androgen receptor (AR) play an important role in the development and 
maintenance of the prostate. The AR serves as an essential survival factor for prostate epithelial 
cells (reviewed in Davey et al. (2016) 23). The normal adult prostate is composed of a glandular 
Figure 1.2 The anatomical location and zones of the prostate.  
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epithelial and a fibromuscular stroma component. The glandular epithelium constitutes 
approximately 95% of the prostate and it is composed of a large peripheral zone and a small 
central zone. The remaining 5% is composed of the transitional zone and the peri-urethral 
glands 21 (Figure 1.2). 
 
1.2.2 The development of prostate cancer 
There are two different types of prostatic disease in adult males, benign prostatic hyperplasia 
(BPH) and PCa. BPH is a common, benign condition that involves the enlargement of the 
prostate, which can restrict the flow of urine and cause pain during urination 24. BPH is non-
life threatening and is neither a premalignant lesion nor a precursor of PCa. PCa is the 
uncontrolled division of prostate cells, with approximately 60-70% of all tumours arising in 
the peripheral zone and about 10-20% in the transitional zone 25 (Figure 1.2). PCa that arise in 
the peripheral zone retain some glandular structure, which classifies them as adenocarcinomas. 
The question remains how dysregulation of normal prostate development and maintenance 
leads to the initiation of cancer, however, it is believed that disruption of normal AR-regulated 
gene expression plays a vital role 26.  
 
1.3 PROSTATE CANCER DIAGNOSIS 
Currently screening guidelines for PCa recommend that men over 50 years of age, or men over 
40 with a family history of PCa discuss testing with their doctor. There are usually no initial or 
early symptoms of PCa, but men experiencing symptoms, including a frequent or sudden urge 
to urinate, difficulty urinating (including discomfort and/or blood in their urine), lower back or 
pelvic pain and fatigue, require follow-up investigation. PCa is commonly diagnosed through 
a physical exam, such as a digital rectal exam (DRE) and a blood test to assess PSA level 27,28. 
If both of these tests are indicative of PCa (enlarged prostate and an increased PSA level) an 
ultrasound-guided biopsy is undertaken.  
 
1.3.1 Prostate-specific antigen testing  
PSA is a glycoprotein produced by the epithelial cells of the prostate gland that can be detected 
in the blood (it is prostate-specific, but not prostate cancer-specific). There is no normal or 
abnormal PSA level for a male, but a higher reading may indicate the presence of cancer; as 
the prostate lumen and capillaries are disrupted and PSA is released into the serum 29. Whilst 
most men who are disease-free have a PSA level under 4ng/mL, about 15% of men with a PSA 
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level under 4ng/mL will have disease on biopsy 30. Conversely, a PSA level greater than 
4ng/mL is not diagnostic for PCa, as common benign conditions, such as BPH also increase 
PSA levels 31. Numerous strategies have been proposed to improve the diagnostic performance 
of PSA testing. This includes age- and race-specific reference ranges, and measuring PSA 
velocity, which is the rate of change of a man’s PSA level 32. The Baltimore Longitudinal Study 
of Aging found that men with a PSA velocity greater than 0.75ng/mL/year were at an increased 
risk of being diagnosed with PCa 33. Carter et al. (2004) also concluded that PSA velocity was 
more specific than a 4ng/mL cutoff (90% versus 60% specificity), however, subsequent 
randomised trials suggested that PSA velocity adds little predictive information to total PSA. 
Thus, the 4ng/mL cutoff remains the gold standard for PCa screening because it balances the 
tradeoff between missing important cancers at a curable stage (about 15%) and avoiding both 
detection of clinically insignificant disease and subjecting men to unnecessary biopsies 27,32,34. 
 
PSA testing was widely adopted for PCa screening in the early 1990s and subsequently, led to 
a dramatic increase in the incidence in developed countries. For example, following the over-
implementation of PSA testing in Australia, the ASR peaked at 79.7 in 1994, compared to 42.0 
just four years prior in 1990, a trend that was also evident in Tasmania 7,35 (Figure 1.3). A large 
proportion of these diagnoses included tumours that were insignificant and without PSA testing 
may not have presented clinically. Implementation of PSA testing saw many men with indolent 
PCa undergo invasive biopsies and radiotherapy, often with complications arising that were 
more severe than their original tumour 36,37. This left clinicians and scientists questioning 
whether PSA was an appropriate tool for PCa diagnosis. As a result, clinical guidelines for the 
screening of PCa using PSA were revised in 2016 by a multidisciplinary expert advisory group 
under the leadership of the Prostate Cancer Foundation of Australia, and approved by the 
National Health and Medical Research Council 38. Adoption of these new guidelines saw a 
10% reduction in the number of PCa cases diagnosed in Australia in 2018 (18,274) compared 






















Presented here is the age-specific incidence and mortality rates per 100,000 men, in Tasmania between 1982 and 2014. In the early 1990’s there was a sharp increase in PCa 
incidence following the over-implementation of PSA testing 7. Age-specific rates are calculated by dividing the number of cases occurring in each specified age group by the 
















Figure 1.3 Trends in incidence and mortality of prostate cancer in Tasmania (age-specific rates per 100,000 men).  
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1.3.2 Gleason scoring system 
If a man has an enlarged prostate and an ‘abnormal’ PSA level, a urologist will perform an 
ultrasound-guided biopsy. This involves the removal of a small sample of prostate in a fine 
needle and it is the only definitive way to diagnose PCa. This sample is stained with 
haematoxylin and eosin (H&E) and is microscopically visualised by a histopathologist, who 
determines if there are any regions of malignancy. If malignant cells are present the 
histopathologist scores the tumour using the Gleason scoring system. A Gleason score (GS) is 
an evaluation of the ability of the prostate to form regular uniform glands and this score reflects 
the aggressiveness of a tumour, and often guides subsequent treatment. It is calculated by the 
addition of the most common and second most common pattern of cancer. Each pattern is 
graded as 1, 2, 3, 4 or 5; with 1 indicating small uniform glands (normal) and 5 representing 
occasional gland formation (cancerous) 40. A GS £6 is considered to be an indicator of less 
aggressive disease with a good prognosis, as it is the most well-differentiated tumour grade. A 
GS of 7 (3+4) is similar, however the density of malignant glands and the tumours invasive 
potential is increased. Whereas, a GS of 7 (4+3) shows a clearly infiltrative tumour. Regardless, 
tumours with a GS £7 are, in most cases, curable. A GS of 9-10 indicates no glandular 
differentiation and these tumours tend to be advanced neoplasms, that are unlikely to be cured 
and have a high likelihood of metastasising 40. 
 
1.3.3 Molecular subclassification to predict patient outcomes 
Molecular profiling of prostate tumours has been undertaken with the aim of identifying early 
genomic alterations that may assist in the clinical setting. Prostate tumour samples in The 
Cancer Genome Atlas (TCGA) have been utilised to identify specific molecular subclasses of 
localised PCa, and these are largely mutually exclusive. Two major molecular subclasses of 
localised PCa are ETS-fusion positive and negative tumours, and both of these subclasses can 
be further subdivided as follows: 
 
1. ETS-fusion positive (including overexpression of ERG, ETV1, ETV4, ETV5 and 
FLI1). Approximately 50% of all prostate tumours are ETS-fusion positive 41. These 
tumours can be further subdivided into the following: 
• ETS-fusion positive with loss of PTEN. A study by Bismar et al. (2018) found 
21.8% of 463 tumour samples had both loss of PTEN and gain of ERG 
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(p<0.001) 42. PTEN loss is found in localised PCa but is much more common 
in advanced, metastatic disease 43,44. 
• ETS-fusion positive with genetic alterations, such as RB1 loss (28%), 
amplification of MYC (10%) and mutations in ATM (19%) and BRCA2 (~7%) 
43,45. 
• ETS-fusion positive with loss of function mutations in TP53 occur in 40-60% 
of cases. Like PTEN loss, TP53 mutations are found in localised PCa, but are 
more common in advanced, metastatic disease 43,44. 
 
2. ETS-fusion negative tumours 41, which can be further subdivided into the following: 
• ETS-fusion negative with recurrent SPOP mutations. These mutations are the 
most common point mutations in PCa, occurring in 6-15% of cases 46. 
o ETS-fusion negative with homozygous deletion of CDH1 occurs most 
commonly in the SPOP mutant subclass. Overall, this subclass occurs 
in 5-10% of PCa cases; 80% of which belong to the mutant SPOP 
subclass. This subclass is more common in advanced, metastatic disease 
46,47. 
• ETS-fusion negative with missense FOXA1 mutations. This subtype has been 
identified in 4% of the TCGA cases, and are mostly mutually exclusive of ETS-
fusion positive and mutant SPOP tumours 43,46. 
• ETS-fusion negative with SPINK1 overexpression. SPINK1 is overexpressed in 
5-10% of PCa and is associated with aggressive disease 43,48,49. 
 
These PCa subtypes remain under investigation, as the acquisition of these changes in tumour 
development and their predicted value for prognosis and treatment remains unclear. However, 
the potential clinical utility of such classification tools could prove invaluable to predict PCa 
progression, aggressiveness and response to treatment 50,51. Overall, it is apparent that each 
subclass of PCa is predisposed to its own defined set of progression events. However, some of 
these later events, such as loss of PTEN, loss of function mutations in TP53, mutations in ATM, 
deletion of CDH1 and overexpression of SPINK1, co-occur in different subclasses throughout 
PCa progression to the metastatic stage 46. There is evidence to suggest that acquisition of 
genetic changes in tumours is not random, and inherited genetic variants may predispose to 
some acquired changes, which will be discussed in Chapters 6 and 7 of this thesis. 
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1.4 PRIMARY PROSTATE CANCER TREATMENT  
1.4.1 ‘Active Surveillance’ 
PCa is clinically and biologically heterogenous and may remain present as indolent disease for 
many years. Autopsy studies have shown a high prevalence of clinically undetected PCa at 
time of death, with as many as 87% of men over 80 years of age found to have indications of 
PCa at the time of autopsy, suggesting that many men can live with indolent PCa 52,53. ‘Active 
surveillance’ programs, or a ‘watch and wait’ approach to treatment is recommended for those 
with low grade disease, GS £6 54,55.  
 
1.4.2 Prostatectomy 
A transurethral resection of the prostate (TURP) is a surgery used to treat urinary problems due 
to an enlarged prostate. It involves a prostate resection to relieve blockages in the urinary tract 
and is a treatment option for BPH. If a biopsy or TURP is suggestive of advanced PCa, GS ³7, 
a radical prostatectomy (RP) is undertaken; the surgical removal of all of the prostate, part of 
the urethra and the seminal vesicles. Surgical castration can often result in nerve damage, loss 
of bladder control, impotence and infertility 56. The RP tissues are histologically reviewed by 
a pathologist and scored using the Gleason scoring system, as well as the stage of disease, i.e. 
is it localised or has it progressed beyond the prostate.  
 
1.4.3 Radiotherapy 
Radiotherapy may be offered to men with early-stage PCa, and/or where surgery may be 
contraindicated. It is delivered externally using external beam radiation therapy (EBRT) or 
internally using brachytherapy. EBRT uses targeted radiation in the form of x-ray beams 
whereas brachytherapy involves the placement of the radiation source directly within the 
prostate, which limits the effects on nearby organs, such as the rectum and bladder 57. Both 
EBRT and brachytherapy have similar side effects including impotence, changes in ejaculation, 
pain when urinating, blood in the urine, poor urine flow and bladder irritation. Studies have 
shown that radiotherapy is often associated with an increase in overall and PCa-specific 
mortality compared with surgical interventions 58. 
 
1.4.4 Androgen deprivation therapy 
Aggressive PCa cells require testosterone to grow, therefore slowing the production may slow 
the growth of the cancer or shrink it temporarily. Androgen-deprivation therapy (ADT) works 
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by blocking the body’s production of testosterone. ADT injections are often used before, during 
and after radiotherapy and can slow the growth of a localised tumour for many years. Side 
effects can include fatigue, erection problems, loss of muscle strength, loss of bone density and 
increased risk of other problems such as, obesity, diabetes and heart disease 59. ADT is the 
main treatment for advanced PCa, and can reduce or eliminate symptoms for months to years 
(reviewed in Abrahamsson et al. (2010) 60). Concomitant chemotherapy is often used in parallel 
with ADT for advanced PCa and is sometimes the last resort for advanced cancers where ADT 
hasn’t slowed tumour growth or relieved symptoms.  
 
1.5 PROSTATE CANCER RISK FACTORS 
On average, one in eight Australian men will be diagnosed with PCa before the age of 85 years, 
however, some men have a higher risk than others. Age, race and family history are the few 
established risk factors of PCa development. Like most other cancers, it is more common in 
older men, with 63% of cases diagnosed in men over 65 years of age 6. Race, another risk 
factor, may explain some of the differences in incidence rates worldwide. Figure 1.1 shows 
that Asian men typically have the lowest PCa incidence rate, followed by Caucasian and 
African American men, respectively 15. Indeed, African American men have a 60% higher 
incidence rate of PCa (275.3 per 100,000 men) than age-matched Caucasian populations (172.9 
per 100,000 men) 61. The higher rate of disease incidence and mortality among men of African 
descent in the United States and the Caribbean reflects the ethnic contribution to PCa 
development 62,63. These studies also show that genetic factors, which underpin race, are an 
important determinant of the variation in risk and thus incidence at the population level. In fact, 
family history is the most consistently identified risk factor of PCa.  
 
1.5.1 Prostate Cancer Heritability 
Population-based cohort studies have frequently demonstrated a strong genetic component to 
PCa. Such studies have estimated that the risk for men with an affected first-degree relative is 
2-3-fold higher than those without. This risk has been shown to increase up to 18-fold as the 
number of affected relatives and the relatedness of the affected case increases 64-67. Further 
evidence of a genetic effect is shown by the observation that the relative risk (RR) to relatives 
increases as the age of the proband decreases 64,68-71. Thus, a brother of a proband diagnosed 
with PCa at the age of 50, has a 1.9-fold higher risk of developing PCa compared with a brother 
of a man diagnosed with the disease at the age of 70 64. A meta-analysis of 33 epidemiological 
case-control and cohort-based studies, including over 12 million individuals and 27,000 PCa 
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cases, found that PCa risk appeared to be far greater for men with affected brothers (RR 3.14; 
95% CI: 2.37-4.15) than for men with affected fathers (RR 2.35; 95% CI: 2.02-2.72) 72. In an 
Italian study of 1,294 cases of PCa, risk was higher for men when the proband was younger, 
when two or more relatives were affected, and when the affected relative was a brother 73. The 
increased RR between brothers compared to fathers is too large to be accounted for solely by 
an environmental effect, and therefore, a significant genetic component is implicated. 
Researchers have consistently identified a strong genetic component of PCa 74,75.  
 
A Scandinavian study by Lichtenstein and colleagues (2000), reported that as much as 42% 
(95% CI, 29%-50%) of PCa risk can be explained by genetics 75. However, a more recent study 
by Hjelmborg and colleagues (2014) of 30,054 dizygotic and 16,680 monozygotic male twin 
pairs, within the population-based registers of Denmark, Finland, Norway and Sweden, found 
that up to 58% (95% CI, 52%-63%) of PCa risk is heritable 74. Previous studies have also 
shown that monozygotic twins have a 3- to 6-fold increased RR of developing PCa compared 
with dizygotic twins 64,68,70. This finding is supported by Hjelmborg et al. (2014) who 
concluded that monozygotic twins have a 75% higher concordance for PCa than dizygotic 
pairs. Indeed, PCa is reported to have the highest degree of genetic transmission of any cancer 
(58%), followed by breast (13.6%) and colorectal cancer (12.8%) 74,75. 
 
1.6 EARLY APPROACHES TO IDENTIFYING PROSTATE CANCER 
SUSCEPTIBILITY GENES 
For decades, researchers have utilised families with a strong inheritance pattern of PCa in an 
effort to identify genetic variants that explain this heritability. One of the earlier approaches 
was segregation analyses, which take into consideration disease clustering, mode of 
inheritance, penetrance and estimated allele frequency of potential disease associated variants 
64,76-78. The first segregation analysis was conducted in 1992, of 740 familial probands who 
underwent RP. This study suggested an inherited predisposition of PCa and concluded that 
familial clustering of disease was due to a rare, highly penetrant variant. Carriers of the variant 
were predicted to have a cumulative risk of PCa development of 88% by the age of 85 years 
compared with risk of 5% for variant non-carriers 64. Cui and colleagues (2001) evaluated 
genetic models in Australian pedigrees and modelled a rare variant that had a larger effect at 
younger ages 79. This was supported by a Finnish study of 1,546 PCa families, in which a 
particular variant had a larger effect on men younger than 66 years of age 80. Other segregation 
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studies have reached similar conclusions however, the identified variants were more common 
and only moderately penetrant 76,77. The difference in allele frequency between studies may be 
explained by the genetic heterogeneity of PCa, in which multiple genes and modes of 
inheritance can be responsible for risk even within the one family 64,76,77,79,81-83.  
 
Candidate-gene association studies have also featured strongly in the search for PCa 
susceptibility genes. These studies look for variants in genes that are involved in normal 
prostate development and/or other cancers, and compare the frequency of genetic variants in 
patients with PCa to individuals without disease. Notably, both breast and PCa tend to cluster 
within families. Therefore, given the known effect of BRCA1 and BRCA2 mutations in breast 
cancer, variants in these genes have been investigated in PCa cohorts. A study by 
Leongamornlert et al. (2012) found that deleterious BRCA1 mutations confer a RR of PCa of 
~3.75-fold (95% CI: 1.02-9.6) translating to a 8.6% cumulative risk by age 65 in their cohort 
of 913 cases aged between 36 and 86 years 84. Examination of 1,864 PCa cases identified 19 
protein-truncating mutations, three in-frame deletions and 69 missense variants in BRCA2 and 
all were significantly associated with disease risk 85. It was estimated that germline mutations 
in the BRCA2 gene confer an increased PCa RR of 8.6-fold by the age of 65 years (95% CI: 
5.1-12.6; 85). Candidate-gene association studies have yielded several other interesting 
candidate genes, including the AR. The role of the AR in PCa is well known; the AR helps 
regulate prostate cellular proliferation and differentiation (reviewed in Montgomery et al. 
(2001) 86). Plus, mutations in the AR enable PCa cells to grow even more rapidly. In fact, 
sequencing of the transcriptional network of the AR in PCa has highlighted novel mechanistic 
and functional insights in to how AR mutated cells gain a growth advantage (reviewed in Chng 
et al. (2013) 87). However, lack of replication of some candidate gene associations, including 
NBS1 88, CHEK2 89 and PALB2 90 has limited their utility and has meant that these findings are 
somewhat unreliable 88,89,91,92. 
 
Linkage analysis has proven a successful approach to gene discovery and is based on co-
segregation of variants with disease in families, comparing the genotypes between PCa affected 
individuals and their unaffected relatives. Linkage analysis is based on the premise that known 
genetic markers in close proximity to the disease variant are inherited together with the disease 
trait. Linkage studies typically search for mutations that are rare in the population, are 
moderately to highly penetrant and have a large effect size (RR >2.0) 93. Thus far, several 
candidate genes have been identified by linkage analysis and these regions are shown in Figure 
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1.4. The RNASEL (HPC1) gene at chromosome 1q25 is one of the most extensively researched 
genes identified by linkage analysis and it has been found to be associated with disease in 
families with five or more affected relatives, father to son transmission, a younger age of 
diagnosis and a higher GS 94. Other genome-wide scans for linkage in PCa families have 
implicated 5p13, the chromosomal region of AMACR 95,96. Replication studies have proven that 
overexpression of AMACR is an important marker of PCa and Zheng et al. (2002) identified 
four missense changes (M9V, G1175D, S291L and K227E) that had significantly different 
genotype frequencies between PCa cases and unaffected controls 97. The AMACR gene 
variants, M9V and D175G have been identified in the Tasmanian PCa resource used in this 
study. In fact, both were found to be significantly associated with PCa risk, and whilst this 
association remained significant, it was diminished when relatedness amongst familial PCa 
cases was considered 98. Conversely, evidence suggests that many of the other PCa genes 
identified through linkage studies, including ELAC2 at 17p11 and MSR1 at 8p21-23 99, account 
for disease in only a small subset of families, which is consistent with the concept that PCa 





















Figure 1.4 Chromosomal regions with evidence of linkage in prostate cancer pedigrees. 
Schematic of the autosomes and sex chromosomes; the regions with suggestive evidence of linkage in PCa pedigrees are shown in red (reviewed in Karayi et al. (2000) 100). 
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High-density screening panels of up to 5 million variants can now be assayed on a genome-
wide scale and studies utilising these arrays in case-control populations are known as genome-
wide association studies (GWAS) 101. The variants identified by GWAS are common in the 
population; defined as having a minor allele frequency (MAF) of >2%, and have an overall 
small effect size. Therefore, a large sample size is required to identify them in a case-control 
cohort-based study. Until recently, GWAS and fine-mapping efforts have identified more than 
100 common PCa risk variants across multi-ancestral populations, most of which were 
identified in populations of European ancestry 102-115. Schumacher and colleagues (2018) 
developed a custom high-density genotyping array designed to tag most common genetic 
variants 9. A meta-analysis combining these summary statistics and seven previous PCa GWAS 
or high-density single nucleotide polymorphism (SNP) panels (totaling 79,194 PCa cases and 
61,112 controls) identified 62 novel loci with 38 variants found within gene-rich regions. Their 
findings included a missense variant, rs1800057 (odds ratio (OR) =1.16; p=8.2x10-9) in ATM 
9, a gene that plays a central role in cell division and DNA repair, and therefore is of great 
interest in cancer 116. This latest meta-analysis brings the total number of identified common 
PCa-risk variants to over 170, which accounts for approximately 38.5% of known familial risk 
(Figure 1.5). Each common variant’s contribution to PCa is only small, with an OR for disease 
risk of less than 1.3 117. In combination, common variants have a greater overall impact on 
disease risk than individually and as a result they are often associated with complex PCa 
phenotypes 118. Overall, given that the majority of identified GWAS variants are not within 
genes and the functional role of those identified remain largely unknown, they have yet to be 
translated into useful clinical biomarkers.  
 
Common, low penetrance variants also contribute to familial disease. The International 
Consortium of Prostate Cancer Genetics (ICPCG) demonstrated that 16 of 25 common variants 
identified by GWAS are also significantly associated with risk in men with a family history, in 
their study of 9,560 familial PCa cases 119. A study by Teerlink et al. (2014) involved a larger 
analysis of the same 25 common variants in over 12,000 individuals, which also showed 
evidence that several common variants identified by GWAS contribute to both sporadic and 
familial disease 120. This familial study also led to the discovery of rare genetic variants that 
underly these common disease loci, following imputation and additional targeted NGS of a 
number of GWAS regions. These underlying risk alleles were rarer and had larger effect sizes 
than the common variants 120. Therefore, this study highlights the potential significance of rare 





















Figure 1.5 The chromosomal regions of the 170 common variants identified by genome wide association studies.  
Schematic of all of the autosomes and sex chromosomes; regions harbouring common PCa risk variants are shown in red, blue, yellow and green. Thus far, 170 common genetic 
variants associated with PCa risk have been identified by 40 GWAS (as highlighted in Schumacher et al. (2018) 9). These variants comprise 115 chromosomal regions and most 
have been identified in European populations however, some studies have included non-European individuals and those of multi-ethnicity. 
 18 
1.7 EXAMINING THE CONTRIBUTION OF RARE VARIANTS TO PROSTATE 
CANCER RISK 
Recent studies have suggested that rare variants may have a more apparent role in PCa risk 
than first thought. Rare disease variants often have a higher effect size compared to common 
variants, which predominantly have a lower impact on disease risk. This suggests that rare 
variants with high effect sizes are likely to have an overall greater contribution to disease risk 
than variants with low effect sizes, however, they are often hard to identify using standard 
genetic analysis methods, such as GWAS. (Figure 1.6). Mancuso and colleagues (2016) 
estimated that ≃ 42% (95% CI: 21%-63%) of the genetic risk of PCa is due to rare (MAF <2%) 
or very rare variants (MAF <1%), and acknowledge that this may be an underestimate 10. 
According to the 1000 Genomes project, rare variants are defined as having a MAF of less than 
2% (though MAF labels are arbitrary) and it is estimated that there are 10 million in the general 
population 121. Rare variants occur too infrequently in the population to be detected by GWAS 
designed studies, yet the recent GWAS meta-analysis by Schumacher et al. (2018) 9 was 
powered enough to detect rarer genetic variants (MAF 1-2%). They are more easily identified 
when studying families with a dense aggregation of disease, as there is reduced genetic 
complexity and rare disease-causing variants are enriched 122. 
Figure 1.6 Relation of minor allele frequencies, effect sizes and feasibility of identifying disease-
associated variants by common genetic tests.  
Rare variants often have higher effect sizes compared with common variants thus, they have a greater contribution 
to disease risk. Adapted from McCarthy et al. (2008) and Manolio et al. (2009) 123,124.  
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Massive parallel sequencing encompasses whole-exome sequencing (WES) and WGS, and 
WGS provides a detailed map of inherited common and rare variants 125. NGS facilitated the 
discovery of a rare PCa-associated variant in HOXB13 (G84E, rs138213197), underpinning a 
previously established region of linkage at chromosome 17q21-22 11. More than 200 genes in 
the 17q21-22 region were screened by sequencing genomic DNA (gDNA) from 94 cases from 
PCa families sharing linkage to 17q21-22 (one case per family). These probands are from the 
University of Michigan Prostate Cancer Genetics Project (n=54) and John Hopkins University 
(n=40) cohorts. The variant was identified in probands from only four of the 94 families, and 
following additional sequencing of family members, all 18 men with PCa in these four families 
carried the G84E variant. Additional sequencing of a larger cohort of cases and controls 
identified a significantly higher carrier frequency in men with early-onset, familial PCa (3.1%) 
than in those with late-onset, non-familial PCa (0.6%; p=2.0x10-6) 11. Overall, this study 
concluded that the novel HOXB13 G84E variant is associated with a significantly increased 
risk of familial PCa. Another study by Zuhlke and colleagues (2012) performed targeted NGS 
of the NBN gene in the same 94 familial probands sequenced by Ewing et al. (2012). One 
proband was found to have a novel heterozygous variant in exon 14 of the gene (S706X) and 
additional sequencing of male relatives showed partial segregation of the variant with PCa 126. 
However, this NBN variant was not observed among 1,859 PCa cases and 909 controls, all of 
whom were unrelated. Further to the study by Ewing et al. (2012), re-analysis of this NGS data 
also led to the identification of a novel SPOP missense variant (N296I) in a proband who had 
an early age of disease onset (43 years). Subsequent sequencing confirmed segregation with 
disease in the proband’s family 14. Interestingly, SPOP mutations are the most frequently 
acquired somatic mutations. Whilst the two later studies did not find an association between 
NBN and SPOP variants and disease in a larger PCa cohort, each study has shown the success 
of applying NGS to family pedigrees to identify rare PCa risk variants through segregation. 
Further studies using this methodology will be discussed in Chapter 3 of this thesis. 
 
1.8 GERMLINE VARIANTS DRIVE SOMATIC TUMOUR EVENTS 
As previously mentioned, several recent studies have revealed evidence to suggest that specific 
germline variants may increase the probability of a tumour acquiring a particular somatic 
mutation and together they may interact to drive carcinogenesis 127,128. Carter et al. (2017) used 
publicly available data from TCGA to identify and validate 395 genetic interactions between 
germline variants and major somatic events 128. For example, germline variants in RBFOX1 
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increased the incidence of SF3B1 somatic mutations, while 19p13.3 germline variants were 
associated with somatic mutations in PTEN. This study concluded that common germline 
variants influence how and where (in the prostate) tumours develop 129. A recent study by 
Mamidi and colleagues (2019) of 305 aggressive tumours and 52 control TCGA samples, 
observed that genes containing germline mutations also had somatic mutations which interact 
and cooperate with one another in molecular networks and biological pathways 130. The 
interaction between germline variants and somatic tumour events will be discussed in further 
Chapters 6 and 7 of this dissertation.  
 
1.9 INHERITED DETERMINANTS OF CLINICAL OUTCOMES 
The identification and characterisation of rare or novel PCa risk variants will enable a better 
understanding of both familial and sporadic disease, in particular, the genes and pathways 
involved. At present there has been relatively little focus on elucidating the role of rare genetic 
variants contributing to PCa. As a result, efforts to develop tools to improve diagnosis, provide 
informed prognostic information, and broaden treatment options beyond the traditional 
therapies of prostatectomy and hormonal and radiation therapy is being hampered. 
Pharmacological targets of the identified genes and pathways associated with PCa may provide 
disease control in the advanced, metastatic setting. For example, PARP inhibitors are effective 
in the treatment of  melanoma, breast and ovarian cancers and now metastatic PCa, in 
individuals who carry inherited or somatic rare variants in BRCA1, BRCA2, CHEK2, PALB2 
or ATM 131,132. Plus, recently, preclinical studies have demonstrated an association between 
ETS gene fusions and the effectiveness of PARP inhibitors, in which the fusion may confer 
increased sensitivity to these DNA repair protein inhibitors 133. Such advances in therapeutic 
options have been made possible as a result of understanding the genetic drivers of disease, 
including the functional role of identified genetic risk variants and somatic tumour alterations. 
Insight into PCa genetical aetiology is required to better understand causal pathways. 
 
1.10 HYPOTHESIS AND AIMS OF THIS STUDY 
Our understanding of PCa heritability has improved in recent years due to the identification of 
both common and rare variants, which explain a proportion of this risk. Rare variants are likely 
to significantly contribute to PCa heritability and Mancuso and colleagues (2016) estimate that 
as much as 42% of disease risk may be explained by rare variants 10. To date, only about 6% 
of disease risk is currently explained by known rare variants, as their identification in complex 
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disease has proven quite challenging due to their rarity in the general population. To maximise 
rare variant discovery, the study of families with an aggregation of disease is a valuable 
approach due to reduced genetic complexity and an enrichment of the rare-disease causing 
variant(s) 122. In recent years the application of NGS to familial studies has also aided in their 
discovery.  
 
Herein the following hypothesis is addressed: 
 
Rare genetic variants contribute to prostate cancer development and they can be 
identified by whole-genome sequencing individuals from families with a dense 
aggregation of disease. The identification of rare prostate cancer risk variants will 
highlight genes and pathways involved in the malignancy and elucidate some of the 
currently unexplained heritability of prostate cancer.  
 
This project will utilise the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian 
Prostate Cancer Case-Control Study (detailed in Chapter 2). The familial cohort is a rare 
collection of 52 large Tasmanian PCa families with densely aggregated disease, and consists 
of genealogical information, clinical and tumour information from pathology reports, and 
blood and tissue samples from affected men and their unaffected relatives. The population-
based case-control study consists of blood and saliva samples from PCa cases and age-matched 
controls, plus tumour samples from sporadic cases with clinical and tumour information from 
pathology reports.  
 
This hypothesis will be tested as follows: 
 
Aim 1: Identify rare genetic variants segregating with disease in selected Tasmanian 
prostate cancer families using whole-genome sequencing data from affected men and 
selected unaffected/unknown relatives.  
 
Aim 2: Examine the contribution of the identified rare variants to prostate cancer risk 
in Tasmania, using the remaining families from the Tasmanian Familial Prostate 
Cancer Cohort, and the Tasmanian Prostate Cancer Case-Control Study.  
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Aim 3: Examine the functional effect of the prioritised rare variants using gene and 
protein expression analyses, as well as determine whether they are associated with 
particular clinical characteristics.  
 
As briefly discussed above (Chapter 1.8), it is apparent that there are inherited germline 
variants underly a proportion of somatic tumour variation.   
 
Therefore, this study specifically hypothesises that: 
 
Germline variants predispose the development of some somatic tumour alterations.  
 
This project will utilise the Tasmanian Prostate Tissue Pathology Resource (described in 
Chapter 2), comprising formalin-fixed paraffin embedded (FFPE) prostate tumour tissue 
samples from the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian Prostate 
Cancer Case-Control Study.  
 
To test this hypothesis, I aim to: 
Aim 4: Examine the occurrence of shared somatic tumour alterations, including copy 
number changes and gene fusions, in Tasmanian prostate cancer families, and, where 




CHAPTER 2 :  METHODS 
 
2.1 THE TASMANIAN FAMILIAL PROSTATE CANCER STUDY 
2.1.1 Ethics approval 
Ethics approval was obtained from the Human Research Ethics Committee Tasmania, Australia 
(H0017040) and this study was conducted in accordance with the Australian National 
Statement Ethical Conduct in Human Research 2007 (updated 2018) and the Australian Code 
for the Responsible Conduct of Research (2018). Written informed consent was obtained from 
all participating individuals. For deceased cases a part of the Tasmanian Familial Prostate 
Cancer Cohort, a waiver of consent was obtained to collect prostate tissue specimens. 
 
2.1.2 The Tasmanian Familial Prostate Cancer Cohort 
This resource is a rare collection of 52 prostate cancer (PCa) families from the founder 
population of Tasmania. The number of affected men in these families ranges from five to over 
140 and include up to five affected brothers and multiple father/son and uncle/nephew pairs. 
DNA samples from blood or saliva have been collected for 251 affected men and 463 
unaffected/unknown male and female relatives. Families selected for whole-genome 
sequencing (WGS) analysis include; PcTas3, PcTas4, PcTas12, PcTas22 and PcTas72 (see 
Table 2.1). PcTas3, 4 and 22 will be discussed in more detail in Chapter 3, PcTas12 in Chapter 
4 and PcTas72 in Chapter 5. The PcTas9 family was chosen for assessment of somatic tumour 
variation and is presented in Chapters 6 and 7 (Table 2.1). Herein, these families are referred 
to as PcTas families, with each family assigned a number (PC1; prostate cancer family 1) and 
each individual a unique identification number (i.e. PC1-1; individual 1 from prostate cancer 
family 1). All familial PCa cases are confirmed by the Tasmanian Cancer Registry (TCR) and 






















PcTas33 14 2 8 14 
PcTas43 25 4 9 45 
PcTas124 35 4 11 36 
PcTas223 89 5 27 70 
PcTas725 23 4 12 52 
PcTas96,7 58 4 30 75 
*The extended pedigrees of the Tasmanian PCa families studied in this thesis 
are shown in the chapters stated3-7. 
 
 
2.1.3 The Tasmanian Prostate Cancer Case-Control Study 
The Tasmanian Prostate Cancer Case-Control Study is a population-based resource, which 
includes DNA from blood or saliva samples from 498 PCa cases and 355 age-matched controls. 
Cases were identified from the TCR and were recruited if they were diagnosed under the age 
of 75 between the years of 1996 and 2005. Controls were selected at random from the 
Tasmanian electoral roll and matched by five-year age groups to the cases. Controls are 
annually checked against the TCR for subsequent PCa diagnosis, hence the number of PCa 
cases have increased and controls decreased. Herein, each sample has its own unique 
identification number (i.e. DVA1; individual 1 in the case-control resource) and are often 
referred to as Tasmanian sporadic cases and controls where required. Following initial variant 
prioritisation, 94 of these controls were randomly chosen to screen for prioritised rare variants 
to ensure they were not enriched in the Tasmanian population.  
 
2.1.4 Extraction of germline DNA from blood and saliva 
For participants in the Tasmanian Familial Prostate Cancer Study cohorts, including the 
familial and case-control resources, genetic material for DNA was extracted from blood using 
the Nucleon BACC3 Kit (GE Healthcare) and from saliva using the Oragene DNA Kit (DNA 
Genotek), according to the manufacturers’ directions. Quality and quantification of DNA was 
performed using the Nanodrop® ND-1000 UV-vis spectrophotometer (Nanodrop® 
Technologies). 
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2.1.5 The Tasmanian Prostate Tissue Pathology Resource 
The Tasmanian Prostate Tissue Pathology Resource comprises 76 familial (PC) and 22 
sporadic (DVA) formalin-fixed paraffin embedded (FFPE) prostate tumours. Clinical 
information including Gleason score (GS), age at diagnosis, and diagnoses and treatment 
history were obtained from pathology reports corresponding to the FFPE tumour blocks 
retrieved for the functional analyses of this study. If reports were vast or unattainable, Dr Shaun 
Donovan (Pathologist, Hobart Pathology, AUS) re-graded the tumour blocks using the 
contemporary Gleason scoring system, as described in Chapter 1.3.2. 
 
2.1.6 The Tasmanian Prostate Tissue Needle Biopsy Resource 
Several prostate needle biopsies were also available for use in this study. These samples were 
collected by a urologist whilst patients underwent a prostate resection. The radical 
prostatectomy was sent to pathology for diagnosis and the biopsies for research purposes 
(stored in RNAlater). These biopsies consist of cores from the right and left lobe of the prostate, 
and are herein referred to as PT samples. Ethics approval was obtained from the Human 
Research Ethics Committee Tasmania, Australia (H0011544) for use of these biopsies in this 
study.  
 
2.1.7 Extraction of genetic material from prostate tumour samples 
FFPE prostate tissue blocks were sectioned to 8µm, dewaxed and rehydrated using a standard 
xylene-ethanol deparaffinisation protocol. Malignant and benign glands were marked on 
haematoxylin and eosin (H&E) stained tissue sections by a pathologist. Marked malignant and 
benign regions were macro-dissected separately for both DNA and RNA. DNA was extracted 
using the QIAamp DNA FFPE Tissue Kit (QIAGEN), according to the manufacturer’s 
instructions and eluted in 50µL of ATE Buffer. DNA was quantified using the Nanodrop® 
ND-1000 UV-vis spectrophotometer (Nanodrop® Technologies). RNA was extracted using 
the RecoverAll Total Nucleic Acid Isolation Kit (ThermoFisher Scientific), according to the 
manufacturer’s instructions and eluted in 30µL of dH2O. RNA quality (% of sample >200nt in 
length) and quantity (ng/µL) was assessed using the 2100 Bioanalzyer (Agilent Technologies) 
and/or the 4200 Tapestation (Agilent Technologies), with their respective software. The 
SuperScriptTM VILOTM cDNA Synthesis Kit (Invitrogen) was used for cDNA synthesis, 
according to the manufacturer’s instructions, using the thermal cycling conditions in Appendix 
1. For the needle biopsy samples in RNAlater, small sections of tissue were transferred to a 
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new tube for extraction of genetic material using the protocols described above. The right and 
left lobe biopsies were extracted separately.  
 
2.2 PCR; PRIMER DESIGN, QUANTIFICATION AND VISUALISATION 
All primers used for amplification of gDNA, and FFPE DNA and RNA were designed using 
Primer3 134,135 or Primer-BLAST 136 and were synthesised by Sigma-Aldrich or Integrated 
DNA Technologies. Veriti 96 thermal cyclers from Life Technologies were used for all PCR 
amplifications, unless otherwise specified in Appendix 1. Primer pairs and their optimal 
annealing temperatures are shown in Appendix 2. PCR products were visualised on 2% agarose 
gel (80 volts for 30 minutes) for length and mass quantification. The agarose gels were 
visualised and photographed with the ChemiDoc XRS+ System (BioRad). PCR products for 
Sanger sequencing were quantified using the Nanodrop® ND-1000 UV-vis spectrophotometer 
(Nanodrop® Technologies). 
 
2.3 QUANTIFICATION OF ABSOLUTE GENE EXPRESSION BY RT-QPCR 
SYBR green real-time quantitative PCR (RT-qPCR) assays were used to determine expression 
of the genes of interest and two housekeeping genes, b-Actin and GAPDH. RT-qPCR primers 
were designed to the most commonly transcribed isoform in the prostate (as per GTEx Analysis 
Release V7 (dbGaP Accession phs000424.v7.p2; https://gtexportal.org/home/)) 137 and are 
displayed in Appendix 3. Amplification was performed on 50ng FFPE cDNA, in triplicate, as 
per the conditions in Appendix 1. Quantitation and melt data was visualised using the Rotor 
Gene 6000 Series Software 1.7 or the QuantStudioTM Design and Analysis Software v1.5 and 
each RT-qPCR run was conducted with a DNA-free NTC.  
 
Standard curves were generated for the genes of interest and the two housekeepers to determine 
PCR efficiency and normalise absolute gene expression of the genes of interest. PCR products 
were pooled and visualised by gel electrophoresis, as described in Chapter 3.2.1.2. Bands were 
excised (SafeImager, Invitrogen) and purified using the QIAquick Gel Extraction Kit 
(QIAGEN). Serial dilutions of this product were amplified by RT-qPCR and standard curves 
plotted (Appendix 4). The copy number of the gene of interest and the two housekeeping genes 
was determined using the log equation from the line of best fit. The absolute gene expression 
was determined by normalising the copy number of the genes of interest to the geometric mean 
of the copy number of GAPDH and b-Actin. 
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The paired Student’s t-test was used to compare absolute gene expression between malignant 
and adjacent benign cells. The unpaired Student’s t-test was used to compare absolute 
expression in the malignant glands of variant carriers versus non-carriers, and in the benign 
glands of variant carriers versus non-carriers. In Chapters 6 and 7, the unpaired Student’s t-test 
was used to compare absolute gene expression in malignant glands of PcTas9 tumours versus 
non-PcTas9 tumours, and likewise in benign glands. P values <0.05 were considered to be 
statistically significant, with fold changes presented in box plot format using R studio, version 
0.99.887. 
 
2.4 QUANTIFICATION OF PROTEIN EXPRESSION BY 
IMMUNOHISTOCHEMISTRY 
Following dewaxing, tissue sections (3.5µm) were pre-treated with Target Retrieval Solution 
(Dako), followed by inactivation of endogenous peroxidases using 3% hydrogen peroxidase 
(Sigma-Aldrich). Non-specific staining was blocked using Protein Block (Dako). Sections 
were incubated with primary antibody (Appendix 5) in a humidified chamber for one hour, 
followed by a 30-minute incubation with a HRP-Labelled Polymer (Dako). Protein staining 
was visualised with 3-3’ diaminobenzidine (DAB+) for 10 minutes, and the sections were 
counterstained using Mayer’s haematoxylin, cleared and cover slipped using the Dako 
Automated Coverslipper.  
 
The immuno-stained sections were scored by a pathologist (Drs Donovan and Malley; Hobart 
Pathology) blinded to variant carrier status. Staining was scored as none, weak, moderate or 
strong, depending on the most common staining intensity in the entire tissue section. 
Immunostaining was assessed using a quasi-continuous score, created by multiplying each 
intensity level (0 for no stain, 1 for weak stain, 2 for moderate stain, and 3 for strong stain) by 
the corresponding percentage of positive cells. As benign prostate tissue was also present in 
some sections, immunostaining was assessed for both malignant and benign glands separately 
138. 
 
The paired Student’s t-test was used to compare protein expression between malignant and 
adjacent benign cells. Unpaired Student’s t-tests were used to compare protein expression in 
the malignant cells of variant carriers versus non-carriers, and in the benign cells of carriers 
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versus non-carriers. P values <0.05 were considered to be statistically significant. Images were 
taken using the Leica DM2500 microscope with the Leica Applicate Suite software, version 




CHAPTER 3 :  PRIORITISATION, VALIDATION, 




Gene discovery has proven useful for attaining a greater understanding of disease and aiding 
in the identification of new targets for therapy. Studies of families with familial 
hypercholesteraemia have not only identified genes and pathways associated with increased 
lipid levels in cardiovascular disease, but have also facilitated the development of statins 139,140. 
The recent emergence of next-generation sequencing (NGS) has proven very successful, 
particularly the combined use of family cohorts in the common disease setting. Such studies 
have highlighted the contribution of rare variants to common disease 141. NGS-based studies 
of families with early-onset Alzheimer’s disease have each identified unique rare variants in 
NOTCH3, SORL1 and TREM2, all associated with disease risk in their respective cohorts 142-
144. The proven role of rare variants in complex disease, including breast and ovarian cancers, 
suggest that such discoveries would also be highly valuable in prostate cancer (PCa). 
 
Cirulli et al. (2010) highlighted that an agnostic NGS approach when applied to families can 
be more successful than a hypothesis driven, targeted sequencing approach, but there are very 
few studies published using this method 122. To date, while not truly genome-wide, there have 
only been two whole-exome sequencing (WES) studies of familial PCa. One of the first studies 
was performed at the Fred Hutchinson Cancer Research Center (FHCRC), which included 91 
individuals from 19 PCa families with an aggressive or early-onset phenotype 12. A total of 130 
rare variants identified from the WES data were then genotyped in an independent set of 270 
PCa families, which included 819 cases and 496 unaffected relatives. Two missense variants 
in BTNL2 (D336N, G454C) were identified in 1.5% (D336N; p=0.0032) and 1.2% (G454C; 
p=0.0070) of affected men, but no unaffected men were observed to carry either variant. 
Further genotyping of the variants in a population-based case-control cohort (n=1,155 PCa 
cases and 1,060 age-matched controls) suggested both variants were associated with an 
elevated risk of PCa (D336N: Odds ratio (OR)=2.7, p=0.010; G454C: OR=2.5, p=0.019) 12.  
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More recently, Karyadi and colleagues (2017) performed a second analysis of WES data 
generated from the FHCRC familial resource, including 160 PCa cases from 75 families. 
Analysis took into account the genetic heterogeneity and incomplete penetrance of PCa 
susceptibility alleles and  identified 341 candidate risk variants 13. Analysis of these variants in 
the FHCRC population-based, case-control resource identified nine variants significantly 
associated with an increased risk of PCa. In a second analysis of an independent case-control 
cohort (n=7,121), there was evidence for association with risk for a rare variant in TANGO2 
(S17X: OR=1.39, p=0.065) and the established HOXB13 variant (G84E: OR=3.78, p=0.0003) 
13. A meta-analysis of the two case-control studies identified two additional variants with 
suggestive evidence for an association with PCa risk, OR5H14 (M59V: OR=1.39, p=0.026) 
and CHAD (A342D: OR=1.53, p=0.046). Similar to the original HOXB13 study, these WES 
studies highlighted novel rare variants that segregated with PCa in multiple high-risk families, 
but were also found to contribute to disease risk in the general population 13. Furthermore, 
several studies have since replicated the HOXB13 finding in Caucasian familial and case-
control populations and estimate the variant to be associated with a 4- to 8-fold increase in PCa 
risk, as well as with early-onset disease 102,145-150. Such studies highlight the success in 
combining familial datasets and NGS technologies to discover rare variants associated with 
PCa risk. 
 
Although NGS studies of PCa families have revealed that rare PCa risk variants exist, studies 
are few and far between 11-13. Studies by Ewing et al. (2012), FitzGerald et al. (2013) and 
Karyadi et al. (2017) assessed the contribution of these rare variants to other PCa families, as 
well as case-control cohorts and found significant associations with PCa risk in their cohorts. 
However, follow-up studies assessing the contribution of the rare variants to other populations 
is non-existent, with the exception of the HOXB13 G84E variant 11,151-156. 
 
Here, I sought to address the hypothesis that rare genetic variants contribute to PCa risk. This 
chapter will describe the application of whole-genome sequencing (WGS) to our rare 
Tasmanian Familial Prostate Cancer Study cohorts, with the aim of identifying rare PCa-risk 
variants. The identification of disease-associated rare variants should be facilitated by the fact 
that Tasmania has an isolated population with reduced genetic heterogeneity 157. Thus, the 
anticipated enrichment of rare variants in our Tasmanian PCa families is likely to reduce 
genetic complexity and increase statistical power for the identification of risk genes 122. Herein, 
five Tasmanian PCa families were selected for WGS based on dense disease aggregation and 
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availability of DNA samples; PcTas3, 4 and 22 are discussed in this chapter, whilst PcTas12 
is discussed in Chapter 4 and PcTas72 in Chapter 5. 
 
3.2 METHODS 
3.2.1 Whole-genome sequencing analysis  
Thirty-three individuals from five Tasmanian PCa families, PcTas3, 4, 12, 22 and 72 (described 
in Chapter 2.1.2), including 23 PCa cases and 10 unaffected relatives, were selected for WGS. 
Individuals were prioritised for WGS based on the following pedigree features; affected first-
degree relatives from densely clustered affected regions of the pedigree; second-degree 
affected relatives; early-onset and/or aggressive disease; and, where possible, unaffected, older, 
first-degree male relatives as a potential comparative genome from the same family, and 
availability of funding. Distantly related, affected family members were also included, as these 
cases will share less of the main pedigrees’ genome, perhaps revealing the shared disease-
causing variants. WGS was performed for eight controls from the Tasmanian Prostate Cancer 
Case-Control Study (described in Chapter 2.1.3) to provide us with rare variant sequence data 
from unaffected age-matched members of the Tasmanian population. WGS was performed at 
the Kinghorn Centre for Clinical Genomics, Australia, on the Illumina HiSeq XTM Ten 
platform, using the TruSeq Nano library preparation. 
 
3.2.2 Whole-genome sequencing analysis pipeline  
Sequence data analysis was undertaken using the Variant Analysis of Sequenced Pedigrees 
(VASP) analytical pipeline, developed specifically to detect disease causing variants in 
sequenced pedigrees 3,4. VASP integrates information from each pedigree member, and 
therefore describes the likely inheritance pattern of shared variants, whilst incorporating 
external annotation of these variants, including population frequency information from Exome 
Aggregation Consortium (ExAC; non-Finnish European, non-TCGA (The Cancer Genome 
Atlas) population) 158, as well as SIFT 159, PolyPhen2 160 and CADD (Combined Annotation 
Dependent Depletion; model v1.3) 161 scores for estimating the functional effect of missense 
mutations. Individual samples were analysed independently, followed by a pedigree-wide 
variation analysis, with all work run in parallel at the National Computational Infrastructure on 
the Raijin cluster. Sequence data were aligned to the human reference genome (hg19) using 
BWA, and BAM files and variants were called using either SAMtools/BCFtools or GATK best 
practices. Variants were annotated using Ensembl Variant Effect Predictor 162 and overlapped 
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with Ensembl canonical transcripts and splice site variants; defined as 10bp either side of a 
coding exon. VASP can accommodate pedigrees of any size and will report disease inheritance 
patterns and gene phasing information when an individual and at least one parent is sequenced. 
Consistent with our hypothesis each family was analysed separately, although cross referencing 
of prioritised rare variants was undertaken. The entirety of this work was performed by Dr Matt 
Field, James Cook University (AUS).  
 
Variant reports for single nucleotide variants and insertions/deletions (indels) were generated 
when variants were detected in at least one pedigree member. Variants and indels were 
categorised as either novel, rare or common, or no frequency data available. Prioritisation was 
firstly guided by the frequency of the variant (minor allele frequency; MAF) in a publicly 
available population database; MAF <2% in ExAC 158 Secondly, whether the variant 
segregated with disease in the sequenced individuals, i.e. most, if not all PCa cases carried the 
variant. And thirdly, in silico functional prediction tools, such as SIFT, PolyPhen2 and CADD. 
SIFT predicts whether an amino acid substitution affects protein function based on sequence 
homology and the physical properties of amino acids 159 (pipeline illustrated in Figure 3.1). 
Each variant is appraised qualitatively, as tolerated (score of 0.05-1.0) and deleterious (score 
of 0.0-0.05) 159. Polyphen2 predicts the possible impact of an amino acid substitution on the 
structure and function of a human protein, with the prediction based on a number of features 
comprising the sequence, phylogenetic and structural information characterising the 
substitution 160. Each variant is appraised qualitatively, as benign (score of 0.0-0.15), possibly 
damaging (score of 0.15-0.85) and probably damaging (score of 0.85-1.0) 160. CADD predicts 
the deleteriousness of single nucleotide polymorphism (SNP) variants and insertion/deletion 
variants by integrating multiple annotations including conservation and functional information 
into one metric 161. CADD provides a ranking rather than a prediction or default cut-off, with 
higher scores more likely to be deleterious. A CADD score above 30 ranks the variant in the 
top 0.1% of deleterious variants in the human genome; a CADD of 20-30 in the top 1% and 
10-20 in the top 10% 161. Finally, the carrier frequency of these prioritised variants were 
determined in the eight controls and a literature search was undertaken (Figure 3.1). ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) 163 and PubMed were used to determine if the variant 
has been associated with a particular disease, identify whether the gene/proteins function is 
biologically relevant to prostate or cancer biology and finally, whether the gene has been 
associated with any type of cancer. Throughout the relevant tables, ClinVar annotations are 
reported, including what condition the variant has been associated with, as well as 
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interpretation of the variant. The interpretation of the variant is based on aggregating data from 
submitters 163.  
 
3.2.3 Validation and segregation of prioritised variants  
Variants identified by WGS were validated in the original sequenced individuals by PCR and 
Sanger sequencing. Upon validation, close relatives were also genotyped by Sanger sequencing 
to determine segregation of the particular variant with PCa (Figure 3.1). If gDNA was 
unavailable, DNA from formalin-fixed paraffin embedded (FFPE) prostate tissue (where 
available) was sequenced to determine carrier status. 10ng/µL of genomic DNA (or FFPE 
DNA) was amplified, according to the conditions in Appendix 1. A no template control (NTC) 
was included with each PCR run. PCR products were visualised by gel electrophoresis and 
then purified prior to sequencing by paramagnetic bead purification, using AGENCOURT 
AMPure XP beads (Beckman Coulter), according to the manufacturer’s instructions. The Big 
Dye Terminator (BDT) v3.1 Cycle Sequencing Kit (Life Technologies) was used to sequence 
the purified product, as per the conditions in Appendix 1. The BDT DNA fragments were 
purified using the AGENCOURT CleanSeq beads (Beckman Coulter), according to the 
manufacturer’s instructions. Purified products were sequenced on the ABI 3500 Genetic 
Analyser (Applied Biosystems). Sanger sequencing results from the 3500 Series Data 
Collection Software 3 were analysed using the Sequencher software package, version 4.10.1 
(Gene Codes Corporation).  
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Following WGS, rare variants (ExAC MAF <2%) that segregated with PCa and were predicted to have a functional consequence by SIFT, PolyPhen2 and CADD were  
prioritised. Variants were screened in eight Tasmanian controls and variants in none or one of these controls were prioritised further. ClinVar 163 and PubMed were used to 
determine if the variant was associated with a particular disease, identify whether the gene/proteins function is biologically relevant to prostate or cancer biology and finally, 
whether the gene has been associated with any type of cancer. These prioritised variants were validated by Sanger sequencing of the individuals who were WGS and then 
determined if they segregated with disease in the founder families. Next, the rare segregating variants were screened in an additional 94 Tasmanian control samples, followed 
by the entire Tasmanian Familial Prostate Cancer Cohort and the Tasmanian Prostate Cancer Case-Control Study . ExAC: ExAC, non-Finnish European, non-The Cancer 
Genome Atlas database; WGS; Whole-genome sequenced; CADD: Combined Annotation Dependent Depletion; Control: Control from the Tasmanian Prostate Cancer Case-
Control Study.  
Figure 3.1 Pipeline for prioritisation of rare variants.  
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3.2.4 TaqMan genotyping of the Tasmanian Familial Prostate Cancer Study cohorts 
Following validation and segregation analyses, rare variants were screened in an additional 94 
Tasmanian control samples to ensure that they are not specifically enriched in Tasmania 
(described in Chapter 2.1.3). Variants with a carrier frequency in the 94 controls less than twice 
as high as the ExAC database MAF were considered not enriched. This cut-off is reasonably 
high given that these 94 controls are a small random representation of the larger control 
resource (n=355). If not enriched, custom TaqMan SNP (single nucleotide polymorphism) 
genotyping assays were used to genotype the remaining 51 PcTas families and the Tasmanian 
Prostate Cancer Case-Control Study for the prioritised variants (Appendix 6; Applied 
Biosystems). This was performed on all available gDNA samples, according to the conditions 
in Appendix 1. Analysis was conducted using the LightCycler® II 480 software, version 
1.5.1.62 SP2, which was used to determine the genotype of each sample. Heterozygous 
individuals were confirmed by Sanger sequencing, as described above (Chapter 3.2.3).  
 
3.2.5 Statistical analysis of genotyping data  
Genotype data were analysed using MQLS 2, an association analysis that maximises power by 
performing tests of association in the combined familial and case-control datasets, while taking 
into account relatedness of individuals. MQLS can distinguish between unaffected controls and 
controls of unknown phenotype (unaffected male yet to reach average age of PCa diagnosis) 
and incorporates phenotype data about relatives who have missing genotype data for the 
particular variant being tested 2. MQLS uses variance components to examine the significance 
of association for related individuals, and when the disease status is known for first-degree 
relatives of cases, MQLS obtains more power by giving increased weighting to those individuals 
with closely related disease-carrying relatives 2. It is computationally feasible in large 
pedigrees and thus, here, a positive association (OR) with a p-value <0.05 was considered to 
be statistically significant, and therefore the variant strongly associated with PCa in the 
Tasmanian cohort. This analysis was performed by our collaborator, Dr Russell Thomson, 
Western Sydney University (AUS). 
 
SOLAR Eclipse version 8.1.1 was also used to determine whether the variant of interest was 
enriched in our Tasmanian resource compared to the ExAC database, as well as comparing 
carrier status within the Tasmanian resource. This analysis was achieved by calculating a 
Maximum Likelihood Estimate (MLE), which is synonymous with allele frequency of each 
genotype in each group. These MLEs were then compared between groups using a Wald test, 
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generating a chi-square test with one degree of freedom, with a p-value <0.05 considered 
statistically significant. This analysis determines whether the variant of interest is enriched in 
Group A versus Group B, it does not weight by PCa case status. This analysis was performed 
by Dr Nicholas Blackburn, University of Texas Rio Grande Valley (USA). 
 
3.3 RESULTS 
3.3.1 Quality check and annotation of variants  
All genomes passed standard quality and coverage assessment (minimum cut-off of 20X 
coverage). The total number of variants  that passed quality assessment in each family are 
shown in Table 3.1. The total number of rare variants (MAF <2%), very rare variants (MAF 
<1%) and novel variants are also presented, with these cut-offs as per ExAC annotations 158. 
Briefly, Illumina HiSeq Paired-End WGS data were aligned to the human reference genome 
(hg19) to identify the genomic variants that differed from the reference genome. Variants were 
called if >10% of the sequence reads at each base pair differed from the reference. The variants 
were then filtered under a set of pre-defined criteria to eliminate false-positives and were then 
annotated using VASP 3,4. The total number of variants identified in all five Tasmanian families 
is presented below (Table 3.1). PcTas3, 4 and 22 analysis is presented in this chapter, whilst 















Table 3.1 The total number of variants that passed quality assessment in each of the families 
















PcTas3 5/0 178,311 103,675 73,315 52,159 
PcTas4 4/1 167,774 147,455 107,195 14,554 
PcTas12 2/1 116,381 66,744 47,952 35,722 
PcTas22 Main* 5/1 332,047 191,172 109,480 70,497 
PcTas22 Sub* 4/2 414,020 160,496 113,512 83,235 
PcTas72 4/4 238,076 139,136 99,520 68,437 
WGS; whole-genome sequenced: MAF; Minor allele frequency as per the ExAC, non-Finnish European, 
non-The Cancer Genome Atlas database: *Due to the number of individuals sequenced in PcTas22 and the 
magnitude of data available, two branches of the family were analysed separately as ‘sub’ and ‘main’ 
pedigree. 
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3.3.2 Rare variant prioritisation in PcTas3 
Tasmanian PCa family PcTas3 comprises 14 known cases across two generations (Figure 3.2). 
DNA was available for eight of these cases and five were successfully WGS (Figure 3.3). Men 
selected for sequencing represent three affected branches of the family and include two affected 
brother pairs (one brother with a relatively younger age of diagnosis (54 years)), plus a 
second/third cousin (Table 3.2). Variants in three, four or five out of the five PCa cases were 
prioritised. It is likely that such rare variants are not completely penetrant therefore, it is 
possible that not all PCa cases may carry the risk variant. Variants that were shared by the 




















Figure 3.2 PcTas3 pedigree. 
PcTas3 pedigree, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability 
of DNA from cases and their unaffected relatives, which is represented by red arrows. The disease status for earlier 
generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals 
have been marked as affected in the pedigrees. This pedigree is included to illustrate the size of the pedigree only, please 
refer to Figure 3.3-3.5 for individual annotations. 
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PC3-01 Male Affected 79 MD - 
PC3-02 Male Affected 75 WD - 
PC3-08 Male Affected 69 MD 6 (3+3) 
PC3-31 Male Affected 54 - 5 (3+2) 
PC3-44 Male Affected 60 Unknown* Unknown* 
1Tumour grade obtained from pathology report; 2Contemporary Gleason Score from FFPE tissue block 
chosen for macrodissection of nucleic acids and IHC; WD: well differentiated; MD: moderately 
differentiated; - : information not present in original pathology report; *Diagnosed interstate. 
Figure 3.3 A condensed PcTas3 pedigree showing individuals chosen for whole-genome 
sequencing.  
Individuals chosen for WGS are indicated by red arrows, in this case, five PCa cases were chosen.  
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Three rare variants and one novel variant were prioritised in this family (Table 3.3). These rare 
variants have not been previously reported as associated with cancer, however the genes they 
reside in are biologically relevant to cell development, growth and proliferation 116. Each 
variant was validated by Sanger sequencing. Following Sanger sequencing of an additional two 
PCa cases and 13 relatives, only the CCL26 and P2RX7 variants were found to segregate with 
disease in the extended family members. Figure 3.4 shows the identification of four additional 
CCL26 variant carriers in this family; an unaffected male and three females. Nine additional 
P2RX7 carriers were identified in PcTas3, including a PCa case, two unaffected males and six 
females (Figure 3.5). The unaffected male, PC3-51, who carriers both of these variants died at 
age 90 and was affected with another cancer. At 50 years of age, PC3-48, an unaffected P2RX7 
carrier, is yet to reach the average age of PCa diagnosis (~65 years of age). The NDE1 variant 
did not appear to segregate with disease. The variant in CLDN4 validated, but only four 




Table 3.3 Rare variants prioritised in the PcTas3 pedigree following whole-genome sequencing of five affected men. 
 




























CCL26 rs41463245 7:75,401,263 0.86 4 out of 5 34 
C > T; 
W44X 
0 out of 8 
Not reported 
Yes Yes 
P2RX7 rs28360447 12:121,600,238 1.27 4 out of 5 32 
G > A; 
G150R 
0 out of 8 
Not reported 
Yes Yes 
NDE1 rs113493697 16:15,785,049 0.88 5 out of 5 23.3 
C > T; 
T191I 





CLDN4 Novel 7:73,246,102 N/A 3 out of 5 20.8 
A > G; 
K191E 
0 out of 8 
N/A 
Yes No 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; N/A: Not found in ExAC or ClinVar; WGS: Whole-genome 
sequenced; 2CADD: Combined Annotation Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 







Figure 3.4 CCL26 variant carriers in PcTas3. 
This is a condensed pedigree of PcTas3 comprising all CCL26 variant carriers (shown in yellow) and their 
relationship. Non-variant carrier family members are shown in grey and the five individuals who were WGS are 
indicated by red arrows.  
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Figure 3.5 P2RX7 variant carriers in PcTas3. 
This is a condensed pedigree of PcTas3 comprising all P2RX7 variant carriers (shown in yellow) and their 
relationship. Non-variant carrier family members are shown in grey and the individuals who were WGS are 
indicated by red arrows.  
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3.3.3 Rare variant prioritisation in PcTas4 
PcTas4 is comprised of 25 PCa cases across four generations (Figure 3.6). A total of five 
individuals were successfully WGS, including an affected brother pair, an affected 
uncle/nephew pair (second cousins of the affected brother pair) and an unaffected cousin of 
these men (Table 3.4 and Figure 3.7). This older unaffected male (76 years of age) was chosen 
as a ‘control’ to enable higher prioritisation of variants only found in his affected relatives. 
However, given that disease-causing variants often exhibit incomplete penetrance, variants 





Figure 3.6 PcTas4 pedigree. 
PcTas4 pedigree, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability of DNA from cases and their unaffected relatives, which is represented by red 
arrows. The disease status for earlier generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals have been marked as affected in the 
pedigrees. This pedigree is included to illustrate the size of the pedigree only, please refer to Figure 3.7 and 3.8 for individual annotations. 
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PC4-01 Male Affected 60 - 6 (3+3) 
PC4-02 Male Affected 73 - 6 (3+3) 
PC4-03 Male Affected 80 M/PD 7 (4+3) 
PC4-95 Male Affected 66 PD 9 (4+5) 
PC4-161 Male Unaffected 76* N/A N/A 
*Unaffected, age at WGS; 1Tumour grade obtained from pathology report; 2Gleason Score obtained from 
pathology report; M/PD: moderately-poorly differentiated; PD: poorly differentiated; -: information not 


















Figure 3.7 A condensed PcTas4 pedigree showing individuals chosen for whole-genome 
sequencing. 
Individuals chosen for WGS are indicated by red arrows, in this case, four PCa cases and one unaffected 
male relative were chosen.  
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Five rare variants and one novel variant were prioritised in this family for follow-up studies 
(Table 3.5). Of these variants, variants in KMT2C and RHPN2 did not validate by Sanger 
sequencing, indicating potential false positives. Subsequent genotyping of additional family 
members, including a further six PCa cases and 17 relatives, suggested that only the ATM 
variant segregated with PCa (Figure 3.8). An additional eight ATM variant carriers were 
identified, including three PCa cases. Unaffected men who carried the ATM variant are only 
now approaching the average age of PCa diagnosis. For example, the eldest unaffected man is 
66 years of age (PC4-94) and the youngest just 40 years old (PC4-125). The variants in IRS1, 
SSH3 and CRIP2 did not segregate with disease. An additional four, two and three variant 
carriers were identified, respectively, however they were present more often in unaffected men, 




Table 3.5 Rare variants prioritised in the PcTas4 pedigree following whole-genome sequencing of four affected men and one older unaffected man. 
 
 





























ATM rs1800057 11:10,814,356 1.69 3 out of 4/ 0 out of 1 27.9 
C > G; 
P1054R 





SSH3 rs373641394 11:67,072,456 0.01 3 out of 4/ 0 out of 1 17.02 
G > A; 
R106K 
0 out of 8 
Not reported 
Yes No 
IRS1 rs41265094 2:227,661,003 0.82 2 out of 4/ 0 out of 1 21.6 
C > G; 
G818R 






CRIP2 rs375691223 14:105,945,992 0.01 2 out of 4/ 0 out of 1 8.02 
C > T; 
Splice 
0 out of 8 
Not reported 
Yes No 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; N/A: Not found in ExAC or ClinVar; WGS: Whole-genome 
sequenced; 2CADD: Combined Annotation Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 
































KMT2C rs76844681 7:151,932,990 0.99 2 out of 4/ 0 out of 1 35 
C > T; 
R894Q 




RHPN2 Novel 19:15,564,233 N/A 2 out of 4/ 0 out of 1 28.8 
A > G; 
V100A 
0 out of 8 
N/A 
No N/A 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; N/A: Not found in ExAC or ClinVar; WGS: Whole-genome 
sequenced; 2CADD: Combined Annotation Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 
3Associated condition: Interpretation of variant 163. 
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Figure 3.8 ATM variant carriers in PcTas4.  
This is a condensed pedigree of PcTas4 comprising all ATM variant carriers (shown in yellow) and their relationship.  
Non-variant carrier family members are shown in grey and the individuals who were WGS are indicated by red arrows.  
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3.3.4 Rare variant prioritisation in PcTas22 
Family PcTas22 is the largest PCa family in the Tasmanian Familial Prostate Cancer Cohort, 
comprising a total of 89 cases of PCa spanning five generations (Figure 3.9). Eleven individuals 
were successfully WGS in this family, comprising two separate branches (Figure 3.10). Due to 
the number of individuals sequenced, and the magnitude of data available these two branches 







Figure 3.9 PcTas22 pedigree. 
PcTas22 pedigree, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability of DNA from cases and their unaffected relatives, which is represented by 
red arrows. The disease status for earlier generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals have been marked as affected in 










Figure 3.10 A condensed PcTas22 pedigree showing individuals from both branches of the family 
(sub and main pedigree) chosen for whole-genome sequencing. 
Individuals chosen for WGS from the sub pedigree are indicated by red arrows, in this case, five PCa cases and 
two unaffected male relatives were chosen. Individuals chosen for WGS from the main pedigree are indicated by 
green arrows, in this case, four PCa cases and one unaffected male relative were chosen.  
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3.3.5 Rare variant prioritisation in the PcTas22 sub pedigree 
Individuals sequenced from the PcTas22 sub pedigree included an affected brother pair and 
their unaffected older brother (died at 76 years of age), another affected brother pair (first 
cousins of the other brother pair) and an unaffected son (56 years of age) of one of these 
affected men (Table 3.6); these are indicated by red arrows in Figure 3.10. Rare variants present 
in all four affected men and not in the unaffected older brother were prioritised. Variants 
present in the four affected men and the unaffected son were also considered for further study, 
given the son is yet to reach the average age of PCa onset (~65 years of age). 
 
 
Table 3.6 Clinicopathological characteristics of individuals from the PcTas22 sub pedigree chosen 













PC22-02 Male Affected 64 MD 6 (3+3) 
PC22-03 Male Affected 62 WD - 
PC22-21 Male Affected 69 - 6 (3+3) 
PC22-274 Male Unaffected 56* N/A N/A 
PC22-387 Male Affected 83 - 8 (4+4) 
PC22-388 Male Unaffected 76* N/A N/A 
*Unaffected, age at WGS; 1Tumour grade obtained from pathology report; 2Gleason Score obtained from 
pathology report; WD: well differentiated; MD: moderately differentiated; 
-: information not present in original pathology report; N/A: not applicable. 
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Two rare variants were prioritised in the sub branch of the PcTas22 family (Table 3.7). Both variants were validated by Sanger sequencing, 
however, sequencing of additional family members, including 16 PCa cases and 17 unaffected relatives, revealed that neither of these segregated 
with disease. HSD3B1 was only identified in one additional individual, an unaffected male, therefore with too few carriers it was not prioritised 
any further. An additional five carriers of the NAT10 variant were identified, including two PCa cases however, the other three were all unaffected 
male relatives. Therefore, four out of the 10 carriers were unaffected men, thus the variant did not segregate with disease in this family. 
 
 
Table 3.7 Rare variants prioritised in the PcTas22 sub pedigree following whole-genome sequencing of four affected men and two older unaffected 
men. 
 































NAT10 rs72910804 11:34,165,079 1.97 4 out of 4/ 1 out of 2 16.14 
A > G; 
Splice 




1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; WGS: Whole-genome sequenced; 2CADD: Combined Annotation 
Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 3Associated condition: Interpretation of variant 163. 
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3.3.6 Rare variant prioritisation in the PcTas22 main pedigree 
Individuals that were sequenced included four affected men and one unaffected older male 
relative (67 years of age), comprising an affected brother trio and an affected and unaffected 
brother pair (first cousins of the trio; Table 3.8). These individuals are indicated by green 
arrows in Figure 3.10. One of the men in each of the brother pair/trio had a relatively early age 
of disease onset (57 and 56 years, respectively). Rare variants were prioritised if they were 
present in all four affected men and not in the older unaffected man. However, variants in all 
five individuals with WGS were considered for follow-up studies, as reduced penetrance of 
such variants could explain why PC22-162 is also a variant carrier.  
 
 
Table 3.8 Clinicopathological characteristics of individuals from the PcTas22 main pedigree 













PC22-04 Male Affected 57 MD 6 (3+3) 
PC22-16 Male Affected 74 WD - 
PC22-17 Male Affected 56 MD 6 (3+3) 
PC22-162 Male Unaffected 67* N/A N/A 
PC22-203 Male Affected 79 PD 8 (4+4) 
PC22-584 Male Affected 63 MD 7 (3+4) 
*Unaffected, age at WGS; 1Tumour grade obtained from pathology report; 2Gleason Score obtained from 
pathology report; WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; -: 
information not present in original pathology report; N/A: not applicable. 
 
 
In total, three novel/rare variants were prioritised in the PcTas22 main pedigree WGS data. 
Subsequent genotyping of an additional 16 PCa cases and 18 relatives found that only the 
variants in WNT1 and RND1 segregated with PCa in PcTas22 (the CHEK2 variant did not 
validate in the WGS individuals). Three additional carriers were identified and interestingly, 
every carrier of either variant, also carried the other. Therefore, Figure 3.11 shows carriers of 
both the WNT1 and RND1 variants. The average age of PCa diagnosis in this branch of the 
PcTas22 family is 68 years, therefore both PC22-162 and PC22-205 are yet to reach this age 




Table 3.9 Rare variants prioritised in the PcTas22 main pedigree following whole-genome sequencing of five affected men and one older unaffected 
man.  
 





























RND1 Novel 12:49,254,905 N/A 4 out of 5/ 1 out of 1 39 
C > A; 
E110X 
0 out of 8 
N/A 
Yes Yes 
WNT1 Novel 12:49,374,959 N/A 4 out of 5/ 1 out of 1 20.8 
G > A; 
E217K 
0 out of 8 
N/A 
Yes Yes 
CHEK2 rs200432447 22:29,083,962 0.002 5 out of 5/ 1 out of 1 24.4 
G > C; 
R565G 







1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; N/A: Not found in ExAC or ClinVar, or did not validate therefore, segregation was not assessed; 
WGS: Whole-genome sequenced; 2CADD: Combined Annotation Dependent Depletion; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight 
were WGS; 3Associated condition: Interpretation of variant 163. 
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Figure 3.11 WNT1 and RND1 variant carriers in the PcTas22 main pedigree.  
This is a condensed pedigree of the PcTas22 main pedigree comprising all WNT1 and RND1 variant carriers (shown in yellow) and their relationship. Notably, the WNT1 and 
RND1 variants co-segregated together and were not found to contribute to the sub pedigree of PcTas22. Non-variant carrier family members are shown in grey and the 
individuals who were WGS are indicated by red arrows.  
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3.3.7 Assessing the possibility of rare variant enrichment in the Tasmanian population 
The rare variants which showed evidence of segregation in their founder family were screened 
in 94 control samples from the Tasmanian Prostate Cancer Case-Control Study (described in 
Chapter 2.1.3). Three out of five of the segregating variants were not found in any of the 94 
controls (Table 3.10). The ATM variant, rs1800057 was found to have the highest carrier 
frequency in the controls (3 out of 94). All variants were considered rare enough in the 
representative Tasmanian population for them to be deemed not enriched. Therefore, the 
Tasmanian Familial Prostate Cancer Study cohorts were genotyped for all five rare 
segregating variants.  
 
 
Table 3.10 Screening of the rare segregating variants in 94 controls from the Tasmanian Prostate 
Cancer Case-Control Study. 
 
Family Identification Gene Variant 
Number of Control 
Carriers 
PcTas3 CCL26 rs41463245 0 out of 94 
 P2RX7 rs28360447 2 out of 94 
PcTas4 ATM rs1800057 3 out of 94 
PcTas22 RND1 Novel; E110X 0 out of 94 
 WNT1 Novel; E217K 0 out of 94 
Control: Control from the Tasmanian Prostate Cancer Case-Control Study. In total, 94 controls were 
genotyped for the prioritised rare variants by Sanger sequencing. 
 
 
3.3.8 Association of the prioritised rare variants with prostate cancer risk in Tasmania 
Validated rare variants, which segregated with PCa in their founder family, and were 
considered to be not enriched in Tasmania, were chosen for high-throughput genotyping 
screens, using a TaqMan assay. The Tasmanian Familial Prostate Cancer Cohort (n=714) and 
the Tasmanian Prostate Cancer Case-Control Study (n=853) were screened for these variants. 
To increase the number of individuals available, pathology specimens for cases from variant 
carrier families, where germline DNA from blood or saliva was not available were also 
genotyped. The carrier frequency (%) of each variant was determined for the familial PCa 
cohort and the case-control study, and MQLS analysis 2 of the two datasets was used to calculate 
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the OR and p-value, where <0.05 was considered statistically significant. The results of these 
analyses are shown in Table 3.11.  
 
Following genotyping of all available DNA in our resource, MQLS analysis 2 of the combined 
familial and case-control genotyping data demonstrated a significant association between PCa 
risk and two variants in the Tasmanian population (Table 3.11). This included the two co-
segregating novel variants in RND1 and WNT1 identified in the main pedigree of PcTas22 
(OR=6.21, p=0.0001; OR=7.81, p=5.01x10-6, respectively). The variants in CCL26, P2RX7 
and ATM were not found to be statistically associated with PCa risk in our Tasmanian resource 



































CCL26 rs41463245 PcTas3 1, 9, 63, 72, 100 8 (3.21%) 11 (2.47%) 10 (2.02%) 7 (2.06%) 0.86 1.54 0.26 
P2RX7 rs28360447 PcTas3 
1, 9, 11, 12, 19, 22, 
23, 63, 65, 837, 3255 
14 (5.62%) 30 (6.77%) 18 (3.64%) 8 (2.35%) 1.27 1.84 0.22 
ATM rs1800057 PcTas4 
1, 4, 9, 11, 12, 16, 
22, 34, 38, 55,63, 65, 
72, 100, 213 








PcTas22 Nil 4 (1.66%) 4 (0.86%) 2 (0.40%) 0 (0%) N/A 7.81 5.01x10-6* 
Familial case and familial unaffected comprise the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian Prostate Cancer 
Case-Control Study; 1(n=total sample size); 2ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; N/A: Not found in 
ExAC; *Significant p-value. 
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Three of the five rare variants (other two are novel) were assessed for enrichment in groups 
within the Tasmanian Familial Prostate Cancer Study cohorts, as well as in comparison to the 
ExAC database and our Tasmanian controls. Table 3.12 shows that the CCL26 variant was not 
enriched in any of our Tasmanian groups, or compared to ExAC. The P2RX7 variant was 
enriched in the Tasmanian familial PCa cases versus ExAC (p=0.03), plus it was enriched in 
all PCa cases within our resource (familial & sporadic) compared to our population controls 
(p=0.02). This difference was still noticeable when comparing carrier status between just the 
Tasmanian familial cases and population controls (p=0.006), however not between the sporadic 
cases and population controls (p=0.28). The ATM variant appeared to be more frequent in the 
Tasmanian population compared to ExAC; all comparisons were significant, including the 
Tasmanian population control carrier frequency versus ExAC. The variant was also enriched 
in the Tasmanian familial cases compared to the Tasmanian controls (p=0.04), but not in the 




Table 3.12 Comparison of variant carrier status in the Tasmanian Familial Prostate Cancer Study cohorts compared to ExAC or Tasmanian controls. 
 





























































































































































1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; Entire Resource includes the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian 
Prostate Cancer Case-Control Study; Familial cases are a part of the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian 
Prostate Cancer Case-Control Study; 2In the chi square test (+/-) indicates directionality, where (+) means the minor allele frequency is greater in the first named 
population versus the comparison dataset, whereas, (-) indicates it is more enriched in the second named population; *Significant p-value. 
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1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; Entire Resource includes the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian 
Prostate Cancer Case-Control Study; Familial cases are a part of the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian 
Prostate Cancer Case-Control Study; 2In the chi square test (+/-) indicates directionality, where (+) means the minor allele frequency is greater in the first named 
population versus the comparison dataset, whereas, (-) indicates it is more enriched in the second named population; *Significant p-value. The WNT1 and RND1 variants 
are novel therefore, a comparison with ExAC cannot be made. 
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3.4 DISCUSSION 
3.4.1 Rare variants in CCL26 and P2RX7 as potential prostate cancer risk variants 
Overall, three rare variants and one novel variant were identified in the PcTas3 pedigree 
following WGS of five affected men. The variants in NDE1 and CLDN4 did not segregate with 
disease, however the variants in CCL26 and P2RX7 did. These two variants were initially 
prioritised as four of the five affected men in PcTas3 were identified as carriers and, 
particularly interesting, they were both predicted to be in the top 0.1% of most deleterious to 
protein function variants in the human genome 161.  
 
CCL26 participates in the promotion of cancer progression in liver and colorectal cancer 165,166, 
yet the CCL26 variant has not previously been associated with any disease, as per ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) 163. Wild-type CCL26 is a 94 amino acid protein, 
whereas the W44X variant causes a premature stop codon, which results in a small mutant 
protein of only 44 amino acids 167. However, it would have to be speculated as to whether this 
mutant protein is actually functionally active. The variant lies within a chemokine domain that 
is important for receptor regulator activity and binding of other molecules 168, which may 
indicate that a premature stop codon could alter these interactions.   
 
P2RX7 plays a role in infection and inflammation and is highly expressed in tumour cells 169,170. 
The prioritised variant has not previously been associated with cancer, however has been found 
to be associated with primary gout and hyperuricemia susceptibility 171, yet is not reported in 
ClinVar 163.The variant amino acid is larger and more basic compared to the small, neutral 
wild-type amino acid, which could cause the structure and function of the P2RX7 protein to be 
altered 168. The variant residue is located in a domain that is responsible for ATP binding, ion 
channel activity and purinergic nucleotide receptor activity 168, thus the variant may affect these 
functions.  
 
Overall, neither the CCL26 or P2RX7 variants were found to be associated with PCa risk in the 
Tasmanian population. In fact, the CCL26 variant was not enriched in any of our patient groups; 
providing no evidence that the variant is associated with PCa. The carrier frequency of the 
P2RX7 variant was significantly higher in Tasmanian PCa cases compared to controls. The 
variant was found to be enriched in the Tasmanian familial cases compared to our control 
population (p=0.006). However, this enrichment was not apparent when comparing Tasmanian 
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sporadic cases to controls (p=0.28). These analyses suggest that there may be a link between 
the P2RX7 variant and inherited PCa predisposition. Overall, the familial unaffected 
individuals had a higher P2RX7 carrier frequency compared to the familial PCa cases, which 
may underpin the lack of association with PCa risk, as per the MQLS analysis. These individuals 
were only included in the enrichment analyses as part of the ‘entire resource’ group, and this 
type of analysis doesn’t take into account the fact that related individuals are more likely to 
carry the variant. The enrichment analysis findings and high carrier frequency of the P2RX7 
variant in the Tasmanian Familial Prostate Cancer Cohort suggests further investigation in 
larger familial PCa cohorts is warranted, to establish whether this association can be replicated.  
 
3.4.2 Prioritisation of a rare variant in ATM, a known prostate cancer predisposition 
gene 
Six rare variants were prioritised in individuals from PcTas4, including three predicted to be 
in the top 1% of most deleterious coding variants in the genome, a splice variant and two 
variants identified in three out of four affected men. The variants in KMT2C and RHPN2 did 
not validate and the variants in IRS2, SSH3 and CRIP2 did not segregate with disease. Thus, 
the highest prioritised variant in PcTas4 was rs1800057 in ATM, which was identified in three 
out of the four PCa cases and predicted to be deleterious to protein function, with a CADD 
score of 27.9 161.  
 
ATM is a DNA repair gene which is responsible for recognising damaged or broken DNA 
strands, but it also controls the rate at which cells grow and divide 116. ATM is associated with 
an increased risk of familial breast, pancreatic and PCa, and is included on a number of gene 
screening panels, including the commonly used BROCA (breast and ovarian cancer associated) 
gene panel 172-176. The ATM variant identified here was recently recognised as one of the latest 
PCa susceptibility loci, following a GWAS meta-analysis 9. Notably, ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) reports the variant to be benign/likely benign 163. The 
variant itself results in the substitution of a neutral amino acid with a larger, basic amino acid, 
which could affect the structure of ATM, potentially resulting in the inability to recognise 
damaged DNA 168. In fact, the wild-type amino acid is a proline, which is known to have a very 
rigid structure, sometimes forcing the backbone into a specific conformation 168, thus, it is 
possible that the variant may disturb this local structure. It also lies within the serine/threonine-
protein kinase domain, which is responsible for the main activity of the protein, including 
molecular function, and transferase and catalytic activity 168. 
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The ATM variant segregated with disease and was found to be present in a number of other 
families in our Tasmanian PCa resource. However, the MQLS analysis OR was undefined for 
this variant because the frequency of the variant allele was too common in the Tasmanian 
control population (OR=0). Enrichment analysis identified the variant to be enriched in all of 
our Tasmanian Familial Prostate Cancer Study resources compared to ExAC (including our 
Tasmanian control population), which is consistent with the observed higher frequency. There 
was also enrichment in the Tasmanian familial cases compared to controls; one would expect 
that a frequent rare variant in Tasmania would result in an enrichment in familial PCa cases 
compared to controls, given their relatedness, but the enrichment analysis does not take in to 
account the relatedness of family members. It is likely that the high frequency of the rare variant 
is due to the fact that Tasmania was established from a small founder population. Additional 
investigation of this variant and its possible association with PCa risk is warranted, as our 
findings suggest that the rs180057 variant plays a role in PCa risk. Given that this variant was 
also recently identified in a large GWAS meta-analysis 9 illustrates the utility of our family-
based approach to rare variant prioritisation. Therefore, it would be worthwhile to look for 
other variants that have a similar pattern in our Tasmanian cohort.  
 
3.4.3 The identification of novel, co-segregating variants in RND1 and WNT1 
A total of eleven individuals, encompassing two separate branches of PcTas22 were WGS. 
Two rare variants were identified in the PcTas22 sub pedigree, including HSD3B1 and NAT10, 
yet neither segregated in the entire PcTas22 family. Three variants were prioritised in the 
PcTas22 main pedigree, including a variant in CHEK2, which did not validate, and novel 
variants in RND1 and WNT1. Both novel variants were initially prioritised because they were 
carried by four out of five affected men. The RND1 was predicted to have a deleterious effect 
on protein function; it is in the top 0.1% of all damaging variants in the genome (CADD=39), 
and the WNT1 variant is in the top 1%.  
 
RND1, a Rho GTPase, is known to promote the growth and migration of cancer cells. RND1 
expression is upregulated in oesophageal squamous cell carcinoma 177 and it is said to confer a 
malignant hepatocellular carcinoma phenotype with a poor prognosis 178. Little is known about 
the role of RND1 and its associated mutations in PCa development, however, increased 
expression is a prognostic signature in glioblastoma 179 and it promotes growth and migration 
of cancer cells 177,180. The novel RND1 variant causes a premature stop codon at position 110 
of the protein, whereas wild-type RND1 has a stop codon at amino acid position 233. This 
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could result in the production of a truncated protein with increased activity, which could affect 
the function of RND1 167. The variant residue is located in a domain that is important for 
binding of other molecules including ions, nucleotides and nucleosides, which is important to 
sustain the proteins molecular, and catalytic and hydrolase activity. It is in contact with residues 
in other domains that are important for the activity of the protein and binding of other residues 
168. 
 
Wnt family member 1 (WNT1) is a Wnt signalling transduction pathway protein that is involved 
in the regulation of gene transcription, cytoskeleton formation and calcium levels within the 
cell 181. This pathway is involved in embryonic development; controlling body axis patterning, 
cell fate specification, proliferation and migration 181. Wnt signalling is also involved in 
carcinogenesis, with its clinical importance demonstrated by the identification of mutations 
that lead to various diseases, including breast and PCa 182,183. Chen and colleagues (2004) also 
concluded that high levels of WNT1 is associated with advanced, metastatic, hormone-
refractory PCa, as they identified low levels in normal prostate cells compared to high levels 
in malignant cells 184. The WNT1 variant in this study causes the acidic wild-type glutamic acid 
residue at position 217 to be mutated to a basic, larger, lysine residue, which may affect protein 
folding, as the change in charge may cause repulsion with other residues in the protein or 
ligands 168. The variant is located in the signalling receptor binding domain, which is important 
for binding of other molecules 168. 
 
MQLS analysis found that each of the variants were significantly associated with PCa in our 
Tasmanian resource (RND1: OR=6.21, p=0.0001; WNT1: OR=7.81, p=5.01x10-6). Given these 
are previously undescribed variants, we were unable to test for enrichment of the RND1 and 
WNT1 variants within our Tasmanian Familial Prostate Cancer Study cohorts, or in 
comparison to ExAC. One interesting finding is that the RND1 and WNT1 variants were 
predominately identified in individuals from PcTas22 (with one additional sporadic carrier) 
and were co-inherited in every instance. Additionally, we tried to link the sporadic carrier in to 
this family, but to date, we cannot find a common ancestor. Co-inheritance of these novel 
variants suggest that they exist on a shared haplotype. A preliminary look at the variants that 
occur between these two genes, including nine common and one rare variant, revealed that 
variant carriers do have the same genotypes, suggesting a shared haplotype. 
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3.5 FUTURE DIRECTIONS 
Currently the RND1 and WNT1 variants appear to be private to PcTas22, yet one sporadic case 
carrier was identified. WGS of this individual would enable us to genetically link this person 
to the family (if they are related). If they are, it would appear that the region of chromosome 
12 between these two variants is linked to PCa risk in this family. If they are not, it is possible 
that there may be some linkage disequilibrium (LD) at the population level. This means that 
alleles at variants positioned close together on the same chromosome tend to occur together 
more often than is expected by chance 185. The region between the two variants is large 
(~120kb) and therefore would represent an unusually large shared haplotype, however it is 
possible that LD may explain why these variants are co-inherited in these individuals. As these 
variants are previously undescribed, we aim to further explore the contribution of this variant 
to independent PCa populations through collaboration with members of the International 
Consortium of Prostate Cancer Genetics (ICPCG) and the Prostate Cancer Association Group 
to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. The 
functional impact of the RND1 and WNT1 variants should also be investigated by assessing 
gene and protein expression in FFPE samples from PcTas22 case carriers and a random 
selection of non-carriers. Whilst these novel variants appear to be private to a single Tasmanian 
family, given the function of these genes it would be prudent to screen the Tasmanian Familial 
Prostate Cancer Study resources for other possible disease-causing variants in these genes.  
 
3.6 CONCLUSION  
This chapter detailed the WGS of 18 familial PCa cases and four unaffected male relatives 
from three Tasmanian PCa families, PcTas3, 4 and 22. Altogether, 15 variants were prioritised, 
12 validated and five segregated with disease in their founder families. Enrichment analysis 
suggested that the rare variants in P2RX7 (rs28360447) and ATM (rs1800057) may be linked 
with inherited PCa predisposition, given the significantly higher carrier frequency in familial 
cases compared to sporadic cases. Yet, only the novel variants in RND1 and WNT1 were found 
to be significantly associated with PCa risk by MQLS analysis (OR=6.21, p=0.0001; OR=7.81, 
p=5.01x10-6, respectively). Neither of these variants have been previously described, however 
both genes have clear biological links to prostate biology and cancer development. Notably, 
the variants were only identified in one Tasmanian PCa family, and in every instance were co-
inherited, suggesting a shared haplotype. Overall, this chapter highlights, firstly, that the study 
of families with a dense aggregation of disease can yield the identification of rare and novel 
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disease-associated variants by WGS. This is especially so, given Tasmania is a relatively 
homogenous population with reduced allelic variability and extended LD. Secondly, this study 
further supports the hypothesis that rare genetic variants do contribute to PCa risk and they do 
explain some of the ‘missing’ portion of known disease heritability.  
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CHAPTER 4 :  IDENTIFICATION AND 
FUNCTIONAL ASSESSMENT OF A RARE PROSTATE 
CANCER RISK VARIANT IN EZH2 
 
4.1 INTRODUCTION 
Targeted and agnostic approaches to rare variant discovery has facilitated advances in recent 
years in the field prostate cancer (PCa) genetics. As discussed in Chapter 1.8, linkage analysis 
and targeted sequencing strategies were utilised to identify the rare PCa risk variant in HOXB13 
11. Replication studies have provided further evidence for an association with PCa risk, 
however functional studies are required to demonstrate how it plays a role in disease initiation.  
The importance of PCa families in identifying rare variants has been realised in recent studies 
by FitzGerald et al. (2013) and Karyadi et al. (2017), as discussed in Chapter 3.1, however 
such studies have been few. The premise on which these studies are based is that rare variants 
contribute to common disease, and they are enriched in families, which make the search for 
disease-causing variants easier, given there is reduced genetic complexity 122. Using a similar 
approach, we selected a Tasmanian Familial Prostate Cancer Cohort family, PcTas12 for 
whole-genome sequencing (WGS), given that it comprises confirmed PCa cases across four 
generations and includes multiple father/son pairs, affected grandfather/father/son trios and 
affected brother pairs/trios (Figure 4.1). 
 
4.2 METHODS 
4.2.1 Whole-genome sequencing analysis 
Three individuals from PcTas12 were WGS on the Illumina HiSeq XTM Ten platform, as per 
Chapter 3.2.1. The data were analysed, annotated and variants called as previously described 
in Chapter 3.2.2. 
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Figure 4.1 PcTas12 pedigree. 
PcTas12 pedigree, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability of DNA from cases and their unaffected relatives, which is represented by red arrows. 
The disease status for earlier generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals have been marked as affected in the pedigrees. This 
pedigree is included to illustrate the size of the pedigree only, please refer to Figure 4.4 and 4.5 for individual annotations. 
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4.2.2 Validation, segregation and association analysis of prioritised rare variants  
Variants prioritised from the WGS data were validated by Sanger sequencing. Sanger 
sequencing of additional family members was used to track segregation with disease, which is 
discussed in Chapter 3.2.3. For those cases without gDNA available, FFPE DNA was 
sequenced (Appendix 2). If found to segregate, rare variants were screened in the entire 
Tasmanian Familial Prostate Cancer Cohort and the Tasmanian Prostate Cancer Case-
Control Study, as discussed in Chapter 3.2.4 (Appendix 6). MQLS analysis 2 was used to 
determine if there was an association between the prioritised rare variants and PCa risk in the 
Tasmanian population, as discussed in Chapter 3.2.5. 
 
4.2.3 Quantification of gene expression 
EZH2 (ENST00000492143.1) gene expression in PCa cell lines, prostate needle biopsies and 
formalin-fixed paraffin embedded (FFPE) prostate tumour samples was initially assessed in 
exon 17 of the gene by RT-qPCR analysis, as per Chapter 2.3. Exon-level expression across a 
number of regions of EZH2, including exon 4/5, 8/9, 12/14, 14/16, 17/18 and 20/21 was also 
examined in these samples. Average EZH2 expression was calculated by averaging the 
absolute expression of these six regions. The expression of EZH2 target genes, CDH1 
(ENST00000261769.5), HOXA9 (ENST00000343483.6) and MSMB (ENST00000358559.2), 
as well as splicing factors, SF3B1 (ENST00000424674.1), SF3B3 (ENST00000291552.4) and 
U2AF1 (ENST00000291552.4) was also determined in these samples. RT-qPCR primers were 
designed to the most commonly transcribed isoform in the prostate (as per GTEx Analysis 
Release V7 (dbGaP Accession phs000424.v7.p2; https://gtexportal.org/home/)) 137 and are 
displayed in Appendix 3.  
 
4.2.4 Plasmid and transformation of the EZH2 insert into competent prostate cancer 
cells 
The pSpliceExpress plasmid was a gift from Stefan Stamm (Addgene plasmid #32485; 
https://www.addgene.org/32485/) and has been described previously by Kishore and 
colleagues (2008) 186 (Figure 4.2). Primers were designed to amplify a region of the EZH2 gene 
surrounding the intronic splice variant, including exons 16-19 and up to 200bp of the 
surrounding introns (Figure 4.3A; Appendix 7). The insert was prepared from genomic DNA 
of an EZH2 variant carrier (PC12-132) by standard PCR using a proofreading DNA 
Polymerase (Phusion® High-Fidelity with GC Buffer, New England Biolabs®; Appendix 1). 
A nested-PCR step was used to add the attB1 and attB2 attachment sites to the insert, as shown 
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in Figure 4.3A, and the product was purified by gel extraction (QIAGEN). The insert was 
mixed with 150ng/µL of the pSpliceExpress vector in a boiling point (BP) recombination 
reaction (Figure 4.3B; ThermoFisher Scientific). StrataClone Stratapack Competent cells 
(Agilent) were transformed and plated on Ampicillin-supplemented LB plates pre-warmed at 
37°C. Single colonies were screened by restriction enzyme digest (ApaI and XbaI) and 
sequencing of isolated plasmid DNA (QIAprep Spin Miniprep Kit, QIAGEN). The 
pSpliceExpress plasmid contains two constitutively expressed rat insulin exons; such that no 





Figure 4.2 The structure of the pSpliceExpress plasmid. 
This schematic details the structure of the pSpliceExpress plasmid, including the location of the rat 
insulin exons, where the restriction enzymes cut, as well as the location of where the EZH2 insert was 
inserted in to the plasmid. During the boiling point reaction, the attP1/2 sites are replaced by the attB1/2 


















A) Schematic of the amplified EZH2 insert (mutation marked as GA), primers were designed in the intron before exon 16 and after exon 19. attB1 and attb2 attachment sites 
were added to the insert using forward and reverse primers with recombination sites (indicated by grey circles). B) The insert was recombined in vitro with the pSpliceExpress 
vector 186. In this case, the attP1/2 sites are cut and the plasmid is recombined with the attB1/2 sites at the end of the EZH2 insert. C) and D) Structure of the final wild-type (C) 
and variant (D) construct, with the specific allele indicated (G: variant; A: wild-type). The inserted region of EZH2 is flanked by constitutive rat insulin exons, indicated by the 
dotted pattern. E) The wild-type and variant constructs were transiently transfected in to PC3 and 22Rv1 cells. The effect of the variant on splicing was determined by Sanger 
sequencing of cDNA, using primers in the rat insulin exons (Appendix 7). The plasmid without an insert was used as a positive control. 
Figure 4.3 Overview of the EZH2 in vitro splicing assay.  
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4.2.5 Cell culture 
PC3 (ATCC® CRL-1435
TM
) and 22Rv1 (ATCC® CRL-2505
TM
) cells were obtained from 
American Type Culture Collection (Virginia, USA) and cultured in RPMI as previously 





 cells/mL. All cells were cultured in a humidified 
incubator at 37°C and 5% CO2.  
 
4.2.6 Transfection and cDNA sequencing 
PC3 and 22Rv1 cells (2 x 10
6
) were transfected with 5µg of variant (Figure 4.2D) or wild-type 
(Figure 4.2C) plasmid at 300V and 500µF, using a Bio-Rad Gene Pulser X Cell as previously 
described {Holloway:2000eg}. At 24 hours post-transfection, total RNA was isolated using Tri 
reagent® (Sigma-Aldrich), and quantified using the Nanodrop® ND-1000 UV 
spectrophotometer (Nanodrop® Technologies). The Superscript
TM
 VILO cDNA Synthesis Kit 
(Invitrogen) was used for cDNA synthesis, as per the manufacturer’s instructions (Appendix 
1). 50ng of cDNA was amplified using rat insulin exon 2 forward and exon 3 reverse primers 
(Appendix 7) 
186
. Sanger sequencing was performed to determine the EZH2 exons transcribed 
in both the rs78589034 variant and wild-type constructs (Figure 4.2E). 
 
4.2.7 Quantification of EZH2 protein expression 
Quantification of EZH2 protein expression in FFPE prostate tumours was assessed by 
immunohistochemistry (IHC), as discussed in Chapter 2.4 (Appendix 5). Cytospins of HEK293 
cells and sections of human colon were used as positive EZH2 controls. Negative controls 












4.3.1 Rare variant prioritisation  
A total of three individuals were successfully WGS in PcTas12, including an affected 
uncle/nephew pair and an older unaffected male cousin of the uncle (83 years of age; Table 
4.1). This cluster of the family was chosen for WGS analysis as it comprises three generations 
affected with PCa, including an affected brother pair. Unfortunately, germline DNA was not 
available for one of the brothers, PC12-06 (Figure 4.4). According to the minor allele frequency 
(MAF) of identified variants in the publicly available database, Exome Aggregation 
Consortium (ExAC; non-Finnish European, non-TCGA (The Cancer Genome Atlas) 
population), a total of 66,744 rare variants (MAF) <2%), 47,952 very rare variants (MAF<1%) 
and 35,722 novel variants were identified in at least one individual from the three that were 
WGS. Rare variants shared by the affected uncle/nephew pair and not by the unaffected cousin 

































PC12-01 Male Affected 63 MD 6 (3+3) 
PC12-96 Male Unaffected 83* N/A N/A 
PC12-132 Male Affected 61 - 8 (4+4) 
*Unaffected, age at WGS; 1Tumour grade obtained from pathology report; 2Contemporary Gleason Score 
from FFPE tissue block chosen for macrodissection of nucleic acids and IHC; MD: moderately differentiated; 
-: information not present in original pathology report;  N/A: not applicable. 
Figure 4.4 A condensed PcTas12 pedigree showing individuals chosen for whole-genome 
sequencing. 
Individuals chosen for WGS are indicated by red arrows, in this case, two PCa cases and one unaffected male 
relative were chosen.  
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Four rare variants were prioritised as potential PCa candidates using filtering methods 
described in Chapter 3.2.2 (Table 4.2). All four variants were validated by Sanger sequencing 
of WGS individuals. However, following sequencing of four additional PCa cases and 11 
unaffected relatives, only the variants in ITGAD and EZH2 segregated with PCa in this family. 
The ITGAD variant was identified in an additional two PcTas12 PCa cases. The intronic EZH2 
variant was found in seven additional PcTas12 individuals; four PCa cases, a female relative 
and two older men who have been diagnosed with bowel cancer and lymphoma (self-reported; 
Figure 4.5). Given the EZH2 variant appeared to segregate in a number of PcTas12 relatives, 
this variant was prioritised for additional study.  
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Table 4.2 Rare variants prioritised in the PcTas12 pedigree following whole-genome sequencing of two affected men and one older unaffected man. 
 
 




























ITGAD rs147321998 16:31,418,867 0.16 2 out of 2/ 0 out of 1 14.53 
C > T; 
R246X 
0 out of 8 
Not reported 
Yes Yes 
EZH2 rs78589034 7:148,508,818 0.19 2 out of 2/ 0 out of 1 11.7 
G > A; 
Splice 





EPS8 rs78763451 12:15,777,273 0.60 2 out of 2/ 0 out of 1 22.9 
C > T; 
A705T 





TIA1 rs115611153 2:70,441,562 0.63 2 out of 2/ 0 out of 1 22.1 
T > C; 
Q318R 






1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; WGS: Whole-genome sequenced; 2CADD: Combined Annotation 






Figure 4.5 EZH2 variant carriers in PcTas12.   
This is a condensed pedigree of PcTas12 comprising all EZH2 variant carriers (shown in yellow) and their relationship. Non-variant carrier family members are shown in grey 
and the individuals who were WGS are indicated by red arrows. Notably, the two unaffected male carriers to the right of the pedigree suffer from bowel cancer and lymphoma, 
respectively. Please note, the genotypes for PC12-03, 06, 08 and 09 were determined from sequencing prostate tumour DNA, which will be discussed below (Chapter 4.3.4). 
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4.3.2 Association of the EZH2 variant with prostate cancer risk in Tasmania 
Screening of 94 Tasmanian controls, as described in Chapter 2.1.3, revealed the absence of any 
EZH2 rs78589034 carriers. Following TaqMan genotyping of the Tasmanian Familial Prostate 
Cancer Study cohorts, an additional PCa case (PcTas9 family) from the Tasmanian Familial 
Prostate Cancer Cohort (n=714), and 3 cases and 1 control from the Tasmanian Prostate 
Cancer Case-Control Study (n=853) were identified as variant carriers. MQLS analysis 2 
demonstrated a significant association of the variant with PCa risk in the Tasmanian population 
(OR=3.27, p=0.001). The number of familial case carriers was much higher compared to their 
unaffected family members (Table 4.3). The EZH2 variant was also assessed for enrichment in 
groups within the Tasmanian Familial Prostate Cancer Study, as well as in comparison to 
ExAC and our Tasmanian controls (Table 4.4). However, there was found to be no enrichment 
of this variant within any of the groups assessed.  
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EZH2 rs78589034 PcTas12 PcTas9 4 (1.61%) 3 (0.68%) 3 (0.61%) 1 (0.29%) 0.19 3.27 0.001* 
Familial case and familial unaffected comprise the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian Prostate Cancer 
Case-Control Study; 1(n=total sample size); 2ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; *Significant p-value. 
 
Table 4.4 Comparison of EZH2 variant carrier status in our Tasmanian Familial Prostate Cancer Study cohorts compared to ExAC or Tasmanian 
controls. 






































0.11 (-)  
p=0.74  






0.42 (+)  
p=0.52 
0.16 (+)  
p=0.69 





























1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; Entire Resource includes the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian 
Prostate Cancer Case-Control Study; Familial cases are a part of the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian 
Prostate Cancer Case-Control Study; 2In the chi square test (+/-) indicates directionality, where (+) means the minor allele frequency is greater in the first named 
population versus the comparison dataset, whereas, (-) indicates it is more enriched in the second named population. 
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4.3.3 Association of the EZH2 variant with clinical characteristics and tumour 
pathology 
The EZH2 variant was identified in three branches of the PcTas12 family and was shown to be 
segregating with PCa (Figure 4.5). No difference was found in the age of diagnosis between 
PcTas12 EZH2 variant carrier cases (mean of 67.8 years, n=6) versus non-carrier cases (mean 
of 68.2 years, n=5, p=0.94; Table 4.5). Comparison of the Gleason score (GS) revealed no 
difference between EZH2 carriers and non-carriers (p=0.54; Table 4.5); with the majority of 
men in each group having a GS of 6 (3+3).  
 
 
Table 4.5 Clinicopathological characteristics of prostate cancer cases from the PcTas12 family, 


















PC12-02 80 GG N/A MD 6 (3+3) 
PC12-04 63 GG N/A MD 6 (3+3) 
PC12-05 64 GG N/A WD - 
PC12-07 59 N/A GG PD 9 (4+5) 
PC12-254 75 GG N/A WD 6 (3+3) 
PC12-01 63 GA GA MD 6 (3+3) 
PC12-03 62 N/A GA WD 4 (2+2) 
PC12-06 80 N/A GA PD 7 (3+4) 
PC12-08 73 N/A GA - 6 (3+3) 
PC12-09 68 N/A GA - 6 (3+3) 
PC12-132 61 GA GA - 8 (4+4) 
N/A: sample not available; 1Tumour grade obtained from pathology report; 2Gleason Score obtained from 
pathology report; WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; -: 
information not present in original pathology report. 
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4.3.4 Targeted collection of prostate tumour specimens from EZH2 variant carriers 
Targeted collection of FFPE prostate specimens from local pathology laboratories was 
undertaken for all PcTas12 tumour samples, and additional familial and sporadic EZH2 variant 
carriers, as well as a random selection of non-carriers (Table 4.6). Tumour samples were 
obtained for 18 cases, and genotyping of malignant DNA confirmed three and identified four 
additional heterozygous EZH2 carriers in PcTas12 (Table 4.6; Figure 4.5).  
 
No difference was found in the age at diagnosis of EZH2 variant carriers (n=7) versus non-
carriers (n=11) used in the functional analyses of this chapter (p=0.41). Likewise, for those 
samples with a GS on their original pathology report, no difference was observed between 
carriers (n=7) and non-carriers (n=10, p=0.31; Table 4.6).  
 
Subsequent genotyping of a number of prostate needle biopsies from the Tasmanian Prostate 
Tissue Needle Biopsy Resource (Chapter 2.1.6) identified an additional EZH2 variant carrier 
(PT0018). Three needle biopsy samples deemed to be non-carriers were also included in this 

















Table 4.6 Clinicopathological characteristics of FFPE prostate tumour samples obtained for 



















PC4-03 80 GG TURP GG M/PD 7 (4+3) 
PC11-11 85 N/A TURP GG - 7 (3+4) 
PC12-07 59 N/A TURP GG PD 9 (4+5) 
PC19-02 50 GG RP GG - 6 (3+3) 
PC60-01 58 GG TURP GG WD 6 (3+3) 
PC72-04 70 GG TURP GG PD 9 (4+5) 
PC72-06 62 GG TURP GG W/MD 5 (3+2) 
PC3250-01 51 GG RP GG PD 9 (4+5) 
DVA 216 64 GG RP GG - 5 (3+2) 
DVA 402 52 GG RP GG MD 6 (3+3) 
DVA 1002 61 GG RP GG - 6 (3+3) 
PC12-01 63 GA RP GA MD 6 (3+3) 
PC12-03 62 N/A TURP GA WD 4 (2+2) 
PC12-06 80 N/A TURP GA PD 7 (3+4) 
PC12-08 73 N/A TURP GA - 6 (3+3) 
PC12-09 68 N/A TURP GA - 6 (3+3) 
PC12-132 61 GA RP GA - 8 (4+4) 
DVA 416 62 GA RP GA MD 6 (3+3) 
N/A: sample not available; 1Tumour grade obtained from pathology report; 2Contemporary Gleason Score 
from FFPE tissue block chosen for macrodissection of nucleic acids and IHC; TURP: Transrectal resection 
of the prostate; RP: Radical prostatectomy; WD: well differentiated; MD: moderately differentiated; W/MD; 
well-moderately differentiated; PD: poorly differentiated; M/PD: moderately-poorly differentiated;  
-: information not present in original pathology report. 
 88 
Table 4.7 Clinicopathological characteristics of the prostate needle biopsy samples obtained for 









Tissue Source Tumour EZH2 Genotype Gleason Score1 
PT0001 70 TRUS GG 9 (4+5) 
PT0002 73 TRUS GG 6 (3+3) 
PT0003 61 TRUS GG 7 (4+3) 
PT0018 59 TRUS GA 6 (3+3) 
TRUS; Transrectal ultrasound biopsy: 1Gleason Score obtained from pathology report. 
Note: Germline samples are not available for any of these men. 
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4.3.5 The effect of the EZH2 variant on EZH2 gene expression 
To investigate EZH2 expression, RNA was extracted from adjacent malignant and benign glands for all prostate specimens (n=18), except for 
three samples where only malignant glands were present. Amplification of the housekeeping genes, GAPDH and b-Actin showed moderate 
expression however, amplification of the gene of interest, EZH2 was poor in both malignant and benign prostate glands. To determine whether 
these results were due to the poor quality FFPE samples, EZH2 gene expression was then investigated in three PCa cell lines and the four needle 
biopsy cores (Appendix 8). EZH2 expression was highest in the LNCaP cells, followed by 22Rv1 and PC3 cells, and in comparison, expression 
was relatively low in the needle biopsy samples, similar to that observed in the PC3 cells. Finally, EZH2 expression in the two cores from the 
EZH2 carrier (PT0018) appeared lower than the non-carriers, however, due to the small sample size, formal statistical analyses could not be 
undertaken (Figure 4.6). 
 
Figure 4.6 EZH2 gene expression analysis in prostate cancer cell lines and prostate needle biopsy samples.  
EZH2 expression was assessed in PCa cell lines and prostate needle biopsy samples. Absolute EZH2 gene expression was calculated for each sample by normalising to the 
expression of two housekeeping genes. A) EZH2 expression in individual PCa cell lines is shown here. B) EZH2 expression in individual prostate biopsy cores is shown here. 
* EZH2 variant carrier. 
* 
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4.3.6 The effect of the EZH2 variant on splicing 
The EZH2, rs78589034 variant is located 6bp before the start of exon 16 and, therefore, could 
affect splicing. EZH2 is a highly variable gene and multiple transcripts have been identified 137 
(Figure 4.7). Notably, exon 16 is not included in three of the 12 most common transcripts 
expressed in the prostate. In this study, splicing was assessed by transient transfection of variant 
(A allele) and wild-type (G allele) constructs, including EZH2 exons 16-19 and 200bp of 
intronic sequence either side, into PC3 and 22Rv1 cells, as shown in Figure 4.3. In both PC3 
and 22Rv1 cells, cDNA sequencing of the transfected constructs showed presence of all exons 
downstream of the variant (within the construct), in both the variant and wild-type constructs 




















Multiple transcripts of EZH2 have been identified in the prostate. The schematic for each transcript consists of exons, which are shown as boxes and introns as lines. As per 
data from the GTEx Analysis Release V8 (dbGaP Accession phs000434.v8.p2; https://gtexportal.org/home/), exon expression is shown in a heatmap format, with greater 
median read count per base depicted in dark blue. Transcription is right to left. The most common transcript, ENST00000492143.1 was used for primer design for EZH2 gene 
expression analyses and the rs78589034 is marked with an orange arrow 137.  
 
Figure 4.7 Screenshot of the GTEx Portal showing the most commonly expressed EZH2 transcripts in the prostate. 
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Given the known differential splicing patterns of EZH2, and the predicted disruption by the 
presence of rs79589034; the presence/absence of selected exons was examined. The exon-level 
expression of EZH2 in six regions across the gene was first assessed in the PCa cell lines and 
needle biopsy cores to determine whether particular exons were more consistently expressed 
in these samples (Appendix 8). Analysis of EZH2 expression in the cell lines revealed that the 
regions of exon 8/9 and 20/21 were more highly expressed compared to the other regions (or 
more easily quantified). However, only exon 20/21 was significantly higher compared to the 
other regions in the needle biopsy samples (Figure 4.8). Interestingly, the EZH2 carrier, 
PT0018 had the lowest EZH2 exon 20/21 expression, with the expression level of both cores 
similar to that of the exon 8/9 region. The right biopsy from PT0001 and PT0002 had higher 
EZH2 expression in the exon 20/21 region compared to the left lobe. Given our ability to 
quantify EZH2 exon 20/21 expression in these samples, the 18 FFPE prostate tissue samples 
were examined. However, once again, amplification was poor and therefore, absolute 




Figure 4.8 EZH2 gene expression analysis in multiple regions of the gene in prostate cancer cell lines and prostate needle biopsy samples.  
EZH2 expression in six different regions of the gene was assessed in PCa cell lines and prostate needle biopsy samples. A schematic of the most commonly transcribed isoform 
of EZH2 in the prostate is shown at the top of the page. Absolute EZH2 gene expression was calculated for each sample by normalising to the expression of two housekeeping 
genes. A) EZH2 expression in individual PCa cell lines is shown here. B) EZH2 expression in individual prostate biopsy cores is shown here. * EZH2 variant carrier.  
* 
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4.3.7 The effect of the EZH2 variant on EZH2 protein expression  
IHC was performed on all 18 FFPE prostate tumours and the four needle biopsy samples, with 
EZH2 protein expression assessed separately in malignant and benign glands. EZH2 staining 
was negative for all prostate samples analysed, in both malignant and benign glands (Figure 
4.9C &D). Cytospins of HEK293 cells and a section of human colon tissue were used as 
positive controls. The HEK293 cells showed moderate to strong staining of EZH2 and the 




Figure 4.9 EZH2 protein expression in HEK293 cells, human colon and FFPE prostate 
tumour samples. 
EZH2  protein expression was assessed in 18 prostate tumour specimens from the Tasmanian Prostate 
Tissue Pathology Resource to determine whether the intronic variant affected EZH2 protein levels. In short, 
IHC using an antibody targeting amino acid 696-745 of the EZH2 protein was utilised to assess protein 
expression. Staining intensity was scored as none, weak, moderate or strong. A) Moderate-strong staining 
of EZH2 in the nucleoplasm of HEK293 cells. B) Moderate-strong staining of EZH2 in the nucleoplasm of 
human colon glands. C) No staining of EZH2 in benign prostate glands. D) No staining of EZH2 in 
malignant prostate glands. Images were taken with a Leica 2500 microscope (x200) using the Leica 
Application Suite V3. 
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4.3.8 The effect of the EZH2 variant on EZH2 target gene expression  
Due to low EZH2 expression it was challenging to detect whether there were differences 
between EZH2 carriers and non-carriers. Therefore, expression of EZH2 target genes, CDH1, 
HOXA9, and MSMB were examined to determine whether the variant had an effect on their 
expression. It is possible that the variant may alter EZH2 expression slightly and thus, could 
have a direct impact on the level of expression of its target genes. Studies have previously 
observed an inverse relationship of CDH1 188, HOXA9 189 and MSMB 190 with EZH2.  
 
Initially, expression levels were assessed in the PCa cell lines and the four needle biopsy 
samples (Appendix 9). CDH1 and HOXA9 expression was 5-fold higher in the androgen-
refractory PC3 cells compared to the level of expression in the androgen-sensitive LNCaP and 
22Rv1 cells (Figure 4.10). CDH1 and HOXA9 expression in the cell lines was inversely 
correlated with the overall average expression of EZH2 (mean of the six regions), except CDH1 
expression was similar to EZH2 in PC3 cells. An inverse relationship between MSMB and 




















Figure 4.10 Average gene expression of EZH2 and absolute gene expression of target genes, CDH1, HOXA9 and MSMB in prostate cancer cell lines. 
A) EZH2 expression in six regions of the gene were assessed in three PCa cell lines. Average (mean) expression of all regions of EZH2 assessed; exon 4/5, 8/9, 12/14, 14/16, 
17/18, 20/21 is shown here. A schematic of the most commonly transcribed isoform of EZH2 in the prostate is shown at the top of the page. CDH1, HOXA9 and MSMB 
expression was assessed in three PCa cell lines. Absolute CDH1, HOXA9 and MSMB gene expression was calculated for each sample by normalising to the expression of 
two housekeeping genes. B) Individual cell line CDH1 expression.is shown here. C) Individual cell line HOXA9 expression is shown here. D) Individual cell line MSMB 
expression is shown here.  
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Analysis of the four needle biopsy samples showed considerable variability across the gene 
expression profiles, similar to the cell lines. CDH1 expression in the two PT0002 cores were 
inversely correlated with EZH2 expression, however, the correlation was not as distinct 
compared to the cell lines (Figure 4.11). HOXA9 expression in the needle biopsy samples was 
similar to PC3 cells, except the right core of PT0002 had higher expression compared to all 
other samples. Unlike the cell lines, no inverse trend in HOXA9 expression with EZH2 was 
found, though MSMB expression in samples from two of the needle biopsies (PT0002 and 
PT0003) was inversely correlated with EZH2 expression. Expression of all target genes did not 
differ between the EZH2 variant carrier (PT0018) and non-carriers (n=3), however given the 




Figure 4.11 Average gene expression of EZH2 and absolute gene expression of target genes, CDH1, HOXA9 and MSMB in prostate needle biopsy samples. 
A) EZH2 expression in six regions of the gene were assessed in four prostate needle biopsy samples. Average (mean) expression of all regions of EZH2 assessed; exon 4/5, 8/9, 
12/14, 14/16, 17/18, 20/21 is shown here. A schematic of the most commonly transcribed isoform of EZH2 in the prostate is shown at the top of the page. CDH1, HOXA9 and 
MSMB expression was assessed in four prostate needle biopsy samples. Absolute CDH1, HOXA9 and MSMB gene expression was calculated for each sample by normalising to 
the expression of two housekeeping genes. B) Individual biopsy core CDH1 expression is shown here. C) Individual biopsy core HOXA9  expression is shown here. D) Individual 































Given the known inverse relationship of EZH2 and its target genes in the literature and our 
ability to quantitate CDH1 and MSMB expression in the PCa cell lines and needle biopsy 
samples, expression was assessed in the 18 FFPE prostate tissue samples (Appendix 10). 
Firstly, differences in expression between malignant and adjacent benign glands was assessed 
in 14 tumour samples. There was found to be no significant difference in CDH1 gene 
expression between paired malignant and benign prostate glands (n=14pairs; p =0.30; Figure 
4.12). MSMB expression was also unchanged between the two groups (p =0.38). Assessment 
of CDH1 in tumours from EZH2 carriers (n=7) and non-carriers (n=11) identified no difference 
in expression between malignant (p=0.12) and benign glands (n= 15, p=0.44), respectively. 
MSMB expression also appeared unaffected by the EZH2 variant, in both malignant (p=0.54) 





Figure 4.12 CDH1 and MSMB gene expression 
analysis in malignant and benign prostate glands, 
and in malignant glands from EZH2 variant 
carriers and non-carriers 
The spread of the data is represented by a box and whisker 
plot. Median expression is shown  by the thick black line, the 
interquartile range (middle 50% of data set) is represented by 
the box, and the minimum and maximum values by the 
whiskers (dotted lines). Individual outliers are shown with 
dots. A/C) CDH1 and MSMB expression was assessed in 
prostate tumours with matched malignant and benign glands 
(npairs=14). Absolute CDH1 and MSMB gene expression was 
calculated for each sample by normalising to the expression 
of two housekeeping genes and expression in malignant and 
benign glands was compared using a paired Student’s t-test 
(CDH1: A; MSMB; C). B/D) CDH1 and MSMB expression 
was assessed in malignant prostate glands from EZH2 variant 
carriers (n=6) and non-carriers (n=11). Absolute CDH1 and 
MSMB gene expression was calculated for each sample by 
normalising to the expression of two housekeeping genes and 
expression in malignant glands from EZH2 variant carriers 
and non-carriers was compared using an unpaired Student’s 
t-test (CDH1: C; MSMB; D). 
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4.3.9 The effect of the EZH2 variant on EZH2 splicing factor expression 
Due to low EZH2 expression and the hypothesised functional effect of the variant on splicing, 
gene expression levels of EZH2 splicing factors, SF3B1, SF3B3 and U2AF1 were determined. 
Initially, expression levels of these splicing factors were assessed in the PCa cell lines and the 
four needle biopsy samples (Appendix 9). Interestingly, U2AF1 was highly expressed in all 
cell lines compared to SF3B1 and SF3B3. Whilst SF3B1 and SF3B3 did not show an inverse 
trend with EZH2, U2AF1 was inversely correlated with the overall average expression of EZH2 











Figure 4.13 Average gene expression of EZH2 and absolute gene expression of splicing factors, SF3B1, SF3B3 and U2AF1 in prostate cancer cell lines. 
A) EZH2 expression in six regions of the gene were assessed in three PCa cell lines. Average (mean) expression of all regions of EZH2 assessed; exon 4/5, 8/9, 12/14, 14/16, 
17/18, 20/21 is shown here. A schematic of the most commonly transcribed isoform of EZH2 in the prostate is shown at the top of the page. SF3B1, SF3B3 and U2AF1 
expression was assessed in three PCa cell lines. Absolute SF3B1, SF3B3 and U2AF1 gene expression was calculated for each sample by normalising to the expression of two 
housekeeping genes. B) Individual cell line SF3B1 expression.is shown here. C) Individual cell line SF3B3 expression is shown here. D) Individual cell line U2AF1 expression 












The needle biopsy samples also had very high expression of the splicing factor, U2AF1. The 
expression pattern of U2AF1 in these samples did not indicate that there was an inverse 
correlation with EZH2 expression however, the two samples with the highest U2AF1 
expression (PT0003 right and PT0018 right) did have the lowest average expression of EZH2. 
But, unlike the cell lines, SF3B1 and SF3B3 expression appeared to follow a similar trend in 
expression to EZH2 (Figure 4.14). While the expression of the splicing factors did not appear 
to differ between the variant carrier (PT0018) and non-carriers, this was not able to be 




Figure 4.14 Average gene expression of EZH2 and absolute gene expression of splicing factors, SF3B1, SF3B3 and U2AF1 in prostate needle biopsy samples. 
A) EZH2 expression in six regions of the gene were assessed in four prostate needle biopsy samples. Average (mean) expression of all regions of EZH2 assessed; exon 4/5, 8/9, 
12/14, 14/16, 17/18, 20/21 is shown here. A schematic of the most commonly transcribed isoform of EZH2 in the prostate is shown at the top of the page. SF3B1, SF3B3 and U2AF1 
expression was assessed in four prostate needle biopsy samples. Absolute SF3B1, SF3B3 and U2AF1 gene expression was calculated for each sample by normalising to the expression 
of two housekeeping genes. B) Individual biopsy core SF3B1 expression is shown here. C) Individual biopsy core SF3B3 expression is shown here. D) Individual biopsy core U2AF1 































As U2AF1 expression was very high in all cell line and needle biopsy samples, U2AF1 
expression was assayed in the 18 FFPE prostate tissue samples (Appendix 10). Not 
surprisingly, given the quality of RNA, U2AF1 expression levels were much lower in the FFPE 
tumours compared to the cell lines and needle biopsy samples. Whilst malignant gland 
expression was generally higher than benign, there was no significant difference in U2AF1 
gene expression between paired malignant and benign prostate glands (npairs=11, p=0.11; 
Figure 4.15). In malignant glands, the majority of EZH2 variant carriers (n=6) had lower 
U2AF1 expression than non-carriers (n=11), however this was not statistically significant 
(p=0.12). A similar expression pattern was observed in benign prostate glands, however the 
difference between EZH2 carriers (n=5) and non-carriers (n=8) was statistically significant 
(p=0.03; Figure 4.15).  
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Figure 4.15 U2AF1 gene expression analysis in malignant and benign prostate glands; in malignant glands from EZH2 variant carriers and non-
carriers, and in benign glands from EZH2 variant carriers and non-carriers 
The spread of the data is represented by a box and whisker plot. Median expression is shown by the thick black line, the interquartile range (middle 50% of data set) is 
represented by the box, and the minimum and maximum values by the whiskers (dotted  lines). Individual outliers are shown with dots. A) U2AF1 expression was assessed in 
prostate tumours with matched malignant and benign glands (npairs=11). Absolute U2AF1 gene expression was calculated for each sample by normalising to the expression of 
two housekeeping genes. U2AF1 expression in malignant and benign glands was compared using a paired Student’s t-test. B) U2AF1 expression was assessed in malignant 
prostate glands from EZH2 variant carriers (n=6) and non-carriers (n=11). Absolute U2AF1 gene expression was calculated for each sample by normalising to the expression 
of two housekeeping genes. U2AF1 expression in malignant glands from EZH2 variant carriers and non-carriers was compared using an unpaired Student’s t-test and the spread 
of the data is shown here. C) U2AF1 expression was assessed in benign prostate glands from EZH2 variant carriers (n=5) and non-carriers (n=8). Absolute U2AF1 gene 
expression was calculated for each sample by normalising to the expression of two housekeeping genes. U2AF1 expression in benign glands from EZH2 variant carriers and 





4.4.1 EZH2 as a potential prostate cancer risk variant 
A rare variant in EZH2 (rs78589034) was initially identified in two PCa cases in PcTas12. It 
is an intronic variant that occurs 6bp from the beginning of exon 16, which according to the 
Human Splicing Finder is an acceptor splice site 191, therefore it may affect expression of EZH2 
transcripts. It has a CADD score of 11.7; predicting it to be in the top 1% of all damaging 
variants in the genome 161 and is highly conserved across species.  
 
The polycomb group (PcG) protein enhancer of zeste homolog 2, EZH2, is the catalytic subunit 
of the Polycomb Repressive Complex 2 (PRC2). Overall, EZH2 acts as a histone 
methyltransferase (HMTase), trimethylating lysine 27 on the histone H3 protein subunit 
(H3K27me3) and as part of the PRC2 complex is ultimately responsible for long term 
transcriptional repression of its target genes 192-194.Whilst it is known that EZH2 expression is 
highly correlated with the progression of PCa, and is associated with disease aggressiveness 
and a poor prognosis 195,196, the mechanism by which the expression of EZH2 increases during 
PCa is currently unknown 196-199. We hypothesised that the rs78589034 variant may contribute 
to dysregulated EZH2 expression. Whilst this intronic variant has been identified in a case of 
parathyroid neoplasm 200, this is the first study to find an association with PCa risk. In other 
cancers, germline and acquired variations in EZH2 have been found to have both activating 
and inactivating effects in cancer, including in B-cell lymphomas, follicular lymphoma, and 
myelodysplastic and myeloproliferative disorders 201-203. Interestingly, a male carrier of this 
variant in our family suffers from lymphoma (Figure 4.5; PC12-73).  
 
Overall, the EZH2 variant was determined to be significantly associated with PCa risk in the 
Tasmanian population (OR=3.27, p=0.001). Notably, the variant was not found to be enriched 
in any groups within our resource or compared to ExAC. This is because the carrier frequency 
of each group was not significantly different, however MQLS analysis did find an association 
with disease. This is due to the fact that MQLS 2 takes in to account the relatedness of individuals, 
can distinguish between unaffected controls and controls of unknown phenotype, incorporates 
phenotype data about relatives who have missing genotype data and obtains more power by 
giving increased weighting to those individuals with closely related disease-carrying relatives 
2. Though, the EZH2 variant was more common in men with a family history of disease (1.61%) 
compared to those with no family history (0.61%), suggesting an inherited predisposition.  
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4.4.2 Examining the effect of the EZH2 variant on EZH2 gene and protein expression 
in prostate tumours 
In the normal prostate, EZH2 expression is relatively low, however it is reported to be 
overexpressed in diverse cancer types, including PCa 196. Clinically localised PCa with high 
EZH2 expression has a poorer prognosis compared to tumours with low expression 196. Plus, 
metastatic PCa has been associated with higher levels of EZH2 at both the transcriptional and 
translational level compared to clinically localised PCa 196. Therefore, it has been suggested 
that EZH2 expression could potentially predict disease progression and treatment outcomes 204. 
A study by Saramaki and colleagues (2006) found that EZH2 was upregulated in more than 
half of hormone refractory PCa tumours, compared to only 27% of early untreated PCa tumours 
199. EZH2 is also recurrently mutated in several forms of cancer, particularly Non-Hodgkin’s 
lymphoma, with heterozygous mutations at Y641 and A678V known as gain-of-function 
mutations which lead to hypertrimethylation of H3K27 201,202. Here, we hypothesised that the 
intronic EZH2 variant may alter the regulation and expression of EZH2, given that EZH2 is 
tightly regulated at the transcriptional, post-transcriptional and post-translational level 205,206. 
EZH2 gene and protein expression was assessed in PCa cell lines and prostate tumours of 
variant carriers and non-carriers. Previous studies have identified higher EZH2 expression in 
PC3 cells compared to LNCaP cells 190, however here, we found expression to be lowest in 
PC3 cells, which may be due to different growth conditions leading to altered expression. EZH2 
expression in all exonic regions was consistently lower in the two needle biopsy cores of the 
EZH2 variant compared to the three non-carrier samples. Unfortunately, no conclusions could 
be made in regards to the difference in expression between variant carriers and non-carriers, 
due to very low levels of EZH2 expression in the FFPE samples.  
 
Protein expression data from the FFPE samples supported the gene expression findings and 
showed no EZH2 staining in any of the samples. The Human Protein Atlas 
(https://www.proteinatlas.org) reports that there is reasonably low expression of EZH2 in the 
prostate, with the majority of tumours showing low or undetectable expression 207. In contrast, 
cDNA microarray profiling enabled Varambally et al. (2002) to conclude that EZH2 was found 
to be overexpressed in invasive and hormone-refractory metastatic PCa 196. This 
overexpression is thought to be due to amplification of the gene itself, or transcriptional 
upregulation by MYC and ETS gene family members 208,209, however we were unable to 
quantitate EZH2 gene or protein expression. The samples analysed in this study were primary 
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tumours of low to moderate GS (unlikely to become metastatic), therefore, low expression of 
EZH2 at both the transcriptional and translational level is plausible.  
 
4.4.3 Examining the effect of the EZH2 variant on EZH2 target gene expression in 
prostate tumours 
Recent reports suggest that EZH2 may promote PCa progression by repressing tumour 
suppressor gene targets, such as CDH1, HOXA9 and MSMB 188,190,210. These genes are silenced 
via two mechanisms; EZH2 can directly bind to their promoter, or cause histone methylation, 
specifically H3K27me3. Both mechanisms lead to reduced expression of the target genes and 
increased cancer cell migration and invasion 210-212. Reduced CDH1 expression has been linked 
to metastasis in breast cancer, following studies of epithelial cell lines 213-215. In our study, we 
observed the highest expression in bone metastasis cells, PC3, and the lowest expression in 
primary PCa cells, 22Rv1. We also observed an inverse relationship between EZH2 and CDH1 
expression in 22Rv1 and LNCaP cells, but not in PC3 cell lines. It has been proposed that 
transcriptional repression of CDH1 during EZH2 overexpression is the result of PRC2 
recruitment to the CDH1 promoter by SNAIL 188,216. Previous studies show that transient down-
regulation of CDH1 occurs in localised PCa 217, however no difference in expression was found 
between malignant and benign prostate glands in our study, following analysis of tumours from 
the Tasmanian Prostate Tissue Pathology Resource. 
 
Changes in HOXA9 expression have been associated with EZH2 mutations in acute myeloid 
leukemia cases (p=0.048) 189. Here, HOXA9 expression was very low in all cell lines and needle 
biopsy samples, and expression appeared to be the same in the EZH2 carrier compared to the 
non-carrier needle biopsy samples. It is known that MSMB expression is silenced by EZH2 in 
advanced PCa cells, as the MSMB promoter binds to PRC2 and H3K27me3 when EZH2 is 
overexpressed 190. The H3K27 methylation-associated silencing of MSMB in such cells is 
believed to contribute to their increased growth, proliferation and invasive potential 218. In fact, 
several studies have shown higher MSMB expression in benign versus malignant prostate tissue 
after a radical prostatectomy (RP) 219. Our study included eight RP samples, however MSMB 
expression was no different between malignant and benign glands in these samples. Overall, 
expression of MSMB was very low in our FFPE samples and it was not possible to draw any 




4.4.4 Examining the effect of the intronic EZH2 variant on splicing mechanisms  
Splicing dysregulation is one of the molecular hallmarks of cancer 220 and the literature 
suggests that carcinogenesis often involves alternative splicing, which can result in protein 
diversity 220,221. Chen et al. (2017) observed that alternative splicing involving the inclusion of 
exon 14 of EZH2 plays a major role in the tumourigenesis of renal cancer, in their study of 24 
clear cell renal cell carcinomas with matched malignant and benign cells 222. The most common 
EZH2 transcript in the prostate involves the inclusion of the full-sized exon 14, however the 
second and third most common transcript involve alternative splicing of exon 14 into three 
smaller exons (Figure 4.7). The EZH2 gene can give rise to over 30 different mRNA transcripts 
223 and multiple transcripts can exist in tissues; the functional implications of which are not yet 
known. Here, it was hypothesised that the rare intronic variant identified in PcTas12 may affect 
splicing. The EZH2 variant lies 6bp away from the beginning of exon 16, which according to 
the Human Splicing Finder is an acceptor splice site 191. The GTEx portal 
(https://gtexportal.org/home/) predicts that the variant causes protein truncation, following the 
identification and assessment of the variant in a sample of a tibial artery 137. Using an in vitro 
splicing assay, our study detected no effect on EZH2 splicing in the presence of the variant 
versus the wild-type allele. However, cell models may not accurately mimic the in vivo 
environment. In addition, only the exons downstream of exon 16 were assessed and the 
potential disruption to upstream splicing was not.  
 
The literature suggests that disrupted expression of EZH2 splicing factors, SF3B1, SF3B3 and 
U2AF1 can cause aberrant splicing and defective EZH2 mRNA production 224. Whilst this was 
not the focus of this study, these studies highlight the relationship of EZH2 and its splicing 
factors, and overall, the potential effect of variants in a splice site recognition sequence. 
Sequence changes in recognition sites have been shown to affect splicing, and all splicing 
factors have preferred recognition sites. To determine whether there are particular splicing 
factors expressed in PCa, expression of SF3B1, SF3B3 and U2AF1 was initially assessed in 
PCa cells lines and our needle biopsy samples. Overall, U2AF1 was highly expressed in all 
assayed samples compared to SF3B1 and SF3B3, indicating that U2AF1 is more prominent in 
the prostate. A study by Daures et al. (2018) of prostate biopsies divided into three clinical 
grades; normal (n=23), GS £7 tumour (n=20) and GS >7 tumour (n=19), identified that 
upregulation of six genes correlated with tumour severity, two of which were EZH2 and U2AF1 
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225. Here, U2AF1 expression was significantly higher in the metastatic cell lines, PC3 and 
LNCaP (GS >7 inferred) compared to the localised PCa cells, 22Rv1’s (GS of 6 or 7 inferred).  
 
U2AF1 is ultimately responsible for pre-mRNA splicing and mRNA 3’-end processing by 
recognising the AG di-nucleotide marking the end of the intron, and interestingly, binds 
directly to EZH2 226. This 3’ splice site recognition takes place in conjunction with a larger 
subunit, U2AF2. U2AF1 recognises a polypyrimidine tract preceding the 3’ splice site and 
directly positions U2AF1 to recognise the downstream AG sequence. Thus, the variant may 
disrupt the target sequence for U2AF2 to recognise the 3’ splice site, and ultimately, may affect 
the affinity of U2AF1 to bind to EZH2, thus resulting in ineffective EZH2 mRNA transcript 
synthesis 227. A polypyrimidine tract is considered strong if it contains four consecutive T bases 
within 30 nucleotides upstream of the 3’ splice site 228. Interestingly, the rs78589034 variant 
causes four consecutive T bases to occur (in comparison to the wild-type sequence; TTCT) just 
three nucleotides upstream of the AG start site. Thus, the EZH2 variant forms a strong 
pyrimidine tract, which is recognised by U2AF2, causing U2AF1 to be directly positioned over 
the AG start site, potentially resulting in an alternate transcript of EZH2. 
 
There is also evidence to suggest that differential splicing is not an all or nothing phenomenon, 
rather that splicing is influenced by the bases surrounding the AG site in the target sequence 
229. Therefore, we aimed to investigate whether the formation of a strong polypyrimidine tract 
by the EZH2 rs78589034 variant results in large or subtle effects of splicing factor expression. 
Following U2AF1 expression analysis in the FFPE samples from the Tasmanian Prostate 
Tissue Pathology Resource, statistical analysis revealed that EZH2 non-carriers trended 
towards having higher U2AF1 expression compared to variant carriers, but this finding was 
only statistically significant in benign glands. It is unclear as to why this finding is only 
observable in benign prostate glands, but given that the variant form of EZH2 is preferentially 
targeted by U2AF2, followed by U2AF1, it is likely that the difference we see is not solely due 
to the variant allele. Overall there are hundreds of other regions of the genome that U2AF2 and 
U2AF1 can bind to therefore, it is likely that a number of unknown factors are also contributing 
to reduced expression. Though, it is worth remembering that the rs78589034 variant is a risk 
allele, therefore it is possible that it has no effect on the splicing of the gene, or expression of 
its target genes and associated splicing factors, and if it does, the effects could be subtle.  
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Notably, there are two isoforms of U2AF1 (U2AF1a and U2AF1b) and they differ by seven 
amino acids in the second RNA recognition motif within the U2AF homology motifs domain 
230. Tissue expression analysis demonstrated that U2AF1a is more highly expressed compared 
to U2AF1b, which may be due to the fact that these isoforms have different target sequence 
preferences 231,232. Kralovicova and colleagues (2015) examined the effect of knocking down 
U2AF1 (and its isoforms) in HEK293 cells and found that a small number of transcripts 
exhibited distinct responses to one isoform over the other, supporting the existence of isoform-
specific interactions 231. Analysis of altered targeted sequences (50 nucleotides) observed that 
6bp from the beginning of an exon was important in the splicing process, which is the intronic 
location of the EZH2 rs78589034 variant. It is plausible that the EZH2 risk variant preferences 
a particular U2AF1 isoform, however due to time constraints and resources we were unable to 
determine this here. It appears that the EZH2 variant produces a 3’ splice site which is preferred 
by U2AF1b 233, however this would need to be confirmed by targeted RNA sequencing of 
U2AF1. This would enable us to determine which transcript is preferentially expressed in our 
FFPE prostate samples and specifically, the EZH2 carriers. It is hypothesised that preference 
for the U2AF1b isoform to bind to the variant form of EZH2 could promote the inclusion of 
exon 16 in more EZH2 transcripts. However, given that U2AF1b is expressed at a lower level 
to U2AF1a it is likely that that the variant may have only subtle effects on the splicing 
mechanisms of EZH2, slightly altering the expression of EZH2 transcripts, yet this was 
undetectable here.  
 
4.4.5 Limitations of this study  
This study has identified a Tasmanian PCa risk variant in EZH2 and has assessed its effect on 
the splicing mechanisms of EZH2, however, several limitations of the study must be 
acknowledged. To date, this study is the first to find an association of the rs78589034 variant 
with PCa risk, therefore it has not been replicated in independent populations of PCa cases and 
controls. Thus, we are unaware as to whether it contributes to PCa risk in other populations. 
Overall, availability of FFPE samples and the rarity of the variant restricted our opportunity to 
identify EZH2 variant carriers, and thus limited the availability of informative tumour tissue 
specimens from carriers. A small sample size results in reduced power and therefore lowers 
the likelihood of detecting real associations. Thus, the concepts explored in this study should 
be accessed in a larger tissue cohort of EZH2 carriers. The quality of DNA and RNA extracted 
from FFPE tissue is also fairly poor, therefore it is important that our findings are validated in 
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larger FFPE cohorts. Data from the GTEx Portal (https://gtexportal.org/home/) 137 suggests that 
each region of EZH2 assessed have similar expression levels, therefore the discrepancies in 
levels of EZH2 expression between different regions of the gene is likely due to poor quality 
RNA samples and different primer efficiencies. Thus, we were only able to compare expression 
within regions and not between. The analysis discussed earlier (4.3.6) was used to determine 
the region of EZH2 that we were able to efficiently quantify. In terms of the needle biopsy 
samples we do not definitively know which lobe contains benign or malignant tissue, therefore 
we cannot draw any real conclusions here. On another note, the splicing assay was performed 
in vitro in PCa cells, PC3 and 22Rv1’s. This approach directly detects the effect of the intronic 
variant on splicing in these cells, but does not replicate the in vivo environment in the prostate. 
For example, this assay does not take into account the effects of other events associated with 
splicing, such as transcription, capping and polyadenylation, or other proteins and complexes 
involved in splicing 234. Lastly, the only positive control we had for this experiment was the 
splicing together of the rat insulin exons.  
 
4.5 FUTURE DIRECTIONS 
Overall, this study identified that the EZH2 rs78589034 variant is significantly associated with 
PCa risk in the Tasmanian population, although enrichment in familial or sporadic cases was 
not demonstrated. Given that it is yet to be replicated in other populations, we aim to further 
explore the contribution of this variant to independent PCa populations through collaboration 
with members of the International Consortium of Prostate Cancer Genetics (ICPCG) and the 
Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the 
Genome (PRACTICAL) consortium. EZH2 expression was unable to be detected in the FFPE 
prostate tissue samples, however it may be because EZH2 expression in these FFPE prostate 
samples is too low to be detected by RT-qPCR. It would be advantageous to use a more precise 
platform for gene expression quantification, such as droplet digital PCR (ddPCRTM, Bio-Rad) 
or the QuantStudio 3D Digital PCR Chip platform (ThermoFisher Scientific). Both of these 
systems can detect very low gene copy numbers from minimal sample input; therefore, they 
could be utilised to determine if the rs78589034 variant alters EZH2 expression in our 
Tasmanian Prostate Tissue Pathology Resource. U2AF1 expression could be quantitated in 
these samples and it was found to be downregulated in EZH2 carriers versus non-carriers, 
however this was only statistically significant in benign cells. Follow-up in vitro studies 
analysing the interaction of EZH2 and U2AF1 in cell lines with and without the intronic variant 
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would be valuable. This could be achieved by ChIP-sequencing, which analyses protein and 
DNA interactions. Overall, the Tasmanian Prostate Tissue Pathology Resource consists of 
only seven EZH2 variant carriers, therefore it would be worthwhile to undertake targeted 
collection of FFPE prostate samples from newly diagnosed or ‘pathology only’ cases from 
PcTas12. Collection of additional tumours from PCa cases in other Tasmanian Familial 
Prostate Cancer Cohort families will increase our sample size and statistical power. This study 
has also suggested that the presence of the EZH2 variant produced no detectable difference in 
EZH2 splicing. As mentioned, the splicing assay assessed exons downstream of the variant, 
therefore it would be beneficial to assess splicing of exons 15 and 16 in EZH2 variant carriers 
in comparison to non-carriers to determine if they are affected. Alternatively, RNA sequencing 
data for the single needle biopsy EZH2 carrier (PT0018) is now available, therefore, we aim to 
assess expression of EZH2 transcripts in this variant carrier.  
 
4.6 CONCLUSION 
This study aimed to prioritise rare variants segregating with PCa, following WGS of 
individuals from family, PcTas12. Subsequent genotyping of the larger Tasmanian Familial 
Prostate Cancer Study cohorts found an intronic variant in EZH2 (rs78589034) to be 
significantly associated with PCa risk (OR=3.27, p=0.001). Given that this association has not 
been previously described, validation in larger cohorts of PCa cases and controls is warranted. 
Presented here are preliminary findings assessing the functional effect of the intronic variant 
on EZH2 gene and protein expression, the splicing capabilities of EZH2 and EZH2 splicing 
factor and target gene expression. A larger sample size of fresh, frozen prostate tissue will 
prove fruitful for this study.  
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CHAPTER 5 :  IDENTIFICATION AND 
FUNCTIONAL ASSESSMENT OF A RARE PROSTATE 
CANCER RISK VARIANT IN HOXB13 
 
Publications arising from this chapter: 
FitzGerald LM*, Raspin K*, Marthick JR, et al. Impact of the G84E variant on HOXB13 
gene and protein expression in formalin-fixed, paraffin embedded prostate tumours. Sci 




In recent years, a number of rare prostate cancer (PCa) susceptibility genes have been 
identified, however the HOXB13 gene is the only one that has been consistently replicated 
11,151-156. It has also been shown that many breast and ovarian cancer predisposition genes, 
including BRCA1, BRCA2, CHEK2 and ATM increase the risk of PCa 235-238, suggesting that 
shared genetic factors predispose to multiple cancer types. To explore this theory, 
Leongamornlert et al. (2019) recently used a targeted sequencing approach to screen 1281 
young-onset PCa cases and 1160 controls for protein truncating variants in known prostate, 
breast and ovarian cancer predisposition genes 239. The study identified 233 unique variants in 
97 genes, each of which had minor allele frequency’s (MAF) of less than 0.50% in their control 
population. Gene-set analysis found a subset of 20 genes associated with increased PCa risk 
(OR=3.2, p=4.1x10-3) 239. The gene list covered 167 DNA repair genes and eight PCa candidate 
genes, with many of these from the breast and ovarian cancer associated (BROCA) cancer risk 
panel designed by Walsh and colleagues (2010) 172-176. DNA repair genes are crucial regulators 
of DNA damage and repair, and therefore, their dysregulation can lead to genomic instability 
and ultimately, cancer 240. Previous studies have observed variants in DNA repair genes in only 
2% of early low-to-intermediate risk PCa, whereas this frequency increases to 6% in high-risk 
localised disease and up to 12% in metastatic disease 241,242. In fact, it is now recommended 
that germline testing for variants in BRCA2 and ATM is undertaken in all men with high-risk 
localised PCa, or more advanced, metastatic disease 243.  
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Previously we have used an agonistic approach to gene discovery, however a more targeted 
approach was used here. A targeted approach enables the concurrent identification of novel 
PCa predisposition variants and validation of previous associations. In this chapter we took an 
alternative approach by selecting a panel of 36 genes for examination. Whole-genome 
sequencing (WGS) data from five Tasmanian Familial Prostate Cancer Cohort families were 
screened for potential disease-associated rare coding variants in 36 genes (Appendix 11). The 
gene list comprised known PCa predisposition genes, including HOXB13 11, MSR1 239, 
TANGO2 and CHAD 244, genes associated with breast cancer, such as BRCA1 and BRCA2 235, 
and other DNA repair genes from the BROCA gene set, including ATM 172-176. The results 
presented in this chapter are published in Scientific Reports 1.  
 
5.2 METHODS 
5.2.1 Whole-genome sequencing analysis  
In total, 33 individuals from five Tasmanian PCa families were selected for WGS as described 
in Chapter 3.2.1. The data were analysed, annotated and variants called as previously 
mentioned (Chapter 3.2.2), with each family analysed separately. In this study, only variants 
in the 36 candidate genes were prioritised further (Appendix 11). Prioritisation was guided by 
the frequency of the variant in the Exome Aggregation Consortium (ExAC; non-Finnish 
European, non-TCGA (The Cancer Genome Atlas) population), a publicly available database 
consisting of sequencing data from 60,706 unrelated individuals 158. Variants with a MAF of 
<2% in ExAC were prioritised for segregation analyses. Rare, segregating variants with 
evidence of functional consequences using in silico functional prediction tools, such as SIFT 
159, PolyPhen2 160 and CADD (Combined Annotation Dependent Depletion; model v1.3) 161 
were prioritised. The carrier frequency of the prioritised variants were determined in the eight 
Tasmanian controls with WGS data, plus a literature search using online search engines, 
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) 163 and PubMed to determine if the variant 
has previously been associated with cancer.  
  
5.2.2 Validation, segregation and association analysis of prioritised rare variants  
Variants prioritised from the WGS data were validated by Sanger sequencing and sequencing 
of additional family members was used to track segregation with disease, as described 
previously (Chapter 3.2.3). For those cases without gDNA, formalin-fixed paraffin embedded 
(FFPE) DNA was sequenced for the prioritised rare variants (Appendix 2). If found to 
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segregate, rare variants were screened in the entire Tasmanian Familial Prostate Cancer 
Cohort and the Tasmanian Prostate Cancer Case-Control Study, as discussed in Chapter 3.2.4 
(Appendix 6). MQLS analysis 2 was used to determine if there was an association between the 
prioritised rare variants and PCa risk in the Tasmanian population as discussed in Chapter 
3.2.5. 
 
5.2.3 Quantification of HOXB13 gene expression 
Absolute HOXB13 gene expression (ENST00000290295.7) was analysed as discussed in 
Chapter 2.3 (Appendix 3). The absolute copy number of HOXB13 was normalised to the copy 
number of the housekeeping genes, b-Actin and GAPDH. RT-qPCR primers were designed to 
the most commonly transcribed isoform in the prostate (as per GTEx Analysis Release V7 
(dbGaP Accession phs000424.v7.p2; https://gtexportal.org/home/)) 137 and are displayed in 
Appendix 3. 
 
5.2.4 Allele-specific next-generation sequencing 
A region surrounding the HOXB13 variant was analysed using the Illumina MiSeq next-
generation sequencing approach (Appendix 12). cDNA samples were PCR amplified and 
visually assessed by agarose gel electrophoresis. Amplicons were then quantitated with the 
Qubit 2.0 Fluorometer, using the dsDNA broad range sensitivity kit (Life Technologies), 
according to the manufacturer’s instructions. PCR products were diluted to 0.5ng/µL and then 
barcoded with a forward and reverse tag each, according to the conditions in Appendix 1. Each 
sample was barcoded with its own unique combination of forward and reverse tags, which were 
10bp in length, with i5 and i7 adaptors 20bp in length. These barcodes were designed by our 
collaborator, Andrea Polanowski (Australian Antarctic Division; Appendix 13). Barcoded 
DNA fragments were pooled, purified and quantitated, as previously described, and the 2nM 
library was sequenced on the Illumina MiSeq platform using the MiSeq® V2 300 Cycle 
Reagent Kit (Illumina).  
 
FastQ files were aligned to the reference genome (hg19) using the web interface wrapper, 
Galaxy version 16.04 245,246.  The FastQ files were converted to Sanger and Illumina 1.8+ format 
using the FASTQ Groomer tool, followed by realignment using BWA-MEM. The allele 
frequency at the variant position (rs138213197, G84E) was visualised using IGV 2.3.68 247. 
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FastQC of BAM files was used to assess the quality of the raw sequence data (an example is 
shown in Appendix 14). 
 
5.2.5 Quantification of HOXB13 protein expression 
Immunohistochemistry (IHC) was undertaken as per Chapter 2.4 (Appendix 5). Normal 
prostate glands (Abcam) ascertained as wild-type for the HOXB13 variant by Sanger 
sequencing, were used as a positive control. Negative controls included primary antibody only, 
secondary antibody only, and a mouse IgG1 isotype control (Dako).  
 
5.2.6 Allele-specific methylation analysis 
FFPE DNA (~200ng) was bisulphite converted using the EZ DNA Methylation-GoldTM Kit 
(Zymo Research Corp), as per the manufacturer’s instructions. Two primer sets were designed 
to amplify fragments covering the HOXB13 promoter/exon 1 CpG island and a CpG island 
~4.5kb upstream of the transcription start site (Appendix 12), using MethPrimer 248. 
Amplification was performed according to the conditions in Appendix 1. Fragments were 
purified using the QIAquick Gel Extraction Kit (Qiagen), as per the manufacturer’s 
instructions, and were cloned into the p-GEM®-T Easy Vector Kit (Promega Corporation), 
using a 3:1 ratio of insert to vector. Top10 competent cells (Invitrogen) were transformed with 
2µL of ligations. Ten white clones per sample were selected for amplification and DNA 
extraction, using the QIAprep Spin Miniprep Kit (Qiagen), as per the manufacturer’s 
instructions. Inserts in the clones were sequenced using the reverse Sp6 primer (ThermoFisher 
Scientific). Each CpG site, for each clone was scored as either 1, methylated or 0, 
unmethylated, and bubble maps were generated using the CpG Bubble Chart Generator, 
Version 20061209 Alpha, created by Mark A Miranda.  
 
A 175bp region of HOXB13, including the G84E mutation and nine surrounding CpG sites, 
was PCR amplified using bisulphite-converted FFPE DNA, as described previously in Chapter 
2.3 (Appendix 12). Products were barcoded with unique forward and reverse tags (Appendix 
13) and sequenced on the Illumina MiSeq platform, as described above (Chapter 5.2.4). 
FASTQ files were quality score checked and separated into reads containing the G84E variant 
allele and the wild-type allele. A beta value (b), the ratio of methylated versus unmethylated 
reads, was determined for all nine CpG sites. An unpaired Student’s t-tests was used to compare 
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methylation in reads containing the G84E variant allele versus reads with the wild-type 
(comparison of b values). P values <0.05 were considered to be statistically significant. 
 
5.3 RESULTS 
5.3.1 Rare variant prioritisation  
Thirty-three individuals from five PCa families were successfully WGS, including five affected 
men from PcTas3 (Table 3.2 and Figure 3.3), five individuals from PcTas4 (Table 3.4 and 
Figure 3.7), eleven individuals from PcTas22 (Table 3.6/8 and Figure 3.10), three individuals 
from PcTas12 (Table 4.1 and Figure 4.4) and nine individuals from PcTas72 (Figure 5.1, Table 
5.1 and Figure 5.2).  
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Figure 5.1 PcTas72 Pedigree. 
This a pedigree of family, PcTas72, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability of DNA from cases and their unaffected relatives, which is represented 
by red arrows. Please note, in each instance, the disease status for earlier generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals have been 
marked as affected in the pedigrees. This pedigree is included to illustrate the size of the pedigree only, please refer to Figure 5.2 and 5.3 for individual annotations.  
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PC72-02 Male Affected 76 MD 6 (3+3) 
PC72-03 Male Affected 67 WD 4 (2+2) 
PC72-04 Male Affected 70 PD 9 (4+5) 
PC72-75 WES Female N/A N/A N/A N/A 
PC72-94 Male Unaffected 68^ N/A N/A 
PC72-97 Female N/A N/A N/A N/A 
PC72-106 Male Unaffected 58* N/A N/A 
PC72-126 Male Affected 51 - 6 (3+3) 
PC72-188 Male Unaffected 33* N/A N/A 
WES: Whole-exome sequenced; ^: Age at death; *Unaffected, age at WGS; 1Tumour grade obtained from 
pathology report; 2Contemporary Gleason Score from FFPE tissue block chosen for macrodissection of 
nucleic acids and IHC; WD: well differentiated; MD: moderately differentiated; 
PD: poorly differentiated; -: information not present in original pathology report; N/A: not applicable. 
Figure 5.2 A condensed PcTas72 pedigree showing individuals chosen for whole-genome or 
whole-exome sequencing. 
Individuals chosen for WGS are indicated by red arrows, in this case, four PCa cases, three PCa unaffected 
male relatives and 2 female relatives were chosen. Note: PC72-75 has WES data.  
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The WGS data from the five families was screened for rare variants in 36 cancer-associated 
genes, including DNA repair genes and previously identified PCa predisposition genes 
(Appendix 11). In total, 17 rare variants and seven novel variants were identified (in AR, ATM, 
BRCA1, BRCA2, HOXB13, NBN, NKX3-1, OR5H14, PALB2, RAD51C, RNASEL, SLX4 and 
TANGO2; Table 5.2 and Appendix 15), however only five had a CADD score >15 and were 
found in two or more affected individuals (Table 5.2). The known PCa risk variant, HOXB13 
G84E was also identified in a single PCa case in PcTas72. Given that the HOXB13 G84E 
variant is known to be associated with PCa 11, the focus of the remainder of this chapter is 
characterising the contribution of this variant to the Tasmanian population and, secondly, 
understanding its functional impact as this has not yet been established.  
 
Subsequent genotyping of PcTas72 identified an additional five carriers, including three PCa 
cases and a female carrier, PC72-97, with Mantle Cell Lymphoma (Figure 5.3). Segregation of 
the HOXB13 variant was observed in two branches of PcTas72.  
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Table 5.2 Prioritised rare variants in known cancer-associated genes following whole-genome sequencing of five Tasmanian prostate cancer families. 
 
























ATM rs56128736 11:108,119,723 0.20 PcTas22 Main 2 out of 5/ 0 out of 1 23.4 T > C; V410A 0 out of 8 Not reported 
ATM rs1800058 11:108,160,100 1.27 PcTas22 Sub 2 out of 4/ 1out of 1 16.54 
C > T; 
L1420F 
1 out of 8 
Hereditary 
cancer: Benign 
ATM rs4986761 11:108,124,511 0.70 PcTas72 2 out of 4/ 1 out of 4 19.39 T > C; S707P 0 out of 8 
Hereditary 
cancer: Benign 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; N/A: Not found in ExAC or ClinVar; WGS: Whole-genome 
sequenced; 2CADD: Combined Annotation Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 
3Associated condition: Interpretation of variant 163. An additional 18 variants were also identified in the 36 cancer-associated genes that were selected (Appendix 11) and 
they are shown in Appendix 15. 
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RAD51C rs61758784 17:56,772,272 0.35 PcTas72 3 out of 4/ 0 out of 4 21.7 
G > A; 
A126T 
0 out of 8 
Hereditary 
cancer: Benign 
RNASEL Novel 1:182,555,547 N/A PcTas3 2 out of 5 16.21 
G > A; 
A132V 
0 out of 8 N/A 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: Minor allele frequency; N/A: Not found in ExAC or ClinVar; WGS: Whole-genome 
sequenced; 2CADD: Combined Annotation Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study; eight were WGS; 
3Associated condition: Interpretation of variant 163. An additional 18 variants were also identified in the 36 cancer-associated genes that were selected (Appendix 11) and 









Figure 5.3 HOXB13 G84E variant carriers in PcTas72.   
This is a condensed pedigree of PcTas72 comprising all HOXB13 variant carriers (shown in yellow) and their relationship. Non-variant carrier family members are shown in 
grey and the individuals who were WGS are indicated by red arrows.  
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5.3.2 Association of the HOXB13 variant with prostate cancer risk in Tasmania 
Screening of 94 Tasmanian controls, as described in Chapter 2.1.3, revealed the absence of any 
HOXB13 G84E carriers. Following TaqMan genotyping of our entire Tasmanian Familial 
Prostate Cancer Cohort (n=714) and Tasmanian Prostate Cancer Case-Control Study 
(n=853), a further 8 familial cases from an additional five PcTas families, plus 3 unaffected 
relatives, 3 sporadic cases and 1 control were identified. MQLS analysis 2 demonstrated a 
significant association between the HOXB13 variant and PCa risk in the Tasmanian population 
(OR=6.59, p=4.2x10-5). The number of familial case carriers was much higher compared to 
their unaffected family members, and the sporadic cases carried the variant at a lower 
percentage than the affected and unaffected family members (Table 5.3). The variant was also 
assessed for enrichment in groups within the Tasmanian Familial Prostate Cancer Study 
cohorts, as well as in comparison to ExAC (Table 5.4). The HOXB13 G84E variant was 
enriched in the Tasmanian familial PCa cases versus the controls (p=0.03), however it was not 
enriched in any Tasmanian patient group compared to ExAC. Familial case carriers in our 































HOXB13 rs138213197 PcTas72 12, 22, 63, 213, 3250 8 (3.21%) 6 (1.34%) 3 (0.61%) 1 (0.29%) 0.22 6.59 4.22x10-5* 
Familial case and familial unaffected comprise the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian Prostate Cancer 
Case-Control Study; 1(n=total sample size); 2ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; *Significant p-value 
Table 5.4 Comparison of HOXB13 variant carrier status in our Tasmanian Familial Prostate Cancer Study cohorts compared to ExAC or Tasmanian controls. 









































1.80 (+)  
p=0.18  
3.02 (+)  
p=0.08 
0.03 (-)  
p=0.86 
1.56 (-)  
p=0.21 
3.44 (+)  
p=0.06  































1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; Entire Resource includes the Tasmanian Familial Prostate Cancer Cohort and the Tasmanian 
Prostate Cancer Case-Control Study; Familial cases are a part of the Tasmanian Familial Prostate Cancer Cohort; Sporadic case and control comprise the Tasmanian 
Prostate Cancer Case-Control Study; 2In the chi square test (+/-) indicates directionality, where (+) means the minor allele frequency is greater in the first named 
population versus the comparison dataset, whereas, (-) indicates it is more enriched in the second named population; *Significant p-value. 
 128 
5.3.3 Association of the HOXB13 variant with clinical characteristics and tumour 
pathology 
Following genotyping of the Tasmanian Familial Prostate Cancer Study cohorts, the HOXB13 
G84E variant was identified in an additional five families. The age at diagnosis of carriers 
versus non-carriers was similar in all six families (Table 5.5). Likewise, for tumour pathology, 
the Gleason score (GS) of carriers and non-carriers was similar. On average the majority of 
tumours had a GS of 6 (3+3) or 7 (3+4) (Table 5.5). 
 
 
Table 5.5 Clinicopathological characteristics of prostate cancer cases from the six HOXB13 








PC72-01 CT 70 WD - 
PC72-02 CT 76 MD 6 (3+3) 
PC72-06 CT 62 - 8 (4+4) 
PC72-154 CT 63 WD 4 (2+2) 
PC72-03 CC 67 WD 4 (2+2) 
PC72-04 CC 70 PD 9 (4+5) 
PC72-05 CC 69 WD 6 (3+3) 
PC72-07 CC 87 - - 
PC72-08 CC 75 - - 
PC72-09 CC 69 WD - 
PC72-77 CC 66 PD 10 (5+5) 
PC72-114 CC 57 - - 
PC72-126 CC 51 - 6 (3+3) 
PC72-134 CC 76 - - 
PC72-150 CC 96 PD - 
PC72-293 CC 57 M/PD 7 (3+4) 
PC72-303 CC 59 - - 
PC72-306 CC 50 M/PD 7 (4+3) 
PC72-307 CC 73 - 8 (4+4) 
1
Tumour grade obtained from pathology report; 
2
Gleason Score obtained from pathology report; WD: well 
differentiated; MD: moderately differentiated; PD: poorly differentiated; M/PD: moderately-poorly 









PC12-03 CT 62 WD 4 (2+2) 
PC12-07 CT 59 PD 9 (4+5) 
PC12-08 CT 73 - 6 (3+3) 
PC12-01 CC 63 MD 6 (3+3) 
PC12-02 CC 80 MD 6 (3+3) 
PC12-04 CC 63 MD 6 (3+3) 
PC12-05 CC 65 WD - 
PC12-06 CC 80 PD 7 (3+4) 
PC12-09 CC 68 - 6 (3+3) 
PC12-132 CC 61 - 8 (4+4) 
PC12-187 CC 71 - 6 (3+3) 
PC12-254 CC 76 WD 6 (3+3) 
PC22-203 CT 79 PD 8 (4+4) 
PC22-576 CT 69 M/PD 7 (3+4) 
PC22-637 CT 70 - 8 (4+4) 
PC22-01 CC 72 WD 5 (2+3) 
PC22-02 CC 64 MD 6 (3+3) 
PC22-03 CC 62 WD - 
PC22-04 CC 57 MD 6 (3+3) 
PC22-05 CC 85 M/PD 8 (4+4) 
PC22-06 CC 63 WD - 
PC22-07 CC 61 WD - 
PC22-16 CC 74 WD - 
PC22-17 CC 56 MD 6 (3+3) 
PC22-21 CC 69 - 6 (3+3) 
PC22-167 CC 69 WD - 
PC22-169 CC 60 M/PD 7 (3+4) 
PC22-183 CC 69 MD 6 (3+3) 
PC22-239 CC 64 MD 7 (3+4) 
PC22-246 CC 66 MD 6 (3+3) 
PC22-249 CC 59 - - 
PC22-387 CC 83 - 8 (4+4) 
PC22-416 CC 58 MD 8 (3+5) 
1
Tumour grade obtained from pathology report; 
2
Gleason Score obtained from pathology report; WD: well 
differentiated; MD: moderately differentiated; PD: poorly differentiated; M/PD: moderately-poorly 









PC22-387 CC 83 - 8 (4+4) 
PC22-416 CC 58 MD 8 (3+5) 
PC22-584 CC 63 MD 7 (3+4) 
PC22-589 CC 72 - 7 (4+3) 
PC22-657 CC 60 - 6 (3+3) 
PC22-660 CC 69 - - 
PC22-698 CC 55 - - 
PC63-01 CC 67 WD - 
PC63-02 CC 63 WD - 
PC63-03 CC 74 MD - 
PC63-06 CC 72 - 7 (3+4) 
PC63-12 CC 78 WD 2 (1+1) 
PC63-18 CC 62 PD 9 (5+4) 
PC63-24 CC 67 MD 6 (3+3) 
PC63-74 CC 65 W/MD 7 (3+4) 
PC63-133 CC 60 - - 
PC63-286 CC 62 MD 6 (3+3) 
PC63-293 CC 63 - 6 (3+3) 
PC213-13 CT 59 MD 6 (3+3) 
PC213-01 CC 68 WD 6 (3+3) 
PC213-17 CC 65 - 6 (3+3) 
PC213-106 CC 75 - - 
PC213-516 CC 68 - 8 (5+3) 
PC213-712 CC 61 - 6 (3+3) 
PC213-718 CC 86 WD 4 (2+2) 
PC213-731 CC 75 - 6 (3+3) 
PC213-756 CC 71 - 7 (3+4) 
PC213-772 CC 73 - 9 (4+5) 
PC213-833 CC 61 - 7 (3+4) 
PC213-845 CC 63 - 6 (3+3) 
PC213-861 CC 58 - 7 (4+3) 
PC213-874 CC 61 - 6 (3+3) 
PC213-881 CC 64 - 6 (3+3) 
1
Tumour grade obtained from pathology report; 
2
Gleason Score obtained from pathology report; WD: well 
differentiated; MD: moderately differentiated; PD: poorly differentiated; W/MD: well-moderately 



















PC213-883 CC 72 - 9 (4+5) 
PC213-935 CC 62 - 7 (4+3) 
PC213-938 CC 75 - 8 (4+4) 
PC213-946 CC 58 - 7 (3+4) 
PC213-971 CC 55 - 7 (4+3) 
PC213-991 CC 68 PD 9 (4+5) 
PC3250-01 CT 51 PD 9 (4+5) 
1
Tumour grade obtained from pathology report; 
2
Gleason Score obtained from pathology report; PD: poorly 
differentiated; -: information not present in original pathology report. 
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5.3.4 Targeted collection of prostate tumour specimens from HOXB13 variant carriers 
Targeted collection of FFPE specimens from local pathology laboratories was undertaken for 
known HOXB13 variant carriers (n=4), as well as a random selection of G84E non-carriers 
(n=7). Where possible, we also collected tumour specimens from affected relatives of known 
carriers for whom we didn’t have a germline sample available (n=11). Genotyping of prostate 
tissue DNA from the 22 blocks confirmed four and identified five additional heterozygous 
G84E carriers, including a case whose germline DNA was genotyped as wild-type (PC22–203; 
Table 5.6). Repeat genotyping of PC22–203 germline and re-extracted tumour DNA samples 
confirmed the discordant result. First-degree relatives of this individual were genotyped as 
G84E wild-type. No additional samples were available for this individual (deceased) therefore, 
this anomaly could not be resolved to determine whether a pathology sample mix-up had 
occurred, mosaicism was present in the individual or the variant arose somatically.  
 
Clinical analyses of the FFPE specimens revealed no detectable difference in the age at 
diagnosis of the G84E variant carriers (n=9) versus non-carriers (n=13; p=0.22, Table 5.6). For 
those samples with malignant glands present, there was no detectable difference observed in 





Table 5.6 Clinicopathological characteristics of FFPE prostate tumour samples obtained for 

















PC4-03 80 CC TURP CC M/PD 7 (4+3) 
PC11-11 85 N/A TURP CC - 7 (3+4) 
PC11-12 58 N/A TURP CC - 9 (4+5) 
PC11-13 72 N/A TURP CC - Benign 
PC11-16 78 N/A TURP CC - 5 (2+3) 
PC12-01 63 CC RP CC MD 6 (3+3) 
PC12-06 80 N/A TURP CC PD 7 (3+4) 
PC12-09 68 N/A TURP CC - 6 (3+3) 
PC22-06 63 CC TURP CC WD Benign 
PC47-02 68 CC TURP CC WD Benign 
PC60-01 58 CC TURP CC WD 6 (3+3) 
PC63-24 67 N/A TRUS CC MD 6 (3+3) 
PC72-04 70 CC TURP CC PD 9 (4+5) 
PC12-03 62 N/A TURP CT WD 4 (2+2) 
PC12-07 59 N/A TURP CT PD 9 (4+5) 
PC12-08 73 N/A TURP CT - 6 (3+3) 
PC22-203 79 CC TRUS CT PD 8 (4+4) 
PC22-576 69 N/A RP CT M/PD 7 (3+4) 
PC22-637 70 CT TRUS CT PD 8 (4+4) 
PC72-06 62 CT TURP CT W/MD 5 (3+2) 
N/A: sample not available; TRUS: Transrectal ultrasound-guided biopsy: TURP: Transrectal resection of the 
prostate; RP: Radical prostatectomy;
 1
Tumour grade obtained from pathology report; 
2
Contemporary Gleason 
Score from FFPE tissue block chosen for macrodissection of nucleic acids and IHC; WD: well differentiated; 
MD: moderately differentiated; PD: poorly differentiated; W/MD: well-moderately differentiated; M/PD: 



















PC72-154 63 CT TRUS CT WD 4 (2+2) 
PC3250-01 51 CT RP CT PD 9 (4+5) 
TRUS: Transrectal ultrasound-guided biopsy: RP: Radical prostatectomy;
 1
Tumour grade obtained from 
pathology report; 
2
Contemporary Gleason Score from FFPE tissue block chosen for macrodissection of 
nucleic acids and IHC; WD: well differentiated; PD: poorly differentiated; -: information not present in 
original pathology report. 
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5.3.5 The effect of the G84E variant on HOXB13 gene expression 
To investigate HOXB13 gene expression, RT-qPCR was undertaken. RNA was extracted 
separately from adjacent malignant and benign glands for 10 cases, and due to limited tissue 
availability, from benign glands only and malignant glands only for four cases each and a 
mixed cell population for one case (Appendix 16). HOXB13 expression was initially assessed 
in the 10 paired malignant-benign samples for both carriers and non-carriers. Significantly 
higher expression was observed in malignant compared to benign cells (1.5-fold increase; 
p=0.01; Figure 5.4A). However, when HOXB13 expression was statistically compared between 
the malignant glands of G84E variant carriers (n=6) and non-carriers (n=8), there was no 
significant difference detected (p=0.21; Figure 5.4B). There was also no detectable difference 
in HOXB13 gene expression between the benign glands of variant carriers (n=4) and non-





Figure 5.4 HOXB13 gene expression analysis in malignant and benign prostate glands, and in malignant glands from G84E carriers and non-
carriers.  
The spread of the data is represented by a box and whisker plot. Median expression is shown by the thick black line, the interquartile range (middle 50% of data set) is 
represented by the box, and the minimum and maximum values by the whiskers (dotted lines). Individual outliers are shown with dots. A) HOXB13 expression was 
assessed in prostate tumours with matched malignant and benign glands (npairs=10). Absolute DAPK3 gene expression was calculated for each sample by normalising 
to the expression of two housekeeping genes. HOXB13 expression in malignant and benign glands was compared using a paired Student’s t-test. B) HOXB13 expression 
was assessed in malignant prostate glands from G84E carriers (n=6) and non-carriers (n=8). Absolute HOXB13 gene expression was calculated for each sample by 
normalising to the expression of two housekeeping genes. HOXB13 expression in malignant glands from G84E carriers and non-carriers was compared using an unpaired 
Student’s t-test. 
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We next examined whether the variant allele was detectable in the tumour tissue of seven G84E 
variant carriers. Next-generation sequencing applied to cDNA from freshly cut FFPE sections 
indicated that only two of seven variant carriers had evidence of variant allele transcription 
(Table 5.7). The variant allele was detectable in both malignant and benign glands in one 
individual (PC12-03) and in benign cells only in the second individual (PC72-06). In all cases, 




















To determine whether imbalanced allele transcription was related to HOXB13 G84E carrier 
status, allele-specific transcription was determined for another variant in relatively close 
proximity to the G84E variant. The HOXB13 variant, rs9900627 (MAF 11.2%), is 262bp 
centromeric to G84E and is also located in exon 1 (Appendix 12). Genotyping of our tumour 
tissue samples identified one carrier of rs9900627 (PC11-11; G84E negative). Unlike carriers 
of G84E, the variant and wild-type alleles of rs9900627 were detectable in equal proportions 
in this tumour.  
 
Sample Identification Tissue Cell Type G84E Variant Allele Transcription1 
PC12-03 Malignant + 
 Benign + 
PC12-07 Malignant - 
PC12-08 Malignant - 
PC22-203 Malignant - 
PC22-576 Benign/Malignant - 
PC72-06 Malignant - 
 Benign + 
PC3250-01 Malignant - 
 Benign - 
1Transcribes (+) or does not transcribe (-) the G84E variant allele. 
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5.3.6 The effect of the G84E variant on HOXB13 protein expression 
IHC was performed on all 22 FFPE pathology samples to determine whether protein expression 
differed between benign and malignant prostate tissue, and between HOXB13 variant carriers 
and non-carriers. HOXB13 staining intensity ranged from weak (1) to strong (3) across the 
dataset, and the percentage of HOXB13 positive nuclei ranged from approximately 50-100% 
(Appendix 16). Analyses of the quasi-continuous nuclear scores (staining intensity x % of 
HOXB13 positive nuclei) of 16 samples with paired malignant and benign glands did not reveal 
any significant difference in HOXB13 protein expression between malignant and benign 
glands (p=0.45; Figure 5.5 and Figure 5.6). Analysis of malignant glands from G84E variant 
carriers (n=9) versus non-carriers (n=9) also indicated no significant difference between the 
two groups (p=0.68; Figure 5.6). A similar result was observed for carriers (n=8) and non-
carriers (n=12) in benign glands (p=0.84). 
Figure 5.5 HOXB13 protein expression in FFPE prostate tumour samples. 
HOXB13  protein expression was assessed in 22 prostate tumour specimens from the Tasmanian Prostate 
Tissue Pathology Resource to determine whether the G84E variant affected HOXB13 protein levels. In short, 
IHC using an antibody targeting amino acid 1-284 of the HOXB13 protein was utilised to assess protein 
expression. Staining intensity was scored as weak, moderate or strong. A/C) Weak staining of HOXB13 in the 
nucleoplasm of malignant prostate glands in a G84E non-carrier (A) and carrier (C). B/D) Strong staining of 
HOXB13 in the nucleoplasm of malignant prostate glands in a G84E non-carrier (B) and carrier (D). Images 
were taken with a Leica 2500 microscope (x200) using the Leica Application Suite V3. 
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Figure 5.6 HOXB13 protein expression analysis in malignant and benign prostate glands, and in malignant glands from G84E carriers and non-
carriers. 
HOXB13 protein expression was calculated as a quasi-continuous score (staining intensity x % of HOXB13 positive nuclei) for both malignant and benign glands in all 
samples. The spread of the data is represented by a box and whisker plot. Median expression is shown by the thick black line, the interquartile range (middle 50% of data 
set) is represented by the box, and the minimum and maximum values by the whiskers. Individual outliers are shown with dots. A) HOXB13 expression was assessed in 
prostate tumours with matched malignant and benign glands (npairs=16). HOXB13 expression in malignant and benign glands was compared using a paired Student’s t-test 
B) HOXB13 expression was assessed in malignant prostate glands from HOXB13 G84E carriers (n=9) and non-carriers (n=9). HOXB13 expression in malignant glands 
from G84E carriers and non-carriers was compared using an unpaired Student’s t-test. 
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5.3.7 The effect of the G84E variant on HOXB13 CpG island methylation  
DNA methylation was investigated at two HOXB13 CpG islands, one spanning the promoter 
region and exon 1 of the gene (19 CpG sites) and the other located ~4.5 kb upstream of the 
HOXB13 transcription start site (22 CpG sites; Figure 5.7). Very low levels of DNA 
methylation was observed across both CpG islands in variant carriers (n=3) and non-carriers 
(n=3; Figure 5.8). Patterns of methylation differed between individuals, however there was no 







This figure depicts the structure of the HOXB13 gene; the two exons are shown in large boxes, with the untranslated regions on either side. The location of the HOXB13 G84E 
variant is marked with a dashed line in exon 1 (rs138213197). Two CpG islands are marked; one spans the promoter/exon 1 region and the other is located ~4.5kb upstream of 
the HOXB13 transcription start site. DNA methylation was investigated in these two regions using primer pairs 1 and 2. Allele-specific methylation was examined across nine 
CpG sites in the promoter/exon 1 CpG island, surrounding the G84E variant (Primer pair 3). Primer sequences were designed using MethPrimer 248 and are shown in Appendix 
12. Please note, this diagram is not to scale. 
 









Figure 5.8 Bubble maps showing methylation patterns across the two HOXB13 CpG islands in G84E carriers and non-carriers.  
DNA methylation was investigated at two HOXB13 CpG islands; the first ~4.5kb upstream of the HOXB13 transcription start site (A and B; primer pair 1 on Figure 5.7) and 
the promoter/exon 1 region (C and D; primer pair 2 on Figure 5.7) in G84E carriers (A and C) and non-carriers (B and D). Bubble maps were produced using CpG Bubble 
Chart Generator, Version 20061209 Alpha. The location of the CpG site is shown from left to right, with every sequenced clone depicted one above the other. Open circles 
indicate non-methylated CpG sites while coloured circles indicate methylated sites. Overall, very low levels of FFPE DNA methylation was observed, however patterns 







Allele-specific methylation was also examined across nine CpG sites within the promoter/exon 
1 CpG island (surrounding the G84E variant) to determine if differential methylation explained 
the observed unbalanced allele transcription. Allele-specific methylation was also consistently 
low across all nine CpG sites in both variant carriers (n=10) and non-carriers (n=7). However, 
methylation of the variant allele was lower than that of the wild-type allele in all instances 
(Figure 5.9). Significant differences in CpG site-specific methylation between the variant and 
wild-type alleles of both carriers and non-carriers was observed at three CpG sites (p<0.05), 
while no difference was observed between the wild-type alleles of carriers and non-carriers 
(Figure 5.9). No statistical correlation between methylation and transcription of the G84E 




















Figure 5.9 Average methylation across nine CpG sites located within the CpG island surrounding the G84E variant.  
Allele-specific methylation was examined across nine CpG sites within the HOXB13 promoter/exon 1 CpG island. CpG sites are labelled 1-9, which are left to right in 
Figure 5.7. Both G84E carriers (n=10) and non-carriers (n=7) were examined. Wild-type and variant allele methylation were assessed separately for G84E carriers, and 
in all instances the percentage of methylated reads versus total reads was calculated, which is shown here. Average methylation was compared between the three groups 
at each CpG site and those statistically significant are marked (*p=<0.05, **p=<0.01).  
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5.4 DISCUSSION 
5.4.1 The HOXB13 G84E variant and prostate cancer risk 
The HOXB13 G84E variant, rs138213197, was initially identified as a PCa risk variant by 
Ewing and colleagues (2012), and has since been replicated in several population and family-
based case-control studies 11. G84E is a missense variant in exon 1 of the HOXB13 gene which 
results in a glycine to glutamic acid substitution at amino acid position 84. The variant amino 
acid residue is larger, less hydrophobic and negatively charged compared to the wild-type, 
suggesting that the variant allele may affect protein structure and/or function 168. It has a CADD 
score of 22.7; predicting it to be in the top 0.1% of all damaging variants in the genome 161, is 
highly conserved across species and is predicted to be deleterious and probably damaging by 
computational algorithms, SIFT and PolyPhen2, respectively 159,160. 
 
In the normal prostate, the highly expressed HOXB13 transcription factor plays a key role in 
prostate development 249. Notably, HOXB13 has been shown to interact with the androgen 
receptor (AR), a protein essential for prostate development and required for all stages of PCa 
growth 250. Norris and colleagues (2009) demonstrated that HOXB13 acts as both a repressor 
and coactivator of AR target genes 250; in target genes with an androgen-response element the 
HOXB13:AR complex inhibits transcription, but in genes with a HOX element, the complex 
enhances transcription 250. HOXB13 has been reported to function as a growth promoter and 
growth suppressor in PCa models, depending on factors such as tumour androgen sensitivity 
status and cellular localisation of the protein (reviewed in 251). Therefore, the role of HOXB13 
in prostate tumour development appears complex. 
 
The HOXB13 G84E variant was initially identified in probands from four PCa families, 
following targeted whole-exome sequencing (WES) of a known and replicated linkage peak 11, 
as described in Chapters 1.7 and 3.1. Subsequent population and family-based studies have 
confirmed the association of the variant with early-onset, familial disease, including an 
Australian study that established a relative risk of 16.4 (95% CI: 2.5-107.2) 252. Other studies 
have simply shown that the G84E variant is more frequently observed among men with PCa 
compared to men without cancer 151,253. This association with overall PCa risk was replicated 
here in our study by MQLS analysis 2 (OR=6.59, p=4.22x10-5). Enrichment analysis found the 
G84E variant to be enriched in the familial PCa case cohort compared to our population 
controls. When comparing familial and sporadic cases to controls, this significant finding was 
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diminished, which may indicate that the G84E variant is more relevant in men with a family 
history of disease. However, the carrier frequency of our familial cohort was not significantly 
different to ExAC. Overall, enrichment analysis doesn’t take in to account the relatedness of 
individuals, whereas MQLS can test for association with risk by taking into account all available 
relationship data.  
 
Notably, the mechanism by which the HOXB13 gene and, specifically, the G84E variant 
promotes prostate carcinogenesis, is largely unknown. Further analyses are required to 
determine whether the G84E variant causes a gain or loss of gene function, or increases PCa 
risk through other mechanisms.  
 
5.4.2 Examining the effect of the G84E variant on HOXB13 gene and protein expression 
and methylation patterns in prostate tumours 
The G84E amino acid change could cause the torsion angles in the wild-type backbone to be 
forced in to an incorrect conformation, which could lead to disturbance of the protein structure 
168. However, a computational modeling study by Chandrasekaran and colleagues (2017) has 
suggested that the G84E variant increases HOXB13 protein stability 254, which may in turn 
cause increased transcription of downstream target genes promoting cell proliferation and 
invasion 255. In an in vitro cell model study using site directed mutagenesis, Cardoso and 
colleagues (2016) found that the G84E variant had no phenotypic impact thus, proliferation 
and apoptotic potential was comparable to the wild-type cell model 256. In our study of FFPE 
prostate tumour tissue, no difference in HOXB13 protein expression was found between G84E 
carriers and non-carriers; a finding supported by a larger IHC study of radical prostatectomy 
samples from 101 G84E carriers and 99 non-carriers 257.  
 
Furthermore, we demonstrated that gene expression was comparable between G84E variant 
carriers and non-carriers. Although tumour tissue samples from carriers were demonstrated to 
be heterozygous for the G84E variant, the variant allele was rarely detectable in G84E carrier 
prostate tissue (benign or malignant glands). In fact, the variant allele was only detectable in 
two of seven carriers and at lower levels than the wild-type allele. To further examine HOXB13 
allelic expression, transcription of another HOXB13 variant (rs9900627) in close proximity to 
G84E was examined. Comparable transcription of both the rs9900627 wild-type and variant 
alleles was observed in the malignant glands of a non-G84E carrier. We therefore hypothesise 
that the unbalanced allele transcription may be related to the presence of the G84E variant. 
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Unbalanced allele transcription has previously been reported in a study of breast cancer patients 
258. Benz and colleagues (2006) investigated the common ERBB2 variant, G1170C, in ERBB2-
positive and ERBB2-negative breast cancer patients and found that although tumour 
genotyping supported the heterozygous state, similar to our study, 70% of tumours showed 
preferential transcription of one allele, or unbalanced allele transcription 258. The authors 
suggested that the unbalanced allele transcription in ERBB2-negative tumours may be due to 
epigenetic mechanisms, whereby methylation silences a particular allele 258. 
 
Two CpG islands are located within or near the HOXB13 gene; the first spans the promoter and 
exon 1 region of the gene and the second is ~4.5 kb upstream of the HOXB13 transcription start 
site 259. In a study of colorectal cancer, Ghoshal and colleagues (2010) found very little 
methylation in the promoter/exon 1 CpG island in both tumour and normal cell lines, whilst 
the upstream CpG island was significantly more methylated in tumour compared to normal cell 
lines 259. They found that hypermethylation of the upstream CpG island partially suppressed 
HOXB13 expression and speculate that this region may function as an enhancer 259. In our 
study, we observed very low levels of DNA methylation at both CpG islands in all prostate 
tumour samples tested, thus no association with HOXB13 expression was able to be examined. 
When we looked further at allele-specific methylation of nine CpG sites surrounding the G84E 
variant in exon 1, overall level of methylation across this region was again very low, however 
methylation was lower at three CpG sites on the variant allele compared to the wild-type. 
Overall, our sample size reduced our statistical power of finding an association between 
patterns of methylation and G84E carrier status. There are significant cis-expression 
quantitative trait loci (cis-eQTL) encompassing HOXB13, which explain how differentially 
methylated CpG sites may act as mediators between genetic variation and gene expression 260. 
Even though the GTEx Portal (https://gtexportal.org/home/) has found no significant cis-
eQTLs in prostate tissue 137, it is possible that other methylation differences explain the 
unbalanced allele transcription we observe in the G84E carriers. Alternatively, copy number 
variation at the HOXB13 site or rapid targeted degradation of the variant mRNA transcript may 






5.4.3 Association of G84E carrier status with clinical characteristics and tumour 
pathology 
Several previous studies have investigated possible associations between the G84E variant and 
clinicopathological factors, and the majority have found no association between carrier status 
and GS 11,154,261,262. However, two studies have presented contrary results. A Danish study of 
995 cases (25 G84E carriers) found G84E carrier status was significantly associated with GS 
≥7 versus GS <7 (p=0.032) 263; that is the variant is associated with more aggressive disease. 
Another study of 1,457 cases (18 G84E carriers) observed that the G84E variant was more 
strongly associated with GS ≥7 (4+3) disease (OR=4.13), but this was not significantly 
different to the association with GS ≤7 (3+4) disease (OR=2.71) 155. Following analysis of all 
Tasmanian PCa cases in the six carrier families, our study found that the G84E variant was not 
associated with GS, with the majority of men, irrespective of carrier status, having a GS of 6 
(3+3) or 7 (3+4). Interestingly, while the numbers were too small for formal analyses, it 
appeared that clinical characteristics differed between G84E variant carriers who did or did not 
transcribe the variant allele. The tumours from PC12–03 and PC72–06, where the variant allele 
was transcribed, were well- to moderately-differentiated with a GS <6, whereas tumours where 
the variant allele was not transcribed, were predominantly poorly differentiated with a GS ≥7, 
with the exception of one sample (PC12–08; GS 6 (3+3)). Due to insufficient tumour material 
(TRUS biopsy), allele-specific transcription was not able to be determined for two variant 
carriers, PC22–637 and PC72–154.  
 
In previous studies, G84E carrier status has been identified to be associated with an earlier age 
of disease onset. The initial study by Ewing and colleagues (2012) found that G84E carriers 
were more likely to be diagnosed at £55 years compared to non-carriers 11. Here, the age of 
diagnosis between G84E variant carriers and non-carriers in the six carrier families was similar 
(mean of 66 versus 67 years, respectively). While it has to be noted that our observations are 
based on limited numbers, the conflicting results of the studies described above may be due to 
the underlying variability in G84E variant allele transcription that we have observed, and this 






5.4.4 Other prioritised rare variants in cancer associated genes 
This study also identified a number of other rare potential PCa risk variants (Table 5.2). The 
RAD51C A126T variant, like the HOXB13 G84E variant was identified in PcTas72, however 
instead of only being present in one WGS affected case, it segregated with disease in three out 
of four of the WGS individuals. It has a CADD score of 21.7 and has been reported by ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) 163 to be associated with familial breast and ovarian 
cancer, yet it is predicted to be benign. The variant causes a substitution of a small amino acid, 
alanine to a nucleophilic amino acid, threonine, which may cause the protein structure to be 
disturbed 168. In fact, the variant is located on the surface of the protein, which may disturb 
interactions with other molecules or parts of the protein 168. The variants in ATM and RNASEL 
are interesting candidates too. As mentioned in Chapter 3, ATM is a DNA repair gene which is 
responsible for recognising damaged or broken DNA strands, but it also controls the rate at 
which cells grow and divide 116. The highest prioritised ATM variant, rs5612873, was identified 
in two out of five PCa cases in the PcTas22 main pedigree and is predicted to be damaging to 
protein function, with a CADD score of 23.4. The variant results in a smaller amino acid, which 
may lead to loss in interactions and an inability to repair defective DNA 168. RNASEL is a 
known PCa susceptibility gene, which has been found to be associated with disease in families 
with five or more affected relatives, father to son transmission, a younger age of diagnosis and 
a higher GS 94. Here, a novel variant was identified in two affected men from PcTas3. It has a 
CADD score of 16.21 and causes the small glycine amino acid to be substituted with a 
hydrophobic, valine 168. The variant is located within a stretch of residues that is repeated in 
the protein, which is known as an ankyrin repeat domain. Thus, the variant may disturb this 
repeat and consequently, its function, which is to bind to other molecules 168.  
 
5.4.5 Limitations of this study 
This study has provided important insights into the effect the HOXB13 variant has on gene 
transcription in prostate tumour tissue, but there are some limitations. Due to the rarity of the 
variant and the limited availability of informative tumour tissue specimens, the number of 
samples available for G84E variant carriers was restricted. A small sample size results in 
reduced power and, therefore lowers the likelihood of detecting statistically significant 
differences between groups. For example, the sample size of our methylation assays 
significantly hampered our power to link carrier status with DNA methylation patterns. Thus, 
the concepts explored in this study should be followed-up in a larger tissue cohort of G84E 
carriers. The quality of DNA and RNA extracted from FFPE tissue is also fairly poor, therefore 
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it is important that our findings are validated in larger FFPE cohorts or, if available, fresh frozen 
samples. Lastly, in our IHC experiment, the antibody used was not specific to the variant form 
of the HOXB13 protein and it would be valuable to verify our gene expression results with a 
variant-specific protein antibody.  
 
5.4.6 Possible interactions between two prostate cancer risk genes identified in our 
Tasmanian cohort  
Previous literature suggests that the PCa risk genes identified in this study, EZH2 and HOXB13, 
may interact. In a study of 148 non-small cell lung cancer, HOXB13 was found to upregulate 
EZH2 expression, via binding directly to the EZH2 promoter 264. Liu and colleagues (2012) 
also observed that EZH2 represses HOXB13 expression through recruitment of DNMT3b to 
the HOXB13 promoter 265. In fact, Xiong et al. (2018) showed that the overexpression of a long 
noncoding RNA, HOXB13-AS1, increased DNMT3b-mediated methylation of the HOXB13 
gene promoter by binding to EZH2, epigenetically suppressing HOXB13 expression 266. 
Therefore, given that we had DNA methylation data from the HOXB13 promoter region, as 
well as ~4.5 kb upstream of the transcription start site, we assessed whether differential 
methylation of HOXB13 was present between EZH2 carriers and non-carriers. Two EZH2 
variant carriers (PC12-03 and PC12-09) and three non-carriers (PC4-03, PC11-11 and PC12-
07) were examined and although our analyses lacked statistical power, Figure 5.6 shows low 
methylation across the HOXB13 region in all tumour DNA samples (some were completely 
unmethylated). Overall, there appeared to be no difference in HOXB13 methylation between 
EZH2 carriers and non-carriers.  
 
5.5 FUTURE DIRECTIONS 
This study has provided insight into the effect of the HOXB13 G84E variant on HOXB13 
expression at the transcriptional and translational level, however it is still unclear how the 
mutation functionally leads to increased cancer risk. It is possible that the G84E variant affects 
the developing prostate during embryonic development when HOXB13 expression levels are 
very high. Future studies should investigate the variants effect on the developing prostate, as 
well as the pathways that may be affected by this variant. Chandrasekaran and colleagues 
(2017) suggested that the G84E variant may cause increased transcription of downstream target 
genes, such as MEIS, AR and FOXA1 and FOXA2, therefore it is possible that these interactions 
are affected by the presence of the variant. Given that MEIS expression has been implicated in 
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collaboration with HOX genes in the development of leukaemia, these interactions are an ideal 
area for future research, as variants in HOXB13 could affect the function of MEIS itself, or its 
target genes 267. HOXB13 interactions with FOXA1 and FOXA2 are also interesting. FOXA1 is 
enriched at tumour-specific AR binding regions, just like HOXB13, and FOXA2 may have the 
ability to bind to the AR enhancer and regulate HOXB13 expression 268,269. To determine 
whether the G84E variant has an effect on these interactions, gene expression assays and 
pathway analysis could be performed in an in vitro setting, using cell lines with and without 
the variant. Overall, through collaboration with members of the Prostate Cancer Association 
Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) 
consortium, we aim to further explore the function of this variant. 
 
This study also identified a number of other rare PCa risk variants, however further follow-up 
studies are required. Table 5.2 details an additional five variants in ATM, RAD51C and 
RNASEL that were prioritised, however given the replicated association of the HOXB13 G84E 
variant this was the only one followed-up. Appendix 15 details an additional eight novel 
variants and 12 rare variants in other DNA repair genes and PCa associated genes that have not 
been further assessed at this stage. Rare variants in ATM, BRAC1, BRCA2 and RNASEL that 
have been previously associated with breast and PCa (RNASEL A132V) were identified here 
(Appendix 15), therefore follow-up analysis is required to characterise their contribution to the 
Tasmanian population. Overall, validation, segregation and association analysis of the 
RAD51C variant is currently underway, however it is also possible to follow up the other 
identified rare/novel variants using the study design described in this thesis.  
 
5.6 CONCLUSION 
In conclusion, this study has found that the well-known HOXB13 G84E variant also contributes 
to PCa risk in the Tasmanian population (OR=6.59, p=4.22x10-5). Functional assessment of 
the effect this variant has on gene and protein expression provided some insight into the 
expression levels of HOXB13 in malignant and benign prostate glands of G84E carriers and 
non-carriers, however questions still remain regarding how this variant promotes cancer 
development. This is because the sample size presented here is too small to make definitive 
conclusions about the functional consequence of this variant. Therefore, it is important that our 
findings are validated in larger FFPE cohorts or, if available, fresh frozen samples. Overall, 
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this chapter has proven that a targeted approach to rare variant prioritisation can aid in the 




CHAPTER 6 :  CHROMOSOMAL ABERRATIONS 
IN TASMANIAN PROSTATE TUMOURS 
 
6.1 INTRODUCTION 
Prostate tumours are extremely heterogenous at the molecular, genetic and phenotypic level 
270. Tumour heterogeneity is the phenomenon of individual tumour foci, and even individual 
cells, presenting distinct characteristics 271. Despite tremendous progress over the last decade, 
we still lack understanding of the extent and effect of intra-tumour heterogeneity, particularly 
in prostate tumours. This makes the diagnosis and treatment of prostate cancer (PCa) difficult 
and can result in poor outcomes for the patient.  
 
Mapping chromosomal aberrations has provided insight into the genetic makeup of a range of 
tumours and, in some instances, formed the basis of cancer classification systems used to 
stratify patients and determine their treatment option, for example in haematological 
malignancies 272,273. Chromosomal aberrations include deletions, amplifications, inversions 
and translocations. Chromosomal deletions, inversions and translocations can result in the 
fusion of two separate genes and this phenomenon will be discussed in Chapter 7. In this 
chapter, deletions and amplifications resulting in DNA copy number variations (CNVs) will 
be examined. CNVs are frequent in PCa tumours of high grade and advanced stage 274,275 and 
have previously been identified in the clinic by traditional chromosomal karyotyping in blood 
samples. However, in research, comparative genomic hybridisation (CGH) is commonly used, 
which is far more advantageous, as DNA can be obtained from cell lines, and fresh, frozen or 
formalin-fixed paraffin embedded (FFPE) tumour tissue.  
 
CGH is a molecular cytogenetic method developed by Kallioniemi and colleagues (1992), 
which examines a tumour genome for DNA sequence CNVs 276. In the late 1990’s, array-based 
CGH (aCGH) superseded CGH, due to its increased resolution (5-10Mb to 1.4Mb) 277,278. It 
has provided the flexibility to gain a genome-wide view of abnormalities, but also provides the 
opportunity to target specific regions of the genome to gain an in-depth picture of CNVs. aCGH 
also significantly improves the detection of genomic aberrations in cancer cells compared to 
previously established whole-genome methodologies 279. 
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To date, most CGH studies have been performed using sporadic tumours, and have confirmed 
loci previously identified by traditional methods. Consistent regions of gain may potentially 
harbour causative proto-oncogenes, whereas regions of loss could identify tumour suppressor 
genes 276,280. Thus far, almost all of the chromosomes have been found to be gained or lost in 
sporadic prostate tumours. Overall, the most frequently altered chromosomes include 6, 7, 8, 
10, 13, 16, 17 and X 281. The 8p chromosomal region is the most commonly deleted region in 
the prostate tumour genome, affecting about a third of all tumours and half of advanced 
tumours 282. This alteration was first described by Matsuyama et al. (1994) in a study of primary 
and metastatic deposits of PCa 283. Since then, many groups have used a variety of methods to 
fine-map this loss to 8p22 (but not exclusively) 284,285. The long arm of chromosome 8 is also 
frequently gained in PCa. In fact, it is the most commonly gained region, affecting about a 
quarter of all tumours and half of advanced tumours 282. The 8q region of gain was shown to 
harbour the c-MYC gene at 8q24 by Jenkins and colleagues (1997), and was one of the first 
chromosomal regions to be linked to a causal gene 286. However, as the amplification event on 
8q is quite large, this suggests that many genes may be affected. Another locus identified by 
CGH that has led to the identification of a candidate gene is the deletion of 10q23, which 
harbours the candidate tumour suppressor gene, PTEN 287,288. The PTEN deletion is now 
considered a likely useful biomarker for the diagnosis of lethal PCa 289,290. The 16q region is 
also frequently deleted in PCa and following fine-mapping by Sun and colleagues (2005) 
resulted in the identified of ATBF1. It is thought that the loss of ATBF1 is one mechanism that 
defines the absence of growth control in PCa 291. Despite these discoveries, there are very few 
additional examples of observed chromosomal aberrations in sporadic prostate tumours where 
the underlying casual gene has been identified. 
 
To date, there are only two published studies that have assessed chromosomal aberrations in 
familial prostate tumours. Verhagen et al. (2000) undertook the first CGH study of high risk 
PCa families, which included six familial cases with sufficient prostate tumour tissue 292. This 
study also included seven sporadic tumours (defined as no linkage to 1q24-25 or Xq27-28). 
Loss of 7q and 10q, and gain of 8q were consistently identified aberrations in both familial and 
sporadic tumours. Distinctive abnormalities observed in familial tumours only, included loss 
of 3p12-3p22 in five tumours (83%) and gain of 6q11-6q21 in four tumours (67%) 292. A later 
CGH analysis of 21 prostate tumours from 19 Finnish PCa families identified common losses 
at 13q14-13q22 (29%), 8p12-pter (24%) and 6q13-6q16 (14%), and gains at 19p (25%), 19q 
(14%) and 7q (14%) 293. Overall, there are many consistently altered regions that have been 
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identified in both sporadic and familial prostate tumours. Notably, two chromosomal regions, 
16q and 18q are consistently lost in sporadic prostate tumours, which was supported by 
Verhagen and colleagues (2000) 292. These two regions were not identified in any of the familial 
tumours included in the familial CGH study by Rokman et al. (2001) 293, suggesting that 
familial PCa tumours harbour some unique genetic changes compared with sporadic prostate 
tumours. This may indicate that underlying genetic predisposition may cause familial tumours 
to acquire different CNVs compared to sporadic tumours. Overall, the completion of further 
familial PCa CGH studies will aid in the identification of somatic tumour alterations and the 
possible link between these and PCa predisposition variants.  
 
Previously our group has used the Spectral ChipTM 2600 BAC array to highlight regions of loss 
and gain in one of our familial PCa families, PcTas9 (Table 6.1) 294. Since this work, next-
generation platforms have emerged as a useful tool for the identification of chromosomal 
abnormalities. These CGH platforms provide far greater resolution and can be used with far 
more confidence on FFPE tumour DNA. This chapter aims to expand on our preliminary 
findings through the analysis of Agilent Oligonucleotide aCGH data from a larger collection 
of PcTas9 tumour samples. We aim to identify consistent regions of loss and gain in these 
tumours that may be caused by underlying inherited germline variants.  
 
 


























6.2.1 Array-Based Comparative Genomic Hybridisation  
Twelve PcTas9 tumours were assayed on a customised SurePrint G3 Human 8 x 60K 
Microarray (Agilent Technologies), designed by Dr Liesel FitzGerald (Menzies Institute for 
Medical Research (AUS). Regions of loss and gain previously identified in tumours from 
PcTas9 were targeted for fine-mapping (Table 6.1; Appendix 17). In addition to this, the array 
also assays the entire genome, providing genome-wide data for each tumour. The aCGH 
procedure and analysis was carried out by the Molecular Anatomical Pathology laboratory at 
PathWest, according to the manufacturer’s instructions for FFPE tissue samples (report in 
Appendix 18). The reference sample used for this analysis was a female, therefore to pass 
quality control (QC) tumour samples had to show loss of chromosome X and gain of 
chromosome Y. Data were visualised in Cytogenomics 5.0.2.5 (Agilent) and analysed for 
CNVs using the Default Analysis Method CGHv2. Regions with a log ratio of > 0.3 (gain) or 
< -0.3 (loss), regardless of the number of probes, were considered chromosomal aberrations.  
 
6.2.2 Quantification of EEF2 and DAPK3 gene expression 
EEF2 (ENST00000309011.6) and DAPK3 (ENST00000301264.3) gene expression in FFPE 
prostate tumour samples was assessed by RT-qPCR analysis (Appendix 3). Expression was 
normalised to the expression of two housekeeping genes, as discussed in Chapter 2.3. RT-
qPCR primers were designed to the most commonly transcribed isoform in the prostate (as per 
GTEx Analysis Release V7 (dbGaP Accession phs000424.v7.p2; 
https://gtexportal.org/home/)) 137 and are displayed in Appendix 3. Absolute gene expression 
was compared between tumours from PcTas9 and non-PcTas9 cases. The non-PcTas9 patient 
group comprised DVA sporadic tumours from the Tasmanian Prostate Cancer Case-Control 
Study and tumours from other Tasmanian Familial Prostate Cancer Cohort families.  
 
6.2.3 Statistical analysis of absolute EEF2 gene expression   
Random intercepts models were used to estimate and compare mean levels of absolute EEF2 
gene expression in the PCa families. A modified Bonferroni procedure was used to prevent the 
family-wise error rate rising above the pre-specified alpha of 0.05. With families ranked in 
terms of descending mean levels of absolute EEF2 gene expression, a binary (0/1) covariate 
for the family with the highest mean was included in the model. If the Wald test of its estimated 
coefficient yielded a p-value less than 0.05, a binary (0/1) covariate for the family with the 
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second-highest mean was included in the model. If the Wald test of its estimated coefficient 
yielded a p-value less than 0.05/2, a binary (0/1) covariate for the family with the third-highest 
mean was included in the model and tested at the 0.05/3 significance level. This sequential 
process was terminated when the null hypothesis was accepted at any step. This analysis was 
performed under the guidance of biostatistician, Professor Leigh Blizzard, Menzies Institute 
for Medical Research (AUS).  
 
6.2.4 Quantification of EEF2 protein expression 
EEF2 protein expression in FFPE prostate tumours was assessed by immunohistochemistry 
(IHC), as discussed in Chapter 2.4 (Appendix 5). Cytospins of HEK293 cells, and sections of 
colon and skin were used as positive controls. Negative controls included primary antibody 
only, secondary antibody only, and a mouse IgG1 isotype control (Dako). EEF2 protein 
expression was compared between tumours from PcTas9 and non-PcTas9 cases. 
 
6.3 RESULTS 
6.3.1 Targeted collection of prostate tumour samples from PcTas9 men for array 
comparative genomic hybridisation analysis  
Targeted collection of prostate tissue specimens from local pathology laboratories was 
undertaken for affected men in the Tasmanian family, PcTas9 (Figure 6.1). In total, 26 FFPE 
samples from PcTas9 PCa cases were obtained (Figure 6.2). In addition, tissue specimens from 
27 familial cases from 14 additional Tasmanian PCa families, and 15 sporadic cases were 
available for this study and together, these 42 FFPE specimens comprised the non-PcTas9 
patient group.  
 
To investigate the prevalence of chromosomal aberrations in PcTas9, 12 samples from across 




Figure 6.1 PcTas9 Pedigree. 
PcTas9 pedigree, depicting the number and relationships of PCa cases (shown in shaded squares), as well the availability of DNA from cases and their unaffected relatives, which is represented by red arrows. 
The disease status for earlier generations is generally unknown, unless this information was obtained from clinical records. And if so, these individuals have been marked as affected in the pedigrees. This 
pedigree is included to illustrate the size of the pedigree only, please refer to Figure 6.2 for individual annotations. 
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Figure 6.2 A condensed PcTas9 pedigree showing tumour samples chosen for array Comparative Genomic Hybridisation analysis. 
This condensed version of PcTas9 indicates those PCa cases with available prostate tumour specimens (shown by red arrows) and their relationship. Tumours chosen for aCGH analysis are shown in yellow.  
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Table 6.2 PcTas9 tumour samples chosen for array Comparative Genomic Hybridisation, 




















6.3.2 Quality assessment of array data 
The 12 FFPE DNA samples were assayed across two separate arrays, with four replicates for 
QC (Table 6.3). The Derivative Log Ratio (DLR) spread was considered the most important 
QC metric, which calculates the probe to probe log ratio noise of an array. A DLR spread of 
>0.3 is defined by Agilent as poor, however as FFPE samples normally lie within 0.3 and 0.6, 
a DLR spread threshold of £0.6 was considered acceptable, but only if the sex chromosome 
patterns were as expected (loss of chromosome X and gain of Y due to a female reference 
sample; Table 6.3; report in Appendix 18). In total, three tumours, including PC9-13, PC9-211 
and PC9-659 failed QC as they had gain of chromosome Y, but no loss of chromosome X 
(Appendix 19). PC9-158 also failed QC as the DLR spread of both replicates was >0.6. Overall, 











PC9-12 66 RP MD 6 (3+3) 
PC9-13 83 TURP - 9 (4+5) 
PC9-20 76 TURP PD 9 (4+5) 
PC9-158 63 RP - 6 (3+3) 
PC9-211 68 TURP PD 9 (4+5) 
PC9-477 55 RP - 6 (3+3) 
PC9-532 70 RP - 6 (3+3) 
PC9-588 63 RP MD 6 (3+3) 
PC9-620 71 RP PD 9 (4+5) 
PC9-627 65 RP - 7 (3+4) 
PC9-645 60 RP - 7 (3+4) 
PC9-659 65 RP PD 9 (4+5) 
RP: Radical prostatectomy; TURP: Transurethral resection of the prostate; 1Tumour grade 
obtained from pathology report; 2Contemporary Gleason Score from FFPE tissue block 
chosen for macrodissection of nucleic acids and IHC; MD: moderately differentiated; PD: 
poorly differentiated; -: information not present in original pathology report. 
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6.3.3 The identification of chromosomal aberrations 
Seven tumours from those that passed QC (n=8) showed regions of chromosomal loss and all 
eight tumours had regions of gain (Table 6.4; Appendix 22). Overall, four tumours were shown 
to harbour four or more chromosomal losses, with only PC9-620 having more than 10. Seven 
tumour samples showed gain at four or more chromosomal regions with one tumour, PC9-645 
shown to harbour more than 10 amplifications. Chromosomal aberrations were considered to 
be consistent across PcTas9 tumours if they were identified in three or more tumours. The most 
consistent losses observed in PcTas9 tumours were found at chromosomal regions 1p36.21 and 
19p13.3 (Table 6.5). The most consistent regions of gain were at 6p23-p22.3, 6p24.2, 17p13.3 
and 19p13.3 (Table 6.5). The 19p13.3 region was amplified across three separate genes, 
including PTPRS (38%), ZBTB7A (50%) and, notably, EEF2 (Eukaryotic Translation 
Elongation Factor 2) was gained in all eight tumours (Figure 6.3).  
 




PC9-12 2 0.52 Yes Pass 
PC9-13 1 & 2 0.64 & 0.52 No & No Fail & Fail 
PC9-20 2 0.48 Yes Pass 
PC9-158 1 & 2 0.65 & 0.62 Yes & Yes Fail & Fail 
PC9-211 1 & 2 0.66 & 0.58 No & No Fail & Fail 
PC9-477 1 0.42 Yes Pass 
PC9-532 1 0.47 Yes Pass 
PC9-588 1 & 2 0.57 & 0.51 Yes & Yes Pass & Pass 
PC9-620 1 0.40 Yes Pass 
PC9-627 2 0.44 Yes Pass 
PC9-645 1 0.52 Yes Pass 
PC9-659 2 0.60 No Fail 
DLR: Derivative Log Ratio; 1Tumour DNA passed quality control if the DLR spread was £0.6 and there 




Table 6.4 Chromosomal aberrations identified by array Comparative Genomic Hybridisation analysis of prostate tumour samples from PcTas9 cases. 
 
 
Sample Identification Chromosomal Losses Chromosomal Gains 
PC9-12 17p13.2 3q11.1-q26.32, 19p13.3 
PC9-20 
6p23-p22.3, 8p23.3-p11.21, 16q22.1-q24.3, 17q25.1-q25.3, 18q21.32-q23, 
21q22.11-q22.3 
1p34.3-p13.2, 3q12.3-q29, 7p21.2, 17p13.3, 19p13.3, 
20p12.3-p11.21, 20p12.2 
PC9-477 1p36.21, 6p24.3-p24.2, 6p23-p22.3, 17p13.3, 19p13.3, 19p13.3-p11 6p24.2, 7p21.1, 17p13.3, 19p13.3 
PC9-532 1p36.21, 6p24.3-p24.2, 6p23-p22.3, 19p13.3 
3q13.11-q25.32, 5q11.2-q12.1, 6p24.2, 6p23-p22.3, 7p21.3, 
17p13.3, 19p13.3 
PC9-588# None 
6q22.31-q26*, 7p22.1-p15.3*, 8q12.1-q24.3*, 10q25.2-
q26.2, 11p15.1-p13*, 20p12.3-p11.1 
PC9-620 
1p36.21, 2p13.1-p11.1, 6p24.3-p24.2, 6p23-p22.3, 6q12-q21, 10p15.1-p11.21, 
13q14.12-q34, 16q22.2-q24.1, 17p13.3, 17p13.2, 19p13.3 
1p36.22, 6p25.3, 6p24.2, 7p22.3-p11.2, 7q21.11-
q22.1,17p13.3, 19p13.3 
PC9-627 6p23-p22.3, 19p13.2-p12 6p24.2, 10q26.2, 17p13.3, 19p13.3 
PC9-645 17p13.3 
3q13.31-q26.2, 4q12-q35.2, 6q12-q26, 7p22.3-p11.2, 
7q11.21-q36.3, 10q25.1-q26.2, 11q12.1-q24.1, 17p13.3-
p13.2, 19p13.3, 20p12.3-11.1 
#Duplicated samples on both arrays; *Chromosomal aberration not identified on both arrays. 
Please Note: PC9-13, PC9-158, PC9-211 and PC9-659 did not pass QC. 
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CNV in PcTas9 
tumours 
Tumours with CNV Known association with cancer 
Interesting genes underlying the 
region of alteration* 
Loss 1p36.21 38% (3/8) PC9-477, 532, 620 Ovarian cancer 295 
PRAME and HNRNPCL gene 
families 
Loss 19p13.3 38% (3/8) PC9-477, 532, 620 Prostate cancer 296 TINCR (lncRNA00036) 
Gain 6p23-p22.3 63% (5/8) PC9-20, 477, 532, 620, 627 Bladder cancer 297 and retinoblastoma tumours 298 JARID2 
Gain 6p24.2 50% (4/8) PC9-477, 532, 620, 627 No known association NEDD9 
Gain 17p13.3 63% (5/8) PC9-20, 477, 532, 620, 627 Prostate cancer 296 DPH1 
Gain 17p13.3 25% (2/8) PC9-477, 620 Prostate cancer 296 MNT 
Gain 17p13.3 25% (2/8) PC9-532, 620 Prostate cancer 296 SMG6 
Gain 19p13.3 38% (3/8) PC9-477, 532, 620 Prostate cancer 296 PTPRS 
Gain 19p13.3 50% (4/8) PC9-20, 532, 620, 627 Prostate cancer 296 ZBTB7A 
Gain 19p13.3 100% (8/8) 
PC9-12, 20, 477, 532, 588, 
620, 627, 645 
Prostate cancer 296 EEF2 










Figure 6.3 Visual representation of the recurrent 19p13.3 amplification identified by array comparative genomic hybridisation of tumour samples 
from PcTas9 cases. 
A) Schematic of all amplifications and deletions across the entire genome in all samples combined; this was visualised using BlueFuse Multi Software (Illumina). Chromosomes 
are represented left to right, with the amplitude of loss and gain on the y axis. Regions considered to be significantly lost or gained are illustrated by the coloured lines above 
the chromosomal region. The q arm of chromosome 19 is amplified in all tumours as indicated by blue. B) A close-up view of 19p encompassing the DAPK3 and EEF2 genes 
(labelled). Each probe on the array is represented by a colour dot, and the coloured lines represent individual samples. The y axis is the CGH pane, with any alteration above 
or below 0 considered be an amplification or deletion, respectively. An amplification encompassing the beginning of EEF2 all the way to the region upstream of DAPK3 was 




6.3.4 Assessment of the chromosomal gain at 19p13.3 by gene expression analysis 
The 19p13.3 chromosomal region was the most commonly altered region in the PcTas9 
tumours. Three genes in this region were amplified, including PTPRS in 38% of tumours, 
ZBTB7A in 50% of tumours and EEF2 in 100% of tumours. EEF2 has previously been shown 
to be overexpressed in prostate tumours and is in a pathway that has recently been suggested 
as a therapeutic target for cancer 299. To further investigate this amplification, gene expression 
analysis using RT-qPCR was undertaken. RNA was extracted from adjacent benign and 
malignant glands for 19 cases, and where limited tissue was available, in only tumour glands 
for 21 cases. These 40 tumours were from PcTas9 (n=17) and non-PcTas9 familial cases 
(n=16), and DVA sporadic PCa cases (n=7). EEF2 expression was analysed in five regions 
across the gene, including 5’UTR/exon 2, exon 2/3, 4/5, 9/10 and 14/15 (Appendix 24). 
Significantly higher expression was observed in malignant compared to benign glands 
(npairs=19) in the regions of exon 2/3 (p=0.003), 4/5 (p=0.04) and 9/10 (p=0.004; Figure 6.4).  
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Figure 6.4 EEF2 gene expression analysis in malignant and benign prostate glands.  
EEF2 expression in five different regions of the gene was assessed in prostate tumours with matched malignant and benign glands (npairs=19). A schematic of the most commonly 
transcribed isoform of EEF2 in the prostate is shown to the right. Absolute EEF2 gene expression was calculated for each sample by normalising to the expression of two 
housekeeping genes. EEF2 expression in malignant and benign glands was compared in each region  using a paired Student’s t-test. The spread of the data is represented by a 
box and whisker plot. Median expression is shown by the thick black line, the interquartile range (middle 50% of data set) is represented by the box, and the minimum and 





















When EEF2 expression in malignant glands was compared across the patient groups, the 
regions of EEF2 5’UTR/exon 2 and exon 4/5 were expressed at a significantly higher level in 
PcTas9 tumours (n=18) compared to tumours from non-PcTas9 cases (n=23; p=0.02 and 




Figure 6.5 EEF2 gene expression analysis in malignant and benign prostate glands from sporadic, familial and PcTas9 tumours. 
EEF2 expression in five different regions of the gene was assessed in prostate tumours from three patient groups, sporadic (DVA), familial (PC) and PcTas9. A schematic of 
the most commonly transcribed isoform of EEF2 in the prostate is shown at the top of the page. Absolute EEF2 gene expression was calculated for each sample by normalising 
to the expression of two housekeeping genes. Shown here is the average absolute EEF2 gene expression for each patient group for benign and malignant glands, with regions 
of EEF2 depicted by different colours. Those considered to be significantly upregulated compared to other PcTas9 tumours are indicated by an *. 
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Initial observation of individual tumour expression revealed that not all PcTas9 tumours were 
overexpressing these two EEF2 regions (Appendix 24). Random intercepts models to estimate 
and compare mean levels of absolute EEF2 gene expression validated this finding and hence, 
the PcTas9 family was included in the model. Analysis of EEF2 gene expression in the 
5’UTR/exon 2 region, in only PcTas9 samples, revealed that the higher expression was driven 
by six samples (p=0.001), five of which showed amplification at 19p13.3 by aCGH analysis 
(PC9-12, 20, 532, 627 and 645; Figure 6.6). Notably, PC9-158 failed array QC, but had 
amplification of EEF2 and this validated in our gene expression analysis, however the three 
other tumours with gain of EEF2 on the array, PC9-447, PC9-588 and PC9-620 did not have 
significantly high 5’UTR/exon 2 expression. The six samples with significantly higher 
5’UTR/exon 2 expression also had significantly higher expression of the exon 4/5 region 









* * * * * * 
Figure 6.6 EEF2 gene expression analysis in malignant prostate glands from PcTas9 tumours.  
EEF2 expression in five different regions of the gene was assessed in prostate tumours from PcTas9 cases. A schematic of the most commonly transcribed isoform of EEF2 
in the prostate is shown at the top of the page. Absolute EEF2 gene expression was calculated for each sample by normalising to the expression of two housekeeping genes. 
Individual PcTas9 malignant gland expression is shown here, with regions of EEF2 depicted by different colours. Those considered to be significantly upregulated compared 
to other PcTas9 tumours are indicated by an *. 
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When EEF2 expression was analysed in benign glands, there were no significant differences 
in gene expression across any of the regions between PcTas9 and non-Pctas9 tumours. 
Furthermore, analysis of EEF2 5’UTR/exon 2 expression in PcTas9 tumours with matched 
malignant and benign samples (n=7), indicated that three of the four tumours with 
overexpression of this region in malignant glands, also had very high 5’UTR/exon 2 
malignant/benign expression ratios compared to tumours with no ‘overexpression’ (Table 6.6). 
These results suggest that EEF2 overexpression is an anomaly of malignant glands only. 
Notably, three of the tumours with 5’UTR/exon 2 overexpression clustered within one specific 
branch of the PcTas9 pedigree (Figure 6.7).  
 
 




Amplification of EEF2 
on the aCGH 




EEF2 5’UTR/Exon 2 Ratio 
PC9-12 Yes Yes 3.14 
PC9-158 Yes (but did not pass QC) Yes 112.51 
PC9-477 Yes No 1.34 
PC9-532 Yes Yes 21.68 
PC9-588 Yes No 0.29 
PC9-620 Yes No 3.01 





Figure 6.7 A condensed PcTas9 pedigree showing tumours with EEF2 5’UTR/Exon 2 overexpression in malignant glands. 
This condensed PcTas9 pedigree indicates those tumours assessed for EEF2 5’UTR/exon 2 gene expression; tumours with EEF2 5’UTR/exon 2 overexpression in malignant glands are shown in yellow and 
those with expression similar to the rest of the dataset, in grey.   
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To determine whether EEF2 overexpression was gene or region specific, expression of a 
neighbouring gene, DAPK3 was determined. DAPK3 expression was analysed by RT-qPCR in 
three regions across the gene, including exon 3/4, 4/5 and 7/8 (Appendix 25). Analysis of 14 
paired malignant-benign samples found DAPK3 expression to be similar in both gland types 
across all three regions (p=0.42, 0.48 and 0.52, respectively; Figure 6.8). However, in 
malignant glands only, DAPK3 exon 3/4 expression was significantly different between PcTas9 
(n=17) and non-PcTas9 samples (n=12; p=0.04; Figure 6.9). DAPK3 expression in the non-
PcTas9 malignant samples was approximately 3.7-fold higher than in the PcTas9 samples. 
When focusing on the six tumours with significantly higher EEF2 5’UTR/exon 2 expression, 
these were found to have lower average malignant DAPK3 expression (n=6) compared to the 
remainder of the PcTas9 tumours (n=11), however this was not statistically significant 
(p=0.12). This also remained insignificant when just comparing DAPK3 exon 3/4 expression 
(p=0.25), yet the six EEF2 overexpressing tumours did on average have lower expression of 
this region. There was no detectable difference in DAPK3 gene expression in any region 
between the benign glands of PcTas9 (n=7) and non-PcTas9 tumours (n=9; p=0.24, 0.38 and 








Figure 6.8 DAPK3 gene expression analysis in malignant and benign prostate glands.  
DAPK3 expression in three different regions of the gene was assessed in prostate tumours with matched malignant and benign glands (npairs=14). A schematic of the most 
commonly transcribed isoform of DAPK3 in the prostate is shown at the top of the page. Absolute DAPK3 gene expression was calculated for each sample by normalising to 
the expression of two housekeeping genes. DAPK3 expression in malignant and benign glands in each region was compared using a paired Student’s t-test. Median expression 
is shown by the thick black line, the interquartile range (middle 50% of data set) is represented by the box, and the minimum and maximum values by the whiskers (dotted 












Figure 6.9 DAPK3 gene expression analysis in malignant glands from non-PcTas9 cases compared to PcTas9 cases. 
DAPK3 expression in three different regions of the gene was assessed in malignant prostate glands from two patient groups, non-PcTas9 (comprising sporadic and familial 
tumours; n=12) and PcTas9 (n=17). A schematic of the most commonly transcribed isoform of DAPK3 in the prostate is shown at the top of the page. Absolute DAPK3 gene 
expression was calculated for each sample by normalising to the expression of two housekeeping genes. DAPK3 expression in malignant glands from non-PcTas9 and PcTas9 
tumours in each region was compared using an unpaired Student’s t-test. The spread of the data is represented by a box and whisker plot. Median expression is shown by the 
thick black line, the interquartile range (middle 50% of data set) is represented by the box, and the minimum and maximum values by the whiskers (dotted lines). Individual 
outliers are shown with dots. 
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6.3.5 Association of EEF2 and DAPK3 expression with clinical characteristics and 
tumour pathology 
EEF2 gene expression was analysed as a mean of malignant gland expression per patient group 
(column 2 in Table 6.7) using an unpaired Student’s t-test. While EEF2 expression appeared 
to be higher in tumours with a lower GS (£7 (3+4), n=25) compared to a higher GS (³7 (4+3), 
n=15), this was not statistically significant (p=0.09). There was also no significant difference 
in average EEF2 expression between patients with an early age of disease onset (<65 years, 
n=21) compared to those diagnosed ³65 years of age (n=20; p=0.37).  
 
In terms of DAPK3 expression (column 4 in Table 6.7), similar levels of expression were 
observed between tumours with a low GS (£7 (3+4), n=17) and tumours with a high GS (³7 
(4+3), n=11; p=0.72). There was also no detectable difference in average DAPK3 expression 
between patients with an early age of disease onset (<65 years, n=11) compared to those 
diagnosed ³65 years of age (n=18, p=0.70).  
 
 
Table 6.7 Clinicopathological characteristics of FFPE prostate tumour samples assayed for EEF2 
























DVA 67  0.70  61 - 6 (2+4) 
DVA 157 58.88  7.55 66 - 7 (3+4) 
DVA 167 16.67 1.60  53 PD 9 (5+4) 
DVA 216 91.89 0.20  64 - 5 (3+2) 
Blank cell= sample was not analysed; 1Tumour grade obtained from pathology report; 2Gleason Score 
obtained from pathology report; WD: well differentiated; MD: moderately differentiated; PD: poorly 
differentiated; W/MD: well-moderately differentiated; M/PD: moderately-poorly differentiated; 
























DVA 220 94.53 0 8.03 63 MD 6 (3+3) 
DVA 302  2.70  65 W/MD 6 (3+3) 
DVA 303  2.40  68 M/PD 7 (3+4) 
DVA 402 86.94 2.00  52 MD 6 (3+3) 
DVA 416 27.90 2.00  62 MD 6 (3+3) 
DVA 422  1.60  60 M/PD 7 (3+4) 
DVA 1002 32.61 1.80  61 WD 6 (3+3) 
DVA 1006  0.70  67 - 6 (3+3) 
DVA 1036  0.50  57 - 6 (3+3) 
DVA 1050  0.60  63 - 5 (3+2) 
DVA 1086  3.00  57 - 7 (4+3) 
PC3-08  2.00  69 MD 6 (3+3) 
PC3-31  0.80  54 - 5 (3+2) 
PC4-03 95.98 1.40 4.56 80 M/PD 7 (4+3) 
PC9-04  1.60  63 MD 6 (3+3) 
PC9-06 90.43 1.60 6.61 79 - - 
PC9-07 56.53 0.50  71 PD 10 (5+5) 
PC9-12 290.55 2.00 2.33 66 MD 6 (3+3) 
PC9-13 70.97 1.40 4.77 83 - 9 (4+5) 
PC9-14 169.14 1.60 4.97 79 MD 6 (3+3) 
PC9-15 66.80 2.40 3.39 64 MD 5 (2+3) 
PC9-20 224.60 0.70 3.36 76 PD - 
PC9-158 783.88 0.60 3.02 63 - 6 (3+3) 
PC9-211 26.46 0.70 3.86 68 PD 9 (4+5) 
PC9-338  2.00  63 - 6 (3+3) 
PC9-474  1.80  74 PD 9 (4+5) 
PC9-477 63.00  3.94 55 - 6 (3+3) 
PC9-532 402.96 0.80 3.95 70 - 6 (3+3) 
PC9-545 75.05 0.80 16.32 55 PD - 
PC9-561  2.00  63 MD 6 (3+3) 
Blank cell= sample was not analysed; 1Tumour grade obtained from pathology report; 2Gleason Score 
obtained from pathology report; WD: well differentiated; MD: moderately differentiated; PD: poorly 
differentiated; W/MD: well-moderately differentiated; M/PD: moderately-poorly differentiated; 




























PC9-588 33.31 2.00 3.28 63 MD 6 (3+3) 
PC9-603 62.82  3.79 73 MD 6 (3+3) 
PC9-620 61.18 1.60 5.28 71 PD 9 (4+5) 
PC9-627 161.46 1.40 1.89 65 - 7 (3+4) 
PC9-645 206.05 0.10 2.97 60 - 7 (3+4) 
PC9-659 30.68 1.60 4.25 65 - 9 (4+5) 
PC9-951  1.00  80 WD - 
PC11-11 56.67 2.40 2.84 85 - 7 (3+4) 
PC11-12 52.47   58 - 9 (4+5) 
PC11-19  0  63 - 3 (2+1) 
PC12-01 47.94 0 4.88 63 MD 6 (3+3) 
PC12-03 29.25 0  62 WD 4 (2+2) 
PC12-06 82.59 1.20 6.94 80 - 7 (3+4) 
PC12-07 23.39 0.60 4.67 59 PD 9 (4+5) 
PC12-08 1.95 1.80  73 - 6 (3+3) 
PC12-09 24.68 0 3.53 68 - 6 (3+3) 
PC19-02 20.29 1.20  50 - 6 (3+3) 
PC22-17 49.94 0.80  56 MD 6 (3+3) 
PC22-576 148.29 1.60 11.19 69 M/PD 7 (3+4) 
PC23-02  0.50  78 MD 7 (3+4) 
PC31-01 32.78 1.00  61 PD 10 (5+5) 
PC60-01  1.60  58 WD 6 (3+3) 
PC72-04 38.93 0.70 2.47 70 PD 9 (4+5) 
PC72-06 20.42 0.70 3.25 62 - 8 (4+4) 
PC213-991  2.00  68 - 9 (4+5) 
PC3250-01 114.12 0.50 2.71 51 PD 9 (4+5) 
Blank cell= sample was not analysed; 1Tumour grade obtained from pathology report; 2Gleason Score 
obtained from pathology report; WD: well differentiated; MD: moderately differentiated; PD: poorly 
differentiated; W/MD: well-moderately differentiated; M/PD: moderately-poorly differentiated; 
-: information not present in original pathology report. 
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6.3.6 Assessment of the chromosomal gain at 19p13.3 by protein expression analysis 
IHC was performed on 56 FFPE prostate tumour samples to assess EEF2 protein expression. 
EEF2 staining intensity ranged from none (0) to strong (3) across the dataset, and the 
percentage of EEF2 positive nuclei ranged from approximately 5-100% (Figure 6.10; 
Appendix 24). Analysis of the quasi-continuous score (staining intensity x % of EEF2 positive 
nuclei) from 49 samples with paired malignant and benign glands, revealed increased EEF2 
expression in malignant compared to benign glands (p=0.02; Figure 6.11). Analysis of 
malignant glands from non-PcTas9 tumours (n=36) and PcTas9 tumours (n=21) indicated no 
significant difference between the two patient groups (p=0.33, Figure 6.11). A similar result 
was observed for benign glands (p=0.57). For those PcTas9 tumours with significantly 
increased EEF2 5’UTR/exon 2 gene expression, there was no corresponding increase in protein 
expression compared to other PcTas9 tumours. 
 
6.3.7 Association of EEF2 protein expression with clinical characteristics and tumour 
pathology 
EEF2 protein expression was analysed as malignant gland expression per patient group using 
an unpaired Student’s t-test (column 3 in Table 6.7). No correlation was observed between 
EEF2 protein expression in malignant glands and GS; tumours with a GS £7 (3+4) had similar 
average expression (n=38) compared to tumours with a GS ³ 7(4+3) (p =0.47; Table 6.7). 
However, analysis of EEF2 expression and age at diagnosis revealed that expression was higher 
in tumours from men diagnosed 65 years of age and over (n=26) compared to those under 65 










Figure 6.10 EEF2 protein expression in FFPE prostate tumour samples.  
EEF2 protein expression was assessed in 56 prostate tumour specimens from the Tasmanian Prostate Tissue Pathology Resource to determine whether the amplification of 
EEF2 was translated to the protein level. In short, IHC using an antibody targeting amino acid 31-80 of the EEF2 protein was utilised to assess protein expression. Staining 
intensity was scored as weak, moderate or strong. A) Weak staining of EEF2 in the plasma membrane and cytosol of benign prostate glands. B) Moderate staining of EEF2 in 
the plasma membrane and cytosol of benign prostate glands. C) Strong staining of EEF2 in the plasma membrane and cytosol of malignant prostate glands. Images were taken 
with an Olympus BX53 microscope, using the DP73 camera and software (x100).  
A B C 
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Figure 6.11 EEF2 protein expression analysis in malignant and benign prostate glands, and in malignant glands from non-PcTas9 and PcTas9 
tumours. 
EEF2 protein expression was calculated as a quasi-continuous score (staining intensity x % of EEF2 positive nuclei) for both malignant and benign glands in all samples. 
The spread of the data is represented by a box and whisker plot. Median expression is shown by the thick black line, the interquartile range (middle 50% of data set) is 
represented by the box, and the minimum and maximum values by the whiskers (dotted lines). A) EEF2 expression was assessed in prostate tumours with matched 
malignant and benign glands (npairs=49). EEF2 expression in malignant and benign glands was compared using a paired Student’s t-test. B) EEF2 expression was assessed 
in malignant prostate glands from two patient groups, non-PcTas9 (comprising sporadic and familial tumours; n=36) and PcTas9 (n=21). EEF2 expression in malignant 
glands from non-PcTas9 and PcTas9 tumours was compared using an unpaired Student’s t-test. 
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6.4 DISCUSSION 
6.4.1 Overall findings  
To date, only two CGH studies have investigated genetic changes in familial PCa tumours from 
high-risk families. To our knowledge, this study is the first to examine whether chromosomal 
alterations are shared by affected individuals within the one family. Plus, the first to validate 
regions of aberrations identified by aCGH using RT-qPCR. aCGH analysis of 12 prostate 
tumours from family PcTas9 identified two consistent regions of loss, including 1p36.21 and 
19p13.3. Four regions of gain were also consistently observed across four or more tumours, 
including 6p23-p22.3, 6p24.2, 17p13.3 and 19p13.3 (Table 6.4). Notably, all eight tumours 
that passed QC were shown to harbor a gain at 19p13.3, a region which has been identified as 
a PCa susceptibility region by linkage analysis 300,301. Three genes were amplified in this 
region, including PTPRS, ZBTB7A and EEF2, however a region of gain overlaid the EEF2 
gene in all eight tumours. Interestingly, EEF2 has been postulated as a potential biomarker of 
PCa 299. Follow-up gene expression analysis of our entire Tasmanian Prostate Tissue 
Pathology Resource identified very high expression of the 5’UTR/exon 2 region of EEF2 in 
PcTas9 malignant glands compared to other familial and sporadic cases. Further statistical 
analysis identified six PcTas9 tumours which were driving this overexpression; all of which 
showed amplification on the array (PC9-158 failed QC, but still showed EEF2 aCGH 
amplification), thus further validating our results. Overall, the aim of this study was to 
determine if there was an inherited genetic predisposition to the tumour CNV changes 
identified in PcTas9. However, due to time and sample size limitations, we were only able to 
identify consistent regions of gain and loss in PcTas9 and validate one of these, an 
amplification of EEF2.  
 
6.4.2 Potential effects of an EEF2 amplification  
Remarkably, eight PcTas9 tumours displayed an amplification of the EEF2 gene at 19p13.3. 
Here, the EEF2 amplification observed by aCGH was validated by RT-qPCR where five of 
these samples had increased expression at the gene level (plus PC9-158). EEF2 is an essential 
factor for protein synthesis as it promotes the GTP-dependent translocation of the nascent 
protein chain from the A to the P-site of the ribosome 116. It is overexpressed in a diverse range 
of cancer types, including PCa, and interestingly, has recently been suggested as a potential 
biomarker of PCa 299. Given that EEF2 mediates protein synthesis, which is one of the key 
characteristics of cancer cells, some studies have examined the contribution of EEF2 to 
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tumourigenesis. A study by Nakamura et al. (2009) found that overexpression of EEF2 in 
gastric cancer cell lines significantly enhanced cell growth through promotion of G2/M 
progression in the cell cycle, activated Akt and cdc2, and inactivated EEF2 kinase 302. 
Overexpression of EEF2 in these cancer cells enhanced in vivo tumourigenicity in a mouse 
xenograft model, suggesting that overexpressed EEF2 promotes G2/M progression and 
enhances cancer cell growth in vitro and in vivo 302. Such studies suggest a link between 
translational elongation and cell cycle mechanisms, and disruption of this link may lead to 
dysregulation and cancer promotion. Thus, the EEF2 amplifications observed in our study may 
result in cell cycle alterations, leading to increased tumourigenesis.   
 
6.4.3 Examining EEF2 gene and protein expression in prostate tumours 
The region of gain identified by aCGH analysis encompassed most of the EEF2 gene, therefore, 
we aimed to determine exon-level expression across a number of EEF2 exons to verify this 
result. At the gene level, significantly higher expression was observed in malignant compared 
to adjacent benign glands, in three out of the five regions assessed. The most significant finding 
from our study was that malignant glands from PcTas9 tumours had higher expression of EEF2 
in the 5’UTR/exon 2 and exon 4/5 regions compared to non-PcTas9 tumours. In fact, 
expression was driven by six PcTas9 tumours, all of which demonstrated amplification on the 
CGH array (PC9-158 failed QC, but showed aCGH amplification). Given this validation, it is 
possible to hypothesise that other samples with apparent high 5’UTR/exon 2 expression (>200) 
may also have amplification of this region. Notably, this included one other PcTas9 tumours 
that was not aCGH assayed (PC9-06), plus three other tumours from families PcTas12, 
PcTas22 and PcTas3250 (Appendix 24).  
 
It has been reported that the EEF2 protein is highly expressed in human carcinoma tissue, but 
not in normal tissue 302,303. Studies have reported EEF2 overexpression in ovarian 304 and breast 
cancer 305, and more recently in lung, gastric, colorectal and hepatocellular carcinoma tissue 
302,303,306,307. In fact, Nakamura and colleagues (2008) demonstrated that EEF2 was 
overexpressed in 92.9% of gastric and 91.7% of colorectal cancers 302. To date, only two studies 
have assessed EEF2 expression levels in PCa, with lower percentages of overexpression 
compared to other cancers. Oji et al. (2014) examined four prostate samples, three of which 
overexpressed EEF2 303. More recently Zhang et al. (2018) examined 97 prostate tumours and 
found that 76.29% were EEF2 positive 299. In our study, a significant increase in EEF2 
expression in malignant glands compared to adjacent benign glands was observed (npairs=49, 
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p=0.02). In total, 49% of tumours had EEF2 overexpression, whereas 20% had comparable 
expression between malignant and benign glands. Overall, 87.72% of malignant and 94.74% 
of benign glands were EEF2 positive, thus, percentages were higher compared to the study by 
Zhang and colleagues (2018).  
 
In terms of EEF2 and clinical characteristics, overexpression has been shown to be associated 
with poor patient survival in ovarian cancer 308 and hormone receptor positive breast cancer 
309. A study by Shi et al. (2018) observed that EEF2 expression gradually increased with GS 
(more aggressive), and it correlated significantly with tumour grade (p=0.045) 309. Zhang and 
colleagues (2018) observed a correlation between EEF2 protein expression and 
clinicopathological characteristics of PCa, in particular, the staining intensity of EEF2 was 
significantly associated with age, level of prostate-specific antigen and GS 299. Our study found 
no significant difference in EEF2 gene or protein expression between tumours with a low and 
high GS (£7 (3+4) versus ³ 7(4+3)) or those diagnosed before or after 65 years of age.  
 
6.4.4 Examining DAPK3 gene expression in prostate tumours 
To determine whether this amplification was a gene or region-specific anomaly, expression of 
a neighboring gene, DAPK3 was also examined. DAPK3 was not amplified on the array, 
therefore we wanted to validate this finding by RT-qPCR. DAPK3 expression in the exon 3/4 
region was determined to be 3.7-fold lower in PcTas9 tumour samples compared to non-PcTas9 
tumours (p=0.04). The six PcTas9 tumours with significant EEF2 5’UTR/exon 2 
overexpression had lower average DAPK3 expression compared to the remaining PcTas9 
tumours, however this was not statistically significant. Death-associated protein kinase 3 
(DAPK3) is involved in the regulation of apoptosis, autophagy, transcription and translation 
116. It has been reported that DAPK3 is frequently methylated or mutated in many cancer types, 
resulting in a loss of tumour suppression via DAPK3 310. A study by Chen et al. (2016) 
identified a link between low DAPK3 expression and shorter overall survival rates in 
endometrial cancer (p=0.023) 311. Das and colleagues (2016) examined DAPK3 expression in 
29 FFPE prostate samples and found decreased expression in samples of higher GS 312. Here, 
we identified no significant difference in DAPK3 expression between tumours with a GS £7 
(3+4) and those ³7 (4+3), nor was the mean GS any different between PcTas9 and non-PcTas9 
tumours. Whilst significant DAPK3 exon 3/4 loss was not apparent in the tumours with 
significant EEF2 5’UTR/exon 2 overexpression, it is possible that both alterations, together or 
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independently, influence carcinogenesis. Given that DAPK3’s main function is to regulate 
apoptosis, and DAPK3 overexpressing cells exhibit extreme apoptotic-like morphology 312, 
loss of DAPK3 may enable cancer cells to bypass apoptosis, thus giving them a selection 
advantage over other cells with normal DAPK3 expression.  
 
6.4.5 Other previously identified regions of loss and gain 
Our study of a single PCa family has identified regions of loss and gain previously identified 
by other studies. The most commonly altered region of the PCa tumour genome is 7p21 and 
here, aCGH analysis revealed three tumours with gain of this region, however the breakpoints 
were not consistent across samples. PC9-477 had an amplification at 7p21.1, overlying the 
histone deacetylase 9 (HDAC9) gene, which is involved in cell cycle regulation and 
development 313. This region has also been shown to harbor risk alleles to pancreatic cancer 
314. PC9-532 had an amplification at 7p21.3, which overlies the islet cell autoantigen 1 (ICA1) 
gene. Interestingly, one PcTas9 sample had an amplification at 7p21.2, which overlies the 
ETV1 gene. ETV1 is a well-known gene in PCa tumorigenesis and is often involved in gene 
fusion events at the tumour level 315. This amplification could therefore be the result of a fusion 
event involving ETV1 and an unknown 5’ fusion partner.  
 
The chromosomal region of 17p13.3 was amplified in five PcTas9 tumours, all of which 
represent different branches of the family. Gain of 17p was reported by Rokman et al. (2001) 
in their study of familial PCa, however, this region of gain has not been identified in any 
sporadic tumours, suggesting an association with familial prostate tumourigenesis 296. A 
number of interesting genes are present in this region and play a role in transcriptional 
repression, initiation of transcription, the replication and maintenance of chromosome 
telomeres, and cell growth and differentiation. Of particular interest is the diphthamide 
biosynthesis 1 (DPH1) gene, which was amplified in three out of the five tumours. DPH1 is an 
enzyme involved in the biosynthesis of diphthamide, a modified histidine found only in EEF2 
116. The fact that we have found disruptions to two different genes in the same pathway 
highlights the potential role of this pathway in tumourigenesis.  
 
All eight of the PcTas9 tumours showed gain at 19p13.3, comprising multiple branches of the 
family, including PC9-20 and his second cousin, PC9-12. The 19p region of amplification has 
previously been identified in tumours from familial PCa cases by Rokman and colleagues 
(2001), however has not been identified in sporadic tumours 296. Aside from EEF2, there are a 
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number of other interesting genes underlying the three regions of 19p13.3 gain that play a role 
in; the clearance of misfolded proteins, protein synthesis, cellular processes, transcriptional 
repression, and malignant cell proliferation 116. One interesting gene is ZBTB7A, which was 
amplified in four PcTas9 samples (50%). ZBTB7A is a zinc finger protein that is moderately 
expressed in the prostate. Functional studies of a transgenic mouse model overexpressing 
Zbtb7a in the prostate, found that ZBTB7A suppresses castration-resistant PCa, through 
repression of a Soxa9-dependent pathway for cellular senescence bypass and tumour invasion 
316. In fact, analysis of PCa samples revealed that men whose tumours had high levels of 
nonfunctional ZBTB7A cells responded poorly to androgen-deprivation therapy 317. Given that 
ZBTB7A upregulation in gastric cancer cells promotes apoptosis and represses cell migration 
318, the amplification identified in these four PCa samples may promote carcinogenesis by 
disrupting transcription or translation leading to downregulation of the gene. 
 
6.4.6 Consistently observed regions of loss in the PcTas9 tumours  
The 1p36.21 region of deletion (up to 1.18Mb) was found in three PcTas9 tumours, which 
encompass both branches of the family. This region of loss has never been observed in PCa 
tumours however, it has been linked to ovarian cancer. A study by Dimova et al. (2009) 
involved CGH analysis of 28 ovarian tumours and the 1p36 region was lost in 40% of tumours 
and associated with late-stage cancers 295. This region of loss includes genes in the PRAME 
and HNRNPCL gene families. Preferentially expressed antigen of melanoma (PRAME) family 
members are expressed in many cancer types, but also function in reproductive tissues during 
development 116. Heterogeneous nuclear ribonucleoprotein C like (HNRNPCL) genes encode 
for RNA binding proteins, which influence pre-mRNA splicing processes and alterations could 
lead to alternative transcripts 116. Thus, this region harbours an extensive number of genes that 
could be important in PCa.  
 
Three PcTas9 tumours had a deletion at 19p13.3 and notably, these cases also had loss of 
1p36.21. The region of 19p13.3 has been extensively studied, with linkage studies of hereditary 
PCa identifying it as a PCa susceptibly region 300,301. This region of loss has only been observed 
in familial and not sporadic prostate tumours. Of the 21 familial tumours investigated by 
Rokman et al. (2001) only a small number showed an alteration 296. Present in this region are 
a number of interesting genes which play a role in the antigen presentation process, the 
generation of cytotoxic T cells, and the activation and development of T and B cells 116. 
Particularly interesting is the TINCR long non-coding RNA (LIC00036), which has been 
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suggested to have altered expression in multiple human cancers 319,320. In a recent study by 
Dong and colleagues (2018), low-expression of TINCR was observed in PCa and correlated 
with advanced clinical tumour stage, lymph node involvement, distant metastasis, high GS and 
poor prognosis in their cohort of 160 tumours 321.  
 
6.4.7 Consistently observed regions of gain in the PcTas9 tumours 
A total of five PcTas9 prostate tumours were shown to harbour an amplification at 6p23-p22.3. 
The recurrent gain has not previously been identified in sporadic or familial PCa studies, 
however an amplification at 6p22 has been identified in bladder cancer 297 and retinoblastoma 
tumours 298. This region of gain encompasses the jumonji and AT-rich interaction domain 
containing 2 (JARID2) gene, which is a putative transcription factor that plays a role in DNA 
binding, nuclear localisation, transcriptional repression and recruitment of the Polycomb-
repressive complex 2 322-324. Whilst no study has explored whether this gene has a role in PCa, 
JARID2 has consistently been identified to play a role in the initiation, proliferation and 
maintenance of tumour cells in ovarian and bladder cancer 325,326. Thus, JARID2 may also have 
a role in PCa initiation and development, and further assessment to determine whether this 
gene is disrupted by the amplification is warranted.  
 
Four PcTas9 tumours were shown to harbor a gain at 6p24.2, a region which overlays the 
neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9). NEDD9 
is frequently overexpressed in diverse cancer types and has been linked to tumorigenesis of 
many different malignancies, including PCa and is reasonably expressed in the normal prostate 
116. NEDD9 is also highly conserved across species, is repressed by estrogen in breast cancer 
cells 327 and is induced by Wnt signaling in colon cancer 328. Interestingly, the region of 
amplification of NEDD9 encompasses only the small transcript (NM_006403) and upon further 
investigation using the GTEx portal (https://gtexportal.org/home/), this is the most highly 
expressed transcript in the prostate 137. Therefore, this region of amplification and specifically, 
NEDD9, seems a fitting candidate for follow-up functional studies in our Tasmanian prostate 
tumour resource. 
 
6.4.8 Somatic tumour variation and germline predisposition 
There is no known observable difference in the histopathology of sporadic and familial PCa 
tumours, however it is interesting that not all chromosomal alterations are observed in both 
sporadic and familial tumours. The two most commonly observed losses in tumours of sporadic 
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PCa, 16q and 18q, were not commonly identified in the tumours from PcTas9 men. These 
results reflect those described by Rokman et al. (2001) 293. The often-unique chromosomal 
alterations of familial tumours, such as those presented here and previously, suggest that 
germline variants may initiate different genetic pathways that then lead to distinct somatic 
alterations compared to sporadic tumours. In this study, each of the consistently observed 
regions of loss and gain contributed to PCa tumours across multiple branches of the PcTas9 
pedigree. Given that previous literature suggests some may be unique to familial tumours and 
in PcTas9 they are shared by distantly related individuals strengthens the likelihood of the CNV 
being linked to underlying inherited genetic factors.  
 
Further evidence for a link between inherited germline variants and somatic chromosomal 
alterations was presented in a study of breast cancer. It is hypothesised that the number and 
types of chromosomal alterations are influenced by underlying predisposition genes. In fact, 
BRAC1- and BRCA2-associated breast cancers have more CNVs per tumour compared to 
sporadic breast cancers, as described by Tirkkonen et al. (1997) 329. More recently, Joosse and 
colleagues (2012) developed a test to identify BRCA2-mutated breast tumours, using aCGH 
profiles of 28 BRCA2-mutated and 28 sporadic breast tumours 330. They subsequently tested 
89 breast tumours from suspected breast cancer families, with unknown BRCA1/2 mutation 
status and they were able to separate BRCA1-like, BRCA2-like and sporadic-like tumours using 
the tumours chromosomal profile 330. This shows that specific germline mutations, such as 
BRCA1 and BRCA2, predispose to some somatic tumour alterations. In terms of PCa, a large 
study of 539 prostate tumours found that a 7p14.3 germline variant positively selects for SPOP 
mutant PCa, as the variant accelerates the DNA damage phenotype 331. Whilst the mechanism 
linking the 7p14.3 germline variant and the SPOP somatic mutation remains elusive, it was 
suggested that future studies should investigate the role of the allele in the emergence of SPOP 
somatic alterations 331. Overall, the association of germline variants and tumour CNVs requires 
further investigation, as the number of studies in this area is small.  
 
6.4.9 Clinical significance of this study  
Results from the study presented here could lead to the clinical implementation of routine 
cytogenetic analysis for prostate tumour tissue. The knowledge of specific somatic tumour 
alterations could define particular disease phenotypes (i.e. indolent or aggressive) and potential 
response to treatment. For example, Zafarana and colleagues (2012) demonstrated that 
overexpression of 8q (cMYC) alone, or when combined with a PTEN loss were increasingly 
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prognostic for relapse after radiotherapy 332. If future studies confirm that the chromosomal 
alterations identified in this study are associated with clinical outcomes, men could be tested 
for these somatic aberrations at diagnostic biopsy, when the disease is most curable.  
 
6.4.10 Limitations of this study 
This study has provided important insights into chromosomal aberrations at the tumour level 
in a large Tasmanian PCa family, but there are some limitations in the interpretation of this 
data. A significant limitation of aCGH analysis is that translocations and inversions cannot be 
identified 333,334. This is because balanced chromosomal rearrangements do not result in any 
loss or gain, however there are other approaches to identify such alterations, which will be 
discussed in Chapter 7. Another significant limitation is admixture, or contamination of 
malignant with benign cells, which can skew results 334-336. In terms of admixture, it is known 
that foci within the one tumour can be genetically very different 270, thus, nucleic acid 
extractions not macrodissected in parallel can result in very different genomic profiles, which 
makes interpretation of data much more complex. Here, three tumours, PC9-477, PC9-588 and 
PC9-620 had gain of EEF2 on the array, however did not show EEF2 overexpression in our 
gene expression analysis. This result is one such example of the potential effect of tumour 
heterogeneity. The FFPE nucleic acid samples were not co-extracted, nor macrodissected at 
the same time, therefore these results may represent the genomic profile of completely different 
tumour foci. Contamination of malignant samples with benign cells can also mask 
chromosomal gains and losses, thereby reducing the detection of true disease-associated 
genetic alterations 336. Laser capture microdissection could deal with both of these issues, by 
almost guaranteeing a homogenous cell population for analysis. On another note, the nature of 
denatured chromosomes and the integration of fluorescent labels, can also cause the colour 
ratio signal to be spread over a larger region than the actual amplicon 334. This could mean that 
the 19p13.3 amplification may not spread over the entirety of the EEF2 gene as observed in 
the aCGH data. Instead, as reflected in the gene expression results, amplification may have 
been restricted to the 5’UTR/exon 2 region only. Although, another region (exon 4/5) was also 
significantly overexpressed in the six PcTas9 tumours that had overexpression of the 
5’UTR/exon 2 region, yet the amplitude of overexpression was on average 60-fold lower than 
the 5’UTR/exon 2 region. Data from the GTEx Portal (https://gtexportal.org/home/) 137 
suggests that these two regions have similar expression levels, therefore the discrepancies in 
levels of expression may be due to the chromosomal amplification or simply due to different 
primer efficiencies. To succumb this issue, the amplification break points could be accurately 
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mapped using PCR or where available, whole-genome data. The quality of DNA and RNA 
extracted from FFPE tissue is also fairly poor, therefore it is possible that this may have 
impacted our gene expression results. Overall, this study’s sample size was quite small, thus, 
the concepts explored in this study should be assessed in a larger tissue cohort. Further studies 
will confirm the presence of  the EEF2 amplification and other chromosomal alterations in 
other Tasmanian Prostate Tissue Pathology Resource tumours and thus, whether they are 
genetically predisposed.  
 
6.5 FUTURE DIRECTIONS 
In summary, this study has identified chromosomal regions of deletion and amplification 
present in prostate tumours from PcTas9 men. Regions that were consistently deleted in three 
or more tumours included 1p36.21 and 19p13.3, whilst gains included 6p23-p22.3, 6p24.2, 
17p13.3 and 19p13.3. The high resolution of aCGH compared to previous CGH analyses 
enabled us to identify genes underlying these regions. Of particular interest, this study 
highlighted chromosomal regions which may harbour genes involved in tumour development, 
including TINCR, JARID2, NEDD9, DPH1, ZBTB7A, and EEF2. EEF2 was targeted for 
follow-up in this study due to the fact that 100% of PcTas9 tumours assayed showed 
amplification. Therefore, future work could involve assessing gene and protein expression of 
the other regions of loss and gain in the larger Tasmanian Prostate Tissue Pathology Resource. 
A particularly interesting candidate is NEDD9, because like EEF2, is frequently overexpressed 
in diverse cancer types and has been linked to tumorigenesis of many different malignancies 
337-339. Overall, the EEF2 amplification was the most predominant alteration detected in 
tumours from PcTas9 cases, suggesting an inherited predisposition. However, single tumours 
from other Tasmanian families (PcTas12, 22 and 3250) also showed a similar pattern of 
overexpression, which would suggest that this phenomenon isn’t restricted to PcTas9, and the 
amplification may in fact be more of a widespread occurrence in familial PCa. Thus, further 
aCGH analysis of tumours from other familial and sporadic PCa cases may provide additional 
insight into this and other chromosomal alterations. Further work will highlight the significance 
of differences between sporadic and familial tumours, plus, facilitate the investigation of the 
link between genetic predisposition and these tumour variations. In the future, the collection of 
additional tumours from newly diagnosed cases in PcTas9 will enable us to assess whether the 
EEF2 amplification (or other tumour CNVs) clusters in closely related individuals in this large 
family. Plus, genome-wide germline genetic data from PcTas9 cases will permit us to perform 
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linkage analysis weighted on the presence/absence of the 19p13.3 amplification. This could 
lead to the identification of chromosomal regions and thus, inherited germline variants 
underpinning this amplification at the tumour level. Finally, the tumours from the other 
Tasmanian PCa families who were identified to have high EEF2 5’UTR/exon 2 expression 
should also be assessed by aCGH to validate this finding.  
 
6.6 CONCLUSION 
This study sought to identify CNVs in prostate tumours from a single Tasmanian family, 
PcTas9, with the overall aim to investigate underlying genetic drivers of these tumour events. 
The EEF2 gene was consistently amplified in all eight tumours examined, and follow-up gene 
expression analysis revealed that six had significantly higher expression of the 5’UTR/exon 2 
and exon 4/5 regions compared to other PcTas9 tumours. This is now one of very few studies 
to examine EEF2 protein expression in prostate tumours, however, to the best of our 
knowledge, the first to assess EEF2 gene expression. Whilst study limitations restricted us from 
investigating whether germline variation predisposes this amplification, the recent generation 
of genome-wide germline data from this family will enable us to assess this hypothesis in the 
near future. Overall, given the known overexpression of EEF2 in cancer and the recent 




CHAPTER 7 :  GENE FUSIONS IN TASMANIAN 
PROSTATE TUMOURS  
 
7.1 INTRODUCTION 
Gene fusions are prominent in malignant tumours, with a total of 297 reported by the Catalogue 
of Somatic Mutations in Cancer (COSMIC) 340. A gene fusion is a hybrid gene formed by the 
combination of two separate genes, with the regions of the genes fused together known as the 
fusion break points. Petrovics and colleagues (2005) identified one of the earliest genetic 
alterations in prostate tumours, the overexpression of the oncogene, ERG, which is a member 
of the large family of erythroblast transformation-specific (ETS) transcription factors 341. It 
was subsequently found that in most cases ERG overexpression was driven by the fusion of 
the ERG gene (21q22.3) with TMPRSS2 (21q22.2) 315. TMPRSS2 is an androgen-regulated 
gene that is preferentially expressed in the prostate and the fusion of the two genes results in 
the androgen-regulated overexpression of ERG 342. Since this original study, many other studies 
have validated this recurrent fusion event in prostate tumours and have discovered additional 
ETS fusion events 343 (Table 7.1). It is now known that ETS genes are frequently involved in 
prostate gene fusions and they often result in the synthesis of chimeric proteins or altered 
expression of the ETS protein. 
 
 











ETS Gene Fusion Partner(s) Frequency 343 
ERG TMPRSS2, SCL45A3 52% 
ETV1 
TMPRSS2, SLC45A3, ACSL3, HERV-K, HERV-K17, FOXP1, 
EST14, chr14q13.3-14q21.1, C15orf21, HNRPA2B1, 
OR51E2 
7% 
ETV4 TMPRSS2, KLK2, CANT1, DDX5, UBTF 1.5% 
ETV5 TMPRSS2, SLC45A3 0.5% 
FLI1 SLC45A3 0.5% 
 193 
To date, the TMPRSS2:ERG fusion is the most common fusion event in prostate tumours, 
occurring in ~50% 315. Normally, the TMPRSS2 and ERG genes are located in close proximity 
(2.7Mb) to each other on chromosome 21 and are both transcribed in the reverse orientation. 
Fusion of TMPRSS2:ERG can occur by two mechanisms; firstly, the genomic region between 
the two genes can be lost by interstitial deletion, which occurs in approximately 60% of fusion 
positive tumours 344,345. Secondly, less frequently, the fusion event can occur as a result of a 
complex genomic rearrangement, involving chromosome 21q22 and presumably other 
chromosomes 344,345. Each mechanism can result in multiple fusion transcripts, in fact, there 
are over eight different TMPRSS2:ERG transcripts, the most common being the fusion of the 




Figure 7.1 Schematic representation of the two most common TMPRSS2:ERG fusion transcripts. 
Exons 1-11 of ERG are shown in blue and exons 1-14 of TMPRSS2 are shown in orange, with the schematic 
showing that they are in the same orientation, 2.7Mb apart. The most common TMPRSS2:ERG transcript includes 
exon 1 of TMPRSS2 and exon 4 onwards of ERG, shown at the bottom of this figure (T1E4). The second most 
common fusion involves exon 1 and 2 of TMPRSS2 and exon 4 onwards of ERG. 
 
 
In the original study by Tomlins et al. (2005), a second recurrent gene fusion between another 
ETS family member, ETV1 (7p21.2), and the TMPRSS2 gene was discovered, with a total of 
24.1% of prostate tumours harbouring the fusion event 315. Currently there are over 10 different 
fusion partners of ETV1 identified 315,346 and later studies have found a much lower frequency 
of events, with ~7% of all prostate tumours ETV1 fusion positive 343. ETV1 gene fusions can 
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lead to overexpression of a truncated ETV1 protein that lacks the N-terminal topologically 
associating domain 315,346. However, it can also be overexpressed as a full-length protein, due 
to translocation of the complete gene to a different genomic region 346.  
 
In the last decade, our understanding of PCa development has changed radically with the 
discovery of ETS gene fusions. As mentioned previously (Chapter 1.3.5), ETS-rearrangements 
are used to subclassify PCa tumours, and recently they have been identified as potential novel 
urinary biomarkers for PCa diagnosis 347. Tomlins and colleagues (2011) reported the use of a 
clinical-grade, transcription-mediated amplification assay to detect and stratify PCa tumours 
based on TMPRSS2:ERG fusion status 348. Such studies demonstrate that urine-detected 
TMPRSS2:ERG, in combination with other PCa markers, enhances the utility of prostate-
specific antigen (PSA) testing 348,349. Several studies have evaluated the clinical significance of 
the TMPRSS2:ERG fusion event in prostate tumours and while some have demonstrated an 
association with advanced and invasive tumours with poor prognoses 350,351, others have shown 
that it is not a predictor of PCa recurrence or mortality 352,353. Whilst the clinical consequence 
of ETV1 fusion events resulting in overexpression of ETV1 is not yet well understood, an ETV1 
expression signature was observed to be associated with aggressive PCa and poorer outcomes 
354. Given its role in testosterone production, the ETV1 fusion may accelerate prostate 
carcinogenesis.  
 
It is now estimated that approximately 50-60% of all PCa tumours harbor recurrent gene 
fusions 355. Given the high frequency of these fusion events, and accumulating evidence from 
previous studies, they are unlikely due to chance. In fact, the TMPRSS2:ERG fusion is very 
consistent in its formation, and a high frequency suggests an underlying genetic predisposition 
356. Common PCa risk variants have been evaluated in cohorts of known TMPRSS2:ERG fusion 
positive (or ERG overexpression) and negative tumours. Penney et al. (2016) identified that 
six of 39 genome-wide association study PCa risk variants were significantly associated with 
ERG overexpression, in their cohort of 227 ERG positive and 260 negative tumours 357. The 
most recent and largest study observed a significant difference between fusion positive and 
negative tumours for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in 
fusion negative and positive tumours, respectively 358. Interestingly, TMPRSS2:ERG has been 
identified more frequently in early-onset PCa, suggesting that the event may also be associated 
with familial PCa and potentially, rare germline variants 359,360. In fact, Luedeke and colleagues 
(2009) studied familial and sporadic tumours and found a significant association of 
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TMPRSS2:ERG fusion-positive PCa with rare variants in POL1 and ESCO1, both of which are 
DNA repair genes 361. These findings suggest that tumours that develop the TMPRSS2:ERG 
fusion have a different germline predisposition from those that do not, and these genetic 
variations may influence fusion event occurrence.  
 
Thus, this study hypothesises that germline variants may predispose some tumours to somatic 
alterations, such as gene fusions. To explore this theory, tumours from men belonging to a 
large Tasmanian PCa family, PcTas9 were assayed on the TruSight RNA Fusion Panel 
(Illumina) to identify gene fusions present in this family. TaqMan® expression assays and RT-
qPCR gene expression analysis were then used to determine their frequency in the entire 
Tasmanian Prostate Tissue Pathology Resource. Ultimately, the overall aim was to investigate 
the relationship between identified fusion events and underlying genetic predisposition.  
 
7.2 METHODS 
7.2.1 TruSight RNA Fusion Panel 
A total of 14 malignant RNA samples from PcTas9 cases were assayed on the TruSight RNA 
Fusion Panel, across two separate assays. This technology enables RNA from poor quality 
formalin-fixed paraffin embedded (FFPE) tumour samples to be assayed for 507 known cancer 
fusion genes, including ETS transcription factors, ERG and ETV1. Novel fusion partners can 
also be identified, as only one of the two genes involved in the fusion event must be present on 
the panel. This is because probes specific to the target RNA region bind appropriately and the 
fusion break point is sequenced. The TruSight RNA Fusion Capture chemistry is illustrated in 
Figure 7.2 and the libraries were prepared using 20-100ng of FFPE RNA (depending on RNA 
quality), as per the manufacturer’s instructions. Targeted sequencing with deep coverage was 
performed on the Illumina MiSeq platform using the MiSeq® V2 300 Cycle Reagent Kit 
(Illumina), and data were analysed using the RNA-Seq Alignment workflow (Illumina) on 
BaseSpace. In short, raw fastq files were aligned to the hg19 reference genome using TopHat2, 
and each reference gene and transcript were given a FPKM (fragments per kilobase million) 
estimation using Cufflinks 2. Variants were called with the Isaac Variant caller and each fusion 
call was given a confidence score. This score (out of 1) is based on the FPKM, split read scores, 
paired read scores, break-end homology and, several other features. A score >0.5 meets all of 
the threshold filters (PASS) whereas, a score <0.5 is considered a low confidence fusion call 







Figure 7.2 TruSight RNA Fusion Capture Chemistry. 
The TruSight RNA Fusion Panel provides a simple, streamlined method for isolating targeted regions of 
interest from total RNA, including from FFPE tumour samples. This figure details the workflow and capture 
chemistry of the panel. Unique oligonucleotide indexes are added to each individual library. Once the RNA-
Seq libraries are pooled they are hybridised to biotin-labelled probes specific for targeted RNA regions. 
These targets are captured by adding streptavidin beads that bind to the biotinylated probes. Magnetic beads 
are then used to remove the bound fragments efficiently from solution. Following amplification, the targeted 
library was clustered generated, followed by targeted sequencing with deep coverage on the Illumina MiSeq 
platform (Illumina, California, USA, 2019). 
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7.2.2 TaqMan® TMPRSS2:ERG Fusion Assays 
In total, 56 Tasmanian Prostate Tissue Pathology Resource tumour samples were screened for 
two isoforms of the TMPRSS2:ERG fusion, including TMPRSS2 (exon 1):ERG (exon 2) 
(T1E2) and TMPRSS2 (exon 1):ERG (exon 4) (T1E4). This was performed using TaqMan® 
probes designed across the breakpoint of the fusion gene (Life Technologies; Appendix 26). 
Amplification was performed on 50ng of FFPE cDNA, in duplicate, as per the conditions in 
Appendix 1. Real-time quantitative (RT-qPCR) thermal cycling was conducted on the 
QuantStudioTM 3 Real-Time PCR System (Applied Biosystems) and quantification visualised 
using the QuantStudioTM Design and Analysis Software v1.5. Each qPCR run was conducted 
with a DNA-free NTC and each sample was run in duplicate for housekeeper, b-Actin (Life 
Technologies; Appendix 26). Samples that appeared to be fusion positive were confirmed by 
Sanger sequencing. In short, a forward primer was designed in the last included exon of 
TMPRSS2 (1 or 2) and a reverse primer in any of the first few included exons of ERG (2, 3 or 
4), thus sequencing the fusion breakpoint. Sanger sequencing was conducted as previously 
described (Chapter 2.2.3; Appendix 27).  
 
7.2.3 Quantification of ETV1 gene expression 
ETV1 (ENST00000405358.4) gene expression in prostate tissue samples was assessed by RT-
qPCR analysis. Expression was normalised to the expression of two housekeeping genes, as 
discussed in Chapter 2.3. Briefly, three different regions of ETV1 were amplified, including a 
region before the fusion breakpoint (exon 8/10) and two after (exon 16/17 and 21/22). RT-
qPCR primers were designed to the most commonly transcribed isoform in the prostate (as per 
GTEx Analysis Release V7 (dbGaP Accession phs000424.v7.p2; 
https://gtexportal.org/home/)) 137 and are displayed in Appendix 3. Absolute gene expression 
was compared between tumours from PcTas9 and non-PcTas9 cases. The non-PcTas9 patient 
group comprised DVA sporadic tumours from the Tasmanian Prostate Cancer Case-Control 
Study and other familial tumours from the Tasmanian Familial Prostate Cancer Cohort. 
 
7.2.4 Quantification of ETV1 protein expression 
Immunohistochemistry (IHC) was performed to quantify ETV1 protein expression in the 
prostate tissue samples, as previously described (Chapter 2.4; Appendix 5). Cytospins of 
HEK293 cells, and sections of colon and skin were used as positive controls. Negative controls 
included primary antibody only, secondary antibody only, and a mouse IgG1 isotype control 
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(Dako). ETV1 protein expression was compared between tumours from PcTas9 and non-
PcTas9 cases.  
 
7.3 RESULTS 
7.3.1 Gene fusion analysis of PcTas9 prostate tumour samples 
In total, 26 PcTas9 and 30 non-PcTas9 FFPE prostate tissue samples were obtained for this 
study (described in Chapter 6.3.1). To investigate the prevalence of gene fusion events in the 
Tasmanian Prostate Tissue Pathology Resource, 14 PcTas9 tumour RNA samples were 
assayed on the TruSight RNA Fusion Panel (Table 7.2; Figure 7.3). Where sufficient RNA was 
available, one affected man from each branch of the family was selected for analysis.  
 












PC9-07 71 TURP PD 9 (5+4) 
PC9-12 66 RP MD 6 (3+3) 
PC9-13 83 TURP - 9 (4+5) 
PC9-14 79 TURP MD 6 (3+3) 
PC9-15 64 TURP MD 5 (2+3) 
PC9-20 76 TURP PD 9 (4+5) 
PC9-158 63 RP - 6 (3+3) 
PC9-211 68 TURP PD 9 (4+5) 
PC9-477 55 RP - 6 (3+3) 
PC9-588 63 RP MD 6 (3+3) 
PC9-603 73 RP MD 6 (3+3) 
PC9-627 65 RP - 7 (3+4) 
PC9-645 60 RP - 7 (3+4) 
PC9-659 65 RP PD 9 (4+5) 
RP: Radical prostatectomy; TURP: Transurethral resection of the prostate; 1Tumour grade 
obtained from pathology report; 2Contemporary Gleason Score from FFPE tissue block 
chosen for macrodissection of nucleic acids and IHC; MD: moderately differentiated; PD: 










Figure 7.3 A condensed PcTas9 pedigree showing tumours chosen for analysis on the TruSight RNA Fusion Panel. 
This condensed version of PcTas9 indicates those PCa cases with available prostate tumour specimens (shown by red arrows) and their relationship. Tumours chosen for the RNA fusion panel are 
shown in yellow.  
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7.3.2 Identification of gene fusion events in tumours from PcTas9 men 
Nine tumours showed evidence of one or more fusion event (Table 7.3). Notably, one tumour 
was shown to harbor three fusion events, including a known TMPRSS2:ERG fusion and two 
novel events involving the ETS fusion genes, ETV4 and FOXP1. In total, four novel fusion 
genes in three different tumours were identified; WHSC1L1:CNKSR3, SLC30A4:ETV1, 
C19orf48:ETV4 and RYBP:FOXP1 (Table 7.3). The WHSC1L1:CNKSR3 and RYBP:FOXP1 
fusions were considered low confidence fusion calls, however this result may indicate low 
expression of the fusion gene. In terms of known fusion events, one tumour was identified as 
TMPRSS2:ETV1 positive and seven were TMPRSS2:ERG positive. Of the TMPRSS2:ERG 
fusion events, six involved exon 1 of TMPRSS2 fused to exon 4 of ERG (T1E4), whereas one 
involved the fusion of exon 1 of TMPRSS2 to exon 2 of ERG (T1E2). The presence of the 
TMPRSS2:ERG fusion transcripts at a frequency close to 50% was consistent with the literature 
315, which suggested that the assay was working optimally (Table 7.3). 
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Gene 1 (Breakpoint) 
Gene 1 
Exon 
Gene 2 (Breakpoint) 
Gene 2 
Exon 
Score1 Filter2 Gene Fusion 













Low Fusion Rate 
TMPRSS2:ERG 
TMPRSS2:ERG 
PC9-13 WHSC1L1 (chr8:38,205,113) 2 CNKSR3 (chr6:154,762,378) 4 0.426 Low Fusion Rate #WHSC1L1:CNKSR3# * 
PC9-14 TMPRSS2 (chr21:42,880,007) 1 ERG (chr21:39,817,543) 4 0.464 PASS TMPRSS2:ERG 
PC9-15 No fusion detected 
PC9-20 No fusion detected 
PC9-158 SLC30A4 (chr15:45,803,402) 3 ETV1 (chr7:13,978,871) 15 0.747 PASS #SLC30A4:ETV1 * 
PC9-211 No fusion detected 
PC9-477 TMPRSS2 (chr21:42,870,045) 2 ERG (chr21:39,817,543) 4 0.519 Low Fusion Rate TMPRSS2:ERG 
PC9-588 TMPRSS2 (chr21:42,880,007) 1 ERG (chr21:39,817,543) 4 0.858 PASS TMPRSS2:ERG 






























PC9-645 TMPRSS2 (chr21:42,880,007) 1 ERG (chr21:39,817,543) 4 0.911 PASS TMPRSS2:ERG 
PC9-659 No fusion detected 
1The confidence score (out of 1) is based on the FPKM, split read scores, paired read scores, break-end homology, and several other features. A score >0.5 meets all of the 
threshold filters (PASS2) whereas, a score <0.5 is considered a low confidence fusion call (Low Fusion Rate2), which may include true positive fusions, but expressed at 
lower levels; *Novel gene fusion; #Novel fusion partner. 
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7.3.3 The frequency of two TMPRSS2:ERG fusion transcripts in the Tasmanian Prostate 
Tissue Pathology Resource 
Following the identification of two TMPRSS2:ERG fusion transcripts (T1E2 and T1E4) in 
PcTas9 tumours, the overall frequency in the Tasmanian Prostate Tissue Pathology Resource 
was determined. In total, 46 prostate tumours from 15 PcTas families, as well as eight sporadic 
cases (DVA) were screened for T1E2 and T1E4 by RT-qPCR. Overall, 17 tumours were 
observed to be TMPRSS2:ERG fusion positive (31.5%; Table 7.4). Five families were 
identified to have at least one case with a fusion positive tumour, four of which had two or 
more cases. Tumours from PcTas9 made up 33% of the available samples and had the highest 
number of fusion positive tumours, with ten out of 18 tumours fusion positive (56%; Figure 
7.4). However, PcTas2 had the highest proportion of positive tumours (60%; Figure 7.5). 
Notably, the two TMPRSS2:ERG fusion transcripts were not detected in any of the eight 
sporadic cases.  
 
 
Table 7.4 The total number of prostate tumours positive for TMPRSS2:ERG. 
 
Family Identification 
Number of PCa cases with 
tumour FFPE RNA 
Number of TMPRSS2:ERG 
positive tumours 
DVA Sporadic Cases 8 0 
PcTas2 5 3 (60%) 
PcTas3 2 0 
PcTas4 1 0 
PcTas9 18 10 (56%) 
PcTas11 2 0 
PcTas12 7 2 (29%) 
PcTas19 1 0 
PcTas22 2 0 
PcTas23 1 0 
PcTas31 1 0 
PcTas60 1 0 
PcTas72 2 1 (50%) 
PcTas213 1 0 
PcTas837 1 1 (100%) 
PcTas3250 1 0 

















Figure 7.4 A condensed PcTas9 pedigree showing TMPRSS2:ERG fusion status.  













Figure 7.5 The PcTas2 pedigree showing TMPRSS2:ERG fusion status.  
This condensed PcTas2 pedigree indicates those tumours assessed for the two TMPRSS2:ERG fusion events; fusion positive are shown in yellow and fusion negative, in grey. 
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7.3.4 Association of TMPRSS2:ERG with clinical characteristics and tumour pathology 
The correlation between TMPRSS2:ERG fusion status and certain clinical characteristics, such 
as age at diagnosis, Gleason score (GS), age at death and cause of death was examined (Table 
7.5 and Appendix 28). There was no difference in the age at diagnosis between TMPRSS2:ERG 
fusion positive (n=17) and negative tumours (n=37; p=0.91). Age at death was slightly younger 
for those with fusion positive compared to negative tumours however, this was not statistically 
significant (p=0.35). There was also no difference in GS (£7 (3+4) versus ³7 (4+3)) between 
tumours with TMPRSS2:ERG fusion positive (n=15) and negative status (n=33; p=0.78), nor 





















PC2-01 T1E4 62 PD 10 (5+5) 64 PCa 
PC2-02 T1E2 53 - 5 (3+2) 75 Other 
PC2-13 T1E4 54 - 4 (2+2)   
PC9-12 T1E4 66 MD 6 (3+3)   
PC9-14 T1E4 79 MD 6 (3+3) 82 Non-Cancer 
PC9-211 T1E4 68 PD 9 (4+5) 70 PCa 
PC9-477 T1E4 55 - 6 (3+3)   
PC9-532 T1E4 70 - 6 (3+3)   
PC9-545 T1E4 55 PD - 55 PCa 
PC9-588 T1E4 63 MD 6 (3+3)   
PC9-620 T1E4 71 PD 9 (4+5) 84 Non-Cancer 
PC9-627 T1E2 & T1E4 65 - 7 (3+4) 68 Non-Cancer 
PC9-645 T1E4 60 - 7 (3+4)   
1Tumour grade obtained from pathology report; 2Contemporary Gleason Score from pathology report (if 
known) or FFPE tissue block chosen for microdissection of nucleic acids; MD: moderately differentiated; 
PD: poorly differentiated; -: information not present in original pathology report; 3Age at death and cause of 
death information was obtained from the Tasmanian Cancer Registry (as at April 2019); PCa: Prostate 
Cancer; Other: Other cancer; *Clinical characteristics of TMPRSS2:ERG fusion negative tumours can be 




7.3.5 The effect of ETV1 fusion events on ETV1 gene expression  
Prostate tumours from two PcTas9 men were found to have an ETV1 gene fusion, each with a 
different isoform. The tumour from individual PC9-158 had a SLC30A4:ETV1 gene fusion, 
with SLC30A4 identified as a novel 5’ fusion partner. The known TMPRSS2:ETV1 gene fusion 
was identified in PC9-603 at a low fusion rate, and it had the same ETV1 breakpoint as PC9-
158 (chr7:13,978,871). Prior literature suggests that ETV1 fusions are fairly rare (~7%) and 
involve multiple 5’ fusion partners 343, which suggests that targeted detection of these two 
fusions using TaqMan would likely uncover very few, if any additional carriers, plus miss other 
fusion events involving ETV1. Therefore, given that ETS-gene fusions often result in the 
overexpression of the ETS gene 341 and RT-qPCR is a more cost effective method for fusion 
detection, it was decided that ETV1 gene expression would be examined to detect additional 
ETV1 fusions in the Tasmanian Prostate Tissue Pathology Resource. This method would also 
determine the effect of the two already identified ETV1 fusion events on ETV1 expression.  
 
RNA was extracted from malignant glands (n=28) and RT-qPCR was undertaken to determine 
the absolute expression of ETV1 in three regions of the gene (exon 8/10, 16/17 and 21/22; 
Appendix 29). There was a borderline significant difference in expression of ETV1 exon 8/10 
between the malignant glands of PcTas9 tumours (n=17) compared to non-PcTas9 tumours 
(n=11; p=0.05; Figure 7.6). PcTas9 tumours had an overall lower level of ETV1 exon 8/10 
expression, however expression was generally very low for this amplified region. Across the 















PC12-01 T1E4 63 MD 6 (3+3) 73 Non-Cancer 
PC12-06 T1E4 80 - 7 (3+4) 84 Non-Cancer 
PC72-04 T1E4 70 PD 9 (4+5) 82 PCa 
PC837-04 T1E4 59 - 9 (4+5)   
1Tumour grade obtained from pathology report; 2Contemporary Gleason Score from pathology report (if 
known) or FFPE tissue block chosen for microdissection of nucleic acids; MD: moderately differentiated; 
PD: poorly differentiated; -: information not present in original pathology report; 3Age at death and cause of 
death information was obtained from the Tasmanian Cancer Registry (as at April 2019); PCa: Prostate 
Cancer; Other: Other cancer; *Clinical characteristics of TMPRSS2:ERG fusion negative tumours can be 
found in Appendix 28. 
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between the malignant glands of PcTas9 and non-PcTas9 tumours (p=0.54 and 0.72, 
respectively; Figure 7.6). In benign prostate glands, there was no significant difference in ETV1 
expression across the three regions in PcTas9 (n=7) versus non-PcTas9 samples (n=8; p=0.15, 









Figure 7.6 ETV1 gene expression analysis in malignant prostate glands from non-PcTas9 cases compared to PcTas9 cases. 
ETV1 expression in three different regions of the gene was assessed in malignant prostate glands from two patient groups, non-PcTas9 (comprising sporadic and familial 
tumours; n=11) and PcTas9 (n=17). A schematic of the most commonly transcribed isoform of ETV1 in the prostate is shown at the top of the figure. Absolute ETV1 gene 
expression was calculated for each sample by normalising to the expression of two housekeeping genes. ETV1 expression in malignant glands from non-PcTas9 and PcTas9 
tumours in each region was compared using an unpaired Student’s t-test. The spread of the data is represented by a box and whisker plot. Median expression is shown by the 
thick black line, the interquartile range (middle 50% of data set) is represented by the box and the minimum and maximum values by the whiskers (dotted lines). Individual 
outliers are shown by dots. 
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The expression level of ETV1 was then examined in the two fusion positive tumours compared 
to other tumours in the PcTas9 family (Figure 7.7). Individual PC9-158 had significantly 
increased ETV1 expression in the two regions after the SLC30A4:ETV1 fusion breakpoint (exon 
16/17 and exon 21/22) compared to other PcTas9 tumours. Notably, the benign glands of PC9-
158 had a low ETV1 expression profile across all assessed regions, suggesting that increased 
expression is an anomaly unique to the malignant glands. PC9-603, who harbours a low fusion 








Figure 7.7 ETV1 gene expression analysis in malignant prostate glands from PcTas9 tumours.  
ETV1 expression in three different regions of the gene was assessed in prostate tumours from PcTas9 cases. A schematic of the most commonly transcribed isoform of ETV1 
in the prostate is shown at the top of the figure. Absolute ETV1 gene expression was calculated for each sample by normalising to the expression of two housekeeping genes. 
Individual PcTas9 malignant gland expression is shown here, with regions of ETV1 depicted by different colours. * ETV1 fusion positive as idnetfiied by the RNA Fusion Panel. 
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Gasi and colleagues (2011) reported that a high ratio between ETV1 expression at the 3’ end 
(after the fusion breakpoint) versus the 5’end (before the fusion breakpoint) was indicative of 
a fusion transcript whereas, a ratio of 1:1 indicated expression of full-length ETV1 362. Here, 
ratios of ETV1 gene expression between exon 16/17:exon 8/10, exon 21/22:exon 8/10 and exon 
21/22:exon 16:17 were determined in all prostate tumours, where data was available (Table 
7.6). A high ETV1 expression ratio between the 5’ and 3’ end was observed in PC9-158, and 
was also apparent in three other PcTas9 tumours, PC9-13, PC9-20 and PC9-603, however the 
ratios were not as high as PC9-158. Notably, PC9-603, the low rate fusion carrier, had a high 
ETV1 exon 16/17:exon 8/10 ratio, comparable to the other two samples, yet previous data from 
the RNA Fusion Panel indicated that neither of these tumours had an ETV1 fusion event (Table 
7.3). Therefore, it is possible that PC9-13 and PC9-20 carry ETV1 fusions but at a level too 




























Exon 16/17:8/10 Ratio 
ETV1 
Exon 21/22:8/10 Ratio 
ETV1 
Exon 21/22:16/17 Ratio 
PC9-158 87.36 65.04 0.74 
PC9-20 35.15 19.78 0.56 
PC9-13 29.22 16.56 0.57 
PC9-603 29.71 8.71 0.29 
DVA 220 3.92 2.54 0.65 
PC9-12 7.00 2.71 0.39 
PC9-14 6.32 0.53 0.08 
PC9-211 8.53 0.99 0.12 
PC9-477 5.50 3.50 0.64 
PC9-532 1.27 1.96 1.55 
PC9-545 9.32 3.79 0.41 
PC9-620 11.69 5.08 0.43 
PC9-627 11.00 7.73 0.70 
PC9-645 2.67 3.29 1.23 
PC9-659 9.32 1.95 0.21 
PC11-11 2.66 4.97 1.87 
PC12-06 2.78 5.49 1.98 
PC12-07 2.65 1.43 0.54 
PC12-09 2.55 0.72 0.28 
PC3250-01 2.85 1.32 0.46 
High ‘Exon 16/17:Exon 8/10’ and ‘Exon 21/22:Exon 8/10’ ratios are indicative of a fusion gene. It 




7.3.6 The effect of ETV1 fusion events on ETV1 protein expression 
An ETV1 gene fusion can result in overexpression of a truncated or a full-length ETV1 protein 
315,346. IHC was undertaken on 56 FFPE prostate tumour samples to determine whether the 
SLC30A4:ETV1 and TMPRSS2:ETV1 fusions cause overexpression of the ETV1 protein. In 
addition, this assay could potentially identify additional ETV1 fusion events in the wider 
Tasmanian Prostate Tissue Pathology Resource. ETV1 staining intensity ranged from negative 
(0) to moderate (2) across the dataset, and the percentage of ETV1 positive nuclei ranged from 
approximately 5-70% (Appendix 29). In total, only 24% (n=16) of the tissue samples were 
positive for the ETV1 protein; five samples had expression in benign glands only, nine in 
malignant glands only and two had expression in both benign and malignant glands (Appendix 
29). There was no significant difference in ETV1 expression between paired malignant and 
benign glands (p=0.49). Notably, 17 samples were found to have weak-moderate staining of 
ETV1 in infiltrating inflammatory cells and nine of these did not express ETV1 in adjacent 
prostate glands (Figure 7.8). PC9-158, the SLC30A4:ETV1 fusion positive tumour, had 
moderate expression of ETV1 in benign glands, but not in malignant glands. PC9-603, the 
carrier of the TMPRSS2:ETV1 fusion, did not express ETV1 in either type of prostate gland. 
The two tumours with similar 5’:3’ ETV1 ratios similar to PC9-603, did not express ETV1 and 








Figure 7.8 ETV1 protein expression in FFPE prostate tumour samples.  
ETV1 protein expression was assessed in 56 prostate tumour specimens from the Tasmanian Prostate Tissue Pathology Resource to determine whether the 
SLC30A4:ETV1 and TMPRSS2:ETV1 fusions result in overexpression of the ETV1 protein. In short, IHC using an antibody targeting the ‘middle region’ of the ETV1 
protein was utilised to assess protein expression. Staining intensity was scored as weak, moderate or strong. A) Weak staining of ETV1 in the nuclei of the prostate gland 
cells. B) Weak-moderate staining of ETV1 in inflammatory cells; identified in 26% of tissue samples. Images were taken with an Olympus BX53 microscope, using the 




7.4.1 Overall findings 
Here, 13 fusion events were observed in nine PcTas9 prostate tumours, including multiple 
events involving three known ETS-fusion transcripts and four novel fusion events. The novel 
events included two previously unobserved gene fusions, WHSC1L1:CNKSR3 and 
RYBP:FOXP1, and two fusions involving novel partners of ETV1 and ETV4; SLC30A4 and 
C19orf48, respectively. Overall, the TMPRSS2:ERG fusion was identified in 31.5% of our 
prostate tumours and was more common in two Tasmanian families, PcTas2 and PcTas9.  
 
7.4.2 TMPRSS2:ERG fusion events in Tasmanian prostate tumours 
Fusion of the androgen-regulated promoter region of TMPRSS2 with ERG is the most common 
ETS rearrangement in prostate tumours. Both of these genes lie within the 21q22.2 
chromosomal region, which is a hot spot for rearrangement, thus multiple fusion transcripts 
have been identified in prostate tumours 344,345,363,364. The transcripts identified in this study 
(T1E2 and T1E4) are likely to be caused by a 2.7Mb interstitial deletion or translocation of 
chromosome 21q22.2. The TMPRSS2 gene encodes an androgen regulated, type II 
transmembrane-bound serine protease that is highly expressed in normal prostate tissue 365,366. 
Normally ERG is lowly expressed in the prostate (as per the GTEx Portal; 
https://gtexportal.org/home/) 137, however a breakthrough study discovered that ERG was 
overexpressed in approximately 55.2% of prostate tumours and 20% of high-grade prostatic 
intraepithelial neoplasia lesions 315. It was suggested that in the majority of tumours, ERG 
overexpression was driven by the fusion of TMPRSS2 to ERG. Here, 31.5% of tumours in the 
Tasmanian Prostate Tissue Pathology Resource were TMPRSS2:ERG positive. The frequency 
of ERG fusions in our study is somewhat lower than initially reported by Tomlins et al. (2005), 
however subsequent studies have found similar frequencies to that reported here 367,368. 
Tomlins and colleagues (2005) discussed that the frequency of ETS gene fusions in their study 
might have been overestimated, as fluorescence in-situ hybridisation assay (FISH) can also 
detect other ERG rearrangements 315.  
 
The association between clinical characteristics and TMPRSS2:ERG fusion status has been 
well assessed in the literature, but with conflicting results. Some studies have demonstrated 
that TMPRSS2:ERG fusions are associated with an increased risk of more advanced and 
invasive PCa tumours with poor prognoses 341,369. Demichelis and colleagues (2007) identified 
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a statistically significant association with fusion status and PCa specific death (cumulative 
incidence ratio 2.7, p<0.01, 95% CI=1.3-5.8) 350, suggesting that TMPRSS2:ERG may be used 
as a diagnostic and prognostic indicator of aggressive PCa in parallel with GS and prostate-
specific antigen (PSA) level. However, other studies have found contrary results, in which 
fusion positive tumours were not associated with stage, GS, PSA-induced recurrence, 
progression, prognosis and/or disease aggressiveness. FitzGerald and colleagues (2008) found 
that TMPRRS2:ERG fusion positive tumours did not exhibit reduced PCa survival (hazard 
ratio=0.92; 95% CI=0.22-3.93) 352 and Gopalan et al. (2009) also found no difference in overall 
survival between the two subtypes 353. Likewise, in our study, no difference in the age at 
diagnosis, GS, age at death or cause of death between fusion positive and negative cases was 
identified. Though, this result may be due to a small sample size, which may have limited the 
probability of finding an association. 
 
The TMPRSS2:ERG fusion was identified in tumours from five Tasmanian families, two of 
which had more than 50% of assayed tumours with a fusion event. PcTas2 had the highest 
percentage of fusion events, and notably, the three positive tumours comprise an affected 
brother trio, and the negative tumours were from two unrelated, married-in cases (Figure 7.5). 
PcTas9 comprises the largest collection of FFPE prostate samples from a single family in the 
Tasmanian Prostate Tissue Pathology Resource, and had the highest number of fusion events. 
We have been able to determine fusion status from cases across the whole pedigree and have 
found fusion positive cases in several branches (Figure 7.4). However, as we were unable to 
source tumour tissue for every case, we were unable to determine clustering at a level of first, 
second or third-degree relatedness like PcTas2. Our hypothesis that there is an underlying 
genetic predisposition to the TMPRSS2:ERG fusion is supported by the presence of the fusion 
in three affected PcTas2 brothers and, further, by the fact that none of the sporadic PCa tumours 
were fusion positive. However, as discussed above this hypothesis wasn’t able to be explored 
further due to a lack of germline genetic information for these families, as discussed further 
below (Chapter 7.5) and in Chapter 8.4. 
 
7.4.3 ETV1 fusion events in Tasmanian prostate tumours 
Two ETV1 fusion events (one novel) in two PcTas9 tumours were identified in our cohort. As 
far as we know, this is the first study to investigate the presence and prevalence of ETV1 gene 
fusions in a familial tissue resource. ETV1 is the second most common ETS gene involved in 
gene fusions, but unlike ERG, at least 10 different fusion partners have been identified to date 
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315,346. Notably, it is well documented that several as yet unidentified 5’ fusion partners of ETV1 
exist 370 and this study has identified an additional one, SLC30A4. Interestingly, this gene is 
highly expressed in the prostate and throughout carcinogenesis, as documented in The Cancer 
Genome Atlas (TCGA) Research Network: https://www.cancer.gov/tcga. Other SLC genes, 
such as SLC45A3 are commonly involved in gene fusion events, including PCa fusions 343. 
SLC45A3 is most commonly fused to ERG or ETV1 in prostate tumours, displays similar tissue 
specificity as TMPRSS2 and can induce androgens 370. It is possible that SLC30A4 has a similar 
role to SLC45A3 and causes ETV1 overexpression 346.  
 
A study by Gasi and colleagues (2011) demonstrated that a high ETV1 exon 11/12 to exon 1/4 
ratio is indicative of a fusion event involving this gene, whereas a ratio of 1:1 indicated 
expression of a full-length ETV1 mRNA 362. A subsequent study also analysed exon-level 
expression of ETV1 and identified four samples with differential expression between the 5’ and 
3’ end, pinpointing fusion breakpoints before exons 4, 7 and 8, respectively 370. These studies 
showed that exon-level expression analysis can be utilised to assess fusion status when one 
fusion partner is known. In our study, exon-level expression analysis of the ETV1 gene revealed 
that PC9-158 had increased ETV1 expression in the exon 16/17 and 21/22 regions compared to 
the exon 8/10 region. This tumour was observed to be SLC30A4:ETV1 fusion positive on the 
RNA Fusion Panel. Unlike ERG, a characteristic of ETV1 is that it can also be overexpressed 
in PCa as a full-length wild-type transcript, occurring in approximately half of the tumours 
assessed by Hermans and colleagues (2008) 346. This study questioned whether overexpression 
of full-length ETV1 is the result of genomic rearrangement of the complete ETV1 locus 346. 
However, gene fusion events can also change the amino acids at the N-terminus of ETV1, or 
result in N-terminal truncation 315,371. Unfortunately, our study was unable to detect whether 
the fusion event/s resulted in overexpression of truncated or wild-type, full-length ETV1. In 
fact, in most instances, ETV1 protein expression was negative in our prostate tumour samples. 
Overall, this begs to question whether the ETV1 antibody used in this study is suitable for the 
detection of fusion events.   
 
7.4.4 The identification of multiple ETS gene fusions in a single prostate tumour 
The initial observation by Tomlins and colleagues (2005) that ETS rearrangements are mutually 
exclusive 315, was evident in the majority of tumours assessed with the RNA Fusion Panel in 
our study. However, one tumour was shown to harbor four different ETS gene fusions, 
including two transcripts of the TMPRSS2:ERG fusion and two novel fusion events, 
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C19orf48:ETV4 and RYBP:FOXP1. This finding confirms results presented by Clark et al. 
(2008), where ERG and ETV1 fusion events were identified in two separate foci within the 
same tumour, indicating that ETS gene alterations can arise independently 372. Another study 
examining ETS rearrangements, including ERG, ETV1 and ETV5 rearrangements in multifocal 
PCa, observed multiple ETS or 5’ fusion partner rearrangements within one prostate gland, 
even occurring within the same nucleus 373.  
 
The combination of fusion events may be biologically relevant. A study by Kluth and 
colleagues (2018) found that a deletion of chromosome 3p13 was twice as likely to occur in 
TMPRSS2:ERG fusion positive than negative tumours 374. Notably, the individual in our study 
with multiple fusion events, is both RYBP:FOXP1 (both genes are located on chr3p13) and 
TMPRRS2:ERG fusion positive. Whilst this study and those in the literature indicate that 
multiple ETS gene fusions can occur in a single prostate tumour 372,373, further investigations 
to determine the biological implications of this is important. 
 
7.4.5 Clinical significance of this study  
While we are still determining what causes ETS gene fusions at the tumour level, the most 
significant implication of these events is that they may provide novel therapeutic options. 
Recently, poly ADP-ribose polymerase (PARP) inhibitors have emerged as promising 
therapeutic candidates that target ERG. Just like BRCA1/2 mutated tumours, ETS positive 
tumours are susceptible to PARP inhibition through the increased incidence of DNA double 
strand breaks 375. The PARP1 inhibitor, olaparib, is approved for use in several countries for 
the treatment of breast, ovarian, fallopian tube and peritoneal cancer patients with an inherited 
BRCA1 or BRCA2 mutation 376.  
 
Another recent study demonstrated that the small molecule inhibitor, YK-4-279, can also 
inhibit the biological activity of ERG and ETV1 377. These small molecules do not significantly 
decrease ERG or ETV1 protein levels, instead they downregulate their targets, thus preventing 
protein-protein interactions 377. An in vivo mouse xenograft model study by the same group 
demonstrated that Etv1 fusion positive mice treated with YK-4-279 developed fewer tumours 
and were less likely to develop lung metastases compared to untreated Etv1 fusion positive 
mice 378. These studies provide promising evidence that ETS-based inhibitors may soon 
become an important tool in the treatment of PCa in ETS fusion-positive patients. 
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More specifically, this project may one day impact many Tasmanian PCa patients by improving 
their screening and treatment options. Screening options could include screening for ETS gene 
fusions in tumour samples using FISH, a cost-effective method that is routinely used in the 
clinic, and/or screening for underlying genetic variants associated with the development of 
somatic gene fusions. Luedeke and colleagues (2016) found that known PCa risk variants at 
8q24 and 17q24 are differentially associated with TMPRSS2:ERG fusion status 379. This 
suggests that subtype-specific risk variants could be ideal for stratifying PCa patients, in turn 
helping a clinician decide whether their patient may benefit from ETS therapies, such as PARP 
and ETV1 small molecule inhibitors.  
 
7.4.6 Limitations of this study 
This study has provided important insights into the frequency and type of fusion events in 
prostate tumours from Tasmanian cases, but there are some limitations that should be raised. 
A small proportion of tumours from a single Tasmanian family were assayed on the RNA 
fusion panel, which may have restricted our opportunity to find a larger range of fusion events, 
given that some of these events may be caused by underlying genetic drivers. As only a 
proportion of tumours from PcTas9 were able to be sourced from pathology laboratories and 
subsequently assayed, it was hard to determine whether fusion events clustered in closely 
related PCa cases. Particularly limiting is that tumours from many affected men in the older 
generations of this family are not available, therefore this study relies on the collection of 
tumours from cases diagnosed within the last 10 years or so. Unfortunately, due to time 
constraints, while it was possible to explore the frequency of the TMPRSS2:ERG and ETV1 
fusions in our tumour resource, it was not possible to examine my hypothesis that germline 
variation predispose to these fusion events nor follow-up the additional novel fusion events 
that were identified. 
 
With regards to the overall tumour resource, the sample size used in the gene and protein 
expression analyses was relatively small, which reduced our power for finding any additional 
tumours that overexpressed ETV1. The quality of DNA and RNA extracted from FFPE tissues 
is also fairly challenging to work with, therefore these findings require validation in larger 
FFPE cohorts or, if available, fresh frozen samples. Lastly, in the IHC experiment, due to a 
lack of information, it was impossible to determine where exactly the ETV1 antibody bound 
(specified as ‘middle region’ by ThermoFisher). Therefore, it is difficult to conclude that it is 
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able to detect the two ETV1 fusion transcripts identified in this study. Notably, in most 
instances, ETV1 protein expression was negative in our prostate tumour samples. 
 
7.4.7 Gene fusions and chromosomal alterations; comparison of Chapters 6 and 7 
In total, 10 PcTas9 tumours were assayed on both the TruSight RNA Fusion Panel and the 
array Comparative Genomic Hybridisation (aCGH). As discussed earlier (7.1) gene fusions are 
often caused by chromosomal inversions, translocations, amplifications or deletions 380. Thus, 
the TMPRSS2:ERG fusion may be the result of a deletion at 21q22 and an ETV1 fusion positive 
tumour may have an amplification or deletion of the 7p21.2 chromosomal region. Six 
TMPRSS2:ERG positive tumours were also assayed on the aCGH, yet none had a 21q22 
deletion. In terms of ETV1, PC9-158 was found to have a SLC30A4:ETV1 fusion and although 
the sample did not pass aCGH quality control, there was an amplification seen across this 
region. On the contrary, PC9-20 had an amplification of the 7p21.2 region on the array, but no 
ETV1 fusion was detected on the RNA Fusion Panel. As discussed in Chapter 7.3.5, PC9-20 
had comparable ETV1 expression ratios to a low rate ETV1 fusion carrier, PC9-603, which may 
indicate that the ETV1 fusion in this tumour is expressed at a level too low to be detected by 
the fusion panel. This is an assumption and it is possible that the 7p21.2 amplification in the 
PC9-20 tumour did not translate to a fusion event. Likewise, the TMPRSS2:ERG fusion is not 
always the result of a chromosomal deletion, however there may be other reasons as to why 
discrepant results were seen between the two methods. 
 
One such explanation is tumour heterogeneity, a known phenomenon of PCa. It is common 
knowledge that PCa arises from multiple, independent clonal expansions 381-383 and as a result,  
56-87% of all PCa cases of contemporary radical prostatectomies have multifocal disease 383. 
Thus, heterogeneity is evident between prostate foci, but it can also vary at different depths 
from the same tumour area in a tissue block 384. As the chromosomal aberrations and gene 
fusion events discussed in Chapters 6 & 7 are somatic changes that occur at the tumour level, 
it is possible that the DNA and RNA extracted from the FFPE samples represent different 
tumour foci as they were not co-extracted. Therefore, their genomic profile may appear 
different, which would explain why we see discrepant results between the fusion panel and 
aCGH analysis. The phenomenon of tumour heterogeneity was also apparent in our gene 
expression results discussed in Chapter 6, in which different PCa foci may have been assessed 
between aCGH analysis (FFPE DNA) compared to our RT-qPCR experiment (FFPE RNA). 
The availability of sufficient tumour tissue is always challenging and it is not always feasible 
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to extract both DNA or RNA, yet alone in parallel. However, the issue of tumour heterogeneity 
could be counteracted by the extraction of nucleic acids in parallel from the same tissue 
microdissection if possible.  
  
7.5 FUTURE DIRECTIONS  
This is the first study to identify the involvement of WHSC1L1, CNKSR3, SLC30A4, C19orf48 
and RYBP in a fusion event in PCa. Therefore, it is essential to screen larger prostate tissue 
cohorts for these fusion events. The literature suggests that both novel fusion events, 
WHSC1L1:CNKSR3 and RYBP:FOXP1, could potentially be biologically relevant in PCa. 
Neither WHSC1L1 or CNKSR3 have previously been associated with PCa 340 however, 
WHSC1L1 is highly expressed and CNKSR3 is lowly expressed in the prostate 137, which is a 
typical 5’ and 3’ expression profile for a fusion gene. Notably, CNKSR3 is an aldosterone-
induced scaffold protein required for assembly of epithelial sodium channels, and sodium 
channels are abnormally expressed in malignant compared to matched benign tissue in a 
number of cancers 385. The second novel fusion gene involved exon 1 of RYBP, a component 
of the Polycomb group multiprotein PRC1-like complex, which was fused to exon 5 of FOXP1 
386. Whilst FOXP1 is a known partner in prostate tumour fusion events, it has only previously 
been identified as the 5’ fusion partner of ETV1, causing transcriptional activation through AR-
binding enhancers 346,387. FOXP1, like other FOX transcription factors, plays an important role 
in the regulation of tissue- and cell-specific gene transcription during both development and 
adulthood 116. This is the first PCa study to observe FOXP1 as the 3’ fusion partner, although, 
this phenomenon has previously been identified in a case of B-cell acute lymphoblastic 
leukemia, in which PAX5 was fused to FOXP1 388. Collaboration with national and 
international groups with access to prostate tissue samples, e.g. the Prostate Cancer Association 
Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) 
consortium, will enable us to determine the frequency of these two novel fusion events in other 
populations.  
 
It is possible that the biological importance of the RYBP:FOXP1 fusion may be due to the 
deletion of the region between the two genes, as deletion of the chromosome 3p13 region has 
been associated with poor prognosis and therapy resistance in PCa 389. In terms of the 
TMPRSS2:ERG fusion, it can be formed due to a chromosomal translocation or an ~3Mb 
intrachromosomal deletion of 21q22.2. Linn et al. (2016) characterised two mouse models 
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representing TMPRSS2:ERG translocation and deletion events and found that mice lacking the 
interstitial region developed prostate tumours marked by poorer differentiation and epithelial-
to-mesenchymal transition 390. This study concluded that the loss of tumour suppressors in this 
region of deletion contributed to disease progression 390. Therefore, it is possible that the 
deletion between RYBP and FOXP1 similarly contributes to carcinogenesis. Investigation of 
this region failed to identify any compelling cancer-associated genes, despite loss of this region 
previously being associated with PCa as mentioned above 389. Screening of additional prostate 
tumours by FISH could identify additional RYBP:FOXP1 carriers and this would also 
determine whether the fusion was formed through deletion or translocation. Additionally, the 
other novel fusion events identified in this study, including SLC30A4:ETV1 and 
C19orf48:ETV4 could also be screened by FISH analysis in a larger prostate tissue cohort.  
 
In this study, the SLC30A4:ETV1 fusion resulted in increased exon-level expression of ETV1 
in the regions downstream of the breakpoint. Similarly, it would be valuable to determine the 
effect of the C19orf48:ETV4 fusion on ETV4 expression. Recently, RNA hybridisation has 
emerged as a useful tool for the in-situ detection of ETV1, ETV4 and ETV5 in FFPE prostate 
sections, therefore, ETS gene rearrangements could be assessed in independent tumour foci 391. 
Thus, ETV4 gene expression could be assessed in the entire Tasmanian Prostate Tissue 
Pathology Resource using this technique, potentially identifying additional ETV4 fusion 
carriers. ETV4 is the third most common ETS gene involved in gene fusions 371 and expression 
has been associated with a poor prognosis in PCa, including a correlation with GS (p=0.045) 
and pathological tumour stage (p=0.041) 392. Thus, a fusion event involving ETV4 could have 
detrimental effects on normal prostatic pathways and may contribute to the progression of 
disease. 
 
As described earlier (Chapter 7.4.2), this study suggests that genetic susceptibility may increase 
the likelihood of some tumours developing the TMPRSS2:ERG fusion, as the event was more 
frequent in tumours from two Tasmanian PCa families, PcTas2 and PcTas9. Unfortunately, 
due to time constraints and a lack of genetic data for these families, this project was unable to 
test for an association between germline variants and somatic fusion events. Genome-wide 
germline genetic data from PcTas2 and 9 individuals would enable us to perform genome-wide 
linkage analysis based on TMPRSS2:ERG fusion status to replicate or identify novel loci 
associated with the fusion. This approach has been used by Hofer and colleagues (2009), who 
identified several loci on chromosomes 9, 18 and X that showed suggestive linkage to the 
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TMPRSS2:ERG fusion positive phenotype. This study assessed 75 patients from 36 German 
PCa families and found that 73% of fusion positive cases accumulated within 16 specific 
families 393. Given that germline DNA is available for 54 Tasmanian cases with known 
TMPRSS2:ERG fusion status, another priority would be to replicate associations with known 
TMPRSS2:ERG-associated variants, including rare variants in POLI and ESCO1 394, as well as 
common GWAS variants 379,395. Overall, targeted collection of additional prostate tumours 
from newly diagnosed cases in PcTas2 and 9 would assist in determining clustering, and 
assessing an underlying genetic predisposition to this fusion event.  
 
As the specificity of the ETV1 antibody used in this study is unknown, an antibody targeting 
the region of ETV1 involved in the fusion event would be beneficial to determine whether 
ETV1 overexpression in this region is translated to the protein level. However, even more 
advantageous would be to assess protein expression in two different regions of ETV1 to 
determine whether there is an overexpression of truncated or full-length ETV1.  
 
7.6 CONCLUSION 
This study sought to identify gene fusion events in prostate tumours from a single Tasmanian 
PCa family, PcTas9, and explore the hypothesis that these somatic events are underpinned by 
inherited predisposition. Overall, we successfully identified the known ERG and ETV1 fusions 
in our dataset, as well as four novel fusion events. Notably, the TMPRSS2:ERG fusion was 
more common in two families, PcTas2 and PcTas9, suggesting a germline genetic 
predisposition. However, due to time limitations we were unable to explore this further and test 
for associations with specific genetic loci or variants. In the future, the acquisition of genome-
wide, germline genetic data and the collection of additional tumours from recently diagnosed 
familial cases will enable our group provide more insight into this area of research.   
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CHAPTER 8 :  FINAL DISCUSSION 
 
8.1 CONTRIBUTION OF RARE VARIANTS TO PROSTATE CANCER RISK IN 
A TASMANIAN RESOURCE 
Genome-wide association studies (GWAS) of large prostate cancer (PCa) case-control cohorts 
have identified many common variants, however because of their frequency in the population, 
they are of limited use in the clinical setting. In recent years, interest has returned to rare 
variants, given only about one third of the genetic component of PCa risk has been described 
by common variants. GWAS are not powered to detect rare variants and instead, the 
combination of family studies and whole-genome sequencing (WGS) has been utilised to 
determine their contribution to cancer risk. However, this approach has been rarely applied to 
PCa. Rare variants are by definition rare in the population (MAF <2%) and although 
individually they may only have a marked effect on disease risk in a small proportion of 
patients, they provide important information about biological pathways that may be 
dysregulated in cancer. 
 
The Tasmanian Familial Prostate Cancer Study cohorts provided an opportunity to examine 
rare variant contribution to risk in large PCa families with a dense aggregation of disease. This 
dissertation has detailed the utilisation of PCa families combined with WGS to identify 
potential risk variants, using both a targeted and agnostic approach. In total, 20 novel/rare 
variants were prioritised for validation and segregation analyses, and two of these variants were 
prioritised for functional assessment. Overall, the total genomic data obtained from sequencing 
the genomes of 33 individuals identified approximately 6,000 pathogenic rare variants (MAF 
<2%; CADD >15) in at least one affected family member.  
 
Novel variants in RND1 and WNT1 were found to co-segregate with PCa in a single Tasmanian 
pedigree, PcTas22. A sporadic case was also identified as a carrier, yet we were unable to find 
a common ancestor with the other variant carriers from PcTas22. Given that they are previously 
undescribed, screening for these variants in additional familial and case-control cohorts is 
warranted to determine whether they contribute to PCa risk in other populations. Both RND1 
and WNT1 are involved in carcinogenesis; RND1 promotes the growth and migration of cancer 
cells 177 and high levels of WNT1 is associated with advanced, metastatic PCa 184. Even though 
these two variants appear to be private (to PcTas22 or the Tasmanian population), it is possible 
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that other variants in these genes contribute to PCa in other families in our resource and/or 
other populations. 
 
Chapter 4 highlighted a previously undescribed association of an intronic EZH2 variant with 
PCa risk. The EZH2 variant was found to segregate with disease in PcTas12 and was identified 
in an additional PcTas family, as well as three sporadic PCa cases and one Tasmanian control. 
EZH2 is a histone methyltransferase 192-194 and its expression is highly correlated with the 
progression of PCa 195,196, however the mechanism by which expression increases is currently 
unknown 196-199. It is possible that rare variants such as the one identified in this study could 
contribute to increased EZH2 expression during PCa progression, although no clear functional 
role for the EZH2 variant could be identified here. As a next step, it is fundamental to determine 
whether this or other variants in EZH2 are associated with risk in additional PCa cohorts, as 
without replication, this result would appear to be specific to our Tasmanian population or a 
false positive.  
 
The previously identified HOXB13 G84E variant 11 was found to contribute to PCa risk in the 
Tasmanian population. Here it was initially identified in two individuals from a single family, 
PcTas72 following examination of WGS data from 33 individuals. Later it was found to 
contribute to disease risk in six Tasmanian pedigrees and was also identified in three sporadic 
cases. In the original family, PcTas72, the G84E variant was only identified in two small 
branches of the large pedigree, demonstrating the heterogeneity of this disease. Thus, it is likely 
that a combination of a number of common and rare variants are contributing to disease risk in 
this and other families.  
 
Rare variants in CCL26, P2RX7 and ATM validated and segregated in their founder families, 
however they were not found to be significantly associated with PCa risk in the Tasmanian 
population by MQLS analysis. Enrichment analysis of the P2RX7 and ATM variants found 
higher carrier frequencies in familial compared to sporadic cases, suggesting that there may be 
a link with inherited PCa predisposition. Through collaboration with members of the 
International Consortium for Prostate Cancer Genetics (ICPCG) we will be able to assess the 
contribution of the rare variants discovered here to PCa risk in other populations, including the 
rare variants in RND1, WNT1 and EZH2. The ICPCG consists of whole-exome sequencing data 
for over 500 PCa cases, the majority with a strong family history of disease and therefore, is 
an ideal cohort for replication analyses. Additionally, data from the Prostate Cancer 
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Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium, a case-control cohort, could be screened for rare variants that were 
replicated in the ICPCG cohort.  
 
8.2 THE UTILISATION OF A FAMILY-BASED APPROACH TO RARE 
VARIANT DISCOVERY 
This study involved a family-based approach to gene discovery and there are many strengths 
to this methodology. The Tasmanian Familial Prostate Cancer Cohort is an extensive, unique 
resource, which consists of multi-generational Tasmanian PCa families. These pedigrees are 
more genetically homogeneous than other populations and therefore, there is likely to be an 
enrichment of disease-causing genes within these extended families. This feature enhances 
statistical power for risk variant discovery, especially rare variants. Plus, families are assumed, 
to some extent, to have similar environmental exposures, which enables the direct association 
of genetic variants with PCa to be realised. An additional advantage is that WGS of family 
members allows for a more stringent quality control measure using Mendelian inheritance 
patterns. However, a major limitation of our WGS study was that we were only able to 
sequence a limited number of individuals per family due to the associated cost and availability 
of genetic material, which meant that we could only focus on a small cluster of disease in each 
family. Whilst sometimes challenging, we aimed to sequence distantly related, affected family 
members as these cases share a smaller proportion of their genomes, which narrows down the 
search for rare disease-causing variants. Because of the infrequency, we were also only able to 
WGS a limited number of unaffected older male relatives who we could use as controls to help 
during the filtering process. Recruitment of additional family members, particularly distantly 
related cases and unaffected, older, first-degree males relatives, and availability of funding 
would enable us to sequence additional genomes to aid in the prioritisation of disease-causing 
rare variants. 
 
A strength of this study was that we were able to utilise the Tasmanian Prostate Cancer Case-
Control Study, which enabled us to assess the impact of rare variants on PCa risk in the wider 
Tasmanian population. Genotyping of this cohort permitted us to determine whether the rare 
variants identified in familial cases also contributed to sporadic disease in Tasmania. If so, it 
is important to screen these variants in larger national and international cohorts.  
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Whilst this study successfully identified rare germline variants associated with PCa risk, the 
focus has been on the coding regions of the genome. It should be noted, however, that rare 
variants within introns, intergenic regions and regulatory elements (e.g. promoters, enhancers, 
silencers and insulators) are also likely to contribute to PCa susceptibility. Such variants can 
alter gene expression or result in cryptic splice sites, impacting gene function and influencing 
the development of disease. WGS of individuals from our valuable Tasmanian families was 
chosen over WES, to provide us with the opportunity to examine non-coding variation in future 
analyses. The in silico tools available for detecting non-coding variants with a functional 
impact are rapidly evolving, however there are still some significant challenges. Functional 
annotation of such variants is a huge task, with non-coding regions making up approximately 
98% of the human genome. As discussed, linkage analysis in appropriate disease-enriched 
families will help us to narrow down regions of interest, including non-coding regions that can 
be examined with more insight and confidence in the near-future. 
 
Overall, this study has provided evidence that the combination of Tasmanian PCa pedigrees 
and WGS can successfully identify rare disease-causing variants in known and novel cancer 
associated genes. The identification of the known HOXB13 G84E variant in our PCa resource 
has shown that this variant also contributes to PCa risk in Tasmania, as it does to many other 
Caucasian PCa cohorts. The ATM variant, rs1800057 identified in PcTas4, was also recently 
identified in a large GWAS meta-analysis 9, following imputation to fine-map this region, 
which illustrates that the agnostic pipeline utilised in this study can successfully identify rare 
segregating variants.  
 
8.3 EXAMINING THE FUNCTIONAL IMPACT OF RARE PROSTATE CANCER 
RISK VARIANTS 
The identification of PCa risk variants requires replication in additional cohorts to provide 
further evidence for an association with PCa risk. Functional studies are also required to 
demonstrate how they play a role in disease initiation, yet this is often challenging. Chapter 4 
detailed the assessment of the functional impact of the intronic EZH2 variant, using an in vitro 
splicing assay, however no effect on splicing was demonstrated. EZH2 expression was unable 
to be quantitated in our formalin-fixed paraffin embedded (FFPE) prostate tumours. Whilst this 
variant didn’t appear to affect EZH2, there was some evidence to suggest that it may affect the 
expression of splicing factors associated with EZH2. Overall, analysis of the functional effect 
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of the EZH2 intronic variant was challenging, partly because the function of untranslated 
regions of genes, including introns, intergenic regions and regulatory elements is not yet fully 
understood. This is further complicated by the fact that these regions may only be functional 
in specific cell types. In silico prediction tools of pathogenicity and deleteriousness of non-
coding variants, in combination with datasets annotated with regulatory elements (such as the 
GTEx Portal; https://gtexportal.org/home/) 137 are now helping researchers gain a better 
understanding of their predicted functional effect before laboratory validation.  
 
Whilst we and numerous other studies have replicated the association of the HOXB13 G84E 
variant with PCa risk 396, no study has reported on the functional effect of this variant. 
Functional assessment of this variant suggested that it was rarely transcribed in G84E carrier 
prostate tissue (benign or malignant glands), nor did it have an effect on gene or protein 
expression (Chapter 5). Further analyses suggested that epigenetic mechanisms don’t appear 
to account for the unbalanced allele transcription seen in G84E variant carriers. Therefore, 
future studies could focus on whether copy number variation at the HOXB13 site or rapid 
targeted degradation of the variant mRNA transcript underpin the observed allelic imbalance. 
Given that HOXB13 is essential for vertebrate embryonic development 116, it is possible that 
the G84E variant may affect the development of the normal prostate during embryonic 
development, when HOXB13 expression levels are very high, and these changes may make the 
prostate susceptible to tumour development later in life.  
 
Given the rarity of the EZH2 and HOXB13 variants it was challenging to collect a considerable 
sample size of prostate specimens from variant carriers. A small sample size results in reduced 
power and therefore lowers the likelihood of detecting real functional effects, which may 
explain why we didn’t see any differences in expression between variant carriers and non-
carriers. The quality of DNA and RNA extracted from FFPE tissues is also fairly poor, which 
makes functional assays challenging. Thus, the concepts explored in this study should be 
applied to a larger tissue cohort of EZH2 and HOXB13 carriers, which could be achieved in 
collaboration with other PCa groups with access to larger FFPE cohorts, or where possible 
fresh frozen cohorts, and this is underway.  
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8.4 EXPLORING GERMLINE VARIANT PREDISPOSITION TO SOMATIC 
TUMOUR ALTERATIONS  
The Tasmanian Familial Prostate Cancer Study is a highly valuable resource as it is one of a 
limited number of cohorts comprised of large families with germline and tumour DNA 
available for multiples cases. This has allowed us to explore the relatively new and non-
traditional hypothesis that there is an inherited predisposition to some somatic alterations in 
prostate tumours. Chapters 6 and 7 described chromosomal alterations identified in Tasmanian 
prostate tumours, including chromosomal amplifications and deletions (Chapter 6), and 
translocations resulting in gene fusions (Chapter 7).  
 
To the best of our knowledge, this is the first study to assay tumours from a single family by 
array Comparative Genomic Hybridisation (aCGH). This study highlighted a novel 
amplification of EEF2 (19p13.3) and follow-up gene expression analysis validated this finding 
in five out of eight tumours. Analysis of matched malignant and benign prostate glands 
suggested that EEF2 overexpression is a feature of malignant glands only. Overall, EEF2 
mediates protein synthesis 116, a key characteristic of cancer cells, and overexpression of EEF2 
in cancer cell lines suggests that it significantly enhances cell growth through cell cycle 
progression 302. Thus, whilst further assessment is required, it is possible that the EEF2 
amplification observed in our study may result in cell cycle alterations, leading to increased 
tumourigenesis. In fact, EEF2 overexpression has recently been suggested as an ideal 
therapeutic target 299. Particularly interesting is that this amplification was consistently 
identified in multiple family members, suggesting an inherited predisposition. This hypothesis 
will be further investigated by utilising genome-wide, germline genetic data from these 
individuals.  
 
Chapter 7 detailed the identification of the TMPRSS2:ERG fusion in our Tasmanian Prostate 
Tissue Pathology Resource, as well as the identification of novel fusion events in tumours, 
including WHSC1L1:CNKSR3, RYBP:FOXP1, SLC30A4:ETV1 and C19orf48:ETV4. Given 
that this study is the first to describe the involvement of WHSC1L1, CNKSR3, SLC30A4, 
C19orf48 and RYBP in a PCa fusion event, it is essential to screen larger prostate tissue cohorts 
to determine their frequency. Currently, ETS-fusion status is the major molecular subclassifier 
of localised PCa, yet it is currently still debated whether these and other fusion events are 
associated with poor clinical outcomes or not. Thus, in addition to those found previously, the 
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novel fusion events and novel ETV1/4 fusion partners identified here must be investigated to 
determine whether all or only particular fusion events are associated with clinical outcomes, 
both good and poor. In the future, screening of ETS gene fusions in prostate tumours may 
provide us with valuable knowledge about the disease and its prognosis, which could inform 
targeted therapeutic options. This study has proven that there are a number of different prostate 
fusion events, therefore screening tools like the RNA Fusion Panel would be advantageous, 
however this is currently too expensive for routine clinical use.  
 
It is apparent that the amplification of the EEF2 gene is more common in tumours from PcTas9, 
with only a few individual tumours from other families showing similar expression patterns. 
The TMPRSS2:ERG fusion was also more frequent in tumours from this same Tasmanian PCa 
family. Appendix 30 shows the overlap of tumours with EEF2 amplification and 
TMPRSS2:ERG fusion status; four tumours had both an EEF2 amplification and were fusion 
positive, eight tumours had only one alteration and six tumours had neither alteration. Given 
that PCa is a complex disease, it is likely that there are multiple drivers of disease even within 
this one family.  
 
Given the high frequency of TMPRSS2:ERG fusion events in these families, and accumulating 
evidence from previous studies, they are unlikely due to chance. The higher frequency of this 
fusion event in two Tasmanian PCa families suggests that there is an underlying genetic 
predisposition. This is further supported by the fact that none of the sporadic PCa tumours were 
fusion positive. It has been suggested that inherited germline variants in DNA repair genes can 
lead to increased chromosomal rearrangements, resulting in TMPRSS2 fusing to ERG 356. 
Whilst germline data was not available for all individuals, we have recently obtained GSA 
(Global Screening Array) SNP (single nucleotide polymorphism) array and WGS data from 
individuals from both PcTas2 and PcTas9. The SNP array data will enable us to perform 
genome-wide linkage analysis, based on TMPRSS2:ERG fusion status. The highlighted linkage 
loci can then be examined in the WGS data, which narrows the search for underlying germline 
genetic variants that may be associated with these somatic tumour events. We could also 
determine whether previously reported TMPRSS2:ERG-associated variants, including rare 
variants in POLI and ESCO1 394, as well as common GWAS variants 379,395 are present in cases 
in our Tasmanian cohort. It would also be interesting to test for association of the 63 common 
variants recently identified by a GWAS meta-analysis 9 with fusion status. Overall, collection 
of additional tumours from newly diagnosed cases in PcTas9 would assist in determining 
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clustering of the TMPRSS2:ERG fusion and EEF2 amplification, which would enable us to 
further assess whether there is an underlying genetic predisposition to these somatic tumour 
events. 
 
8.5 CLINICAL SIGNIFICANCE OF THIS STUDY 
The research presented in this thesis has primarily been undertaken to advance our 
understanding of the underlying mechanisms of PCa risk and progression, with the longer-term 
goal of translating this knowledge in to the clinical setting. A Prostate Cancer Comprehensive 
Panel is currently offered to men with a family history of disease (Fulgent Genetics, CA, USA). 
This panel examines 12 genes associated with an increased risk for PCa, including ATM, 
BRCA1, BRAC2, CHEK2, HOXB13 and NBN. This test is designed to identify germline 
pathogenic variants that may increase PCa risk. A positive result can prompt screening options 
for early detection and treatment of cancer, as well as encouraging the testing of other relatives. 
For our Tasmanian families carrying the HOXB13 G84E, genetic testing has been offered free 
of charge, through the Tasmanian Genetic Counselling Service (with ethics approval). Given 
that variants in the 12 above-mentioned genes only explain a minor proportion of disease 
heritability, the identification of additional pathogenic variants and/or PCa predisposition 
genes will enable us to better inform men of their risk. For example, three previously 
undescribed associations with PCa were identified in this study and this knowledge could be 
disseminated to these families to inform their disease risk. If these findings are replicated and 
further investigation strengthens the argument that these genes are involved in cancer, the 
RND1, WNT1 and EZH2 genes may be included in PCa screening panels in the future. There 
is also currently a strong push to implement polygenic risk scores based on common variants 
in the clinical setting, yet with only one-third of genetic predisposition explained, this may be 
premature. Therefore, identification of rare germline risk variants will aid in the 
implementation of polygenic risk scores in to the clinic. 
 
Routine cytogenetic analysis aids in the diagnosis of many cancers, particularly haematological 
malignancies, yet the clinical implementation of this has not yet been realised for PCa. The 
knowledge of specific somatic tumour alterations could define particular disease phenotypes 
and inform a man’s response to treatment. If the recurrent EEF2 amplification and/or the novel 
fusion events identified in this study were found to be associated with certain clinical outcomes, 
men could be tested for these at diagnostic biopsy, when the disease is most curable.  
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Knowledge of both inherited and somatic genetic alterations is now also informing treatment 
strategies. One promising therapeutic candidate which impairs tumorigenesis and cell invasion 
is the Poly-ADP ribose polymerase (PARP) inhibitors 397. The PARP1 inhibitor, olaparib, is 
approved for use in several countries for the treatment of breast, ovarian, fallopian tube and 
peritoneal cancer patients with an inherited BRCA1 or BRCA2 mutation 376. In the presence of 
a PARP inhibitor, a cell is PARP1 deficient, and together with a BRCA1 or BRCA2 variant, the 
cells cannot repair DNA damage effectively and die. PARP inhibitors also appear to be 
effective in the presence of deleterious variants in other DNA repair genes, including ATM, 
CHEK2 and PALB2 and clinical trials have been initiated in metastatic PCa patients. However, 
a study by Marshall and colleagues (2018) found that metastatic castration-resistant PCa with 
somatic ATM mutations responded poorly to PARP inhibitors, compared to those with BRCA1 
or BRCA2 mutations, and concluded that alternative therapies should be explored for PCa cases 
with variants in ATM 398.  
 
Somatic tumour events, such as ERG, ETV1 and other ETS gene fusions may also benefit from 
PARP1 inhibitors as these tumours are susceptible to PARP inhibition through the increased 
incidence of DNA double strand breaks 375. Another recent study demonstrated that a small 
molecule inhibitor, YK-4-279, has also been developed to inhibit the biological activity of ERG 
and ETV1 399,400. Overall, targeting DNA repair genes, ETS fusion proteins, or their binding 
partners, their DNA binding sites, or their downstream effectors provides multiple avenues 
through which tumour progression or metastasis can be effectively prevented.  
 
8.6 FINAL CONCLUSION 
In conclusion, this study has highlighted the success of combining Tasmanian PCa pedigrees 
with a dense aggregation of disease and WGS to narrow the search for rare disease-causing 
variants. Four novel/rare variants in RND1, WNT1 EZH2 and HOXB13 were found to be 
significantly associated with PCa risk in the Tasmanian population, three of which were 
previously undescribed. Despite the heterogenous nature of this disease, this study has also 
shown that some somatic alterations are shared by family members. The EEF2 amplification 
in tumours from PcTas9 is a particularly interesting finding as EEF2 overexpression has 
recently been suggested as an ideal therapeutic target. Overall the findings of this study have 
highlighted genes and biological pathways that may be involved in PCa development in 
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Tasmania. The rare variants identified here could help explain some of the ‘missing’ PCa 
heritability, while our tumour work will lead to a better understanding of the link between 
germline variants and somatic events. Understanding the genetic determinants of disease 
development and somatic tumour variation will ultimately lead to better screening, diagnostic 
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CHAPTER 10 :  APPENDICES 
 
APPENDIX 1 
Thermal cycling conditions. 
 
• cDNA synthesis (Chapter 2.1.7) 
20uL reactions, per sample: 
 4.0µL 5X VILOTM Reaction Mix (Invitrogen) 
 2.0µL 10X SuperScriptTM Enzyme Mix (Invitrogen) 
 XµL FFPE RNA 
 H2O to 20uL final volume 
   X – Variable, up to 2.5µg 
 
Thermal cycling conditions: 
25 °C – 10 minutes 
42 °C – 120 minutes 
85 °C – 5 minutes 
 
• Amplification of DNA for Sanger sequencing (Chapter 2.2) 
10µL reactions, per sample: 
5.0µL MyTaqTM HS Mastermix (Bioline)  
0.8µL forward primer at 10µM (Sigma-Aldrich) 
0.8µL reverse primer at 10µM (Signma-Aldrich) 
2.4µL H2O 
1.0µL DNA at 10ng/µL 
 
Thermal cycling conditions: 
95°C – 1 minute 
95°C – 10 seconds 
X°C – 10 seconds        40 cycles 
72°C – 20 seconds * 
4°C – ¥ 
X – Annealing temperature is primer pair specific (Appendix 2) 
* Extension time increased to 30 seconds for larger fragments 
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• Quantification of gene expression by RT-qPCR (Chapter 2.3) 
10µL reactions, per sample: 
5.0µL SensiFASTTM SYBR® No-Rox Mastermix (Bioline) or  
5.0 µL PowerUpTM SYBR® Green Mastermix (ThermoFisher Scientific) 
0.3µL forward primer at 10µM (Sigma-Aldrich) 
0.3µL reverse primer at 10µM (Sigma-Aldrich) 
3.4µL H2O 
1.0µL FFPE cDNA at 50ng/µL 
 
Thermal cycling was conducted on the Rotor Gene 6000 (Qiagen) when using 
SensiFASTTM SYBR® (Chapter 5), as per the following conditions: 
95°C – 3 minutes 
95°C – 10 seconds 
60°C – 10 seconds   
72°C – 10 seconds  
 
Thermal cycling was conducted on the QuantStudioTM 3 Real-Time PCR System when 
using PowerUpTM SYBR Green (Chapters 4, 6 and 7), as per the following conditions: 
50°C – 2 minutes 
95°C – 2 minutes 
95°C – 1 second     
60°C – 20 seconds  
 
• Big Dye Terminator sequencing reaction (Chapter 3.2.3) 
10µL reactions, per sample: 
0.25µL BigDye® Terminator v3.1 Ready Reaction Mix 
1.75µL 5X Sequencing Buffer 
1.6µL primer at 3.3µM (forward or reverse) (Sigma-Aldrich)  
5.4µL H2O 
~ 1.0µL AMPure purified PCR product * 






Thermal cycling conditions: 
96°C – 1 minute 
96°C – 10 seconds 
50°C – 5 seconds          25 cycles  
60°C – 1 minute 15 seconds 
4°C - ¥ 
 
• TaqMan® SNP genotyping (Chapter 3.2.4) 
8µL reactions, per sample: 
  4.0µL SensiFASTTM Probe No-Rox Mastermix (Bioline) 
  0.1µL 40x TaqMan® SNP genotyping probe (Applied Biosystems; Appendix 6) 
  2.9µL H2O 
  1.0µL gDNA at 10ng/µL 
 
Thermal cycling was conducted on the LightCycler® 480 system (Roche), as per the 
following conditions: 
  95°C – 10 minutes 
  95°C – 15 seconds 
  60°C – 1 minute 
 
• Allele-specific next-generation sequencing (Chapter 5.2.4) 
10µL reaction, per sample: 
  5µL Phusion® (GeneSearch) 
  1µL forward tag (Integrated DNA Technologies; Appendix 13) 
  1µL reverse tag (Integrated DNA Technologies; Appendix 13) 
  1µL H2O 
 
Thermal cycling was conducted on the Mastercycler® nexus (Eppendorf), as per the 
following conditions: 
  
  98°C – 5 seconds 
  98°C – 20 seconds      10 cycles 




• Allele-specific methylation analysis (Chapter 5.2.6) 
10µL reaction, per sample: 
5.0µL MyTaqTM HS Mastermix (Bioline) 
0.8µL forward primer at 10µM (Sigma Aldrich) 
0.8µL reverse primer at 10µM (Sigma Aldrich) 
2.0µL Q solution (Qiagen) 
0.4µL H2O 
1.0µL bisulphite-converted DNA @ 25ng 
 
Thermal cycling conditions: 
95°C – 2 minutes 
95°C – 10 seconds 
56°C – 10 seconds      45 cycles 
64°C – 30 seconds 
4°C -  ¥ 
 
• TaqMan® TMPRSS2:ERG expression assay (Chapter 7.2.2) 
10µL reactions, per sample: 
5.0µL TaqMan® Fast Advanced Mastermix (ThermoFisher Scientific) 
  0.5µL TaqMan® expression probe (Applied Biosystems; Appendix 26) 
  2.5µL H2O 
  2.0µL FFPE cDNA at 50ng/µL 
 
Thermal cycling was conducted on the QuantStudioTM 3 Real-Time PCR System, as 
per the following conditions:    
50°C – 2 minutes 
  95°C – 2 minutes 
  95°C – 1 second        




Primers designed for Sanger sequencing of prioritised rare variants and their optimal annealing temperatures. 
All sequencing primers were designed using Primer3 135 or PrimerBLAST 136.  
 Gene Variant 
Allele 
Change 









CCL26 rs41463245 C > T CATCCCAAGGCTCATCCTG CTGCTTCTGTTCCCAACCAC 500 64 
P2RX7 rs28360447 G > A ATGATGTCCCTCCTGGAGAA ATGGCCCTCCCAGAGATACT 354 62 
NDE1 rs113493697 C > T CTCCCAAAGTGCTGGCATTA GCTCTGAGCCTGATGCAAAT 366 60 
CLDN4 Novel A > G CTGGTCTGCTCACACTTGCT AGAGAGGCTGAAGGCTGCTG 969 66 
ATM rs1800057 C > G TGGCAAGGTGAGTATGTTGG TACTGCCATCTGCAGCATTC 526 64 
SSH3 rs373641394 G > A CAATGATGATGCAGCAGAGG AGCAGGGTCACTGGGATATG 336 64 
IRS1 rs41265094 C > G GGCCAGACAAGTAGCCAGAC TCTTCCTCTTCCACCAGCAG 316 64 
CRIP2 rs375691223 C > T CTCCCTCCACAGGAGTGAAC GATTCGGACACGCAGACAC 320 64 
KMT2C rs76844681 C > T GGAGTCAAAGAGGAAGGTAAGAAA TACATAGGGCCGTGGGTCT 337 64 
RHPN2 Novel A > G ACTCAACCCCAAACCTGATG GAGGGCACTTCTCTCCCTCT 315 64 
HSD3B1 rs4986952 G > T TTTTTGGTTCTAGAATTTCACATCA TGCCCTTCTTTGTGATCCTT 443 66 
NAT10 rs72910804 A > G CCCTCTGTCCTTTCTGCTGT AGGGGACTCTCAAAGGGAAG 380 66 













WNT1 Novel G > A GGAGAGGGCAGTGTCTGG CGGGCGACGAGCTGTTAC 410 66 
CHEK2 rs200432447 G > C CCAGGTTCCATCAGGTTTTT TGAGATGGGAGAGAAACAGATG 369 62 
ITGAD rs147321998 C > T ATGTGAGGGTGCCAGGACT CTGAAGGAGATGCAGGCTGA 314 60 
EZH2 rs78589034 G > A CTGGGATTGCAGGAGTCG TTTGTCCCCAGTCCATTTTC 365 60 
EPS8 rs78763451 C > T ATGCAGTCTGTGCCCTTATG GACTAGAGAAGAGCCAGGGAGTT 493 64 
TIA1 rs115611153 T > C CGCTTTACATAAGAGGCCCTA TGATGGCCCTGTGTGTTTT 355 62 
HOXB13 rs138213197 C > G CACAACGGTCCCTCTTGTCT GTTCAGCGGACGTAAGCG 696 62 
FFPE 
DNA 
EZH2 rs78589034 G > A CAGATGGTGCCAGCAATAGA TGAAGCTGTGTGCCCAATTA 170 60 
HOXB13 rs138213197 C > G CCGGATAGAAGGCAAACTCA GCTGATGCCTGCTGTCAACT 272 62 
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APPENDIX 3 
Primers designed for gene expression analysis in prostate tissue specimens by RT-qPCR. 
This table also details the most commonly transcribed isoform in the prostate, for each gene and the median TPM (transcripts per million) 





Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Product 
size (bp) 
b-Actin ENST00000331789.5 3095 GAGCGCGGATACAGCTT 401 TCCTTAATGTCACGCACGATTT 401 59 
GAPDH ENST00000396859.1 786.1 CAACGGATTTGGTCGTATTGG 401 GCAACAATATCCACTTTACCAGAGTTAA 401 72 
EZH2 
Exon 17 
ENST00000492143.1 3.220 AAGCACAGTGCAACACCAAG AGCGGCTCCACAAGTAAGAC 86 
EZH2 
Exon 4/5 
ENST00000492143.1 3.220 GCGACTGAGACAGCTCAAGA CCAAAATTTTCTGACGATTGGAACT 80 
EZH2 
Exon 8/9 
ENST00000492143.1 3.220 ATGGGAAAGTACACGGGGATAG GGCATTCACCAACTCCACAAAAA 71 
EZH2 
Exon 12/14 
ENST00000492143.1 3.220 GGACCACAGTGTTACCAGCA TTGGTGGGGTCTTTATCCGC 82 
EZH2 
Exon 14/16 
ENST00000492143.1 3.220 GAGGAAACACCGGTTGTGGG TGTAAACATGGTTAGAGGAGCCG 77 
EZH2 
Exon 17/18 
ENST00000492143.1 3.220 TATTCAGCGGGGCTCCAAAA GATAAAAATCCCCCAGCCTGC 70 
EZH2 
Exon 20/21 
ENST00000492143.1 3.220 TTCGGTAAATCCAAACTGCTATGC CCAGTCTGGATGGCTCTCTTG 90 





Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Product 
size (bp) 
CDH1 ENST00000261769.5 58.33 AAGGGGTCTGTCATGGAAGG GGTGTTCACATCATCGTCCG 84 
MSMB ENST00000358559.2 1160 TGATCTTTGCCACCTTCGTGA ACAGGTGTAGAAACATCCTGGTT 99 
HOXA9 ENST00000343483.6 26.19 ATCCCAATAACCCAGCAGCC TTTGTATAGGGGCACCGCTT 70 
SF3B1 ENST00000424674.1 145.1 TTGTTGGTCGTATTGCTGACA TCAAAGCAAATCCTCATCCACTC 70 
SF3B3 ENST00000565990.2 34.10 GCATCCTTGTGCCATTCACG TCAGACCGCAGGTGCATTTC 73 
U2AF1 ENST00000291552.4 71.93 TGTGGAGATGCAGGAACACT ACTTCCCCATACTTCTCCTCC 75 








ENST00000309311.6 1213 CGACTCGCTTCTTTCGGTTC CGGATCTGGTCTACCGTGAAG 88 
EEF2 
Exon 2/3 
ENST00000309311.6 1213 AGACACGCTTCACTGATACCC AGGGAGATGGCAGTTGACTTG 73 
EEF2 
Exon 4/5 
ENST00000309311.6 1213 ATCATCTCCACCTACGGCGA CGGTACCGAGGACAGGATCG 73 
EEF2 
Exon 9/10 
ENST00000309311.6 1213 GAGGACCTCTACCTGAAGCC CCACAAGGCACATCCTCGAT 83 
EEF2 
Exon 14/15 
ENST00000309311.6 1213 AAGGCCTATCTGCCCGTCAA AAGGCCTATCTGCCCGTCAA 89 
DAPK3 
Exon 3/4 
ENST00000301264.3 68.91 ATGTCCACGTTCAGGCAGG CTTCCGCACGATCGCAAAC 87 
DAPK3 
Exon 4/5 
ENST00000301264.3 68.91 GCGTTCACTACCTGCACTCTA ACGTTCTTGTCCAGCAGCAT 79 










ENST00000301264.3 68.91 CTATATCCTCCTGAGCGGTGC TTCACGGCTGAGATGTTGGT 78 
ETV1 
Exon 8/10 
ENST00000405358.4 2.885 AACAGAGATCTGGCTCATGATTC CTTCTGCAAGCCATGTTTCCTG 76 
ETV1 
Exon 16/17 
ENST00000405358.4 2.885 GATAGCAGCTACCCCATGGAC TCGTCGGCAAAGGAGGAAAG 79 
ETV1 
Exon 20/21 
ENST00000405358.4 2.885 GACTGGTCGAGGCATGGAAT TTTCTGAATGCCCCAACGTC 70 






Standard curves for each RT-qPCR primer pair.  
The lines of best fit were used to calculate the copy number of each gene in each sample and 


























b- Actin – SensiFASTTM SYBR® No-Rox 
b- Actin – SensiFASTTM SYBR® No-Rox 
b- Actin – PowerUPTM SYBR® Green 




























GAPDH – PowerUPTM SYBR® Green 
EZH2 Exon 17 – PowerUPTM SYBR® Green 
EZH2 Exon 4/5 – PowerUPTM SYBR® Green 















EZH2 Exon 12/14 – PowerUPTM SYBR® Green 
EZH2 Exon 14/16 – PowerUPTM SYBR® Green 
EZH2 Exon 17/18 – PowerUPTM SYBR® Green 




















CDH1 – PowerUPTM SYBR® Green 
MSMB – PowerUPTM SYBR® Green 
HOXA9 – PowerUPTM SYBR® Green 












SF3B3 – PowerUPTM SYBR® Green 
U2AF1 – PowerUPTM SYBR® Green 
HOXB13 – SensiFASTTM SYBR® No-Rox 




































EEF2 Exon 2/3 – PowerUPTM SYBR® Green 
EEF2 Exon 4/5 – PowerUPTM SYBR® Green 
EEF2 Exon 9/10 – PowerUPTM SYBR® Green 




























DAPK3 Exon 3/4 – PowerUPTM SYBR® Green 
ETV1 Exon 8/10 – PowerUPTM SYBR® Green 
DAPK3 Exon 4/5 – PowerUPTM SYBR® Green 










ETV1 Exon 20/21 – PowerUPTM SYBR® Green 
ETV1 Exon 16/17 – PowerUPTM SYBR® Green 
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APPENDIX 5 
Primary antibodies used for protein expression analyses. 
This table details the chosen primary antibody and the expression of the protein in the prostate, as per the Human Protein Atlas 
(https://www.proteinatlas.org) 403. 
 
Protein Antibody Working Dilution Immunogen Expression at the protein level 403 
EZH2 ab186006 (abcam) 1:150 Amino acid 696-746 
Nuclear expression in the testis, lymphoid tissues and gastrointestinal tract. 
Not detected in the prostate, as reported by the Human Protein Atlas, 
however 4 of 11 PCa patients had moderate/strong staining of EZH2. 
HOXB13 sc-28333 (Santa Cruz) 1:50 Amino acid 1-284 
Nuclear expression in the prostate and gastrointestinal tract. Highly 
expressed in the prostate, as reported by the Human Protein Atlas and 10 of 
12 PCa patients had moderate/strong staining of HOXB13. 
ETV1 PA5-41484 (ThermoFisher) 1:150 ‘Middle region’ 
Localised to the nucleoplasm. Expression of the protein in any tissue is not 
reported by the Human Protein Atlas.  
EEF2 SAB4500695 (Sigma-Aldrich) 1:150 Amino acid 31-80 
Cytoplasmic and membranous expression in most tissues. Highly expressed 
in the prostate, as reported by the Human Protein Atlas and 10 of 11 PCa 




TaqMan® SNP genotyping assay identification numbers (Applied Biosystems). 
 




RND1 Custom Designed Probe 























 Forward Primer (5’-3’) Reverse Primer (5’-3’) Amplicon Size (bp) 
EZH2 insert (exon 16-19) AGAGCACCTTGCTGAACGAT CTGTCAACAGCAGGGTGAGA 3,181 
EZH2 insert with attB1 and attB2 







Rat insulin exon 2 (forward) 404 
and 3(reverse) 405 
CCTGCTCATCCTCTGGGAGC ATGCTGGTGCAGCACTGAT 253; 717* 
*The amplicon size is dependent on whether the insert is present or not. If present, the product would be 717bp and if absent, the product would be 253bp. 
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APPENDIX 8 
EZH2 gene expression analysis in prostate cancer cell lines and prostate needle biopsy 
samples (raw data). 
 
 Absolute EZH2 Gene Expression 
Sample 









PC3 0.06 0.44 11.08 1.21 0.15 0.16 18.33 
22Rv1 0.22 4.07 32.24 3.84 0.17 0.25 39.16 
LNCaP 0.57 0.12 8.18 0.80 0.10 0.18 34.94 
PT0001 Right 0.05 0.01 1.11 0.23 0.01 0.03 9.73 
PT0001 Left 0.02 0.04 0.75 0.36 0.03 0.01 0.60 
PT0002 Right 0.09 0.02 1.68 0.43 0.03 0.06 17.86 
PT0002 Left 0.11 0.02 0.74 0.26 0.02 0.02 5.80 
PT0003 Right 0.03 0.01 0.32 0.13 0.01 0.01 1.67 
PT0003 Left 0.06 0.07 1.91 0.40 0.03 0.04 4.92 
PT0018 Right 0.03 0.02 0.91 0.36 0.02 0.03 1.45 




EZH2 target gene and splicing factor expression analysis in prostate cancer cell lines 
and prostate needle biopsy samples (raw data). 
 
 Absolute Gene Expression 
Sample 
Identification CDH1 HOXA9 MSMB SF3B1 SF3B3 U2AF1 
PC3 4.74 0.04 0.01 0.35 1.06 140.67 
22Rv1 0.30 0.01 0.03 0.31 0.61 28.69 
LNCaP 1.07 0.01 0.04 0.29 1.23 59.00 
PT0001 Right 2.06 0.03 0.15 0.73 1.07 48.82 
PT0001 Left 1.31 0.02 0.02 0.40 0.63 23.52 
PT0002 Right 1.58 0.16 0.02 1.09 0.62 55.74 
PT0002 Left 2.71 0.06 0.11 0.81 0.51 35.32 
PT0003 Right 3.80 0.02 0.52 0.73 0.80 104.43 
PT0003 Left 4.10 0.04 0.32 0.73 1.08 75.31 




















PC4-03 Malignant 7.17 1.30 101.18 
 Benign 6.58 1.80 20.54 
PC11-11 Malignant 5.93 0.23 32.34 
 Benign 1.71 0.43 18.45 
PC12-07 Malignant 1.37 0.02 6.42 
PC19-02 Malignant 19.39 4.20 18.94 
PC60-01 Malignant 14.96 1.26 19.11 
 Benign 3.86 1.45 16.82 
PC72-04 Malignant 1.24 0.14 22.34 
 Benign 201.94 8.30 11.01 
PC72-06 Malignant 7.99 3.04 8.12 
 Benign 22.86 3.08 37.24 
PC3250-01 Malignant 1.21 1.86 76.92 
 Benign 16.73 21.54 29.61 
DVA 216 Malignant 8.07 18.33 18.95 
 Benign 4373.71 11.17 27.34 
DVA 402 Malignant 8.09 18.17 12.54 
 Benign 2.87 1.70 37.24 
DVA 1002 Malignant 46.19 126.73 14.84 




PC12-01 Malignant 4.80 2.24 1514.76 
 Benign 35.58 1.35 6.32 
PC12-03 Malignant 397.72 5.25 2.25 
 Benign 0.95 1.88 5.64 
PC12-06 Malignant 19.68 14.10 24.50 
PC12-08 Malignant 6.83 8.00 12.51 
PC12-09 Malignant 2.52 0.10 6.19 
 Benign 2.02 0.28 13.94 
PC12-132 Malignant 12.91 1.90 23.50 
 Benign 46.94 17.63 18.03 
DVA 416 Malignant 134.76 17.18 - 
 Benign 162.64 0.41 11.44 
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APPENDIX 11 
Gene panel of cancer predisposition and DNA repair genes. 
Genes include known prostate, breast and ovarian cancer predisposition genes and DNA repair 
genes commonly disrupted in cancer (from the BROCA gene panel) 172-176. WGS data from 





































HOXB13 rs138213197 GGACACTCGGCAGGAGTAGTA GCTGATGCCTGCTGTCAACT 
224 with  
Illumina Adaptors 
HOXB13 rs9900627 GGGAACCTACCAGCCTATGG GTTCTGTTCTCCCTGGCAAC 










Upstream CpG Island 
(Product 1 in Figure 5.7) 
TTCTCCCAACTAAAACAAACTCTAT GTAAAGGTTATAGGTTGTTTGTGGG 254 
HOXB13 Promoter/Exon 1 
CpG Island 406 
(Product 2 in Figure 5.7) 
ACTTATTCTCTCTCTCTCTCT CCTTAACTCCATCCAAAATAAC 314 
HOXB13 Allele-Specific  
Methylation Analysis 
(Product 3 in Figure 5.7) 
TTAATTATGTTTTTTTGGATTTGTTAGGT ACTACCTAAACACAAAATTTCAAC 175 
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APPENDIX 13 
Primer sequences of the forward and reverse tags used to barcode PCR products for the 
allele-specific next-generation sequencing assays.  
Forward and reverse tags were designed by our collaborator, Andrea Polanowski (Australian 
Antarctic Division), and purchased from Integrated DNA Technologies. 
Forward Tag 
Identification 
Primer Sequence (5’–3’) 
Reverse Tag 
Identification 
Primer Sequence (5’-3’) 
F16 AGCCTGGCAT R20 GTCCACCAGT 
F17 AGTTCGGACT R21 ATCCGCCAGT 
F18 AGTTCTTGAC R23 ACTTGCCGAT 
F19 ACGGTCCATG R24 GCTTACCGAT 
F20 ACTTGTTCAG R27 GACCTAACTG 
F21 ACTTGCCGAT R28 ATGGCAACTG 
F22 ACGGTGGATC R33 GCTTACCATG 
F23 ATCCGCCTAG R43 CGAATGGTCA 
F47 TCAAGCCAGT R44 ATCCGTTGCA 
F48 TCAAGAATGC   
F49 CTGGACCTGA   
F50 CGTTACCGTA   
F51 TGCCATTGCA   
F52 TCGGATTCGA   
F53 AGCCTGGCTA   
F54 AGCCTCCTGA   
F55 ACTTGTTCGA   
F56 ATCCGCCGTA   
F57 ATCCGTTCGA   
F58 ATGGCGGTCA   
F59 CAGGTGGCTA   
F60 CTAAGTTGCA   
F61 CGTTAGGTCA   
F62 TCGGACCGTA   
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APPENDIX 14 
Allele-specific next-generation sequencing; Galaxy FastQC report for PC12-08.  
Figure A depicts ‘Per Base Sequence Quality’, with high quality scores (for each base position) 
shown in the green area and lower quality in red. As the ‘position in read’ increases the quality 
of the reads decrease significantly, which may be due to poor quality FFPE RNA used in this 
















Rare variants in known cancer-associated/DNA repair genes, following examination of WGS data from five Tasmanian prostate cancer 
families. 
 























AR Novel X:66,766,342 N/A 
PcTas22 
Main 
3 out of 5/ 0 out of 1 6.738 G > T; G452C 0 out of 8 N/A 
ATM Novel 11:108,235,819 N/A PcTas3 1 out of 5 20.5 
A > G; 
Y2954C 
0 out of 8 N/A 
ATM rs1800056 11:108,137,753 0.90 PcTas4 3 out of 4/ 0 out of 1 8.76 T > C; F858L 0 out of 8 
Hereditary cancer: 
Benign 
BRCA1 rs4986852 17:41,244,179 1.32 PcTas4 1 out of 4/ 1 out of 1 14.94 
C > T; 
S1040N 
0 out of 8 
Hereditary breast and 
ovarian cancer: Benign 
BRCA1 rs28897673 17:41,256,016 <0.01 PcTas22 Sub 1 out of 4/ 1 out of 2 24.7 T > C; Y105C 0 out of 8 
Hereditary breast and 
ovarian cancer: Benign 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; WGS: Whole-genome sequenced; 2CADD: Combined Annotation 
Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study, eight were WGS; 3Associated condition: Interpretation of variant 163. 
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BRCA2 rs56403624 13:32,906,750 0.02 PcTas3 1 out of 5 16.12 A > G; E462G 0 out of 8 
Hereditary breast and 
ovarian cancer: Benign 
BRCA2 rs28897727 13:32,912,500 0.68 PcTas4 1 out of 4/ 0 out of 1 16.04 
G > T; 
D1420Y 
0 out of 8 
Hereditary breast and 
ovarian cancer: Benign 
BRCA2 rs4987117 13:32,913,986 1.79 PcTas12 1 out of 2/ 0 out of 1 7.558 
C > T; 
T1915M 
1 out of 8 
Hereditary breast and 
ovarian cancer: Benign 
NBN Novel 8:90,976,638 N/A PcTas3 1 out of 5 25 C > T; G332R 0 out of 8 N/A 
NBN Novel 8:90,958,439 <0.01 PcTas22 Sub 2 out of 4/ 0 out of 2 0.073 A > G; S667P 0 out of 8 N/A 
NKX3-1 rs199879315 8:23,540,125 0.39 PcTas22 Sub 2 out of 4/ 0 out of 2 10.18 C > G; G10R 0 out of 8 Not reported 
OR5H14 rs112084609 3:97,868,154 0.73 
PcTas22 
Main 
2 out of 5/ 0 out of 1 12.72 A > G; M59V 0 out of 8 Not reported 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; WGS: Whole-genome sequenced; 2CADD: Combined Annotation 
Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study, eight were WGS; 3Associated condition: Interpretation of variant 163. 
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PALB2 rs45494092 16:23,646,607 1.43 
PcTas3, 4, 22 
Sub, 72 
1 out of 5; 2 out of 4/ 1 
out of 1; 
2 out of 1/ 1 out of 2; 0 
out of 4/ 1 out of 4 
8.68 A > G; L337S 0 out of 8 
Hereditary breast cancer: 
Benign 
RAD51C Novel 17:56,787,286 N/A 
PcTas22 
Main 
1 out of 5/ 0 out of 1 34 C > T; R258C 0 out of 8 N/A 
RNASEL rs56250729 1:182,555,403 0.77 PcTas3 2 out of 5 13.87 T > G; I97L 0 out of 8 Not reported 
SLX4 rs759305861 16:3,633,131 0.02 PcTas4 2 out of 4/ 1 out of 1 5.784 
G > C; 
P1624A 
0 out of 8 Not reported 
SLX4 rs148542931 16:3,638,822 <0.01 PcTas12 1 out of 2/ 0 out of 1 14.12 
C > G; 
E1532Q 
0 out of 8 Not reported 
TANGO2 Novel 22:20,050,921 0.01 PcTas3 1 out of 5 15.48 C > A; S222R 0 out of 8 N/A 
1ExAC, non-Finnish European, non-The Cancer Genome Atlas database; MAF: minor allele frequency; WGS: Whole-genome sequenced; 2CADD: Combined Annotation 
Dependent Depletion 164; Control: Control from the Tasmanian Prostate Cancer Case-Control Study, eight were WGS; 3Associated condition: Interpretation of variant 163. 
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APPENDIX 16 
HOXB13 gene and protein expression analysis, G84E allele transcription and methylation 




















PC4-03 Malignant 1.36 2 (69%) 1.38 1, 2, 3 
 Benign 0.02 3 (83%) 2.49  
PC11-11 Malignant 0.59 3 (94%) 2.82 1, 2, 3 
 Benign 0.17 2 (88%) 1.76  
PC11-12 Malignant 0.50 3 (98%) 2.94  
 Benign  2 (59%) 1.18  
 Benign 0.44 3 (89%) 2.67 3 
 Benign 0.23 3 (79%) 2.37 2, 3 
PC12-01 Malignant 2.72 1 (77%) 0.77  
 Benign 0.38 1 (34%) 0.34  
PC12-06 Malignant 0.69 2 (81%) 0.62 3 
 Benign  2 (72%) 1.44  
PC12-09 Malignant 0.43 2 (92%) 1.84 1, 3 
 Benign 0.37 3 (93%) 2.79  
PC22-06 Benign 0.42 3 (91%) 2.73  
PC47-02 Benign 0.30 1 (55%) 0.55  
PC60-01 Malignant 0.58 2 (80%) 1.6  
 Benign 0.02 2 (59%) 1.18  
PC63-24 Malignant  2 (100%) 2  
PC72-04 Malignant 1.34 2 (88%) 1.76 3 




PC12-03 Malignant 0.25 3 (90%) 2.7 1, 2, 3 
 Benign 0.05 3 (80%) 2.4 3 
PC12-07 Malignant 0.40 2 (91%) 1.82 1, 2, 3 
PC12-08 Malignant 0.38 1 (69%) 0.69  
 Benign  2 (77%) 1.54 3 
PC22-203 Malignant  2 (69%) 1.38 1, 2, 3* 
PC22-203 Benign  2 (65%) 1.3  
Blank cell= sample was not analysed; 1Staining intensity: 1=weak, 2=moderate, 3=strong (% of HOXB13 
positive cells); 2Final score is calculated by multiplying staining intensity (1, 2 or 3) by % of HOXB13 
positive cells; 3Primer pair used to assess CpG island methylation (as per Figure 5.7 and Appendix 12); 
























PC22-576 Malignant 0.97 3 (93%) 2.79 3 
 Benign 0.21 1 (72%) 0.72 3 
PC22-637 Malignant  3 (80%) 2.4  
 Benign  3 (78%) 2.34  
PC72-06 Malignant 0.78 3 (91%) 2.73 3 
 Benign 0.37 3 (81%) 2.43 3 
PC72-154 Malignant  2 (81%) 1.62  
 Benign  3 (80%) 2.4  
PC3250-01 Malignant 1.06 1 (100%) 1 3 
 Benign 1.08 1 (100%) 1  
Blank cell= sample was not analysed; 1Staining intensity: 1=weak, 2=moderate, 3=strong (% of HOXB13 
positive cells); 2Final score is calculated by multiplying staining intensity (1, 2 or 3) by % of HOXB13 
positive cells; 3Primer pair used to assess CpG island methylation (as per Figure 5.7 and Appendix 12). 
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APPENDIX 17 
Array-Based Comparative Genomic Hybridisation fine-mapped regions. 
Those listed are regions of loss and gain previously identified in tumours from PcTas9 cases 
(unpublished). These regions were targeted for fine-mapping on the array, as described in 





Start (bp) Stop (bp) Region Size 
Loss 1p22-1p31.1 80,299,794 82,299,794 2,000,000 
 1q23.3-1q25.2 170,547,117 178,547,117 8,000,000 
 6p25.1-6p25.3 1 2,000,000 2,000,000 
 6q22-6q22.1 121,938,845 124,438,845 2,500,000 
 7p21-7p21.3 7,300,002 21,089,819 13,789,818 
 10q26.2 126,918,814 128,918,814 13,789,818 
 17p13-17p13.3 1 6,500,000 6,500,500 
 19p13.3 1 6,900,000 6,900,000 




6,516,515 15,616,515 9,100,000 
 6q25.3-6q27 160,828,366 162,828,366 2,000,000 
 17p13-17p13.3 1 6,500,000 6,500,000 
 20p12-20p12.2 7,555,344 11,055,344 3,500,000 
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APPENDIX 18 
Array-Based Comparative Genomic Hybridisation quality report. 
This report was prepared by PathWest Pathology Laboratory (Drs Thomas and Robinson) and 





Cytogenomics 5.0.2.5 (Agilent) plots of the PcTas9 tumour samples that failed quality control. 
PC9-13 (array 1 & 2), PC9-211 (array 1 & 2) and PC9-659 (array 2) failed QC as there was no loss of the X chromosome (in comparison to a 







Cytogenomics 5.0.2.5 (Agilent) plots of the PcTas9 tumour samples that passed quality control on array 1. 
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APPENDIX 21 













Genes underlying the 
region 
PC9-12 3q11.1-q26.32 634 0.160 1.89E-12 PROS1, ARL13B, ARL6 
PC9-12 17p13.2 1,745 -0.195 2.77E-50 
ANKFY1, UBE2G1, 
SPNS3 
PC9-12 19p13.3 7 3.589 1.18E-72 
EEF2, MIR1268A, 
SNORD37 
PC9-20 1p34.3-p13.2 1684 0.153 6.34E-31 RRAGC, MYCBP, GJA9 
PC9-20 3q12.3-q29 723 0.224 1.03E-30 RPL24, CEP97, NFKBIZ 
PC9-20 6p23-p22.3 134 -0.215 2.09E-13 JARID2, JARID2-AS1 
PC9-20 7p21.2 66 0.570 1.90E-13 ETV1 
PC9-20 8p23.3-p11.21 311 -0.418 8.51E-35 
CLN8, ARHGEF10, 
MCPH1 
PC9-20 16q22.1-q24.3 155 -0.379 1.73E-16 COG8, HAS3, CHTF8 
PC9-20 17p13.3 558 0.195 4.39E-21 DPH1, RTN4RL1, OVCA2 
PC9-20 17q25.1-q25.3 72 -0.439 7.69E-12 DNAI2, RPL38, TTYH2 
PC9-20 18q21.32-q23 174 -0.347 2.61E-14 RAX, LMAN1, CCBE1 
PC9-20 19p13.3 7 3.593 1.38E-84 
EEF2, MIR1268A, 
SNORD37 




1690 0.156 2.03E-33 PLCB1, PLCB4, SNAP25 




77 -0.399 8.89E-10 KCNE2, KCNE1, ITSN1 
PC9-477 1p36.21 206 -0.195 1.02E-11 
LRRC38, PDPN, 
LINC01784 
PC9-477 6p24.3-p24.2 451 -0.175 4.57E-19 TFAP2A, GCNT2, MAK 
PC9-477 6p24.2 25 0.687 5.17E-17 NEDD9 
PC9-477 6p23-p22.3 155 -0.279 4.23E-17  
PC9-477 7p21.1 298 0.162 2.10E-11 HDAC9 
PC9-477 17p13.3 48 -0.428 1.63E-12 RPA1, SMYD4 
PC9-477 17p13.3 53 0.362 9.58E-11 DPH1, OVCA2, MIR132 
PC9-477 17p13.3 28 0.524 1.04E-11 MNT 








Genes underlying the 
region 
PC9-477 19p13.3 139 0.268 1.21E-14 ABCA7, GPX4, GRIN3B 
PC9-477 19p13.3 107 -0.266 2.27E-11 ZNF77, ZNF554, ZNF555 
PC9-477 19p13.3 7 2.550 2.46E-58 
EEF2, MIR1268A, 
SNORD37 
PC9-477 19p13.3 38 0.468 2.20E-12 PTPRS 
PC9-477 19p13.3 5 -1.295 2.95E-11  
PC9-477 19p13.3 70 -0.348 1.15E-12 TNFSF9, CD70 
PC9-477 19p13.3 73 -0.312 7.90E-11 SH2D3A, VAV1 
PC9-477 19p13.3-p11 113 -0.241 3.53E-10 
INSR, ARHGEF18, 
MCOLN1 




410 0.152 3.54E-12 ALCAM, CBLB, DUBR 
PC9-532 5q11.2-q12.1 13 1.138 7.50E-21 PDE4D 
PC9-532 6p24.3 105 -0.280 7.22E-10 DSP, CAGE1, RIOK1 
PC9-532 6p24.2 30 0.830 5.49E-25 NEDD9 
PC9-532 6p23 56 0.391 3.33E-11 SIRT5, NOL7, RANBP9 
PC9-532 6p23-p22.3 176 -0.263 6.16E-15 JARID2, JARID2-AS1 
PC9-532 7p21.3 87 0.336 1.50E-12 ICA1, LOC100505938 
PC9-532 17p13.3 15 0.704 3.39E-10 MYO1C 
PC9-532 17p13.3 468 0.175 1.27E-17 DPH1, RTN4RL1, OVCA2 
PC9-532 17p13.3 9 1.080 3.87E-10 SMG6 
PC9-532 17p13.2 126 0.151 2.19E-10 
CAMKK1, P2RX1, 
ATP2A3 
PC9-532 17p13.2 47 0.308 2.54E-10 SPNS2, MYBBP1A, GGT6 
PC9-532 19p13.3 119 0.333 9.28E-17 ABCA7, GPX4, GRIN3B 
PC9-532 19p13.3 14 0.852 2.58E-13 MKNK2 
PC9-532 19p13.3 7 3.663 6.91E-96 
EEF2, MIR1268A, 
SNORD37 
PC9-532 19p13.3 10 0.850 5.71E-10 ZBTB7A 
PC9-532 19p13.3 88 -0.303 1.18E-10 TICAM1, FEM1A, PLIN3 
PC9-532 19p13.3 15 0.925 2.50E-16 PTPRS 
PC9-532 19p13.3 162 -0.238 6.45E-12 PTPRS, ZNRF4, TINCR 
PC9-5881 8q12.1-q24.3 634 0.154 1.64E-10 CA8, CHC7, ASPH 
PC9-5881 10q25.2-q26.2 915 0.171 5.56E-18 TCF7L2, HABP2, ADRB1 
PC9-5881 20p12.2-p11.1 378 0.201 8.20E-11 JAG1, NDUFAF5, FLRT3 








Genes underlying the 
region 
PC9-5882 6q22.31-q26 2602 0.155 9.79E-43 TRDN, LAMA2, ARG1 
PC9-5882 7p22.1-p15.3 7097 0.159 1.28E-114 ACTB, RNF216, PMS2 
PC9-5882 10q25.3-q26.2 1030 0.187 2.24E-28 PNLIP, VAX1, KCNK18 
PC9-5882 11p15.1-p13 134 0.297 2.61E-10 KCNJ11, ABCC8, USH1C 
PC9-5882 20p12.3-p12.2 1588 0.164 7.44E-31 PLCB1, PLCB4, JAG1 
PC9-620 1p36.22 42 0.435 2.96E-13 DHRS3, MIR6730 
PC9-620 1p36.21 33 -0.561 7.18E-16 
HNRNPCL3, 
HNRNPCL4, HNRNPCL1 
PC9-620 2p13.1-p11.1 124 -0.242 4.53E-11 DCTN1, MOGS, HTRA2 
PC9-620 6p25.3 244 0.182 1.36E-12 EXOC2, HUS1B 
PC9-620 6p24.3-p24.2 255 -0.169 1.65E-11 GCNT2, MAK, GCM2 
PC9-620 6p24.2 24 0.892 2.77E-29 NEDD9 
PC9-620 6p23-p22.3 77 -0.305 1.40E-11  
PC9-620 6q12-q21 329 -0.176 6.95E-15 EYS, LMBRD1, COL9A1 
PC9-620 7p22.3-p11.2 7407 0.168 1.11E-281 
FAM20C, DNAAF5, 
MAD1L1 




241 -0.230 1.34E-18 
AKR1C2, AKR1C4, 
IL2RA 
PC9-620 13q14.12-q34 520 -0.162 1.51E-19 
HTR2A, SUCLA2, 
NUDT15 
PC9-620 16q22.2-q24.1 113 -0.233 3.91E-10 TAT, DHODH, HP 
PC9-620 17p13.3 1300 0.169 6.20E-54 BHLHA9, INPP5K, DPH1 
PC9-620 17p13.3 38 -0.254 1.64E-11 ABR, BHLHA9 
PC9-620 17p13.3 13 0.939 6.45E-13 MY01C 
PC9-620 17p13.3 9 1.264 2.20E-17 SMG6 
PC9-620 17p13.3 20 0.849 3.66E-15 MNT 
PC9-620 17p13.2 244 -0.169 2.25E-11 KIF1C, SLC52A1, INCA1 
PC9-620 19p13.3 216 0.228 5.26E-18 ABCA7, GPX4, STK11 
PC9-620 19p13.3 11 0.801 5.76E-12 MKNK2 
PC9-620 19p13.3 5 1.762 3.68E-24 AES 
PC9-620 19p13.3 7 3.278 1.32E-87 
EEF2, MIR1268A, 
SNORD37 
PC9-620 19p13.3 10 1.036 2.82E-17 ZBTB7A 
PC9-620 19p13.3 50 0.463 3.65E-17 PTPRS 
PC9-620 19p13.3 28 -0.491 3.14E-11 CATSPERD 








Genes underlying the 
region 
PC9-620 19p13.3 62 0.392 1.95E-15 RFX2 
PC9-620 19p13.3 9 0.800 4.28E-10 MLLT1 
PC9-620 19p13.3 10 0.884 5.32E-13 C3 
PC9-627 6p24.2 26 0.659 1.69E-14 NEDD9 
PC9-627 6p23-p22.3 232 -0.187 1.45E-10 JARID2, JARID2-AS1 
PC9-627 10q26.2 374 0.159 4.48E-12 
FANK1, ADAM12, 
C10orf90 
PC9-627 17p13.3 172 0.209 3.03E-10 SRR, TSR1, MNT 
PC9-627 19p13.3 10 0.885 8.78E-11 ZBTB7A 
PC9-627 19p13.2-p12 89 -0.298 2.68E-10 
CD320, RPS28, 
ANGPTL4 
PC9-645 3q13.31-q26.2 422 0.23 2.35E-15 
ZBTB20, ARHGAP31, 
POGLUT1 
PC9-645 4q12-q35.2 1016 0.179 7.43E-21 SGCB, CHIC2, PDGFRA 
PC9-645 6q12-q26 3401 0.162 2.13E-52 EYS, LMBRD1, COL9A1 
PC9-645 7p22.3-p11.2 7393 0.309 4.9E-324 
FAM20C, DNAAF5, 
MAD1L1 
PC9-645 7q11.21-q36.3 705 0.271 1.89E-34 GUSB, ASL, KCTD7 
PC9-645 10q25.1-q26.2 1180 0.162 2.27E-21 ADD3, MXI1, SMC3 
PC9-645 11q12.1-q24.1 487 0.167 3.26E-10 
CTNND1, FAM111B, 
FAM111A 
PC9-645 17p13.3-p13.2 3118 0.164 2.12E-60 
VPS53, BHLHA9, 
INPP5K 
PC9-645 17p13.2 423 -0.291 7.52E-25 
ZMYND15, CHRNE, 
GP1BA 
PC9-645 19p13.3 7 3.351 1.55E-60 
EEF2, MIR1268A, 
SNORD37 
PC9-645 20p12.3-11.1 1895 0.184 1.88E-39 PLCB1, PLCB4, SNAP25 
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CNV in PcTas9 
tumours 
Tumours with CNV Known association with cancer 
Interesting genes underlying the 
region of alteration 
Loss 1p36.21 38% (3/8) PC9-477, 532, 620 
Ovarian cancer; CGH analysis of 28 
ovarian tumours found that the 1p36 
region was lost in 40% of tumours 295. 
A study of pheochromocytomas and 
abdominal paragangliomas also found 
this region to be frequently deleted 407. 
Genes underlying this region of loss, include genes in the 
PRAME and HNRNPCL gene families. PRAME family 
members are expressed in many cancer types, but also 
function in reproductive tissues during development 116. 
HNRNPCL genes encode for RNA binding proteins, which 
influence pre-mRNA splicing processes and alterations 
could lead to alternative transcripts 116. 
Loss 19p13.3 38% (3/8) PC9-477, 532, 620 
Prostate cancer; The 19p region of 
deletion has previously been identified 
in tumours from familial PCa cases by 
Rokman and colleagues (2001), 
however has not been identified in 
sporadic tumours 296. 
Present in this region are a number of interesting genes 
which play a role in the antigen presentation process, the 
generation of cytotoxic T cells, and the activation and 
development of T and B cells 116. Particularly interesting is 
the TINCR lncRNA (LIC00036), which has been 
suggested to have altered expression in multiple human 
cancers 319,320.  
Gain 6p23-p22.3 63% (5/8) 
PC9-20, 477, 532, 
620, 627 
Bladder cancer 297 and retinoblastoma 
tumours 298 
This region of gain encompasses the JARID2 gene, which 
is a putative transcription factor that plays a role in DNA 
binding, nuclear localisation, transcriptional repression and 
recruitment of the Polycomb-repressive complex 2 322-324. 
Whilst the gene has never been found to be associated with 
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PCa, JARID2 has consistently been identified to play a role 
in the initiation, proliferation and maintenance of tumour 
cells in other cancers.  
Gain 6p24.2 50% (4/8) 
PC9-477, 532, 620, 
627 
No known association 
NEDD9 is frequently overexpressed in diverse cancer 
types and has been linked to tumorigenesis of many 
different malignancies, including PCa and is reasonably 
expressed in the normal prostate 116. Interestingly, the 
region of amplification of NEDD9 encompasses only the 
small transcript (NM_006403) and upon further 
investigation using the GTEx Portal, this is the most highly 
expressed transcript in the prostate 137. 
Gain 17p13.3 63% (5/8) 
PC9-20, 477, 532, 
620, 627 
Prostate cancer;  Gain of 17p was 
reported by Rokman et al. (2001) in 
their study of familial PCa. This region 
of gain was not identified in any 
sporadic tumours, suggesting an 
association with familial prostate 
tumourigenesis 296. 
A number of interesting genes are present in this region 
that play a role in transcriptional repression, initiation of 
transcription, the replication and maintenance of 
chromosome ends, and cell growth and differentiation. The 
DPH1 gene was amplified in three out of the five tumours. 
DPH1 is an enzyme involved in the biosynthesis of 
diphthamide, a modified histidine found only in EEF2 116.  
Gain 17p13.3 25% (2/8) PC9-477, 620 
Prostate cancer;  Gain of 17p was 
reported by Rokman et al. (2001) in 
their study of familial PCa. This region 
of gain was not identified in any 
sporadic tumours, suggesting an 
association with familial prostate 
tumourigenesis 296. 
MNT, a member of the Myc/Max/Mad network of 
transcription factors that co-interact to regulate gene-
specific transcription 116. As MYC plays a role in cell cycle 
progression, apoptosis and cellular transformation, this 
interaction could be a key driver in prostate carcinogenesis 
116. In fact, it has now emerged that the MNT protein has 
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the most substantial impact on MYC activities (reviewed 
in 408). 
Gain 17p13.3 25% (2/8) PC9-532, 620 
Prostate cancer;  Gain of 17p was 
reported by Rokman et al. (2001) in 
their study of familial PCa. This region 
of gain was not identified in any 
sporadic tumours, suggesting an 
association with familial prostate 
tumourigenesis 296. 
SMG6 is a gene which encodes a component of the 
telomerase ribonucleoprotein complex, which is 
responsible for the replication and maintenance of 
chromosome ends 116. Whilst this gene has never been 
implicated in PCa 409, it has recently been identified as a 5’ 
fusion partner of ALK in cases of non-small-cell lung 
cancer 410. 
Gain 19p13.3 38% (3/8) PC9-477, 532, 620 
Prostate cancer; The 19p region of 
amplification has previously been 
identified in tumours from familial PCa 
cases by Rokman and colleagues 
(2001), however has not been 
identified in sporadic tumours 296. 
PTPRS, like other PTP family members, is a signaling 
molecule that regulates a variety of cellular processes 
including, cell growth, differentiation, the mitotic cycle 
and oncogenic transformation 116.  
Gain 19p13.3 50% (4/8) 
PC9-20, 532, 620, 
627 
Prostate cancer; The 19p region of 
amplification has previously been 
identified in tumours from familial PCa 
cases by Rokman and colleagues 
(2001), however has not been 
identified in sporadic tumours 296. 
ZBTB7A is a zinc finger protein that is moderately 
expressed in the prostate. Given that ZBTB7A 
upregulation in gastric cancer cells promotes apoptosis and 
represses cell migration 318, the amplification identified in 
these four PCa samples may promote carcinogenesis by 
downregulation of the gene. 
Gain 19p13.3 100% (8/8) 
PC9-12, 20, 477, 
532, 588, 620, 627, 
645 
Prostate cancer; The 19p region of 
amplification has previously been 
identified in tumours from familial PCa 
cases by Rokman and colleagues 
All eight tumours had amplification of the EEF2 gene. 
EEF2 is an essential factor for protein synthesis as it 
promotes the GTP-dependent translocation of the nascent 




(2001), however has not been 
identified in sporadic tumours 296. 
It is overexpressed in a diverse range of cancer types, 
including PCa, and interestingly, has been suggested as a 
potential biomarker of PCa 299. 
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EEF2 gene and protein expression analysis in FFPE prostate tissue samples (raw data). 















IHC Score1 Final Score2 
DVA 67 Malignant      1 (70%) 0.70 
 Benign      1 (20%) 0.20 
DVA 157 Malignant 120.12 104.18 5.04 23.91 41.16 N/A N/A 
 Benign      2 (100%) 2.00 
DVA 167 Malignant 17.32 32.38 3.30 26.12 4.22 2 (80%) 1.60 
DVA 216 Malignant 177.66 146.06 14.45 71.32 49.96 1 (20%) 0.20 
 Benign 1.78 47.64 0.45 3.95 13.79 1 (50%) 0.50 
DVA 220 Malignant 176.21 107.26 7.00 39.63 142.54 0 (0%) 0 
 Benign      1 (30%) 0.30 
DVA 302 Malignant      3 (90%) 2.70 
 Benign      2 (50%) 1.00 
DVA 303 Malignant      3 (80%) 2.40 
 Benign      1 (50%) 0.50 
DVA 402 Malignant 158.41 167.64 0.88 37.67 70.09 2 (100%) 2.00 
 Benign 168.12 43.45 3.40 16.38 22.07 2 (50%) 1.00 
DVA 416 Malignant 2.07 25.98 5.00 84.45 21.99 2 (100%) 2.00 
 Benign 29.08 62.83 2.57 12.09 17.26 2 (80%) 1.60 
DVA 422 Malignant      2 (80%) 1.60 
 Benign      1 (10%) 0.10 
DVA 1002 Malignant 20.32 86.21 4.89 20.79 30.86 2 (90%) 1.80 
 Benign      2 (50%) 1.00 
DVA 1006 Malignant      1 (70%) 0.70 
 Benign      2 (90%) 1.80 
DVA 1036 Malignant      1 (50%) 0.50 
 Benign      2 (80%) 1.60 
DVA 1050 Malignant      2 (30%) 0.60 
 Benign      2 (50%) 1.00 
DVA 1086 Malignant      3 (100%) 3.00 
 Benign      3 (100%) 3.00 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate, 3=strong (% of 
EEF2 positive cells); 2Final score is calculated by multiplying staining intensity (0, 1, 2 or 3) by % of EEF2 
positive cells; N/A: No tissue. 
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IHC Score1 Final Score2 
PC3-08 Malignant      2 (100%) 2.00 
 Benign      3 (100%) 3.00 
PC3-31 Malignant      1 (80%) 0.80 
 Benign      1 (80%) 0.80 
PC4-03 Malignant 47.16 171.9 9.49 190.3 61.05 2 (70%) 1.40 
 Benign 5.88 67.59 1.56 12.56 248.79 1 (50%) 0.50 
PC9-04 Malignant      2 (80%) 1.60 
 Benign      2 (80%) 1.60 
PC9-05 Benign      2 (80%) 1.60 
PC9-06 Malignant 225.41 123.58 12.37 57.57 33.20 2 (80%) 1.60 
 Benign      3 (100%) 3.00 
PC9-07 Malignant 27.81 152.67 13.87 66.94 21.37 1 (50%) 0.50 
PC9-12 Malignant 985.42 149.0 75.64 142.7 99.97 2 (100%) 2.00 
 Benign 314.16 71.72 9.05 38.02 57.34 2 (80%) 1.60 
PC9-13 Malignant 141.86 91.75 21.64 71.03 28.56 2 (70%) 1.40 
PC9-14 Malignant 134.43 200.8 21.81 433.0 55.66 2 (80%) 1.60 
 Benign      1 (80%) 0.80 
PC9-15 Malignant 96.21 123.6 16.47 56.91 40.83 3 (80%) 2.40 
 Benign      3 (80%) 2.40 
PC9-20 Malignant 837.59 113.7 41.97 74.16 55.60 1 (70%) 0.70 
PC9-140 Benign      2 (100%) 2.00 
PC9-158 Malignant 3740.95 69.12 22.42 49.99 36.94 1 (60%) 0.60 
 Benign 33.25 21.37 27.82 62.13 13.62 1 (80%) 0.80 
PC9-211 Malignant 81.70 27.91 1.57 11.14 9.98 1 (70%) 0.70 
 Benign      1 (40%) 0.40 
PC9-338 Malignant      2 (100%) 2.00 
 Benign      2 (100%) 2.00 
PC9-474 Malignant      2 (90%) 1.80 
 Benign      1 (50%) 0.50 
PC9-477 Malignant 140.60 45.18 9.94 43.90 75.36 N/A N/A 
 Benign 105.02 33.87 13.30 29.96 25.48 1 (50%) 0.50 
PC9-532 Malignant 1813.13 74.64 18.95 48.58 59.52 1 (80%) 0.80 
 Benign 86.61 53.84 12.15 32.49 33.20 0 (0%) 0 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate, 3=strong (% of 
EEF2 positive cells); 2Final score is calculated by multiplying staining intensity (0, 1, 2 or 3) by % of EEF2 
positive cells; N/A: No tissue. 
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IHC Score1 Final Score2 
PC9-545 Malignant 151.38 111.5 11.12 36.02 65.20 1 (80%) 0.80 
PC9-561 Malignant      2 (100%) 2.00 
 Benign      2 (100%) 2.00 
PC9-588 Malignant 45.01 44.13 9.52 44.53 23.38 2 (100%) 2.00 
 Benign 153.76 49.99 5.98 23.05 18.04 2 (80%) 1.60 
PC9-603 Malignant 151.59 74.62 13.40 50.30 24.20 N/A N/A 
 Benign      2 (30%) 0.60 
PC9-620 Malignant 190.74 42.67 9.14 39.97 23.36 2 (80%) 1.60 
 Benign 63.17 62.21 5.37 32.41 22.73 2 (80%) 1.60 
PC9-627 Malignant 649.75 50.71 20.53 45.99 40.31 2 (70%) 1.40 
 Benign      0 (0%) 0 
PC9-645 Malignant 769.13 96.96 25.97 72.63 65.58 1 (10%) 0.10 
 Benign 49.75 19.62 2.17 12.44 7.79 1 (70%) 0.70 
PC9-659 Malignant 61.31 44.21 6.02 21.41 20.46 2 (80%) 1.60 
 Benign      1 (20%) 0.20 
PC9-951 Malignant      1 (100%) 1.00 
 Benign      1 (100%) 1.00 
PC11-11 Malignant 82.14 65.00 25.63 50.50 60.08 3 (80%) 2.40 
 Benign 164.61 58.28 11.92 21.21 61.78 3 (80%) 2.40 
PC11-12 Malignant 9.78 58.90 4.47 20.54 8.64 N/A N/A 
PC11-13 Benign      2 (80%) 1.60 
PC11-16 Benign      3 (90%) 2.70 
PC11-19 Malignant      0 (0%) 0 
 Benign      1 (20%) 0.20 
PC12-01 Malignant 37.17 78.73 6.97 68.61 48.21 0 (0%) 0 
 Benign 27.19 16.93 5.65 23.23 5.29 1 (10%) 0.10 
PC12-03 Malignant 13.19 76.79 2.20 18.50 35.56 0 (0%) 0 
 Benign 17.32 25.87 2.41 13.20 27.07 1 (5%) 0.05 
PC12-06 Malignant 293.02 63.63 3.24 22.52 30.55 2 (60%) 1.20 
 Benign      1 (40%) 0.40 
PC12-07 Malignant 70.24 32.91 2.56 17.47 23.78 1 (60%) 0.60 
PC12-08 Malignant 1.10 4.59 0.64 0.43 3.01 3 (60%) 1.80 
 Benign      3 (90%) 2.70 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate, 3=strong (% of 
EEF2 positive cells); 2Final score is calculated by multiplying staining intensity (0, 1, 2 or 3) by % of EEF2 
positive cells; N/A: No tissue. 
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IHC Score1 Final Score2 
PC12-09 Malignant 32.67 47.83 2.39 21.24 19.288 0 (0%) 0 
 Benign 17.17 46.82 3.18 24.52 23.75 1 (30%) 0.30 
PC19-02 Malignant 0.79 50.50 0.54 38.04 11.59 2 (60%) 1.20 
 Benign      2 (90%) 1.80 
PC22-06 Benign      2 (80%) 1.60 
PC22-17 Malignant 3.66 118.39 22.19 73.73 31.71 1 (80%) 0.80 
 Benign      1 (5%) 0.05 
PC22-576 Malignant 452.95 120.51 18.14 69.37 80.49 2 (80%) 1.60 
 Benign 27.97 42.13 1.53 11.86 17.10 1 (50%) 0.50 
PC23-02 Malignant      1 (50%) 0.50 
 Benign      1 (10%) 0.10 
PC27-01 Malignant      1 (30%) 0.30 
PC31-01 Malignant 11.58 69.97 0.61 14.62 67.11 1 (100%) 1.00 
 Benign      1 (50%) 0.50 
PC47-02 Benign      2 (80%) 1.60 
PC60-01 Malignant      2 (80%) 1.60 
 Benign      2 (80%) 1.60 
PC72-04 Malignant 27.20 88.43 5.39 42.10 31.53 1 (70%) 0.70 
 Benign 0.98 42.45 1.31 17.29 43.37 0 (0%) 0 
PC72-06 Malignant 53.08 35.37 1.15 9.24 3.27 1 (70%) 0.70 
 Benign 13.80 61.55 1.08 49.22 6.02 1 (50%) 0.50 
PC213-991 Malignant      2 (100%) 2.00 
 Benign      1 (10%) 0.10 
PC3250-01 Malignant 224.99 112.8 42.17 92.27 98.37 1 (50%) 0.50 
 Benign 36.37 131.1 42.25 74.96 18.11 N/A N/A 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate, 3=strong (% of 
EEF2 positive cells); 2Final score is calculated by multiplying staining intensity (0, 1, 2 or 3) by % of EEF2 
positive cells; N/A: No tissue. 
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DAPK3 gene expression analysis in FFPE prostate tissue samples (raw data). 
  Absolute DAPK3 Gene Expression 
Sample Identification Tissue Cell Type Exon 3/4 Exon 4/5 Exon 7/8 
DVA 157 Malignant 5.18 5.06 12.40 
DVA 220 Malignant 7.93 5.80 10.37 
DVA 416 Benign 14.44 83.77  
PC4-03 Malignant 0.76 6.01 6.90 
 Benign 3.27 0.39 8.97 
PC9-12 Malignant 0.35 1.07 5.57 
 Benign 1.23 4.43 7.90 
PC9-13 Malignant 1.93 4.04 8.34 
PC9-14 Malignant 1.09 4.04 9.78 
PC9-15 Malignant 0.45 3.52 6.21 
PC9-158 Malignant 0.47 3.05 5.54 
 Benign 0.98 1.53 5.13 
PC9-20 Malignant 0.38 2.59 7.12 
PC9-211 Malignant 2.37 3.85 5.35 
PC9-477 Malignant 0.60 2.14 9.08 
 Benign 1.38 3.51 14.23 
PC9-532 Malignant 2.12 2.58 7.15 
PC9-532 Benign 0.83 2.340 11.87 
PC9-545 Malignant 6.56 12.48 29.91 
PC9-588 Malignant 0.61 1.32 7.92 
 Benign 1.13 3.29 5.59 
PC9-06 Malignant 1.58 4.72 13.54 
PC9-603 Malignant 0.85 2.61 7.92 
PC9-620 Malignant 0.39 3.02 12.44 
 Benign 1.01 3.22 6.16 
PC9-627 Malignant 0.28 1.49 3.89 
PC9-645 Malignant 0.61 2.96 5.34 
 Benign 0.21 2.98 4.96 
PC9-659 Malignant 1.28 2.92 8.54 
PC11-11 Malignant 1.36 1.59 5.57 
 Benign 0.47 1.20 4.12 
PC12-01 Malignant  3.17 6.59 

































  Absolute DAPK3 Gene Expression 
Sample Identification Tissue Cell Type Exon 3/4 Exon 4/5 Exon 7/8 
PC12-01 Benign 2.44 2.40 6.05 
PC12-03 Benign 0.89 2.74 4.88 
PC12-06 Malignant 9.04 3.86 7.92 
PC12-07 Malignant 2.78 2.18 9.06 
PC12-09 Malignant 0.87 1.13 8.60 
 Benign  3.52 6.10 
PC22-576 Malignant 23.25 5.68 4.64 
 Benign 3.02 6.16 11.77 
PC72-04 Malignant 2.64 1.82 2.96 
PC72-06 Malignant 0.55 3.41 5.78 
 Benign 1.59 3.02 6.23 
PC3250-01 Malignant 0.79 2.08 5.25 
 Benign 0.32 8.63 5.99 
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TaqMan® TMPRSS2:ERG expression assay identification numbers (Applied Biosystems). 
 
Fusion/Gene Assay Identification Assay Location Amplicon Length 
T1E2 Hs04396946_ft 60 105 
T1E4 Hs03063375_ft 49 106 
T1E4 Custom N/A 112 
b-Actin Hs01060665_g1 208 63 
T1E2: TMPRSS2 (Exon 1): ERG (Exon 2); 




Primers designed for Sanger sequencing validation of TMPRSS2:ERG fusion positive tumours. 
 
Fusion TMPRSS2 Forward Primer (5’-3’) ERG Reverse Primer (5’-3’) Product size (bp) 
Optimal annealing 
temperature (°C) 
T1E2 CGCGAGCTAAGCAGGAGGCG 411 TAAGCCAGCCCATCTACCAG 211 64 
T1E4 GGAGGCGGAGGCGGAGGG 411 TTTTGATGGTGACCCTGGCT 236 60 
T1E2: TMPRSS2 (Exon 1): ERG (Exon 2); T1E4: TMPRSS2 (Exon 1): ERG (Exon 4) 
 304 
APPENDIX 28 










Age at Death3 Cause of Death3 
DVA 67 61 - 6 (2+4) 74 Non-Cancer 
DVA 157 66 - 7 (3+4)   
DVA 167 53 PD 9 (5+4) 60 PCa 
DVA 216 64 - 5 (3+2) 68 Other 
DVA 220 63 MD 6 (3+3)   
DVA 402 52 MD 6 (3+3)   
DVA 416 62 MD 6 (3+3)   
DVA 1002 61 WD 6 (3+3)   
PC2-46 52 M/PD 7 (4+3)   
PC2-47 51 - 6 (3+3)   
PC3-08 69 MD 6 (3+3) 85 Non-Cancer 
PC3-31 54 - 5 (3+2)   
PC4-03 80 M/PD 7 (4+3) 84 Non-Cancer 
PC9-06 79 - - 88 PCa 
PC9-07 71 PD 10 (5+5) 73 PCa 
PC9-13 83 - - 87 Non-Cancer 
PC9-15 64 MD 5 (2+3) 75 PCa 
PC9-20 76 PD - 83 PCa 
PC9-158 63 - 6 (3+3)   
PC9-603 73 MD 6 (3+3) 86 Non-Cancer 
PC9-659 65 - 9 (4+5)   
PC11-11 85 - 7 (3+4) 87 Non-Cancer 
PC11-12 58 - 9 (4+5) 60 Other 
PC12-03 62 WD 4 (2+2)   
PC12-07 59 PD 9 (4+5) 71 PCa 
PC12-08 73 - 6 (3+3) 75 Other 
PC12-09 68 - 6 (3+3) 82 Non-Cancer 
PC12-132 61 - 8 (4+4)   
1Tumour grade obtained from pathology report; 2Contemporary Gleason Score from pathology report 
(if known) or FFPE tissue block chosen for microdissection of nucleic acids; WD: well 
differentiated; MD: moderately differentiated; PD: poorly differentiated; -: information not present in 
original pathology report; 3Age at death and cause of death information was obtained from the 











Age at Death3 Cause of Death3 
PC19-02 50 - -   
PC22-17 56 MD 6 (3+3)   
PC22-576 69 M/PD 7 (3+4)   
PC23-02 78 MD 7 (3+4) 86 Non-Cancer 
PC31-01 61 PD 5 (3+2)   
PC60-01 58 WD 6 (3+3) 70 Other 
PC72-06 62 - 8 (4+4) 72 PCa 
PC213-991 68 - 9 (4+5)   
PC3250-01 51 PD 9 (4+5)   
1Tumour grade obtained from pathology report; 2Contemporary Gleason Score from pathology report 
(if known) or FFPE tissue block chosen for microdissection of nucleic acids; WD: well 
differentiated; MD: moderately differentiated; PD: poorly differentiated; -: information not present in 
original pathology report; 3Age at death and cause of death obtained from the Tasmanian Cancer 
Registry (as at April 2019);  PCa: Prostate Cancer; Other: Other cancer. 
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APPENDIX 29 
ETV1 gene and protein expression analysis in FFPE prostate tissue samples (raw data). 





Exon 8/10 Exon 16/17 Exon 21/22 IHC Score1 
Final 
Score2 
DVA 67 Malignant    0 (0%) 0 
 Benign    2 (10%) 0.2 
DVA 157 Malignant  5.04  N/A N/A 
 Benign    0 (0%) 0 
DVA 167 Malignant    0 (0%) 0 
DVA 216 Malignant    1 (40%) 0.4 
 Benign    0 (0%) 0 
DVA 220 Malignant 0.87 3.41 2.21 0 (0%) 0 
 Benign    0 (0%) 0 
DVA 302 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 303 Malignant    1 (20%) 0.2 
 Benign    0 (0%) 0 
DVA 402 Malignant    0 (0%) 0 
 Benign  6.07  0 (0%) 0 
DVA 416 Malignant    0 (0%) 0 
 Benign  2.58  0 (0%) 0 
DVA 422 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 1002 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 1006 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 1036 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 1050 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
DVA 1086 Malignant    1 (70%) 0.7 
 Benign    0 (0%) 0 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate, 3=strong (% of 
ETV1 positive cells); 2Final score is calculated by multiplying staining intensity (0, 1, 2 or 3) by % of ETV1 
positive cells; N/A: No tissue. 
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Exon 8/10 Exon 16/17 Exon 21/22 IHC Score1 
Final 
Score2 
PC3-31 Malignant    0 (0%) 0 
PC4-03 Malignant  7.62  0 (0%) 0 
 Benign  8.95 2.55 0 (0%) 0 
PC9-04 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC9-05 Benign    0 (0%) 0 
PC9-06 Malignant  2.05  0 (0%) 0 
 Benign    0 (0%) 0 
PC9-07 Malignant  3.03 0.68 0 (0%) 0 
PC9-12 Malignant 0.07 0.49 0.19 0 (0%) 0 
 Benign 0.72 1.43 0.85 1 (50%) 0.5 
PC9-13 Malignant 0.09 2.63 1.49 0 (0%) 0 
PC9-14 Malignant 0.59 3.73 0.31 0 (0%) 0 
 Benign    0 (0%) 0 
PC9-15 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC9-20 Malignant 0.13 4.57 2.57 1 (50%) 0.5 
PC9-140 Benign    0 (0%) 0 
PC9-158 Malignant 0.28 24.46 18.21 0 (0%) 0 
 Benign 0.38 2.29 1.13 2 (50%) 1 
PC9-211 Malignant 0.87 7.42 0.86 0 (0%) 0 
 Benign    0 (0%) 0 
PC9-338 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC9-474 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC9-477 Malignant 0.08 0.44 0.28 N/A N/A 
 Benign 0.06 0.57 0.19 0 (0%) 0 
PC9-532 Malignant 0.79 1.00 1.55 0 (0%) 0 
 Benign 0.36 0.72 0.38 1 (10%) 0.1 
PC9-545 Malignant 0.53 4.94 2.01 0 (0%) 0 
PC9-561 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate (% of ETV1 positive 
cells); 2Final score is calculated by multiplying staining intensity (0, 1 or 2) by % of ETV1 positive  cells; 
N/A: No tissue. 
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Exon 8/10 Exon 16/17 Exon 21/22 IHC Score1 
Final 
Score2 
PC9-588 Malignant 0.32 1.08  1 (5%) 0.05 
 Benign 0.37 1.39  1 (10%) 0.1 
PC9-603 Malignant 0.14 4.16 1.22 N/A N/A 
 Benign    0 (0%) 0 
PC9-620 Malignant 0.13 1.52 0.66 0 (0%) 0 
 Benign 0.15 2.47 1.37 1 (10%) 0.1 
PC9-627 Malignant 0.11 1.21 0.85 0 (0%) 0 
 Benign    0 (0%) 0 
PC9-645 Malignant 0.21 0.56 0.69 0 (0%) 0 
 Benign 0.22 0.96 0.15 0 (0%) 0 
PC9-659 Malignant 0.19 1.77 0.37 0 (0%) 0 
 Benign    0 (0%) 0 
PC9-951 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC11-11 Malignant 0.32 0.85 1.59 0 (0%) 0 
PC11-11 Benign 1.14 0.45 0.26 0 (0%) 0 
PC11-13 Benign    1 (10%) 0.1 
PC11-16 Benign    1 (5%) 0.05 
PC11-19 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC12-01 Malignant 0.17 2.50  0 (0%) 0 
 Benign  1.74 0.62 0 (0%) 0 
PC12-03 Malignant    0 (0%) 0 
 Benign 0.22   0 (0%) 0 
PC12-06 Malignant 0.76 2.11 4.17 0 (0%) 0 
 Benign    0 (0%) 0 
PC12-07 Malignant 0.51 1.35 0.73 0 (0%) 0 
PC12-08 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC12-09 Malignant 0.58 1.48 0.42 0 (0%) 0 
 Benign 0.71 2.49 0.89 0 (0%) 0 
PC19-02 Malignant    1 (20%) 0.2 
 Benign    1 (20%) 0.2 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate (% of ETV1 positive 
cells); 2Final score is calculated by multiplying staining intensity (0, 1 or 2) by % of ETV1 positive cells; 
















Exon 8/10 Exon 16/17 Exon 21/22 IHC Score1 
Final 
Score2 
PC22-06 Benign    0 (0%) 0 
PC22-17 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC22-576 Malignant    0 (0%) 0 
 Benign   1.66 0 (0%) 0 
PC23-02 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC27-01 Malignant    1 (70%) 0.7 
PC31-01 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC47-02 Benign    0 (0%) 0 
PC60-01 Malignant    0 (0%) 0 
 Benign    0 (0%) 0 
PC72-04 Malignant 0.61 2.62  0 (0%) 0 
 Benign    0 (0%) 0 
PC72-06 Malignant 0.43 1.91 0.71 0 (0%) 0 
 Benign 7.24 2.38  0 (0%) 0 
PC213-991 Malignant    0 (0%) 0 
 Benign    1 (10%) 0.1 
PC3250-01 Malignant 0.41 1.17 0.54 0 (0%) 0 
 Benign 0.81 3.44  N/A N/A 
Blank cell= sample was not analysed; 1Staining intensity: 0=none, 1=weak, 2=moderate (% of ETV1 positive 
cells); 2Final score is calculated by multiplying staining intensity (0, 1 or 2) by % of ETV1 positive cells; 
N/A: No tissue. 
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APPENDIX 30 
This condensed PcTas9 pedigree indicates those tumours assessed for EEF2 5’UTR/exon 2 expression and the two TMPRSS2:ERG fusion events; EEF2 5’UTR/exon 2 
overexpressing and/or TMPRSS2:ERG fusion positive tumours are shown in yellow and tumours with no overexpression of EEF2 and TMPRSS2:ERG fusion negative, in grey. 
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